10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2013

OR

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from             to

COMMISSION FILE NUMBER 001-16789

ALERE INC.

(Exact name of registrant as specified in its charter)

DELAWARE	04-3565120
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

51 SAWYER ROAD, SUITE 200

WALTHAM, MASSACHUSETTS 02453

(Address of principal executive offices)(Zip code)

(781) 647-3900

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	x	Accelerated filer	¨
Non-accelerated filer	¨  (Do not check if a smaller reporting company)	Smaller reporting company	¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

The number of shares outstanding of the registrant’s common stock, par value of $0.001 per share, as of May 6, 2013 was 81,288,432.

ALERE INC.

REPORT ON FORM 10-Q

For the Quarterly Period Ended March 31, 2013

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Readers can identify these statements by forward-looking words such as “may,” “could,” “should,” “would,” “intend,” “will,” “expect,” “anticipate,” “believe,” “estimate,” “continue” or similar words. A number of important factors could cause actual results of Alere Inc. and its subsidiaries to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the risk factors detailed in Part I, Item 1A, “Risk Factors,” of our Annual Report on Form 10-K, as amended, for the fiscal year ended December 31, 2012 and other risk factors identified herein or from time to time in our periodic filings with the Securities and Exchange Commission. Readers should carefully review these risk factors, and should not place undue reliance on our forward-looking statements. These forward-looking statements are based on information, plans and estimates at the date of this report. We undertake no obligation to update any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or other changes.

Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to “we,” “us” and “our” refer to Alere Inc. and its subsidiaries.

TABLE OF CONTENTS

	PAGE
PART I. FINANCIAL INFORMATION		3
Item 1. Financial Statements		3
a) Consolidated Statements of Operations for the Three Months Ended March 31, 2013 and 2012		3
b) Consolidated Statements of Comprehensive Income (Loss) for the Three Months Ended March  31, 2013 and 2012		4
c) Consolidated Balance Sheets as of March 31, 2013 and December 31, 2012		5
d) Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2013 and 2012		6
e) Notes to Consolidated Financial Statements		7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		30
Item 3. Quantitative and Qualitative Disclosures About Market Risk		38
Item 4. Controls and Procedures		38
PART II. OTHER INFORMATION		38
Item 6. Exhibits		38
SIGNATURES		40

2

PART I—FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

ALERE INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

(in thousands, except per share amounts)

	Three Months Ended March 31,
	2013			2012
Net product sales	$	508,276		$	475,787
Services revenue		226,909			192,434
Net product sales and services revenue		735,185			668,221
License and royalty revenue		4,064			2,908
Net revenue		739,249			671,129
Cost of net product sales		253,078			225,554
Cost of services revenue		120,158			90,860
Cost of net product sales and services revenue		373,236			316,414
Cost of license and royalty revenue		1,756			1,644
Cost of net revenue		374,992			318,058
Gross profit		364,257			353,071
Operating expenses:
Research and development		41,454			39,000
Sales and marketing		156,456			158,578
General and administrative		135,858			120,435
Total operating expenses		333,768			318,013
Operating income		30,489			35,058
Interest expense, including amortization of original issue discounts and deferred financing costs		(57,399	)		(50,727	)
Other income (expense), net		(470	)		11,831
Loss before benefit for income taxes		(27,380	)		(3,838	)
Benefit for income taxes		(36,871	)		(1,455	)
Income (loss) before equity earnings of unconsolidated entities, net of tax		9,491			(2,383	)
Equity earnings of unconsolidated entities, net of tax		2,934			3,412
Net income		12,425			1,029
Less: Net loss attributable to non-controlling interests		(25	)		(185	)
Net income attributable to Alere Inc. and Subsidiaries		12,450			1,214
Preferred stock dividends		(5,250	)		(5,309	)
Net income (loss) available to common stockholders	$	7,200		$	(4,095	)
Basic net income (loss) per common share attributable to Alere Inc. and Subsidiaries:	$	0.09		$	(0.05	)
Diluted net income (loss) per common share attributable to Alere Inc. and Subsidiaries:	$	0.09		$	(0.05	)
Weighted-average shares-basic		81,199			80,240
Weighted-average shares-diluted		81,300			80,240

The accompanying notes are an integral part of these consolidated financial statements.

3

ALERE INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(unaudited)

(in thousands)

	Three Months Ended March 31,
	2013			2012
Net income	$	12,425		$	1,029
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment		(75,355	)		35,939
Unrealized gains on available for sale securities		—			431
Unrealized gains on hedging instruments		11			1,107
Minimum pension liability adjustment		605			(165	)
Other comprehensive income (loss), before tax		(74,739	)		37,312
Income tax benefit related to items of other comprehensive income		—			(41	)
Other comprehensive income (loss), net of tax		(74,739	)		37,353
Comprehensive income (loss)		(62,314	)		38,382
Less: Comprehensive loss attributable to non-controlling interests		(25	)		(185	)
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	$	(62,289	)	$	38,567

The accompanying notes are an integral part of these consolidated financial statements.

4

ALERE INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(unaudited)

(in thousands, except par value)

	March 31, 2013			December 31, 2012
ASSETS
Current assets:
Cash and cash equivalents	$	327,233		$	328,346
Restricted cash		11,649			3,076
Marketable securities		884			904
Accounts receivable, net of allowances of $41,337 and $36,395 at March 31, 2013 and December 31, 2012, respectively		540,093			524,332
Inventories, net		336,442			337,121
Deferred tax assets		83,530			67,722
Prepaid expenses and other current assets		167,346			145,236
Total current assets		1,467,177			1,406,737
Property, plant and equipment, net		529,164			534,469
Goodwill		3,116,857			3,048,405
Other intangible assets with indefinite lives		58,393			36,451
Finite-lived intangible assets, net		1,874,636			1,834,225
Deferred financing costs, net, and other non-current assets		99,300			108,857
Investments in unconsolidated entities		94,295			90,491
Deferred tax assets		8,653			8,293
Total assets	$	7,248,475		$	7,067,928
LIABILITIES AND EQUITY
Current liabilities:
Current portion of long-term debt	$	52,210		$	60,232
Current portion of capital lease obligations		6,146			6,684
Accounts payable		166,012			169,974
Accrued expenses and other current liabilities		470,919			411,919
Total current liabilities		695,287			648,809
Long-term liabilities:
Long-term debt, net of current portion		3,788,842			3,628,675
Capital lease obligations, net of current portion		11,615			12,917
Deferred tax liabilities		415,452			428,188
Other long-term liabilities		212,376			166,635
Total long-term liabilities		4,428,285			4,236,415
Commitments and contingencies (Note 17)
Stockholders’ equity:
Series B preferred stock, $0.001 par value (liquidation preference: $709,763 at March 31, 2013 and December 31, 2012); Authorized: 2,300 shares; Issued: 2,065 shares at March 31, 2013 and December 31, 2012; Outstanding: 1,774 shares at March 31, 2013 and December 31, 2012		606,468			606,468
Common stock, $0.001 par value; Authorized: 200,000 shares; Issued: 88,959 shares at March 31, 2013 and 88,576 shares at December 31, 2012; Outstanding: 81,280 shares at March 31, 2013 and 80,897 shares at December 31, 2012		89			89
Additional paid-in capital		3,304,448			3,299,935
Accumulated deficit		(1,552,523	)		(1,564,973	)
Treasury stock, at cost, 7,679 shares at March 31, 2013 and December 31, 2012		(184,971	)		(184,971	)
Accumulated other comprehensive income (loss)		(50,865	)		23,874
Total stockholders’ equity		2,122,646			2,180,422
Non-controlling interests		2,257			2,282
Total equity		2,124,903			2,182,704
Total liabilities and equity	$	7,248,475		$	7,067,928

The accompanying notes are an integral part of these consolidated financial statements.

5

ALERE INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(in thousands)

	Three Months Ended March 31,
	2013			2012
Cash Flows from Operating Activities:
Net income	$	12,425		$	1,029
Adjustments to reconcile net income to net cash provided by operating activities:
Non-cash interest expense, including amortization of original issue discounts and write-off of deferred financing costs		5,217			5,278
Depreciation and amortization		104,970			102,721
Non-cash charges for sale of inventories revalued at the date of acquisition		461			4,681
Non-cash stock-based compensation expense		4,123			3,874
Impairment of inventory		—			5
Impairment of long-lived assets		—			134
Loss on sale of fixed assets		172			566
Equity earnings of unconsolidated entities, net of tax		(2,934	)		(3,412	)
Deferred income taxes		(50,907	)		(13,752	)
Other non-cash items		1,941			—
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net		(20,167	)		(12,942	)
Inventories, net		(17,171	)		9,351
Prepaid expenses and other current assets		(5,833	)		3,521
Accounts payable		(1,988	)		(17,806	)
Accrued expenses and other current liabilities		39,957			3,985
Other non-current liabilities		795			14,697
Net cash provided by operating activities		71,061			101,930
Cash Flows from Investing Activities:
(Increase) decrease in restricted cash		(8,573	)		6,302
Purchases of property, plant and equipment		(36,105	)		(30,385	)
Proceeds from sale of property, plant and equipment		1,143			527
Cash paid for acquisitions, net of cash acquired		(158,421	)		(38,008	)
Cash received from equity method investment		10,771			6,066
Cash paid for marketable securities		—			(2	)
Increase in other assets		(5,569	)		(8,554	)
Net cash used in investing activities		(196,754	)		(64,054	)
Cash Flows from Financing Activities:
Cash paid for financing costs		(1,427	)		(1,876	)
Cash paid for contingent purchase price consideration		(19,098	)		(48	)
Proceeds from issuance of common stock, net of issuance costs		6,135			7,674
Proceeds from issuance of long-term debt		10,053			199,141
Payments on long-term debt		(19,638	)		(16,911	)
Net proceeds under revolving credit facilities		162,483			1,339
Payments on short-term debt		—			(6,240	)
Cash paid for dividends		(5,323	)		(5,323	)
Excess tax benefits on exercised stock options		104			148
Principal payments on capital lease obligations		(1,721	)		(1,720	)
Net cash provided by financing activities		131,568			176,184
Foreign exchange effect on cash and cash equivalents		(6,988	)		864
Net increase (decrease) in cash and cash equivalents		(1,113	)		214,924
Cash and cash equivalents, beginning of period		328,346			299,173
Cash and cash equivalents, end of period	$	327,233		$	514,097

The accompanying notes are an integral part of these consolidated financial statements.

6

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

(1) Basis of Presentation of Financial Information

The accompanying Consolidated Financial Statements of Alere Inc. are unaudited. In the opinion of management, the unaudited Consolidated Financial Statements contain all adjustments considered normal and recurring and necessary for their fair statement. Interim results are not necessarily indicative of results to be expected for the year. These interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these Consolidated Financial Statements do not include all of the information and footnotes necessary for a complete presentation of financial position, results of operations, comprehensive income and cash flows. Our audited Consolidated Financial Statements for the year ended December 31, 2012 included information and footnotes necessary for such presentation and were included in our Annual Report on Form 10-K, as amended, filed with the Securities and Exchange Commission, or SEC, on March 1, 2013. These unaudited Consolidated Financial Statements should be read in conjunction with our audited Consolidated Financial Statements and notes thereto for the year ended December 31, 2012.

Certain reclassifications of prior period amounts have been made to conform to current period presentation. These reclassifications had no effect on net income or equity.

Certain amounts presented may not recalculate directly, due to rounding.

(2) Cash and Cash Equivalents

We consider all highly-liquid cash investments with original maturities of three months or less at the date of acquisition to be cash equivalents. At March 31, 2013, our cash equivalents consisted of money market funds.

(3) Inventories

Inventories are stated at the lower of cost (first in, first out) or market and are comprised of the following (in thousands):

	March 31, 2013		December 31, 2012
Raw materials	$	101,477	$	99,498
Work-in-process		82,574		89,895
Finished goods		152,391		147,728
	$	336,442	$	337,121

(4) Note Receivable from FGST Investments, Inc.

In December 2012, we entered into an arrangement whereby we issued a $40.0 million short-term note to an unrelated party, FGST Investments, Inc., or FGST, for the primary purpose of providing funding in connection with FGST’s acquisition of the Polymedica Corporation (“Liberty”) line of business, a medical supply business, from a subsidiary of Express Scripts Holding Company. The note bears interest at a rate of 3.25% per annum and is collateralized by substantially all of the assets of FGST and its parent entity, ATLS Acquisition, LLC, or ATLS, and was guaranteed by various subsidiaries of FGST. The $40.0 million short-term note is classified within prepaid expenses and other current assets on our Consolidated Balance Sheet as of March 31, 2013. In connection with the note, we obtained a call option to purchase certain of the assets acquired by FGST for a purchase price of $40.0 million. Under the terms of the option, we could exercise the option and satisfy the purchase price by cancellation of the principal amount of the note. On February 4, 2013, we exercised the option. On February 15, 2013, the issuer of the note filed for protection under Chapter 11 of the U.S. Bankruptcy Code. Subsequently, in April 2013, we entered into an amendment of the option agreement and settlement stipulation related to these matters. (See Note 21)

7

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(unaudited)

(5) Stock-based Compensation

We recorded stock-based compensation expense in our Consolidated Statements of Operations for the three months ended March 31, 2013 and 2012, respectively, as follows (in thousands):

	Three Months Ended March 31,
	2013			2012
Cost of net revenue	$	232		$	269
Research and development		747			771
Sales and marketing		716			917
General and administrative		2,428			1,917
		4,123			3,874
Benefit for income taxes		(862	)		(541	)
	$	3,261		$	3,333

(6) Net Income (Loss) per Common Share

The following table sets forth the computation of basic and diluted net income (loss) per common share for the three months ended March 31, 2013 and 2012 (in thousands, except per share data):

	Three Months Ended March 31,
	2013			2012
Numerator:
Net income	$	12,425		$	1,029
Preferred stock dividends		(5,250	)		(5,309	)
Less: Net loss attributable to non-controlling interest		(25	)		(185	)
Net income (loss) available to common stockholders	$	7,200		$	(4,095	)
Denominator:
Weighted-average common shares outstanding—basic		81,199			80,240
Effect of dilutive securities:
Stock options		101			—
Weighted-average common shares outstanding—diluted		81,300			80,240
Basic net income (loss) per common share attributable to Alere Inc. and Subsidiaries	$	0.09		$	(0.05	)
Diluted net income (loss) per common share attributable to Alere Inc. and Subsidiaries	$	0.09		$	(0.05	)

The following potential dilutive securities were not included in the calculation of diluted net income (loss) per common share because the inclusion thereof would be antidilutive (in thousands):

	Three Months Ended March 31,
	2013		2012
Denominator:
Options to purchase shares of common stock		9,987		9,776
Warrants		4		152
Conversion shares related to 3% convertible senior subordinated notes		3,411		3,411
Conversion shares related to subordinated convertible promissory notes		27		27
Conversion shares related to Series B convertible preferred stock		10,239		10,239
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding		23,668		23,605

8

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(unaudited)

(7) Stockholders’ Equity and Non-controlling Interests

(a) Preferred Stock

For both the three months ended March 31, 2013 and 2012, Series B preferred stock dividends amounted to $5.3 million which reduced earnings available to common stockholders for purposes of calculating net income (loss) per common share for each of the respective periods. As of April 15, 2013, payments have been made covering all dividend periods through March 31, 2013.

The Series B preferred stock dividends for the three months ended March 31, 2013 and 2012 were paid in cash.

(b) Changes in Stockholders’ Equity and Non-controlling Interests

A summary of the changes in stockholders’ equity and non-controlling interests comprising total equity for the three months ended March 31, 2013 and 2012 is provided below (in thousands):

	Three Months Ended March 31,
	2013									2012
	Total Stockholders’ Equity			Non- controlling Interests			Total Equity			Total Stockholders’ Equity			Non- controlling Interests			Total Equity
Equity, beginning of period	$	2,180,422		$	2,282		$	2,182,704		$	2,229,234		$	2,340		$	2,231,574
Exercise of common stock options, warrants and shares issued under employee stock purchase plan		6,135			—			6,135			7,674			—			7,674
Preferred stock dividends		(5,323	)		—			(5,323	)		(5,323	)		—			(5,323	)
Stock-based compensation related to grants of common stock options		4,123			—			4,123			3,874			—			3,874
Excess tax benefits on exercised stock options		(422	)		—			(422	)		104			—			104
Net income (loss)		12,450			(25	)		12,425			1,214			(137	)		1,077
Total other comprehensive income (loss)		(74,739	)		—			(74,739	)		37,353			—			37,353
Equity, end of period	$	2,122,646		$	2,257		$	2,124,903		$	2,274,130		$	2,203		$	2,276,333

(8) Business Combinations

Acquisitions are accounted for using the acquisition method and the acquired companies’ results have been included in the accompanying Consolidated Financial Statements from their respective dates of acquisition. During the three months ended March 31, 2013 and 2012, we expensed acquisition-related costs of $0.9 million and $1.5 million, respectively, in general and administrative expense.

Our business acquisitions have historically been made at prices above the fair value of the assets acquired and liabilities assumed, resulting in goodwill, based on our expectations of synergies and other benefits of combining the businesses. These synergies and benefits include elimination of redundant facilities, functions and staffing; use of our existing commercial infrastructure to expand sales of the products of the acquired businesses; and use of the commercial infrastructure of the acquired businesses to expand product sales in a cost-efficient manner.

Net assets acquired are recorded at their fair value and are subject to adjustment upon finalization of the fair value analysis. We are not aware of any information that indicates the final fair value analysis will differ materially from the preliminary estimates. The estimated useful lives of the individual categories of intangible assets were based on the nature of the applicable intangible asset and the expected future cash flows to be derived from the intangible asset. Amortization of intangible assets with finite lives is recognized over the shorter of the respective lives of the agreement or the period of time the intangible assets are expected to contribute to future cash flows. We amortize our finite-lived intangible assets based on patterns on which the respective economic benefits are expected to be realized.

(a) Acquisitions in 2013

(i) Epocal

On February 1, 2013, we acquired Epocal, Inc., or Epocal, located in Ottawa, Canada, a provider of technologies that support blood gas and electrolyte testing at the point of care. The preliminary aggregate purchase price was approximately $248.5 million, which consisted of $173.5 million in cash and a contingent consideration obligation with an aggregate acquisition date fair value of $75.0 million. The operating results of Epocal are included in our professional diagnostics reporting unit and business segment. The amount allocated to goodwill from this acquisition is not deductible for tax purposes.

(ii) Mega Medika

On January 7, 2013, we acquired certain assets of PT Mega Medika Mandiri, or Mega Medika, located in South Jakarta, Indonesia, a distributor of infectious disease products to the Indonesian marketplace as well as materials for vaccines to a pharmaceutical customer. The preliminary aggregate purchase price was approximately $10.7 million, which consisted of $10.4 million in cash and a contingent consideration obligation with an aggregate acquisition date fair value of $0.3 million. Included in our Consolidated Statement of Operations for the three months ended March 31, 2013 is revenue totaling approximately $0.4 million related to Mega Medika. The operating results of Mega Medika are included in our professional diagnostics reporting unit and business segment. The amount allocated to goodwill from this acquisition is deductible for tax purposes.

A summary of the preliminary fair values of the net assets acquired for the acquisitions consummated in 2013 is as follows (in thousands):

	Epocal		Mega Medika		Total
Current assets(1)	$	11,935	$	1,142	$	13,077
Property, plant and equipment		1,267		229		1,496
Goodwill		99,519		655		100,174
Intangible assets		164,400		9,460		173,860
Other non-current assets		17,610		—		17,610
Total assets acquired		294,731		11,486		306,217
Current liabilities		2,543		549		3,092
Non-current liabilities		43,727		211		43,938
Total liabilities assumed		46,270		760		47,030
Net assets acquired		248,461		10,726		259,187
Less:
Contingent consideration		75,000		295		75,295
Cash paid	$	173,461	$	10,431	$	183,892

⁽¹⁾  Includes approximately $2.6 million of acquired cash.

The following are the intangible assets acquired and their respective fair values and weighted-average useful lives (dollars in thousands):

	Epocal		Mega Medika		Total		Weighted- average Useful Life
Core technology and patents	$	119,700	$	—	$	119,700		20.0 years
Trademarks and trade names		20,500		—		20,500		19.2 years
Customer relationships		—		9,460		9,460		21.0 years
In-process research and development		24,200		—		24,200		N/A
Total intangible assets	$	164,400	$	9,460	$	173,860

(b) Acquisitions in 2012

During 2012, we acquired the following businesses for a preliminary aggregate purchase price of $494.8 million, which included cash payments totaling $419.2 million and contingent consideration obligations with aggregate acquisition date fair values of $75.6 million.

• Reatrol Comercializacao De Produtos De Saude, LDA, subsequently renamed Alere Lda, located in Vila Nova de Gaia, Portugal, a distributor of products for drugs of abuse testing (Acquired January 2012)

• Kullgren Holding AB, or Kullgren, located in Gensta, Sweden, a company that manufactures and distributes high-quality intimacy and pharmaceutical products (Acquired February 2012)

9

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(unaudited)

• Wellogic ME FZ-LLC, or Wellogic UAE, located in Dubai, United Arab Emirates, a company that provides development services to Alere Wellogic, LLC, which acquired the assets of Method Factory, Inc. (d/b/a Wellogic), or Wellogic, in December 2011 (Acquired February 2012)

• certain assets, primarily including customer and patient lists, of AmMed Direct LLC, or AmMed, located near Nashville, Tennessee, a privately-owned mail-order provider of home-diabetes testing products and supplies (Acquired March 2012)

• eScreen, Inc., or eScreen, headquartered in Overland Park, Kansas, a technology-enabled provider of employment drug screening solutions for hiring and maintaining healthier and more efficient workforces (Acquired April 2012)

• MedApps Holding Company, Inc., or MedApps, headquartered in Scottsdale, Arizona, a developer of innovative remote health monitoring solutions that deliver efficient cost-effective connectivity between patient, care provider and electronic medical records (Acquired July 2012)

• Amedica Biotech, Inc., or Amedica, located in Hayward, California, a company focused on the development and manufacture of in vitro diagnostic tests (Acquired July 2012)

• DiagnosisOne, Inc., or DiagnosisOne, located in Lowell, Massachusetts, a software company that provides clinical analytics technology and data-driven content to hospitals, physician groups, insurers and governments (Acquired July 2012)

• Seelen Care Laege-og & Hospitalsartikler ApS, or Seelen, located in Holstebro, Denmark, a distributor of consumables, instruments and equipment to doctors, specialists and physiotherapists (Acquired August 2012)

• certain assets of Diagnostik Nord, or Diagnostik, located in Schwerin, Germany, a company focused on the sale of drug screening and in vitro diagnostic medical devices and a provider of diagnostic solutions (Acquired September 2012)

• Healthcare Connections Limited, or HCC, located in Buckinghamshire, United Kingdom, an occupational health provider specializing in employment medical programs, preventative health schemes and drug and alcohol sample collection services (Acquired November 2012)

• the diagnostic division of Medial spol. s.r.o., subsequently renamed Alere s.r.o., located in Prague, Czech Republic, a distributor of laboratory diagnostic devices, devices operating in the point-of-care testing regime, diagnostic kits and tests for biochemistry, hematology, and microbiology (Acquired November 2012)

• certain assets of Quantum Diagnostics, or Quantum Australia, located in Australia, an on-line medical supply company that provides a range of affordable drug and alcohol tests for personal, business and professional medical use (Acquired November 2012)

• certain assets of NationsHealth, Inc., or NationsHealth, headquartered in Sunrise, Florida, a privately-owned mail-order provider of diabetes home-testing products and supplies, and a share acquisition of NationsHealth’s subsidiary in the Philippines, or NationsHealth Philippines (Acquired December 2012)

• Branan Medical Corporation, or Branan, headquartered in Irvine, California, a manufacturer of drugs of abuse testing products (Acquired December 2012)

The operating results of Alere Lda, AmMed, eScreen, MedApps, Amedica, Seelen, Diagnostik, HCC, Alere s.r.o., Quantum Australia, NationsHealth and Branan are included in our professional diagnostics reporting unit and business segment. The operating results of Wellogic UAE and DiagnosisOne are included in our health information solutions reporting unit and business segment. The operating results of Kullgren are included in our consumer diagnostics reporting unit and business segment.

Our Consolidated Statement of Operations for the three months ended March 31, 2012 included revenue totaling approximately $1.4 million related to the businesses that were acquired during that period. Goodwill has been recognized in all of these acquisitions and amounted to approximately $259.2 million. Goodwill related to the acquisitions of AmMed, Diagnostik and the U.S.-based assets of NationsHealth, which totaled $8.8 million, is deductible for tax purposes. The goodwill related to the remaining 2012 acquisitions is not deductible for tax purposes.

10

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(unaudited)

A summary of the preliminary fair values of the net assets acquired for the acquisitions consummated in 2012 is as follows (in thousands):

Current assets(1)	$	46,041
Property, plant and equipment		9,029
Goodwill		259,231
Intangible assets		325,223
Other non-current assets		629
Total assets acquired		640,153
Current liabilities		28,802
Non-current liabilities		116,580
Total liabilities assumed		145,382
Net assets acquired		494,771
Less:
Contingent consideration		75,620
Cash paid	$	419,151

⁽¹⁾  Includes approximately $3.8 million of acquired cash.

The following are the intangible assets acquired and their respective fair values and weighted-average useful lives (dollars in thousands):

	Amount		Weighted- average Useful Life
Core technology and patents	$	148,103		18.7 years
Trademarks and trade names		19,390		18.3 years
Customer relationships		136,485		18.1 years
Non-competition agreements		1,118		5.1 years
Other		15,227		9.2 years
In-process research and development		4,900		N/A
Total intangible assets	$	325,223

(9) Restructuring Plans

The following table sets forth aggregate restructuring charges recorded in our Consolidated Statements of Operations for the three months ended March 31, 2013 and 2012 (in thousands):

	Three Months Ended March 31,
Statement of Operations Caption	2013		2012
Cost of net revenue	$	623	$	964
Research and development		—		624
Sales and marketing		1,099		827
General and administrative		2,170		3,113
Total operating expenses		3,892		5,528
Interest expense, including amortization of original issue discounts and deferred financing costs		55		60
Total charges	$	3,947	$	5,588

11

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(unaudited)

(a) 2013 Restructuring Plans

In 2013, management developed cost reduction efforts within our professional diagnostics and health information solutions business segments, including businesses in our Europe and Asia Pacific regions. The following table summarizes the restructuring activities related to our 2013 restructuring plans for the three months ended March 31, 2013 (in thousands):

	Professional Diagnostics		Health Information Solutions		Total
Severance-related costs	$	833	$	69	$	902
Facility and transition costs		13		—		13
Total charges	$	846	$	69	$	915

We anticipate incurring approximately $1.4 million in additional costs under our 2013 restructuring plans related primarily to our professional diagnostics business segment in Europe and may develop additional plans over the remainder of 2013. As of March 31, 2013, $0.1 million in severance costs arising under our 2013 restructuring plans remain unpaid.

(b) 2012 Restructuring Plans

In 2012, management developed cost reduction plans within our professional diagnostics business segment, including the integration of our business in Brazil, Europe and the United States. Additionally, management developed new plans to continue our efforts to reduce costs within our health information solutions business segment, including the termination of certain projects, which resulted in charges for the impairment of related fixed assets and intangibles. The following table summarizes the restructuring activities related to our 2012 restructuring plans for the three months ended March 31, 2013 and 2012 and since inception (in thousands):

	Three Months Ended March 31,					Since
Professional Diagnostics	2013			2012		Inception
Severance-related costs	$	62		$	1,973	$	4,794
Facility and transition costs		63			—		182
Cash charges		125			1,973		4,976
Fixed asset and inventory impairments		—			—		304
Total charges	$	125		$	1,973	$	5,280
	Three Months Ended March 31,					Since
Health Information Solutions	2013			2012		Inception
Severance-related costs	$	1,819		$	797	$	4,864
Facility and transition costs		659			—		1,893
Other exit costs		20			—		35
Cash charges		2,498			797		6,792
Fixed asset and inventory impairments		—			—		2,689
Intangible asset impairments		—			5		2,988
Other non-cash (recoveries)		(45	)		—		(76	)
Total charges	$	2,453		$	802	$	12,393

We anticipate incurring approximately $3.7 million in additional severance and facility costs under these plans related primarily to our health information solutions business segment through 2014. As of March 31, 2013, $3.8 million in severance and exit costs under these plans remain unpaid.

(b) 2011, 2010 and 2008 Restructuring Plans

In 2011, management executed a company-wide cost reduction plan, which impacted our corporate and other business segment, as well as the health information solutions and professional diagnostics business segments. Management also developed plans within our professional diagnostics business segment to consolidate operating activities among certain of our U.S., European and Asia Pacific subsidiaries, including transferring the manufacturing of our Panbio products from Australia to our Standard Diagnostics facility in South Korea and eliminating redundant costs among our newly acquired Axis-Shield subsidiaries. Additionally, within our health information solutions business segment, management executed plans to further reduce costs and improve efficiencies, as well as cease operations at our GeneCare Medical Genetics Center, Inc., or GeneCare, facility in Chapel Hill, North Carolina and transfer the majority of our Quality Assured Services, Inc. operation in Orlando, Florida to our facility in Livermore, California.

12

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(unaudited)

In 2010, management developed several plans to reduce costs and improve efficiencies within our health information solutions and professional diagnostics business segments. Additionally in 2008, management developed and initiated plans to transition the businesses of Cholestech to our San Diego, California facility.

The following table summarizes the restructuring activities related to our 2011, 2010 and 2008 restructuring plans for the three months ended March 31, 2013 and 2012 and since inception (in thousands):

	Three Months Ended March 31,					Since
Professional Diagnostics	2013		2012			Inception
Severance-related costs	$	250	$	1,965		$	19,963
Facility and transition costs		169		723			7,396
Other exit costs		16		19			714
Cash charges		435		2,707			28,073
Fixed asset and inventory impairments		—		134			6,374
Total charges	$	435	$	2,841		$	34,447
	Three Months Ended March 31,					Since
Health Information Solutions	2013		2012			Inception
Severance-related costs	$	—	$	—		$	6,901
Facility and transition costs (recoveries)		—		(86	)		8,010
Other exit costs		19		41			531
Cash charges (recoveries)		19		(45	)		15,442
Fixed asset and inventory impairments		—		—			1,114
Intangible asset impairments		—		—			2,935
Other non-cash charges		—		—			761
Total charges (recoveries)	$	19	$	(45	)	$	20,252
	Three Months Ended March 31,					Since
Corporate and Other	2013		2012			Inception
Severance-related costs	$	—	$	17		$	1,190
Cash charges		—		17			1,190
Fixed asset and inventory impairments		—		—			3
Total charges	$	—	$	17		$	1,193

We anticipate incurring approximately $1.6 million in additional costs under these plans related primarily to our professional diagnostics business segment. A majority of these additional costs relate to the transfer of the Panbio product manufacturing to Korea and are for severance and facility exit costs. We may also incur impairment charges on assets as plans are finalized. We do not anticipate incurring significant additional costs under these plans related to our health information solutions business segment. As of March 31, 2013, $2.6 million in cash charges remain unpaid, primarily related to facility lease obligations.

13

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(unaudited)

(e) Restructuring Reserves

The following table summarizes our restructuring reserves related to the plans described above, of which $5.4 million is included in accrued expenses and other current liabilities and $1.0 million is included in other long-term liabilities on our accompanying Consolidated Balance Sheets (in thousands):

	Severance- related Costs			Facility and Transition Costs			Other Exit Costs			Total
Balance, December 31, 2012	$	3,167		$	2,429		$	622		$	6,218
Cash charges		3,033			904			55			3,992
Payments		(2,923	)		(763	)		(72	)		(3,758	)
Currency adjustments		(4	)		—			—			(4	)
Balance, March 31, 2013	$	3,273		$	2,570		$	605		$	6,448

(10) Long-term Debt

We had the following long-term debt balances outstanding (in thousands):

	March 31, 2013			December 31, 2012
A term loans(1)(2)	$	866,875		$	878,438
B term loans(1)		911,125			913,438
Incremental B-1 term loans(1)		246,875			247,500
Incremental B-2 term loans(1)		196,314			196,739
Revolving line of credit(1)		192,500			22,500
7.25% Senior notes		450,000			450,000
7.875% Senior notes		—			1,809
9% Senior subordinated notes		393,383			392,933
8.625% Senior subordinated notes		400,000			400,000
3% Convertible senior subordinated notes		150,000			150,000
Other lines of credit		1,328			31,957
Other		32,652			3,593
		3,841,052			3,688,907
Less: Current portion		(52,210	)		(60,232	)
	$	3,788,842		$	3,628,675

⁽¹⁾  Incurred under our secured credit facility.

⁽²⁾  Includes “A” term loans and “Delayed Draw” term loans under our secured credit facility.

In connection with our significant long-term debt issuances, we recorded interest expense, including amortization and write-offs of deferred financing costs and original issue discounts, in our accompanying Consolidated Statements of Operations for the three months ended March 31, 2013 and 2012, respectively, as follows (in thousands):

	Three Months Ended March 31,
	2013			2012
Secured credit facility (1)	$	27,275		$	22,851
7.25% Senior notes		8,356			—
7.875% Senior notes		(27	)		5,758
9% Senior subordinated notes		10,394			10,354
8.625% Senior subordinated notes		9,273			9,274
3% Convertible senior subordinated notes		1,246			1,246
	$	56,517		$	49,483

⁽¹⁾  Includes “A” term loans, including the “Delayed-Draw” term loans; “B” term loans; “Incremental B-1” term loans; “Incremental B-2” term loans; and revolving line of credit loans. For the three months ended March 31, 2013 and 2012, the amounts include $1.0 million and $1.3 million, respectively, related to the amortization of fees paid for certain debt modifications.

14

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(unaudited)

The following summarizes the material terms of our secured credit facility that have changed significantly since December 31, 2012. All other terms of our secured credit facility as described in our Annual Report on Form 10-K, as amended, for the year ended December 31, 2012, but omitted below, have not changed since that date.

On March 22, 2013, we and certain of our subsidiaries entered into a fourth amendment to the credit agreement that governs our secured credit facility, or the credit agreement. The fourth amendment provides for 50 basis point reductions in the interest rate margins applicable to the “B” term loans, the “Incremental B-1” term loans and the “Incremental B-2” term loans and certain other changes. Under the terms of the credit agreement as amended by the fourth amendment, the “B” term loans, the “Incremental B-1” term loans and the “Incremental B-2” term loans bear interest at a rate per annum of, at our option, either (i) the Base Rate, as defined in the credit agreement, plus an applicable margin, which varies between 2.00% and 2.75% depending on our consolidated secured leverage ratio, or (ii) the Eurodollar Rate, as defined in the credit agreement, plus an applicable margin, which varies between 3.00% and 3.75% depending on our consolidated secured leverage ratio. Interest on “B” term loans, “Incremental B-1” term loans and “Incremental B-2” term loans based on the Eurodollar Rate is subject to a 1.00% floor with respect to the base Eurodollar Rate. Furthermore, under the terms of the credit agreement as amended by the fourth amendment, we may make optional prepayments of the term loans under our secured credit facility from time to time without any premium or penalty, except that if, on or before September 22, 2013, we repay or prepay any “B” term loans, “Incremental B-1” term loans or “Incremental B-2” term loans with the proceeds of, or convert any “B” term loans, “Incremental B-1” term loans or “Incremental B-2” term loans into, any new term loans bearing interest with an effective yield (as defined in the credit agreement) less than the effective yield applicable to the “B” term loans, the “Incremental B-1” term loans or the “Incremental B-2” term loans, as applicable, we must pay a premium equal to 1.0% of the principal amount of the “B” term loans, “Incremental B-1” term loans or “Incremental B-2” term loans so repaid, prepaid or converted.

(11) Derivative Financial Instruments

We may manage our economic and transaction exposure to certain market-based risks through the use of derivative instruments. Our objective for holding derivative instruments has been to reduce volatility of net earnings and cash flows associated with changes in interest rates and foreign currency exchange rates. We do not hold or issue derivative financial instruments for speculative purposes.

(a) Foreign Currency Risk

In connection with our acquisition of Axis-Shield, we acquired a number of foreign currency forward contracts. The specific risk hedged in these contracts was the undiscounted foreign currency spot rate risk on forecasted foreign currency revenue. As of December 31, 2012, all of the acquired foreign currency forward contracts were settled. We report the effective portion of the gain or loss on a cash flow hedge as a component of other comprehensive income, and it was subsequently reclassified into net earnings in the period in which the hedged transaction affected net earnings or the forecasted transaction was no longer probable of occurring.

The following table summarize the effect of derivative instruments in our accompanying Consolidated Statement of Operations (in thousands):

Derivative Instruments	Location of Gain Recognized in Income	Amount of Gain Recognized During the Three Months Ended March 31, 2012
Foreign currency forward contracts	Other comprehensive income (loss)	$	1,107
Total gain	Other comprehensive income (loss)	$	1,107

(12) Fair Value Measurements

We apply fair value measurement accounting to value our financial assets and liabilities. Fair value measurement accounting provides a framework for measuring fair value under U.S. GAAP and requires expanded disclosures regarding fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value.

15

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(unaudited)

Described below are the three levels of inputs that may be used to measure fair value:

Level 1—Quoted prices in active markets for identical assets or liabilities.

Level 2—Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2013 and December 31, 2012, and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value (in thousands):

Description	March 31,  2013		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Unobservable Inputs (Level 3)
Assets:
Marketable securities	$	884	$	884	$	—	$	—
Total assets	$	884	$	884	$	—	$	—
Liabilities:
Contingent consideration obligations (1)	$	240,604	$	—	$	—	$	240,604
Total liabilities	$	240,604	$	—	$	—	$	240,604
Description	December 31, 2012		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Unobservable Inputs (Level 3)
Assets:
Marketable securities	$	904	$	904	$	—	$	—
Total assets	$	904	$	904	$	—	$	—
Liabilities:
Contingent consideration obligations (1)	$	176,172	$	—	$	—	$	176,172
Total liabilities	$	176,172	$	—	$	—	$	176,172

⁽¹⁾  We determine the fair value of the contingent consideration obligations based on a probability-weighted approach derived from earn-out criteria estimates and a probability assessment with respect to the likelihood of achieving the various earn-out criteria. The measurement is based upon significant inputs not observable in the market. Significant increases or decreases in any of these inputs could result in a significantly higher or lower fair value measurement. Changes in the fair value of these contingent consideration obligations are recorded as income or expense within operating income in our Consolidated Statements of Operations.

Changes in the fair value of our Level 3 contingent consideration obligations during the three months ended March 31, 2013 were as follows (in thousands):

Fair value of contingent consideration obligations, January 1, 2013	$	176,172
Acquisition date fair value of contingent consideration obligations recorded		75,295
Foreign currency		(557	)
Payments		(21,323	)
Present value accretion		3,474
Adjustments, net (income) expense		7,543
Fair value of contingent consideration obligations, March 31, 2013	$	240,604

16

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(unaudited)

At March 31, 2013 and December 31, 2012, the carrying amounts of cash and cash equivalents, restricted cash, receivables, accounts payable and other current liabilities approximated their estimated fair values.

The carrying amount and estimated fair value of our long-term debt were $3.8 billion and $3.9 billion, respectively, at March 31, 2013. The carrying amount and estimated fair value of our long-term debt were $3.7 billion at December 31, 2012. The estimated fair value of our long-term debt was determined using market sources that were derived from available market information (Level 2 in the fair value hierarchy) and may not be representative of actual values that could have been or will be realized in the future.

(13) Defined Benefit Pension Plan

Our subsidiary in England, Unipath Ltd., has a defined benefit pension plan established for certain of its employees. The net periodic benefit costs are as follows (in thousands):

	Three Months Ended March 31,
	2013			2012
Service cost	$	—		$	—
Interest cost		182			198
Expected return on plan assets		(156	)		(152	)
Amortization of prior service cost		103			104
Realized losses		—			—
Net periodic benefit cost	$	129		$	150

(14) Financial Information by Segment

Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision-making group is composed of the chief executive officer and members of senior management. Our reportable operating segments are professional diagnostics, health information solutions, consumer diagnostics and corporate and other. Our operating results include license and royalty revenue which are allocated to professional diagnostics and consumer diagnostics on the basis of the original license or royalty agreement.

We evaluate performance of our operating segments based on revenue and operating income (loss). Segment information for the three months ended March 31, 2013 and 2012 is as follows (in thousands):

	Professional Diagnostics		Health Information Solutions			Consumer Diagnostics		Corporate and Other			Total
Three Months Ended March 31, 2013:
Net revenue	$	582,492	$	134,207		$	22,550	$	—		$	739,249
Operating income (loss)	$	59,840	$	(13,893	)	$	2,280	$	(17,738	)	$	30,489
Depreciation and amortization	$	82,794	$	20,737		$	1,153	$	286		$	104,970
Non-cash charge associated with acquired inventory	$	461	$	—		$	—	$	—		$	461
Restructuring charge	$	1,389	$	2,503		$	—	$	—		$	3,892
Stock-based compensation	$	—	$	—		$	—	$	4,123		$	4,123
Three Months Ended March 31, 2012:
Net revenue	$	518,357	$	130,784		$	21,988	$	—		$	671,129
Operating income (loss)	$	70,179	$	(19,356	)	$	365	$	(16,130	)	$	35,058
Depreciation and amortization	$	77,467	$	23,774		$	1,259	$	221		$	102,721
Non-cash charge associated with acquired inventory	$	4,681	$	—		$	—	$	—		$	4,681
Restructuring charge	$	4,794	$	717		$	—	$	17		$	5,528
Stock-based compensation	$	—	$	—		$	—	$	3,874		$	3,874
Assets:
As of March 31, 2013	$	6,414,701	$	608,161		$	175,285	$	50,328		$	7,248,475
As of December 31, 2012	$	6,214,847	$	593,172		$	192,748	$	67,161		$	7,067,928

17

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(unaudited)

The following tables summarize our net revenue from the professional diagnostics and health information solutions reporting segments by groups of similar products and services for the three months ended March 31, 2013 and 2012 (in thousands):

	Three Months Ended March 31,
Professional Diagnostics Segment	2013		2012
Cardiology	$	114,933	$	138,826
Infectious disease		189,844		151,016
Toxicology		149,049		121,740
Diabetes		50,083		28,161
Other		74,719		75,706
Net product sales and services revenue		578,628		515,449
License and royalty revenue		3,864		2,908
Professional diagnostics net revenue	$	582,492	$	518,357
	Three Months Ended March 31,
Health Information Solutions Segment	2013		2012
Disease and case management	$	54,126	$	53,380
Wellness		26,300		27,026
Women’s & children’s health		29,080		29,771
Patient self-testing services		24,701		20,607
Health information solutions net revenue	$	134,207	$	130,784

(15) Related Party Transactions

In May 2007, we completed the formation of SPD, our 50/50 joint venture with P&G, for the development, manufacturing, marketing and sale of existing and to-be-developed consumer diagnostic products, outside the cardiology, diabetes and oral care fields. Upon completion of the arrangement to form the joint venture, we ceased to consolidate the operating results of our consumer diagnostic products business related to the joint venture and instead account for our 50% interest in the results of the joint venture under the equity method of accounting.

We had a net receivable from the joint venture of $0.6 million and $2.3 million as of March 31, 2013 and December 31, 2012, respectively. Included in the $0.6 million receivable balance as of March 31, 2013 is approximately $1.5 million of costs incurred in connection with our 2008 SPD-related restructuring plans. Included in the $2.3 million receivable balance as of December 31, 2012 is approximately $1.6 million of costs incurred in connection with our 2008 SPD-related restructuring plans. We have also recorded a long-term receivable totaling approximately $13.7 million and $14.6 million as of March 31, 2013 and December 31, 2012, respectively, related to the 2008 SPD-related restructuring plans. Additionally, customer receivables associated with revenue earned after the joint venture was completed have been classified as other receivables within prepaid and other current assets on our accompanying Consolidated Balance Sheets in the amount of $8.9 million and $6.9 million as of March 31, 2013 and December 31, 2012, respectively. In connection with the joint venture arrangement, the joint venture bears the collection risk associated with these receivables. Sales to the joint venture under our manufacturing agreement totaled $17.1 million during each of the three-month periods ended March 31, 2013 and 2012. Additionally, services revenue generated pursuant to the long-term services agreement with the joint venture totaled $0.3 million during each of the three-month periods ended March 31, 2013 and 2012. Sales under our manufacturing agreement and long-term services agreement are included in net product sales and services revenue, respectively, in our accompanying Consolidated Statements of Operations.

18

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(unaudited)

Under the terms of our product supply agreement, the joint venture purchases products from our manufacturing facilities in the U.K. and China. The joint venture in turn sells a portion of those tests back to us for final assembly and packaging. Once packaged, the tests are sold to P&G for distribution to third-party customers in North America. As a result of these related transactions, we have recorded $8.7 million and $7.3 million of trade receivables which are included in accounts receivable on our accompanying Consolidated Balance Sheets as of March 31, 2013 and December 31, 2012, respectively, and $15.7 million and $21.3 million of trade accounts payable which are included in accounts payable on our accompanying Consolidated Balance Sheets as of March 31, 2013 and December 31, 2012, respectively. During the three months ended March 31, 2013 and 2012, we received $10.8 million and $6.1 million, respectively, in cash from SPD as a return of capital.

The following table summarizes our related party balances with SPD within our Consolidated Balance Sheets (in thousands):

Balance Sheet Caption	March 31, 2013		December 31, 2012
Accounts receivable, net of allowances	$	8,667	$	7,317
Prepaid expenses and other current assets	$	9,425	$	9,161
Deferred financing costs, net, and other non-current assets	$	13,665	$	14,629
Accounts payable	$	15,676	$	21,258

(16) Other Arrangements

On February 19, 2013, we entered into an agreement with the Bill and Melinda Gates Foundation, or the Gates Foundation, whereby we were awarded a grant by the Gates Foundation in the amount of $21.6 million to support the development and commercialization of a validated, low-cost, nucleic-acid assay for clinical Tuberculosis, or TB, detection and drug-resistance test cartridges and adaptation of an analyzer platform capable of operation in rudimentary laboratories in low-resource settings. In connection with this agreement, we also entered into a loan agreement with the Gates Foundation, or the Gates Loan Agreement, which provides for the making of subordinated term loans by the Gates Foundation to us from time to time, subject to the achievement of certain milestones, in an aggregate principal amount of up to $20.6 million. Funding under the Gates Loan Agreement will be used in connection with the purchase of equipment for an automated high-throughput manufacturing line and other uses as necessary for the manufacture of the TB and HIV-related products. All loans under the Gates Loan Agreement are evidenced by promissory notes that we have executed and delivered to the Gates Foundation, bear interest at the rate of 3% per annum and, except to the extent earlier repaid by us, mature and are required to be repaid in full on December 31, 2019. As of March 31, 2013, we had borrowed no amounts under the Gates Loan Agreement. As of March 31, 2013, we had received approximately $7.9 million in grant-related funding from the Gates Foundation, which was recorded as restricted cash and deferred grant funding. The deferred grant funding is classified within accrued expenses and other current liabilities on our accompanying consolidated balance sheet. As qualified expenditures are incurred under the terms of the grant, we use the deferred funding to recognize a reduction of our related qualified research and development expenditures. For the three months ended March 31, 2013, we recognized $0.5 million of qualified expenditures, which was recorded as an offset to our research and development expenses.

(17) Material Contingencies

(a) Acquisition-related Contingent Consideration Obligations

The following summarizes our principal contractual acquisition-related contingent consideration obligations as of March 31, 2013 that have changed significantly since December 31, 2012. Other acquisition-related contingent consideration obligations that were presented in our Annual Report on Form 10-K, as amended, for the year ended December 31, 2012, but which are omitted below, represent those that have not changed significantly since that date.

• Accordant

With respect to Accordant, the terms of the acquisition agreement require us to pay an earn-out upon successfully meeting certain revenue and cash collection targets starting after the second anniversary of the acquisition date and completed prior to the third anniversary of the acquisition date. An earn-out totaling $4.5 million was earned and accrued as of December 31, 2012. A payment of $1.5 million was made during the first quarter of 2013 and the remaining payments will be made in quarterly installments of $1.5 million during the second and third quarter of 2013.

• Branan

With respect to Branan, the terms of the acquisition agreement require us to pay earn-outs upon successfully achieving various regulatory product approval milestones by the second anniversary of the acquisition date. Four milestones were achieved during 2012, resulting in an accrual totaling approximately $2.0 million as of December 31, 2012. During the first quarter of 2013, two additional milestones were achieved, resulting in an incremental accrual of $1.0 million. Payment of these earn-outs was made during the first quarter of 2013. The maximum remaining amount of the earn-out payments is $2.0 million.

• Epocal

With respect to Epocal, the terms of the acquisition agreement require us to pay earn-outs and management incentive payments upon successfully meeting certain product development and United States Food and Drug Administration regulatory approval milestones from the date of acquisition through December 31, 2018. The maximum amount of the earn-out payments is $90.5 million, of which $15.0 million was paid at the acquisition closing date. The maximum amount of the management incentive payments is $9.4 million.

• ROAR

With respect to Forensics Limited, or ROAR, the terms of the acquisition agreement require us to pay an earn-out upon successfully meeting certain EBITDA targets during 2012 through 2014. Payment of the 2012 earn-out totaling approximately £1.0 million (approximately $1.5 million), which was previously accrued, was made during the first quarter of 2013. The maximum remaining amount of the earn-out payments is £9.5 million (approximately $14.4 million at March 31, 2013).

(18) Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position, results of operations, comprehensive income or cash flows upon adoption.

Recently Adopted Standards

Effective January 1, 2013, we adopted ASU No. 2012-02, Intangibles —   Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment, or ASU 2012-02. ASU 2012-02 allows an entity the option to first assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that the indefinite-lived intangible asset is impaired. If an entity concludes that it is not more likely than not that the indefinite-lived intangible asset is impaired, then the entity is not required to take further action. However, if an entity concludes otherwise, then it is required to determine the fair value of the indefinite-lived intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying amount. An entity also has the option to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to performing the quantitative impairment test. An entity will be able to resume performing the qualitative assessment in any subsequent period. The adoption of this standard is not expected to have an impact on our financial position, results of operations, comprehensive income or cash flows.

(19) Equity Investments

We account for the results from our equity investments under the equity method of accounting in accordance with ASC 323, Investments — Equity Method and Joint Ventures, based on the percentage of our ownership interest in the business. Our equity investments primarily include the following:

(a) SPD

In May 2007, we completed the formation of SPD, our 50/50 joint venture with P&G for the development, manufacturing, marketing and sale of existing and to-be-developed consumer diagnostic products, outside the cardiology, diabetes and oral care fields. Upon completion of the arrangement to form SPD, we ceased to consolidate the operating results of our consumer diagnostics business related to SPD. For the three months ended March 31, 2013 and 2012, we recorded earnings of $2.5 million and $2.8 million, respectively, in equity earnings of unconsolidated entities, net of tax, in our accompanying Consolidated Statements of Operations, which represented our 50% share of SPD’s net income for the respective periods.

(b) TechLab

In May 2006, we acquired 49% of TechLab, Inc., or TechLab, a privately-held developer, manufacturer and distributor of rapid non-invasive intestinal diagnostics tests in the areas of intestinal inflammation, antibiotic-associated diarrhea and parasitology. For the three months ended March 31, 2013 and 2012, we recorded earnings of $0.2 million and $0.7 million, respectively, in equity earnings of unconsolidated entities, net of tax, in our accompanying Consolidated Statements of Operations, which represented our minority share of TechLab’s net income for the respective periods.

19

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(unaudited)

Summarized financial information for SPD and TechLab on a combined basis is as follows (in thousands):

	Three Months Ended March 31,
Combined Condensed Results of Operations:	2013		2012
Net revenue	$	49,155	$	52,525
Gross profit	$	37,113	$	35,179
Net income after taxes	$	5,577	$	6,993
Combined Condensed Balance Sheet:	March 31, 2013		December 31, 2012
Current assets	$	65,835	$	79,842
Non-current assets		37,603		38,991
Total assets	$	103,438	$	118,833
Current liabilities	$	32,950	$	45,084
Non-current liabilities		6,986		6,791
Total liabilities	$	39,936	$	51,875

(20) Guarantor Financial Information

Our 7.25% senior notes due 2018, our 9% senior subordinated notes due 2016, and our 8.625% senior subordinated notes due 2018 are guaranteed by certain of our consolidated wholly owned subsidiaries, or the Guarantor Subsidiaries. The guarantees are full and unconditional and joint and several. The following supplemental financial information sets forth, on a consolidating basis, balance sheets as of March 31, 2013 and December 31, 2012, the related statements of operations, statements of comprehensive income (loss) and cash flows for each of the three months ended March 31, 2013 and 2012, for Alere Inc., the Guarantor Subsidiaries and our other subsidiaries, or the Non-Guarantor Subsidiaries. The supplemental financial information reflects the investments of Alere Inc. and the Guarantor Subsidiaries in the Guarantor and Non-Guarantor Subsidiaries using the equity method of accounting.

We have extensive transactions and relationships between various members of the consolidated group. These transactions and relationships include intercompany pricing agreements, intellectual property royalty agreements and general and administrative and research and development cost-sharing agreements. Because of these relationships, it is possible that the terms of these transactions are not the same as those that would result from transactions among wholly unrelated parties.

For comparative purposes, certain amounts for prior periods have been reclassified to conform to the current period classification.

20

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(unaudited)

CONSOLIDATING STATEMENT OF OPERATIONS

For the Three Months Ended March 31, 2013

(in thousands)

	Issuer			Guarantor Subsidiaries			Non- Guarantor Subsidiaries			Eliminations			Consolidated
Net product sales	$	—		$	233,493		$	320,897		$	(46,114	)	$	508,276
Services revenue		—			206,171			20,738			—			226,909
Net product sales and services revenue		—			439,664			341,635			(46,114	)		735,185
License and royalty revenue		—			3,035			3,533			(2,504	)		4,064
Net revenue		—			442,699			345,168			(48,618	)		739,249
Cost of net product sales		948			120,594			173,216			(41,680	)		253,078
Cost of services revenue		—			115,611			8,502			(3,955	)		120,158
Cost of net product sales and services revenue		948			236,205			181,718			(45,635	)		373,236
Cost of license and royalty revenue		—			17			4,243			(2,504	)		1,756
Cost of net revenue		948			236,222			185,961			(48,139	)		374,992
Gross profit (loss)		(948	)		206,477			159,207			(479	)		364,257
Operating expenses:
Research and development		4,423			17,380			19,651			—			41,454
Sales and marketing		1,392			82,838			72,226			—			156,456
General and administrative		14,027			64,983			56,848			—			135,858
Total operating expenses		19,842			165,201			148,725			—			333,768
Operating income (loss)		(20,790	)		41,276			10,482			(479	)		30,489
Interest expense, including amortization of original issue discounts and deferred financing costs		(56,858	)		(7,021	)		(3,417	)		9,897			(57,399	)
Other income (expense), net		4,770			6,259			(1,603	)		(9,896	)		(470	)
Income (loss) before provision (benefit) for income taxes		(72,878	)		40,514			5,462			(478	)		(27,380	)
Provision (benefit) for income taxes		(62,811	)		17,926			8,127			(113	)		(36,871	)
Income (loss) before equity earnings of unconsolidated entities, net of tax		(10,067	)		22,588			(2,665	)		(365	)		9,491
Equity in earnings (losses) of subsidiaries, net of tax		22,244			(614	)		—			(21,630	)		—
Equity earnings of unconsolidated entities, net of tax		248			—			2,688			(2	)		2,934
Net income		12,425			21,974			23			(21,997	)		12,425
Less: Net loss attributable to non-controlling interests		—			—			(25	)		—			(25	)
Net income attributable to Alere Inc. and Subsidiaries		12,425			21,974			48			(21,997	)		12,450
Preferred stock dividends		(5,250	)		—			—			—			(5,250	)
Net income available to common stockholders	$	7,175		$	21,974		$	48		$	(21,997	)	$	7,200

21

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(unaudited)

CONSOLIDATING STATEMENT OF OPERATIONS

For the Three Months Ended March 31, 2012

(in thousands)

	Issuer			Guarantor Subsidiaries			Non- Guarantor Subsidiaries			Eliminations			Consolidated
Net product sales	$	—		$	223,417		$	285,599		$	(33,229	)	$	475,787
Services revenue		—			176,715			15,719			—			192,434
Net product sales and services revenue		—			400,132			301,318			(33,229	)		668,221
License and royalty revenue		—			4,304			2,546			(3,942	)		2,908
Net revenue		—			404,436			303,864			(37,171	)		671,129
Cost of net product sales		850			106,202			151,598			(33,096	)		225,554
Cost of services revenue		—			83,643			7,217			—			90,860
Cost of net product sales and services revenue		850			189,845			158,815			(33,096	)		316,414
Cost of license and royalty revenue		—			5			5,581			(3,942	)		1,644
Cost of net revenue		850			189,850			164,396			(37,038	)		318,058
Gross profit (loss)		(850	)		214,586			139,468			(133	)		353,071
Operating expenses:
Research and development		5,196			17,482			16,322			—			39,000
Sales and marketing		1,057			86,337			71,184			—			158,578
General and administrative		11,631			64,644			44,160			—			120,435
Total operating expenses		17,884			168,463			131,666			—			318,013
Operating income (loss)		(18,734	)		46,123			7,802			(133	)		35,058
Interest expense, including amortization of original issue discounts and deferred financing costs		(49,716	)		(11,067	)		(3,254	)		13,310			(50,727	)
Other income (expense), net		(8,074	)		9,428			23,787			(13,310	)		11,831
Income (loss) before provision (benefit) for income taxes		(76,524	)		44,484			28,335			(133	)		(3,838	)
Provision (benefit) for income taxes		(26,998	)		16,782			8,690			71			(1,455	)
Income (loss) before equity earnings of unconsolidated entities, net of tax		(49,526	)		27,702			19,645			(204	)		(2,383	)
Equity in earnings (losses) of subsidiaries, net of tax		49,895			(348	)		—			(49,547	)		—
Equity earnings of unconsolidated entities, net of tax		660			—			2,736			16			3,412
Net income		1,029			27,354			22,381			(49,735	)		1,029
Less: Net loss attributable to non-controlling interests		—			—			(185	)		—			(185	)
Net income attributable to Alere Inc. and Subsidiaries		1,029			27,354			22,566			(49,735	)		1,214
Preferred stock dividends		(5,309	)		—			—			—			(5,309	)
Net income (loss) available to common stockholders	$	(4,280	)	$	27,354		$	22,566		$	(49,735	)	$	(4,095	)

22

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(unaudited)

CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS)

For the Three Months Ended March 31, 2013

(in thousands)

	Issuer			Guarantor Subsidiaries		Non-Guarantor Subsidiaries			Eliminations			Consolidated
Net income	$	12,425		$	21,974	$	23		$	(21,997	)	$	12,425
Other comprehensive loss, before tax:
Changes in cumulative translation adjustment		(201	)		—		(75,154	)		—			(75,355	)
Unrealized gains on hedging instruments		—			—		11			—			11
Minimum pension liability adjustment		—			—		605			—			605
Other comprehensive loss, before tax		(201	)		—		(74,538	)		—			(74,739	)
Income tax provision (benefit) related to items of other comprehensive loss		—			—		—			—			—
Other comprehensive loss, net of tax		(201	)		—		(74,538	)		—			(74,739	)
Comprehensive income (loss)		12,224			21,974		(74,515	)		(21,997	)		(62,314	)
Less: Comprehensive loss attributable to non-controlling interests		—			—		(25	)		—			(25	)
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	$	12,224		$	21,974	$	(74,490	)	$	(21,997	)	$	(62,289	)

23

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(unaudited)

CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

For the Three Months Ended March 31, 2012

(in thousands)

	Issuer		Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations			Consolidated
Net income	$	1,029	$	27,354		$	22,381		$	(49,735	)	$	1,029
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment		329		(306	)		35,251			665			35,939
Unrealized gains on available for sale securities		429		2			—			—			431
Unrealized gains on hedging instruments		17		—			1,090			—			1,107
Minimum pension liability adjustment		—		—			(165	)		—			(165	)
Other comprehensive income (loss), before tax		775		(304	)		36,176			665			37,312
Income tax benefit related to items of other comprehensive income		—		—			(41	)		—			(41	)
Other comprehensive income (loss), net of tax		775		(304	)		36,217			665			37,353
Comprehensive income		1,804		27,050			58,598			(49,070	)		38,382
Less: Comprehensive loss attributable to non-controlling interests		—		—			(185	)		—			(185	)
Comprehensive income attributable to Alere Inc. and Subsidiaries	$	1,804	$	27,050		$	58,783		$	(49,070	)	$	38,567

24

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(unaudited)

CONSOLIDATING BALANCE SHEET

March 31, 2013

(in thousands)

	Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations			Consolidated
ASSETS
Current assets:
Cash and cash equivalents	$	8,626		$	52,407		$	266,200		$	—		$	327,233
Restricted cash		7,933			2,309			1,407			—			11,649
Marketable securities		—			771			113			—			884
Accounts receivable, net of allowances		—			242,772			297,321			—			540,093
Inventories, net		—			147,580			209,509			(20,647	)		336,442
Deferred tax assets		32,145			37,079			11,367			2,939			83,530
Prepaid expenses and other current assets		453,291			(315,140	)		29,231			(36	)		167,346
Intercompany receivables		312,349			603,711			64,077			(980,137	)		—
Total current assets		814,344			771,489			879,225			(997,881	)		1,467,177
Property, plant and equipment, net		2,387			290,253			236,980			(456	)		529,164
Goodwill		—			1,820,992			1,295,865			—			3,116,857
Other intangible assets with indefinite lives		—			13,900			44,493			—			58,393
Finite-lived intangible assets, net		10,927			1,092,551			771,158			—			1,874,636
Deferred financing costs, net and other non-current assets		69,133			10,357			19,881			(71	)		99,300
Investments in subsidiaries		4,345,418			353,666			(67,215	)		(4,631,869	)		—
Investments in unconsolidated entities		34,384			—			48,363			11,548			94,295
Deferred tax assets		—			—			8,653			—			8,653
Intercompany notes receivable		1,672,676			752,565			64,766			(2,490,007	)		—
Total assets	$	6,949,269		$	5,105,773		$	3,302,169		$	(8,108,736	)	$	7,248,475
LIABILITIES AND EQUITY
Current liabilities:
Current portion of long-term debt	$	45,000		$	985		$	6,225		$	—		$	52,210
Current portion of capital lease obligations		—			3,207			2,939			—			6,146
Accounts payable		7,390			67,623			90,999			—			166,012
Accrued expenses and other current liabilities		84,912			199,618			186,418			(29	)		470,919
Intercompany payables		584,562			133,102			262,472			(980,136	)		—
Total current liabilities		721,864			404,535			549,053			(980,165	)		695,287
Long-term liabilities:
Long-term debt, net of current portion		3,770,784			299			17,759			—			3,788,842
Capital lease obligations, net of current portion		—			4,845			6,770			—			11,615
Deferred tax liabilities		(15,907	)		319,914			111,497			(52	)		415,452
Other long-term liabilities		18,099			69,963			124,385			(71	)		212,376
Intercompany notes payables		331,783			1,602,374			555,850			(2,490,007	)		—
Total long-term liabilities		4,104,759			1,997,395			816,261			(2,490,130	)		4,428,285
Stockholders’ equity		2,122,646			2,703,843			1,934,598			(4,638,441	)		2,122,646
Non-controlling interests		—			—			2,257			—			2,257
Total equity		2,122,646			2,703,843			1,936,855			(4,638,441	)		2,124,903
Total liabilities and equity	$	6,949,269		$	5,105,773		$	3,302,169		$	(8,108,736	)	$	7,248,475

25

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(unaudited)

CONSOLIDATING BALANCE SHEET

December 31, 2012

(in thousands)

	Issuer			Guarantor Subsidiaries		Non-Guarantor Subsidiaries			Eliminations			Consolidated
ASSETS
Current assets:
Cash and cash equivalents	$	3,623		$	67,449	$	257,274		$	—		$	328,346
Restricted cash		—			1,680		1,396			—			3,076
Marketable securities		—			787		117			—			904
Accounts receivable, net of allowances		—			241,050		283,282			—			524,332
Inventories, net		—			142,413		203,230			(8,522	)		337,121
Deferred tax assets		12,193			39,601		13,138			2,790			67,722
Prepaid expenses and other current assets		(20,636	)		99,271		66,634			(33	)		145,236
Intercompany receivables		298,812			1,254,727		55,847			(1,609,386	)		—
Total current assets		293,992			1,846,978		880,918			(1,615,151	)		1,406,737
Property, plant and equipment, net		2,679			293,260		239,082			(552	)		534,469
Goodwill		—			1,820,438		1,227,967			—			3,048,405
Other intangible assets with indefinite lives		—			14,600		21,851			—			36,451
Finite-lived intangible assets, net		24,701			1,132,656		676,868			—			1,834,225
Deferred financing costs, net and other non-current assets		78,522			10,341		20,065			(71	)		108,857
Investments in subsidiaries		4,114,478			358,088		(67,799	)		(4,404,767	)		—
Investments in unconsolidated entities		33,979			—		56,512			—			90,491
Deferred tax assets		—			782		7,511			—			8,293
Intercompany notes receivable		1,724,650			722,552		1,278			(2,448,480	)		—
Total assets	$	6,273,001		$	6,199,695	$	3,064,253		$	(8,469,021	)	$	7,067,928
LIABILITIES AND EQUITY
Current liabilities:
Current portion of long-term debt	$	45,000		$	349	$	14,883		$	—		$	60,232
Current portion of capital lease obligations		—			3,209		3,475			—			6,684
Accounts payable		7,993			76,256		85,725			—			169,974
Accrued expenses and other current liabilities		(388,830	)		586,116		214,659			(26	)		411,919
Intercompany payables		557,578			806,507		245,300			(1,609,385	)		—
Total current liabilities		221,741			1,472,437		564,042			(1,609,411	)		648,809
Long-term liabilities:
Long-term debt, net of current portion		3,617,068			374		11,233			—			3,628,675
Capital lease obligations, net of current portion		—			5,412		7,505			—			12,917
Deferred tax liabilities		(5,329	)		333,388		100,216			(87	)		428,188
Other long-term liabilities		17,678			72,890		76,138			(71	)		166,635
Intercompany notes payables		241,421			1,630,376		576,684			(2,448,481	)		—
Total long-term liabilities		3,870,838			2,042,440		771,776			(2,448,639	)		4,236,415
Stockholders’ equity		2,180,422			2,684,818		1,726,153			(4,410,971	)		2,180,422
Non-controlling interests		—			—		2,282			—			2,282
Total equity		2,180,422			2,684,818		1,728,435			(4,410,971	)		2,182,704
Total liabilities and equity	$	6,273,001		$	6,199,695	$	3,064,253		$	(8,469,021	)	$	7,067,928

26

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(unaudited)

CONSOLIDATING STATEMENT OF CASH FLOWS

For the Three Months Ended March 31, 2013

(in thousands)

	Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations			Consolidated
Cash Flows from Operating Activities:
Net income	$	12,425		$	21,974		$	23		$	(21,997	)	$	12,425
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Equity in earnings (losses) of subsidiaries, net of tax		(22,244	)		614			—			21,630			—
Non-cash interest expense, including amortization of original issue discounts and write-off of deferred financing costs		5,153			55			9			—			5,217
Depreciation and amortization		1,287			61,956			41,756			(29	)		104,970
Non-cash charges for sale of inventories revalued at the date of acquisition		—			—			461			—			461
Non-cash stock-based compensation expense		1,660			1,096			1,367			—			4,123
(Gain) loss on sale of fixed assets		—			227			(55	)		—			172
Equity earnings of unconsolidated entities, net of tax		(248	)		—			(2,688	)		2			(2,934	)
Deferred income taxes		(30,889	)		(10,300	)		(9,605	)		(113	)		(50,907	)
Other non-cash items		(762	)		275			2,428			—			1,941
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net		—			(1,722	)		(18,445	)		—			(20,167	)
Inventories, net		—			(10,475	)		(7,271	)		575			(17,171	)
Prepaid expenses and other current assets		(473,927	)		413,773			35,134			19,187			(5,833	)
Accounts payable		(604	)		(7,960	)		6,576			—			(1,988	)
Accrued expenses and other current liabilities		478,082			(387,332	)		(31,606	)		(19,187	)		39,957
Other non-current liabilities		(126	)		(2,946	)		3,867			—			795
Intercompany payable (receivable)		63,473			(80,252	)		16,779			—			—
Net cash provided by (used in) operating activities		33,280			(1,017	)		38,730			68			71,061
Cash Flows from Investing Activities:
Increase in restricted cash		(7,933	)		(630	)		(10	)		—			(8,573	)
Purchases of property, plant and equipment		(37	)		(14,354	)		(26,736	)		5,022			(36,105	)
Proceeds from sale of property, plant and equipment		—			2,106			4,085			(5,048	)		1,143
Cash paid for acquisitions, net of cash acquired		(151,372	)		—			(7,049	)		—			(158,421	)
Cash received from equity method investments		—			—			10,771			—			10,771
Increase in other assets		(3,210	)		(928	)		(1,431	)		—			(5,569	)
Net cash used in investing activities		(162,552	)		(13,806	)		(20,370	)		(26	)		(196,754	)
Cash Flows from Financing Activities:
Cash paid for financing costs		(1,427	)		—			—			—			(1,427	)
Cash paid for contingent purchase price consideration		(19,098	)		—			—			—			(19,098	)
Proceeds from issuance of common stock, net of issuance costs		6,135			—			—			—			6,135
Proceeds from issuance of long-term debt		—			1,007			9,046			—			10,053
Payments on long-term debt		(16,845	)		(445	)		(2,348	)		—			(19,638	)
Net proceeds (payments) under revolving credit facilities		170,000			—			(7,517	)		—			162,483
Cash paid for dividends		(5,323	)		—			—			—			(5,323	)
Excess tax benefits on exercised stock options		71			17			16			—			104
Principal payments on capital lease obligations		—			(814	)		(907	)		—			(1,721	)
Net cash provided by (used in) financing activities		133,513			(235	)		(1,710	)		—			131,568
Foreign exchange effect on cash and cash equivalents		762			16			(7,724	)		(42	)		(6,988	)
Net increase (decrease) in cash and cash equivalents		5,003			(15,042	)		8,926			—			(1,113	)
Cash and cash equivalents, beginning of period		3,623			67,449			257,274			—			328,346
Cash and cash equivalents, end of period	$	8,626		$	52,407		$	266,200		$	—		$	327,233

27

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(unaudited)

CONSOLIDATING STATEMENT OF CASH FLOWS

For the Three Months Ended March 31, 2012

(in thousands)

	Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations			Consolidated
Cash Flows from Operating Activities:
Net income	$	1,029		$	27,354		$	22,381			$(49,735)		$	1,029
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Equity in earnings (losses) of subsidiaries, net of tax		(49,895	)		348			—			49,547			—
Non-cash interest expense, including amortization of original issue discounts and write-off of deferred financing costs		5,219			59			—			—			5,278
Depreciation and amortization		2,074			63,363			37,345			(61	)		102,721
Non-cash charges for sale of inventories revalued at the date of acquisition		—			1,400			3,281			—			4,681
Non-cash stock-based compensation expense		1,007			1,377			1,490			—			3,874
Impairment of inventory		—			5			—			—			5
Impairment of long-lived assets		—			134			—			—			134
Loss on sale of fixed assets		—			508			58			—			566
Equity earnings of unconsolidated entities, net of tax		(660	)		—			(2,736	)		(16	)		(3,412	)
Deferred income taxes		(11,105	)		(614	)		(2,033	)		—			(13,752	)
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net		—			(4,605	)		(8,337	)		—			(12,942	)
Inventories, net		—			13,349			(3,733	)		(265	)		9,351
Prepaid expenses and other current assets		10,526			(4,386	)		(2,619	)		—			3,521
Accounts payable		(863	)		(4,101	)		(12,842	)		—			(17,806	)
Accrued expenses and other current liabilities		(14,901	)		34,232			(15,346	)		—			3,985
Other non-current liabilities		4,309			(10,015	)		20,332			71			14,697
Intercompany payable (receivable)		131,413			(128,235	)		(3,178	)		—			—
Net cash provided by (used in) operating activities		78,153			(9,827	)		34,063			(459	)		101,930
Cash Flows from Investing Activities:
Decrease in restricted cash		—			—			6,302			—			6,302
Purchases of property, plant and equipment		(4	)		(17,375	)		(13,465	)		459			(30,385	)
Proceeds from sale of property, plant and equipment		—			201			326			—			527
Cash paid for acquisitions, net of cash acquired		(22,500	)		—			(15,508	)		—			(38,008	)
Cash received from equity method investments		—			—			6,066			—			6,066
Cash paid for marketable securities		—			(2	)		—			—			(2	)
Increase in other assets		(6,144	)		(397	)		(2,013	)		—			(8,554	)
Net cash used in investing activities		(28,648	)		(17,573	)		(18,292	)		459			(64,054	)
Cash Flows from Financing Activities:
Cash paid for financing costs		(1,876	)		—			—			—			(1,876	)
Cash paid for contingent purchase price consideration		(48	)		—			—			—			(48	)
Proceeds from issuance of common stock, net of issuance costs		7,674			—			—			—			7,674
Proceeds from issuance of long-term debt		198,000			951			190			—			199,141
Payments on long-term debt		(10,750	)		(656	)		(5,505	)		—			(16,911	)
Net proceeds under revolving credit facilities		—			(2	)		1,341			—			1,339
Payments on short-term debt		(6,240	)		—			—			—			(6,240	)
Cash paid for dividends		(5,323	)		—			—			—			(5,323	)
Excess tax benefits on exercised stock options		98			48			2			—			148
Principal payments on capital lease obligations		—			(502	)		(1,218	)		—			(1,720	)
Net cash provided by (used in) financing activities		181,535			(161	)		(5,190	)		—			176,184
Foreign exchange effect on cash and cash equivalents		(429	)		73			1,220			—			864
Net increase (decrease) in cash and cash equivalents		230,611			(27,488	)		11,801			—			214,924
Cash and cash equivalents, beginning of period		12,451			95,212			191,510			—			299,173
Cash and cash equivalents, end of period	$	243,062		$	67,724		$	203,311		$	—		$	514,097

28

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(unaudited)

(21) Subsequent Event

On April 26, 2013, we settled our $40.0 million note receivable with FGST (see Note 4). In exchange for our surrender of the note, we acquired certain of the assets of the Medicare fee-for-service diabetes business (the “Liberty Assets”) of FGST, and its affiliates, including Liberty Medical, for $17.5 million and received $22.5 million in cash, along with all accrued and unpaid interest.

29

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Statements

This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You can identify these statements by forward-looking words such as “may,” “could,” “should,” “would,” “intend,” “will,” “expect,” “anticipate,” “believe,” “estimate,” “continue” or similar words. You should read statements that contain these words carefully because they discuss our future expectations, contain projections of our future results of operations or of our financial condition or state other “forward-looking” information. Forward-looking statements include, without limitation, statements regarding anticipated expansion and growth in certain of our product and service offerings, the impact of our research and development activities, potential new product and technology achievements, the potential for selective acquisitions, including acquisitions of health information solutions businesses outside the United States, our ability to improve our working capital and operating margins, our expectations with respect to Apollo, our integrated health information solutions technology platform, our ability to improve care and lower healthcare costs for both providers and patients, and our funding plans for our future working capital needs and commitments. Actual results or developments could differ materially from those projected in such statements as a result of numerous factors, including, without limitation, those risks and uncertainties set forth in Part I, Item 1A, “Risk Factors,” of our Annual Report on Form 10-K, as amended, for the year ended December 31, 2012 and other risk factors identified herein or from time to time in our periodic filings with the SEC. We do not undertake any obligation to update any forward-looking statements. This report and, in particular, the following discussion and analysis of our financial condition and results of operations, should be read in light of those risks and uncertainties and in conjunction with our accompanying Consolidated Financial Statements and notes thereto.

Overview

We enable individuals to take greater control of their health at home, under the supervision of their healthcare providers, by combining near-patient diagnostics, health monitoring capabilities and information technology solutions. A leading global provider of point-of-care diagnostics and services, we have developed a strong commercial presence in cardiology, infectious disease, toxicology, and diabetes. Our products and services help healthcare practitioners make earlier, more effective treatment decisions and improve outcomes for individuals living with chronic disease.

During 2012, we focused on completing the foundation for this business model by expanding our presence in toxicology and diabetes through acquisitions. Our toxicology group is now a full-service provider to a broad range of domestic and foreign employers in industries that require rigorous drug testing. We built a strong presence in diabetes from the ground up. Our diabetes revenues have grown to over $144.0 million in 2012, and including the effect of acquisitions completed in early 2013, we now service more than 250,000 active diabetes customers. We believe that the strong foundation that we have built in diabetes, specifically in our mail-order diabetes testing supply business, provides us with a competitive advantage in dealing with the impact that CMS’ competitive bidding program, which will significantly reduce current reimbursement rates starting in July 2013, is expected to have on competition and pricing in the market for diabetes testing supplies.

Core to our strategy are health information technologies that enable diagnostic data to be fed directly into an information exchange that integrates the diagnostic data with other patient-related information in a single health record. In recent periods, we have focused on acquiring health information technologies that will supplement our internally developed information technologies, including Apollo, and improve our ability to execute our business strategy. We now offer a variety of software-based analytics, clinical decision support tools, and health improvement programs that enable healthcare providers to initiate earlier interventions, personalize treatment plans, lower costs by reducing hospital readmissions, and measure improvements in outcomes at both a patient and population level.

We also continue to build momentum behind our next generation of novel diagnostic platforms that we expect to drive our growth in future years. With our novel molecular diagnostic platforms launched, or in the late stages of development, we have now begun to refocus our research and development efforts away from long-term projects towards product enhancements and menu expansion for our existing platforms.

Financial Highlights

• Net revenue increased by $68.1 million, or 10%, to $739.2 million for the three months ended March 31, 2013, from $671.1 million for the three months ended March 31, 2012.

30

• Gross profit increased by $11.2 million, or 3%, to $364.3 million for the three months ended March 31, 2013, from $353.1 million for the three months ended March 31, 2012.

• For the three months ended March 31, 2013, we generated net income available to common stockholders of $7.2 million, or $0.09 per diluted common share, compared to a net loss available to common stockholders of $4.1 million, or $(0.05) per diluted common share, for the three months ended March 31, 2012.

Results of Operations

Where discussed, results excluding the impact of foreign currency translation are calculated on the basis of local currency results, using foreign currency exchange rates applicable to the earlier comparative period. We believe presenting information using the same foreign currency exchange rates helps investors isolate the impact of changes in those rates from other trends. Our results of operations were as follows:

Net Product Sales and Services Revenue, Total and by Business Segment. Total net product sales and services revenue increased by $67.0 million, or 10%, to $735.2 million for the three months ended March 31, 2013, from $668.2 million for the three months ended March 31, 2012. Excluding the impact of currency translation, net product sales and services revenue for the three months ended March 31, 2013 increased by $70.3 million, or 11%, compared to the three months ended March 31, 2012. Net product sales and services revenue by business segment for the three months ended March 31, 2013 and 2012 are as follows (in thousands):

	Three Months Ended March 31,				% Change
	2013		2012
Professional diagnostics	$	578,628	$	515,449		12	%
Health information solutions		134,207		130,784		3	%
Consumer diagnostics		22,350		21,988		2	%
Net product sales and services revenue	$	735,185	$	668,221		10	%

Professional Diagnostics

The following table summarizes our net product sales and services revenue from our professional diagnostics business segment by groups of similar products and services for the three months ended March 31, 2013 and 2012 (in thousands):

	Three Months Ended March 31,				% Change
	2013		2012
Cardiology	$	114,933	$	138,826		(17	)%
Infectious disease		189,844		151,016		26	%
Toxicology		149,049		121,740		22	%
Diabetes		50,083		28,161		78	%
Other		74,719		75,706		(1	)%
Professional diagnostics net product sales and services revenue	$	578,628	$	515,449		12	%

Net product sales and services revenue from our professional diagnostics business segment increased by $63.2 million, or 12%, to $578.6 million for the three months ended March 31, 2013, from $515.4 million for the three months ended March 31, 2012. Excluding the impact of currency translation, net product sales and services revenue from our professional diagnostics business segment increased by $66.7 million, or 13%, comparing the three months ended March 31, 2013 to the three months ended March 31, 2012. Revenue increased primarily as a result of acquisitions, which contributed an aggregate of $62.0 million of the non-currency-adjusted increase. Contributing to the increase in net product sales and services revenue was an increase in our North American flu-related net product sales during the three months ended March 31, 2013, as compared to the three months ended March 31, 2012. Net product sales from our North American flu-related sales increased approximately $27.7 million, from $6.6 million during the three months ended March 31 2012 to $34.3 million during the three months ended March 31, 2013. Net product sales and services revenue from our professional diagnostics business segment were negatively impacted by the FDA recall matters related to our Alere Triage^® meter-based products. Net product sales of meter-based Triage products in the U.S. totaled $21.6 million during the three months ended March 31, 2013, as compared to $50.5 million during the three months ended March 31, 2012. Excluding the impact of acquisitions, the increase in flu-related sales during the comparable periods and the impact of the reduction in net product sales from meter-based Triage products in the U.S., the currency-adjusted organic growth for our professional diagnostics net product sales and services revenue was approximately $5.8 million, or 1%, from the three months ended March 31, 2012 to the three months ended March 31, 2013.

31

Within our professional diagnostics business segment, net product sales and services revenue for our cardiology business decreased by approximately $23.9 million, or 17%, to $114.9 million for the three months ended March 31, 2013, from $138.8 million for the three months ended March 31, 2012, driven principally by the impact of the FDA recall of certain of our meter-based Triage products in the U.S. Net product sales and services revenue for our infectious disease business increased by approximately $38.8 million, or 26%, to $189.8 million for the three months ended March 31, 2013, from $151.0 million for the three months ended March 31, 2012. The change was driven principally by an increase in flu-related sales during the comparable periods. Net product sales and services revenue for our toxicology business increased by approximately $27.3 million, or 22%, to $149.0 million for the three months ended March 31, 2013, from $121.7 million for the three months ended March 31, 2012, with our recent acquisitions of eScreen, Inc., or eScreen, Amedica Biotech, Inc., or Amedica, and Branan Medical Corporation, or Branan, contributing a combined net $41.7 million of the non-currency adjusted increase. Partially offsetting the increase in net product sales and services revenue for our toxicology business contributed by acquisitions was a decrease in net product sales related to our Triage toxicology products and a reduction in commercial pricing for our pain and rehab businesses which was implemented in the second quarter of 2012. Our diabetes business increased by approximately $21.9 million, or 78%, to $50.1 million for the three months ended March 31, 2013, from $28.2 million for the three months ended March 31, 2012, with our recent acquisitions of AmMed and NationsHealth contributing a combined net $16.0 million of the non-currency adjusted increase.

Health Information Solutions

The following table summarizes our net product sales and services revenue from our health information solutions business segment by groups of similar products and services for the three months ended March 31, 2013 and 2012 (in thousands):

	Three Months Ended March 31,				% Change
	2013		2012
Disease and case management	$	54,126	$	53,380		1	%
Wellness		26,300		27,026		(3	)%
Women’s and children’s health		29,080		29,771		(2	)%
Patient self-testing services		24,701		20,607		20	%
Health information solutions net product sales and services revenue	$	134,207	$	130,784		3	%

Our health information solutions net product sales and services revenue increased by $3.4 million, or 3%, to $134.2 million for the three months ended March 31, 2013, from $130.8 million for the three months ended March 31, 2012. Our patient self-testing services net product sales and services revenue increased approximately $4.1 million, or 20%, to $24.7 million for the three months ended March 31, 2013, from $20.6 for the three months ended March 31, 2012, principally driven by an increase in our home coagulation monitoring programs resulting from a larger patient population and a simultaneous reduction in customer attrition rates.

Consumer Diagnostics

Net product sales and services revenue from our consumer diagnostics business segment revenue increased by $0.4 million, or 2%, to $22.4 million for the three months ended March 31, 2013, from $22.0 million for the three months ended March 31, 2012. Net product sales by our 50/50 joint venture with P&G, or SPD, were $43.1 million during the three months ended March 31, 2013, as compared to $46.2 million during the three months ended March 31, 2012.

License and Royalty Revenue. License and royalty revenue represents license and royalty fees from intellectual property license agreements with third parties. License and royalty revenue increased by approximately $1.2 million, or 40%, to $4.1 million for the three months ended March 31, 2013, from $2.9 million for the three months ended March 31, 2012. The increase in royalty revenue for the three months ended March 31, 2013, compared to the three months ended March 31, 2012, is primarily a result of higher royalties earned under existing licensing agreements.

Gross Profit and Margin. Gross profit increased by $11.2 million, or 3%, to $364.3 million for the three months ended March 31, 2013, from $353.1 million for the three months ended March 31, 2012. The increase in gross profit during the three months ended March 31, 2013, compared to the three months ended March 31, 2012, was largely attributed to the increase in net product sales and services revenue resulting from acquisitions.

Cost of net revenue included amortization expense of $19.2 million and $15.7 million for the three months ended March 31, 2013 and 2012, respectively and $0.5 million and $4.7 million of non-cash charges relating to the write-up of inventory to fair value in connection with certain acquisitions during the three months ended March 31, 2013 and 2012, respectively.

32

Overall gross margin was 49% and 53% for the three months ended March 31, 2013 and 2012, respectively.

Gross Profit from Net Product Sales and Services Revenue, Total and by Business Segment. Gross profit from net product sales and services revenue increased by $10.1 million, or 3%, to $361.9 million for the three months ended March 31, 2013, from $351.8 million for the three months ended March 31, 2012. Gross profit from net product sales and services revenue by business segment for the three months ended March 31, 2013 and 2012 is as follows (in thousands):

	Three Months Ended March 31,				% Change
	2013		2012
Professional diagnostics	$	300,175	$	290,909		3	%
Health information solutions		57,350		57,369		0	%
Consumer diagnostics		4,424		3,529		25	%
Gross profit from net product sales and services revenue	$	361,949	$	351,807		3	%

Professional Diagnostics

Gross profit from our professional diagnostics net product sales and services revenue increased by $9.3 million, or 3%, to $300.2 million for the three months ended March 31, 2013, compared to $290.9 million for the three months ended March 31, 2012, principally as a result of gross profit earned on revenue from acquired businesses, as discussed above. Gross profit was negatively impacted by a decrease in our U.S. meter-based Triage product sales and a reduction in commercial pricing for our pain and rehab businesses, as discussed above. The FDA recall relating to our meter-based Triage products also resulted in incremental costs during the three months ended March 31, 2013, principally due to unfavorable manufacturing variances and the lost margin on the reduced volume of tests sold during the three months ended March 31, 2013, as compared to the three months ended March 31, 2012. Cost of professional diagnostics net product sales and services revenue during the three months ended March 31, 2013 and 2012, included a non-cash charge of $0.5 million and $4.7 million, respectively, relating to the write-up of inventory to fair value in connection with certain acquisitions. Reducing gross profit during the three months ended March 31, 2013 and 2012 was $0.2 million and $0.6 million, respectively, in restructuring charges.

Cost of professional diagnostics net product sales and services revenue included amortization expense of $17.4 million and $13.8 million during the three months ended March 31, 2013 and 2012, respectively.

As a percentage of our professional diagnostics net product sales and services revenue, gross margin for the three months ended March 31, 2013 and 2012 was 52% and 56%, respectively. Increased revenue from our recently acquired toxicology businesses, which contribute lower-than-segment-average gross margin, and a decrease in our U.S. meter-based Triage product sales, which contribute higher-than-segment-average gross margin, contributed to the decrease in gross margin in the three months ended March 31, 2013 from the three months ended March 31, 2012.

Health Information Solutions

Gross profit from our health information solutions net product sales and services revenue remained flat for the three months ended March 31, 2013, compared to the three months ended March 31, 2012. Reducing gross profit during each of the three months ended March 31, 2013 and 2012 was $0.4 million in restructuring charges.

Cost of health information solutions net product sales and services revenue included amortization expense of $1.5 million and $1.6 million during the three months ended March 31, 2013 and 2012, respectively.

As a percentage of our health information solutions net product sales and services revenue, gross margin for the three months ended March 31, 2013 and 2012 was 43% and 44%, respectively.

Consumer Diagnostics

Gross profit from our consumer diagnostics net product sales and services revenue increased by $0.9 million, or 25%, to $4.4 million for the three months ended March 31, 2013, compared to $3.5 million for the three months ended March 31, 2012. The increase in gross profit was primarily the result of a one-time cost of goods sold adjustment totaling approximately $0.7 million related to our manufacturing agreement with SPD recorded during the three months ended March 31, 2012.

Cost of consumer diagnostics net product sales and services revenue included amortization expense of $0.3 million during each of the three months ended March 31, 2013 and 2012.

33

As a percentage of net product sales and services revenue, gross margin for the three months ended March 31, 2013 and 2012 was 20% and 16%, respectively.

Research and Development Expense. Research and development expense increased by $2.5 million, or 6%, to $41.5 million for the three months ended March 31, 2013, from $39.0 million for the three months ended March 31, 2012. Research and development expense during the three months ended March 31, 2013 is reported net of grant funding of $0.5 million arising from the research and development funding relationship with the Bill and Melinda Gates Foundation that we entered into in February 2013. Included in research and development expense for the three months ended March 31, 2012 were restructuring charges associated with our various restructuring plans to integrate our newly-acquired businesses totaling approximately $0.6 million. Amortization expense of $1.3 million and $2.7 million was included in research and development expense for the three months ended March 31, 2013 and 2012, respectively.

Research and development expense as a percentage of net revenue was 6% for each of the three months ended March 31, 2013 and 2012.

Sales and Marketing Expense. Sales and marketing expense decreased by $2.1 million, or 1%, to $156.5 million for the three months ended March 31, 2013, from $158.6 million for the three months ended March 31, 2012. The decrease in sales and marketing expense was primarily driven by lower amortization expense during the three months ended March 31, 2013, compared to the three months ended March 31, 2012. Amortization expense of $53.5 million and $57.8 million was included in sales and marketing expense for the three months ended March 31, 2013 and 2012, respectively. Restructuring charges associated with our various restructuring plans to integrate our newly-acquired businesses totaling approximately $1.1 million and $0.8 million were included in sales and marketing expense for the three months ended March 31, 2013 and 2012, respectively.

Sales and marketing expense as a percentage of net revenue was 21% and 24% for the three months ended March 31, 2013 and 2012, respectively.

General and Administrative Expense. General and administrative expense increased by approximately $15.4 million, or 13%, to $135.9 million for the three months ended March 31, 2013, from $120.4 million for the three months ended March 31, 2012. The increase in general and administrative expense relates primarily to additional spending related to newly-acquired businesses. During the three months ended March 31, 2013 and 2012, we recorded expenses of $11.0 million and $5.0 million, respectively, in connection with fair value adjustments to acquisition-related contingent consideration obligations. Acquisition-related costs of $0.9 million and $1.5 million were included in general and administrative expense for the three months ended March 31, 2013 and 2012, respectively. Restructuring charges associated with our various restructuring plans to integrate our newly-acquired businesses totaling approximately $2.2 million and $3.1 million were included in general and administrative expense for the three months ended March 31, 2013 and 2012, respectively. Amortization expense of $1.9 million and $2.0 million was included in general and administrative expense for the three months ended March 31, 2013 and 2012, respectively.

General and administrative expense as a percentage of net revenue was 18% for each of the three months ended March 31, 2013 and 2012.

Interest Expense. Interest expense includes interest charges and the amortization of deferred financing costs and original issue discounts associated with certain debt issuances. Interest expense increased by $6.7 million, or 13%, to $57.4 million for the three months ended March 31, 2013, from $50.7 million for the three months ended March 31, 2012. The increase is principally due to higher interest expense recorded in connection with higher outstanding debt balances during the first quarter of 2013 under our secured credit facility, compared to the outstanding debt balances during the first quarter of 2012.

Other Income (Expense), Net. Other income (expense), net includes interest income, realized and unrealized foreign exchange gains and losses, and other income and expense. The components and the respective amounts of other income (expense), net are summarized as follows (in thousands):

	Three Months Ended March 31,						Change
	2013			2012
Interest income	$	1,023		$	562		$	461
Foreign exchange gains (losses), net		(467	)		(774	)		307
Other		(1,026	)		12,043			(13,069	)
Total other income (expense), net	$	(470	)	$	11,831		$	(12,301	)

34

Other income of $12.0 million for the three months ended March 31, 2012 includes a $13.5 million final royalty termination payment received from Quidel.

Benefit for Income Taxes. The benefit for income taxes increased by $35.4 million to a $36.9 million benefit for the three months ended March 31, 2013, from a $1.5 million benefit for the three months ended March 31, 2012. Our effective tax rate is calculated based on projected income across many different jurisdictions, and can change based on the location of income, losses and credits. The change in the effective tax rate, from the three months ended March 31, 2012 to the three months ended March 31, 2013, results primarily from our forecasted jurisdictional mix of income, as well as from U.S. federal research and development tax credits of approximately $1.6 million projected to be generated in 2013. In addition, we recognized a discrete tax benefit of $1.5 million for 2012 U.S. federal research and development tax credits during the three months ended March 31, 2013.

Equity Earnings in Unconsolidated Entities, Net of Tax. Equity earnings in unconsolidated entities is reported net of tax and includes our share of earnings in entities that we account for under the equity method of accounting. Equity earnings in unconsolidated entities, net of tax for the three months ended March 31, 2013 reflects the following: (i) our 50% interest in SPD in the amount of $2.5 million, (ii) our 40% interest in Vedalab S.A., or Vedalab, in the amount of $0.2 million and (iii) our 49% interest in TechLab, Inc., or TechLab, in the amount of $0.2 million. Equity earnings in unconsolidated entities, net of tax for the three months ended March 31, 2012 reflects the following: (i) our 50% interest in SPD in the amount of $2.8 million, (ii) our 40% interest in Vedalab in the amount of $(0.1) million and (iii) our 49% interest in TechLab in the amount of $0.7 million.

Net Income (Loss) Available to Common Stockholders. For the three months ended March 31, 2013, we generated net income available to common stockholders of $7.2 million, or $0.09 per diluted common share. For the three months ended March 31, 2012, we generated a net loss available to common stockholders of $4.1 million, or $0.05 per diluted common share. Net income (loss) available to common stockholders reflects $5.3 million of preferred stock dividends paid during each of the three months ended March 31, 2013 and 2012. See Note 6 of the accompanying Consolidated Financial Statements for the calculation of net income (loss) per common share.

Liquidity and Capital Resources

Based upon our current working capital position, current operating plans and expected business conditions, we expect to fund our short—and long-term working capital needs primarily using existing cash and our operating cash flow, and we expect our working capital position to improve as we improve our future operating margins and grow our business through new product and service offerings and by continuing to leverage our strong intellectual property position. As of March 31, 2013, we had $327.2 million of cash and cash equivalents, of which $74.8 million was held by domestic subsidiaries and $252.4 million was held by foreign entities. We do not plan to repatriate cash held by foreign entities due to adverse tax implications, including incremental U.S. tax liabilities and potential foreign withholding tax liabilities.

We may also utilize our secured credit facility or other new sources of financing to fund a portion of our capital needs and other commitments, including our contractual contingent consideration obligations and future acquisitions. As of March 31, 2013, we had outstanding borrowings totaling $192.5 million under the $250.0 million revolving line of credit under our secured credit facility, leaving $57.5 million available to us for additional borrowings. Our ability to access the capital markets may be impacted by the amount of our outstanding debt and equity and the extent to which our assets are encumbered by our outstanding secured debt. The terms and conditions of our outstanding debt instruments also contain covenants which expressly restrict our ability to incur additional indebtedness and conduct other financings. As of March 31, 2013, we had $3.8 billion in outstanding indebtedness comprised of $2.4 billion under our secured credit facility, including borrowings under our revolving line of credit, $450.0 million of 7.25% senior notes due 2018, $400.0 million of 8.625% senior subordinated notes due 2018, $393.4 million of 9% senior subordinated notes due 2016 and $150.0 million of 3% convertible senior subordinated notes due 2016.

If the capital and credit markets experience volatility or the availability of funds is limited, we may incur increased costs associated with issuing debt instruments. In addition, it is possible that our ability to access the capital and credit markets could be limited by these or other factors at a time when we would like, or need, to do so, which could have an adverse impact on our ability to refinance maturing debt and/or react to changing economic and business conditions.

Our funding plans for our working capital needs and other commitments may be adversely impacted by unexpected costs associated with integrating the operations of newly-acquired companies, executing our cost-savings strategies and prosecuting and defending our existing lawsuits and/or unforeseen lawsuits against us. We also cannot be certain that our underlying assumed levels of revenues and expenses will be realized. In addition, we intend to continue to make investments in our research and development efforts related to the substantial intellectual property portfolio we own. We may also choose to further expand our research and development efforts and may pursue the acquisition of new products and technologies through licensing arrangements, business

35

acquisitions, or otherwise. We may also choose to make significant investment to pursue legal remedies against potential infringers of our intellectual property rights. If we decide to engage in such activities, or if our operating results fail to meet our expectations, we could be required to seek additional funding through public or private financings or other arrangements. In such event, adequate funds may not be available when needed or may be available only on terms which could have a negative impact on our business and results of operations. In addition, if we raise additional funds by issuing equity or convertible securities, dilution to then-existing stockholders may result.

	Three Months Ended March 31,
Cash Flow Summary (in thousands)	2013			2012
Net cash provided by operating activities	$	71,061		$	101,930
Net cash used in investing activities		(196,754	)		(64,054	)
Net cash provided by financing activities		131,568			176,184
Foreign exchange effect on cash and cash equivalents		(6,988	)		864
Net increase (decrease) in cash and cash equivalents		(1,113	)		214,924
Cash and cash equivalents, beginning of period		328,346			299,173
Cash and cash equivalents, end of period	$	327,233		$	514,097

Summary of Changes in Cash Position

As of March 31, 2013, we had cash and cash equivalents of $327.2 million, a $1.1 million decrease from December 31, 2012. Our primary sources of cash during the three months ended March 31, 2013 included $71.1 million generated by our operating activities, $162.5 million of net proceeds under various revolving credit facilities, which included $170.0 million borrowed against our secured credit facility revolving line-of-credit, $10.8 million return of capital from SPD, $10.1 million received from long-term debt borrowings and $6.1 million of cash received from common stock issuances under employee stock option and stock purchase plans. Our primary uses of cash during the three months ended March 31, 2013 were $158.4 million net cash paid for acquisitions, $36.1 million of capital expenditures, $19.6 million related to the repayment of long-term debt obligations, $19.1 million related to payments of acquisition-related contingent consideration obligations, $5.6 million related to an increase in other assets and $5.3 million for cash dividends paid on our Series B Preferred Stock. Fluctuations in foreign currencies negatively impacted our cash balance by $7.0 million during the three months ended March 31, 2013.

Cash Flows from Operating Activities

Net cash provided by operating activities during the three months ended March 31, 2013 was $71.1 million, which resulted from net income of $12.4 million, $63.0 million of non-cash items and $4.4 million of cash utilized by changes in net working capital requirements during the period. The $63.0 million of non-cash items included, among other items, $105.0 million related to depreciation and amortization, $5.2 million of interest expense related to the amortization of deferred financing costs and original issue discounts, $4.1 million related to non-cash stock-based compensation, $1.9 million related to other non-cash items and a $0.5 million non-cash charge related to the write up of inventory to fair value in connection with the acquisition of Epocal, Inc., or Epocal, partially offset by a $50.9 million decrease related to changes in our deferred tax assets and liabilities, which resulted in part from amortization of intangible assets, and $2.9 million in equity earnings in unconsolidated entities, net of tax.

Cash Flows from Investing Activities

Our investing activities during the three months ended March 31, 2013 utilized $196.8 million of cash, including $158.4 million net cash paid for acquisitions, $36.1 million of capital expenditures, an increase in our restricted cash balance of $8.6 million which was principally driven by $7.9 million of cash received from the Bill and Melinda Gates Foundation and $5.6 million related to an increase in other assets, partially offset by a $10.8 million return of capital from SPD and $1.1 million of proceeds received from the sale of property, plant and equipment.

Cash Flows from Financing Activities

Net cash provided by financing activities during the three months ended March 31, 2013 was $131.6 million. Financing activities during the three months ended March 31, 2013 primarily included approximately $162.5 million of net proceeds under various revolving credit facilities, which included $170.0 million borrowed against our secured credit facility revolving line-of-credit,

36

$10.1 million received from long-term debt borrowings and $6.1 million of cash received from common stock issuances under employee stock option and stock purchase plans. We utilized approximately $19.6 million for the payment of certain long-term debt obligations, $19.1 million for payments of acquisition-related contingent consideration obligations, $5.3 million for dividend payments related to our Series B preferred stock, $1.7 million for payment of capital lease obligations and $1.4 million related to the payment of debt-related financing costs.

As of March 31, 2013, we had an aggregate of $17.4 million in outstanding capital lease obligations which are payable through 2018.

Income Taxes

As of December 31, 2012, we had approximately $60.6 million of domestic NOL and domestic capital loss carryforwards, approximately $981.1 million of state NOL carryforwards and $211.6 million of foreign NOL and foreign capital loss carryforwards, which either expire on various dates through 2032 or can be carried forward indefinitely. As of December 31, 2012, we had approximately $57.7 million of domestic research and development, foreign tax and alternative minimum tax credits which either expire on various dates through 2031 or can be carried forward indefinitely. These loss carryforwards and tax credits may be available to reduce future federal, state and foreign taxable income, if any, and are subject to review and possible adjustment by the appropriate tax authorities.

Furthermore, all domestic losses and credits are subject to the limitations imposed by Sections 382 and 383 of the Internal Revenue Code, and may be limited in the event of certain cumulative changes in ownership interests of significant shareholders over a three-year period in excess of 50%. Sections 382 and 383 impose an annual limitation on the use of these losses or credits to an amount equal to the value of the company at the time of the ownership change multiplied by the long-term tax exempt rate. We have recorded a valuation allowance against a portion of the deferred tax assets related to our NOLs and credits and certain of our other deferred tax assets to reflect uncertainties that might affect the realization of such deferred tax assets, as these assets can only be realized via profitable operations.

Off-Balance Sheet Arrangements

We had no material off-balance sheet arrangements as of March 31, 2013.

Contractual Obligations

The following summarizes our principal contractual obligations as of March 31, 2013 that have changed significantly since December 31, 2012 and the effects such obligations are expected to have on our liquidity and cash flow in future periods. Contractual obligations that were presented in our Annual Report on Form 10-K, as amended, for the year ended December 31, 2012, but omitted below, represent those that have not changed significantly since that date.

	Payments Due by Period (in thousands)
	Total		2013		2014-2015		2016-2017		Thereafter
Long-term debt obligations	$	3,849,355	$	48,018	$	99,247	$	2,849,537	$	852,553

With respect to our February 1, 2013 acquisition of Epocal, the terms of the acquisition agreement require us to pay earn-outs and management incentive payments upon successfully meeting certain product development and United States Food and Drug Administration regulatory approval milestones from the date of acquisition through December 31, 2018. The maximum amount of the earn-out payments is $90.5 million, of which $15.0 million was paid at the acquisition closing date. The maximum amount of the management incentive payments is $9.4 million.

Critical Accounting Policies

The discussion and analysis of our financial condition and results of operations are based on our Consolidated Financial Statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements in accordance with generally accepted accounting principles requires us to make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On a quarterly basis, we evaluate our estimates, including those related to revenue recognition and related allowances, bad debt, inventory, valuation of long-lived assets, including intangible assets and goodwill, income taxes, including any valuation allowance for our net deferred tax assets, contingencies and litigation, and stock-based compensation. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions.

37

There have been no significant changes in our critical accounting policies or management estimates since December 31, 2012. A comprehensive discussion of our critical accounting policies and management estimates is included in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K, as amended for the year ended December 31, 2012.

Recent Accounting Pronouncements

See Note 18 in the notes to the Consolidated Financial Statements included in this Quarterly Report on Form 10-Q, regarding the impact of certain recent accounting pronouncements on our Consolidated Financial Statements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our market risks, and the ways we manage them, are summarized in Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk” of our Annual Report on Form 10-K, as amended, for the year ended December 31, 2012. There have been no material changes in the three months ended March 31, 2013 to our market risks or management of such risks.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management evaluated, with the participation of our Chief Executive Officer (CEO) and Chief Financial Officer (CFO), the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our management, including the CEO and CFO, concluded that our disclosure controls and procedures were effective at that time. We and our management understand nonetheless that controls and procedures, no matter how well designed and operated, can provide only reasonable assurances of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating and implementing possible controls and procedures. In reaching their conclusions stated above regarding the effectiveness of our disclosure controls and procedures, our CEO and CFO concluded that such disclosure controls and procedures were effective as of such date at the “reasonable assurance” level.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the most recent fiscal quarter covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

ITEM 6. EXHIBITS

Exhibits:

Exhibit No.	Description
4.1	Fourteenth Supplemental Indenture to Indenture dated as of May 12, 2009 (to add the guarantees of Alere Informatics, Inc., Alere Wellogic, LLC, ATS Laboratories, Inc., Avee Laboratories Inc., eScreen, Inc., Global Analytical Development LLC, Ionian Technologies Inc., Pembrooke Occupational Health, Inc., Screen Tox, Inc., and Standing Stone, Inc.) dated as of April 3, 2013 among Alere Informatics, Inc., Alere Wellogic, LLC, ATS Laboratories, Inc., Avee Laboratories Inc., eScreen, Inc., Global Analytical Development LLC, Ionian Technologies Inc., Pembrooke Occupational Health, Inc., Screen Tox, Inc., and Standing Stone, Inc., as guarantors, the Company as issuer, the other guarantor subsidiaries named therein, as guarantors, and U.S. Bank National Association, as trustee (incorporated by reference to Exhibit 4.13 to Alere Informatics, Inc., Alere Wellogic, LLC, ATS Laboratories, Inc., Avee Laboratories Inc., eScreen, Inc., Global Analytical Development LLC, Ionian Technologies Inc., Pembrooke Occupational Health, Inc., Screen Tox, Inc., and Standing Stone, Inc.’s Registration Statement on Form 8-A, filed on April 3, 2013)
*4.2	Fifteenth Supplemental Indenture to Indenture dated as of May 12, 2009 (to add the guarantees of Alere Informatics, Inc., Alere Wellogic, LLC, ATS Laboratories, Inc., Avee Laboratories Inc., eScreen, Inc., Global Analytical Development LLC, Ionian Technologies Inc., Pembrooke Occupational Health, Inc., Screen Tox, Inc., and Standing Stone, Inc.) dated as of April 3, 2013 among Alere Informatics, Inc., Alere Wellogic, LLC, ATS Laboratories, Inc., Avee Laboratories Inc., eScreen, Inc., Global Analytical Development LLC, Ionian Technologies Inc., Pembrooke Occupational Health, Inc., Screen Tox, Inc., and Standing Stone, Inc., as guarantors, the Company as issuer, the other guarantor subsidiaries named therein, as guarantors, and U.S. Bank National Association, as trustee

38

4.3	Sixteenth Supplemental Indenture (to add the guarantees of Alere Informatics, Inc., Alere Wellogic, LLC, ATS Laboratories, Inc., Avee Laboratories Inc., eScreen, Inc., Global Analytical Development LLC, Ionian Technologies Inc., Pembrooke Occupational Health, Inc., Screen Tox, Inc., and Standing Stone, Inc.), dated as of April 3, 2013, by and among the Company, the subsidiary guarantors named therein and Bank of New York Mellon Trust Company, N.A., as trustee (incorporated by reference to Exhibit 4.6 of the Company’s Registration Statement on Form S-4 (File No. 333-187776))
*10.1	Fourth Amendment to Credit Agreement, dated as of March 22, 2013, among the Alere Inc., as Borrower, each of the Guarantors (as defined therein), the Lenders party thereto, and General Electric Capital Corporation, as Administrative Agent
*31.1	Certification by Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
*31.2	Certification by Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
*32.1	Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
*101	Interactive Data Files regarding (a) our Consolidated Statements of Operations for the Three Months Ended March 31, 2013 and 2012, (b) our Consolidated Statements of Comprehensive Income (Loss) for the Three Months Ended March 31, 2013 and 2012, (c) our Consolidated Balance Sheets as of March 31, 2013 and December 31, 2012, (d) our Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2013 and 2012 and (e) the Notes to such Consolidated Financial Statements.

* Filed herewith

39

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	ALERE INC.
Date: May 9, 2013	/s/ David Teitel
	David Teitel
	Chief Financial Officer and an authorized officer

40

EX-4.2

Exhibit 4.2

FIFTEENTH SUPPLEMENTAL INDENTURE

FIFTEENTH SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of April 3, 2013, among IONIAN TECHNOLOGIES INC., STANDING STONE, INC., AVEE LABORATORIES INC., ALERE INFORMATICS, INC., ALERE WELLOGIC, LLC, ESCREEN, INC., ATS LABORATORIES, INC., SCREEN TOX, INC., GLOBAL ANALYTICAL DEVELOPMENT LLC, AND PEMBROOKE OCCUPATIONAL HEALTH, INC. (collectively, the “New Guarantors”), which are Subsidiaries of Alere Inc. (or its successor) (the “Issuer”), ALERE INC., a Delaware corporation, on behalf of itself and the Guarantors (the “Existing Guarantors”) under the Indenture referred to below, and U.S. BANK NATIONAL ASSOCIATION, as Trustee under the Indenture referred to below (the “Trustee”).

WITNESSETH:

WHEREAS the Issuer has heretofore executed and delivered an Indenture dated as of May 12, 2009, as amended, supplemented and modified by a Ninth Supplemental Indenture dated as of September 21, 2010, an Eleventh Supplemental Indenture dated as of June 16, 2011, and a Thirteenth Supplemental Indenture dated as of June 16, 2011 (as so amended, supplemented or modified, and as further amended, supplemented or modified to date, the “Indenture”), by and among the Issuer, the Existing Guarantors and the Trustee, providing for the issuance of 8.625% Senior Subordinated Notes due 2018 (the “Notes”);

WHEREAS Section 4.13 of the Indenture provides that under certain circumstances the Issuer is required to cause each of the New Guarantors to execute and deliver to the Trustee a supplemental indenture pursuant to which each of the New Guarantors shall unconditionally and irrevocably guarantee all of the Issuer’s obligations under the Notes pursuant to a guarantee on the terms and conditions set forth herein; and

WHEREAS pursuant to Section 9.01 of the Indenture, the Trustee, the Issuer and the Existing Guarantors are authorized to execute and deliver this Supplemental Indenture;

NOW THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, the New Guarantors, the Trustee and, on behalf of itself and the Existing Guarantors, the Issuer mutually covenant and agree for the equal and ratable benefit of the Holders as follows:

SECTION 1. Definitions. For all purposes of this Supplemental Indenture, except as otherwise herein expressly provided or unless the context otherwise requires: (i) the terms and expressions used herein shall have the same meanings as corresponding terms and expressions used in the Indenture; and (ii) the words “herein,” “hereof” and “hereby” and other words of similar import used in this Supplemental Indenture refer to this Supplemental Indenture as a whole and not to any particular section hereof.

SECTION 2. Agreement to Guarantee. Each of the New Guarantors hereby unconditionally and irrevocably agrees, jointly and severally with all other Guarantors, to guarantee the Issuer’s obligations under the Notes and the Indenture on the terms and subject to the conditions set forth in Article Eleven of the Indenture and to be bound by all other applicable provisions of the Indenture.

SECTION 3. Ratification of Indenture; Supplemental Indenture Part of Indenture. Except as expressly amended hereby, the Indenture is in all respects ratified and confirmed and all the terms, conditions and provisions thereof shall remain in full force and effect. This Supplemental Indenture shall form a part of the Indenture for all purposes, and every Holder of Notes heretofore or hereafter authenticated and delivered shall be bound hereby.

SECTION 4. Governing Law. This Supplemental Indenture shall be governed by, and construed in accordance with, the laws of the State of New York, but without giving effect to applicable principles of conflicts of laws to the extent that the application of the laws of another jurisdiction would be required thereby.

SECTION 5. Trustee Makes No Representation. The Trustee makes no representation as to the validity or sufficiency of this Supplemental Indenture or for the recitals contained herein.

SECTION 6. Counterparts. The parties may sign any number of copies of this Supplemental Indenture. Each signed copy shall be an original, but all of them together represent the same agreement.

SECTION 7. Effect of Headings. The Section headings herein are for convenience only and shall not effect the construction thereof.

- 2 -

IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly executed as of the date first above written.

NEW GUARANTORS: IONIAN TECHNOLOGIES INC. STANDING STONE, INC. AVEE LABORATORIES INC. ALERE INFORMATICS, INC. ALERE WELLOGIC, LLC ESCREEN, INC. ATS LABORATORIES, INC. SCREEN TOX, INC. PEMBROOKE OCCUPATIONAL HEALTH, INC., as New Guarantors
By:	/s/ Ellen V. Chiniara
	Name: Ellen V. Chiniara Title: Secretary
GLOBAL ANALYTICAL DEVELOPMENT LLC, as a New Guarantor

By: ATS LABORATORIES, INC., ITS MANAGING MEMBER
By:	/s/ Ellen V. Chiniara
Name: Ellen V. Chiniara
Title: Secretary

Signature Page to Fifteenth Supplemental Indenture

ISSUER: ALERE INC.
By:	/s/ David A. Teitel
	Name: David A. Teitel Title: Chief Financial Officer and Treasurer

Signature Page to Fifteenth Supplemental Indenture

EXISTING GUARANTORS: ALERE HEALTH, LLC ALERE HEALTHCARE OF ILLINOIS, INC. ALERE HEALTH IMPROVEMENT COMPANY ALERE HOME MONITORING, INC. ALERE INTERNATIONAL HOLDING CORP. ALERE NEWCO, INC. ALERE NEWCO II, INC. ALERE NORTH AMERICA, INC. ALERE OF NEW YORK, INC. ALERE SAN DIEGO, INC. ALERE SCARBOROUGH, INC. ALERE US HOLDINGS, LLC ALERE WELLBEING ALERE WELLOLOGY, INC. ALERE WOMEN’S AND CHILDREN’S HEALTH, LLC AMEDITECH INC. BINAX, INC. BIOSITE INCORPORATED FIRST CHECK DIAGNOSTICS CORP. FIRST CHECK ECOM, INC.
By:	/s/ David A. Teitel
	Name: David A. Teitel Title (respectively): Vice President and Treasurer; Vice President, Finance and Treasurer; Vice President and Treasurer; Vice President, Finance; President; President; President; Vice President, Finance; Vice President, Finance; Vice President, Finance; Vice President, Finance; President; Vice President, Finance and Treasurer; Vice President and Treasurer; Vice President, Finance; Chief Financial Officer; Vice President, Finance; Vice President, Finance; Vice President, Finance; Vice President, Finance

Signature Page to Fifteenth Supplemental Indenture

EXISTING GUARANTORS (continued): INNOVACON, INC. INSTANT TECHNOLOGIES, INC. INVERNESS MEDICAL, LLC IVC INDUSTRIES, INC. QUALITY ASSURED SERVICES, INC. REDWOOD TOXICOLOGY LABORATORY, INC. RMD NETWORKS, INC. RTL HOLDINGS, INC. SELFCARE TECHNOLOGY, INC. ZYCARE, INC.
By:	/s/ David A. Teitel
	Name: David A. Teitel Title (respectively): Vice President, Finance; Vice President, Finance; Vice President, Finance; President; Vice President, Finance; Vice President, Finance; Vice President, Finance and Treasurer; Vice President, Finance; Vice President, Finance; Chief Financial Officer and Treasurer

Signature Page to Fifteenth Supplemental Indenture

EXISTING GUARANTORS (continued): ALERE TOXICOLOY SERVICES, INC. LABORATORY SPECIALISTS OF AMERICA, INC.
By:	/s/ Jay McNamara
	Name: Jay McNamara Title: Assistant Secretary

Signature Page to Fifteenth Supplemental Indenture

U.S. BANK NATIONAL ASSOCATION, as Trustee
By:	/s/ Thomas E. Tabor
	Name: Thomas E. Tabor Title: Vice President

Signature Page to Fifteenth Supplemental Indenture

EX-10.1

Exhibit 10.1

EXECUTION VERSION

FOURTH AMENDMENT TO CREDIT AGREEMENT

THIS FOURTH AMENDMENT TO CREDIT AGREEMENT (this “Fourth Amendment”), dated as of March 22, 2013, among ALERE INC., a Delaware corporation (the “Borrower”), each of the Guarantors (as defined in the Credit Agreement referred to below) party hereto, the Lenders (as defined in the Credit Agreement referred to below) party hereto and GENERAL ELECTRIC CAPITAL CORPORATION, as administrative agent (in such capacity, the “Administrative Agent”) for the Lenders, is made with reference to that certain Credit Agreement, dated as of June 30, 2011 (as amended, modified or supplemented through, but not including, the date hereof, the “Credit Agreement”), by and among the Borrower, the Lenders, the Administrative Agent and the other parties thereto. Unless otherwise indicated, all capitalized terms used herein and not otherwise defined herein shall have the respective meanings ascribed to such terms in the Credit Agreement.

W I T N E S S E T H:

WHEREAS, the Borrower, the Administrative Agent and each Lender party hereto desire to amend the Credit Agreement to decrease the interest rate applicable to the B Term Loans, the Incremental B-1 Term Loans and the Incremental B-2 Term Loans and to make certain other changes to the Credit Agreement, in each case, as provided herein; and

WHEREAS, the Borrower, the Guarantors, the Administrative Agent and each Lender party hereto desire to amend the Guaranty and Security Agreement, as provided herein;

NOW, THEREFORE, it is agreed:

I. Amendments and Modifications to Credit Agreement.

1. The definition of “Applicable Margin” appearing in Section 1.1 of the Credit Agreement is hereby restated in its entirety as follows:

“Applicable Margin” means (a) with respect to A Term Loans, Delayed-Draw Term Loans, Revolving Loans and Swing Loans, in each case a percentage equal to (i) during the period commencing on the Closing Date and ending on the next date of determination that is at least 180 days after the Closing Date, the percentage set forth in the applicable column opposite Level III in the table set forth below and (ii) thereafter, as of each date of determination (and until the next such date of determination), a percentage equal to the percentage set forth below in the applicable column opposite the level corresponding to the Consolidated Secured Leverage Ratio in effect as of the last day of the most recently ended Fiscal Quarter and (b) with respect to B Term Loans, Incremental B-1 Term Loans and Incremental B-2 Term Loans, in each case a percentage equal to (i) during the period prior to the Fourth Amendment Effective Date, as provided in this Agreement prior to giving effect to the Fourth Amendment, (ii) during the period commencing on the Fourth Amendment Effective Date and ending on the next date of determination thereafter, the percentage set forth in the applicable column opposite Level II in the table set forth below and (iii) thereafter, as of each date of determination (and until the next such date of determination), a percentage equal to the percentage set forth below in the applicable column opposite the level corresponding to the Consolidated Secured Leverage Ratio in effect as of the last day of the most recently ended Fiscal Quarter:

LEVEL	CONSOLIDATED SECURED LEVERAGE RATIO	A TERM LOANS, DELAYED-DRAW TERM LOANS, REVOLVING LOANS AND SWING LOANS						B TERM LOANS, INCREMENTAL B-1 TERM LOANS AND INCREMENTAL B-2 TERM LOANS
		BASE RATE LOANS			EURODOLLAR RATE LOANS (EXCEPT FOR SWING LOANS)			BASE RATE LOANS			EURODOLLAR RATE LOANS
I	Greater than 4.00: 1.00		2.50	%		3.50	%		2.75	%		3.75	%
II	Less than or equal to 4.00: 1.00 and greater than 3.00 : 1.00		2.00	%		3.00	%		2.25	%		3.25	%
III	Less than or equal to 3.00: 1.00		1.75	%		2.75	%		2.00	%		3.00	%

Each date of determination for the “Applicable Margin” shall be the date that is 3 Business Days after delivery by the Borrower to the Administrative Agent of a new Compliance Certificate pursuant to Section 6.1(c). Notwithstanding anything to the contrary set forth in this Agreement (including the then effective Consolidated Secured Leverage Ratio), the Applicable Margin with respect to Loans shall equal the percentage set forth in the appropriate column opposite Level I in the table above, effective immediately upon (x) the occurrence of any Event of Default under Section 9.1(e)(ii) or (y) the delivery of a notice by the Administrative Agent or the Required Lenders to the Borrower during the continuance of any other Event of Default and, in each case, for as long as such Event of Default shall be continuing.”

2. Section 1.1 of the Credit Agreement is hereby further amended by inserting in the appropriate alphabetical order the following new definitions:

“Commodity Exchange Act” means the Commodity Exchange Act (7 U.S.C. § 1 et seq.).

“Excluded Swap Obligation” means, with respect to any Guarantor, any Swap Obligation if, and to the extent that, all or a portion of the Guaranty Obligation of such Guarantor of, or the grant by such Guarantor of a security interest to secure, such Swap Obligation (or any Guaranty Obligation thereof) is or becomes illegal under the Commodity Exchange Act or any rule, regulation or order of the Commodity Futures Trading Commission (or the application or official interpretation of any thereof) by virtue of such Guarantor’s failure for any reason to constitute an “eligible contract participant” as defined in the Commodity Exchange Act and the regulations thereunder at the time the Guaranty Obligation of such Guarantor or the grant of such security interest becomes effective with respect to such Swap Obligation. If a Swap Obligation arises under a master agreement governing more than one swap, such exclusion shall apply only to the portion of such Swap Obligation that is attributable to swaps for which such Guaranty Obligation or security interest is or becomes illegal.

“Fourth Amendment” means the Fourth Amendment to Credit Agreement, dated as of March 22, 2013, among Borrower, the Guarantors party thereto, the Lenders party thereto and Administrative Agent.

“Fourth Amendment Effective Date” means the date on which the Fourth Amendment is effective pursuant to the terms thereof.

“Swap Obligation” means, with respect to any Guarantor, any obligation to pay or perform under any Secured Hedging Agreement that constitutes a “swap” within the meaning of section 1a(47) of the Commodity Exchange Act.

3. Section 2.11(d) of the Credit Agreement is hereby amended by deleting the text “on or prior to the first anniversary of the Closing Date” appearing therein an inserting the text “after the Fourth Amendment Effective Date and on or prior to the sixth month anniversary of the Fourth Amendment Effective Date” in lieu thereof.

4. In connection with the transactions contemplated by this Fourth Amendment, if any Affected Lender holding outstanding B Term Loans, Incremental B-1 Term Loans or Incremental B-2 Term Loans does not consent to this Fourth Amendment and does not execute and deliver to the Administrative Agent a duly completed Assignment and/or any other documentation necessary to reflect the replacement of such Affected Lender by a Substitute Lender by the later of (x) the date on which the Substitute Lender executes and delivers such Assignment and/or such other documentation and (y) the date as of which all obligations of Borrower owing to such Affected Lender relating to the B Term Loans, Incremental B-1 Term Loans and Incremental B-2 Term Loans so assigned shall be paid in full by the Substitute Lender and/or Borrower to such Affected Lender, then the Affected Lender shall be deemed to have executed and delivered such Assignment and/or such other documentation as of such date and Borrower shall be entitled (but not obligated) to execute and deliver such Assignment and/or such other documentation on behalf of such Affected Lender.

II. Amendments and Modifications to the Guaranty and Security Agreement.

1. Section 1.1(c) of the Guaranty and Security Agreement is hereby amended by adding the following definition in the appropriate alphabetical order:

“Qualified ECP Guarantor” means, in respect of any Swap Obligation, each Guarantor that has total assets exceeding $10,000,000 at the time the relevant Guaranty Obligation or grant of the relevant security interest becomes effective with respect to such Swap Obligation or such other person as constitutes an “eligible contract participant” under the Commodity Exchange Act or any regulations promulgated thereunder and can cause another person to qualify as an “eligible contract participant” at such time by entering into a keepwell under Section 1a(18)(A)(v)(II) of the Commodity Exchange Act.

2. Section 2.1 of the Guaranty and Security Agreement shall be amended by adding the following proviso at the end of the first sentence thereof:

“; provided that in no event shall Guaranteed Obligations be deemed to include any Excluded Swap Obligations”.

3. Article II of the Guaranty and Security Agreement is hereby further amended by inserting the following new Section 2.8 immediately after Section 2.7 thereof:

“Section 2.8. Keepwell. Each Qualified ECP Guarantor hereby jointly and severally absolutely, unconditionally and irrevocably undertakes to provide such funds or other support as may be needed from time to time by each other Guarantor to honor all of its obligations under this Guaranty in respect of Swap Obligations (provided, however, that each Qualified ECP Guarantor shall only be liable under this Section 2.8 for the maximum amount of such liability that can be hereby incurred without rendering its obligations under this Section 2.8, or otherwise under this Guaranty, as it relates to such other Guarantor, voidable under applicable law relating to fraudulent conveyance or fraudulent transfer, and not for any greater amount). The obligations of each Qualified ECP Guarantor under this Section shall remain in full force and effect until the payment in full of the Guaranteed Obligations. Each Qualified ECP Guarantor intends that this Section 2.8 constitute, and this Section 2.8 shall be deemed to constitute, a “keepwell, support, or other agreement” for the benefit of each other Loan Party for all purposes of Section 1a(18)(A)(v)(II) of the Commodity Exchange Act.”

4. Section 3.2 of the Guaranty and Security Agreement shall be amended by inserting the following proviso at the end thereof:

“; provided that in no event shall Secured Obligations be deemed to include any Excluded Swap Obligations”.

III. Miscellaneous Provisions.

1. Representations and Warranties. To induce the Administrative Agent and the Lenders to enter into this Fourth Amendment, each Loan Party represents and warrants to the Administrative Agent and the Lenders on and as of the Fourth Amendment Effective Date that:

(a) The execution, delivery and performance by the Borrower and each Guarantor of this Fourth Amendment and the performance of the Credit Agreement and the Guaranty and Security Agreement by each Loan Party party thereto, as amended by this Fourth Amendment (the “Amended Loan Documents”): (i) are within each such Loan Party’s corporate or similar powers and, at the time of execution thereof, have been duly authorized by all necessary corporate and similar action, (ii) do not (A) contravene such Loan Party’s Constituent Documents, (B) violate any Requirement of Law, (C) conflict with, contravene, constitute a default or breach under, any material Contractual Obligation of any Loan Party or any of their respective Subsidiaries other than those which could not reasonably be expected to have, either

individually or in the aggregate, a Material Adverse Effect, or (D) result in the imposition of any Lien (other than a Permitted Lien) upon any property of any Loan Party or any of their respective Subsidiaries and (iii) do not require any Loan Party or any of their respective Subsidiaries to obtain any Permit from, or make any filing with, any Governmental Authority or obtain any consent from, or notice to, any Person, other than as has been obtained and made on or prior to the Fourth Amendment Effective Date and which remains in full force and effect on the Fourth Amendment Effective Date except where the failure to obtain any such Permit, make any such filing or obtain any such consent could not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect.

(b) This Fourth Amendment has been duly executed and delivered by or on behalf of such Loan Party.

(c) Each of this Fourth Amendment and each Amended Loan Document is the legal, valid and binding obligation of such Loan Party to the extent a party thereto and is enforceable against such Loan Party in accordance with its terms, except as may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent transfer or other similar laws affecting creditors’ rights generally or by general equitable principles relating to enforceability.

(d) No Default or Event of Default has occurred and is continuing on the Fourth Amendment Effective Date or would occur after giving effect to this Fourth Amendment.

(e) No action, claim or proceeding is now pending or, to the knowledge of any Loan Party, threatened against such Loan Party, at law, in equity or otherwise, before any court, board, commission, agency or instrumentality of any foreign, federal, state, or local government or of any agency or subdivision thereof, or before any arbitrator or panel of arbitrators, which (i) challenges any Loan Party’s right or power to enter into or perform any of its obligations under this Fourth Amendment, the Amended Loan Documents, or any other Loan Document to which it is or will be, a party, or the validity or enforceability of this Fourth Amendment, the Amended Loan Documents or any other Loan Document or any action taken thereunder, or (ii) has a reasonable risk of being determined adversely to such Loan Party and that, if so determined, could reasonably be expected to have a Material Adverse Effect.

2. No Waivers/Consents/Amendments. Except as expressly provided herein, (a) the Credit Agreement and the other Loan Documents shall be unmodified and shall continue to be in full force and effect in accordance with their terms, and (b) this Fourth Amendment shall not be deemed a waiver or modification of any other term or condition of any Loan Document and shall not be deemed to prejudice any right or rights which Administrative Agent or any Lender may now have or may have in the future under or in connection with any Loan Document or any of the instruments or agreements referred to therein, as the same may be amended from time to time.

3. Affirmation of Obligations. Each of the Loan Parties hereby acknowledges, agrees and affirms (a) its obligations under the Credit Agreement and the other Loan Documents, including, without limitation, its guaranty obligations under the Guaranty and Security Agreement, (b) that such guaranty shall apply to the Obligations in accordance with the

terms thereof, (c) the grant of the security interest in all of its assets pursuant to the Loan Documents and (d) that such liens and security interests created and granted are valid and continuing and secure the Obligations in accordance with the terms thereof, in each case after giving effect to this Fourth Amendment.

4. Costs and Expenses. The Borrower hereby reconfirms its obligations pursuant to Section 11.3 of the Credit Agreement to pay and reimburse the Administrative Agent for all reasonable costs and expenses (including, without limitation, reasonable fees of counsel) incurred in connection with the negotiation, preparation, execution and delivery of this Fourth Amendment and all other documents and instruments delivered in connection herewith.

5. Amendment Effectiveness. This Fourth Amendment shall become effective on the date on which each of the following conditions shall have been satisfied (the “Fourth Amendment Effective Date”):

(a) Amendment. The Borrower, each Guarantor, the Administrative Agent, the Required Lenders and each Lender with an outstanding B Term Loan, Incremental B-1 Term Loan and Incremental B-2 Term Loan (including any Substitute Lender that replaces an Affected Lender with outstanding B Term Loans, Incremental B-1 Term Loans or Incremental B-2 Term Loans) shall have signed a counterpart hereof (whether the same or different counterparts) and shall have delivered (including by way of facsimile or other electronic transmission) the same to the Administrative Agent c/o White & Case LLP, 1155 Avenue of the Americas, New York, New York 10036, Attention: Liza Carens (facsimile number: 212-354-8113 / email address: AlereAmendment@whitecase.com).

(b) Payment of Fees, Costs and Expenses. The Borrower shall have paid, by wire transfer of immediately available funds:

(i) to the Administrative Agent, all costs, fees and expenses owing in connection with this Fourth Amendment and the other Loan Documents and due to the Administrative Agent; and

(ii) to White & Case LLP, as counsel to the Administrative Agent, all fees and expenses of White & Case LLP as set forth in the invoice submitted to the Borrower on or about March 14, 2013 in connection with the Loan Documents and this Fourth Amendment.

(c) No Default; Representations and Warranties. (i) No Default or Event of Default shall have occurred and be continuing or would occur after giving effect to this Fourth Amendment and (ii) the representations and warranties made by or on behalf of each Loan Party in this Fourth Amendment, the Credit Agreement and the other Loan Documents shall be true and correct in all material respects on and as of the Fourth Amendment Effective Date (it being understood that (x) any representation or warranty that is qualified by materiality or Material Adverse Effect shall be required to be true and correct in all respects and (y) any representation or warranty which by its terms is made as of a specified date shall be required to be true and correct in all material respects (or all respects, as the case may be) as of such specified date).

(d) Officer’s Certificate. The Borrower shall have delivered to the Administrative Agent a certificate executed by a Responsible Officer of the Borrower certifying that the conditions set forth in preceding clause (c) have been satisfied as of the Fourth Amendment Effective Date.

6. Governing Law. This Fourth Amendment, and the rights and obligations of the parties hereto, shall be governed by, and construed and interpreted in accordance with, the law of the State of New York.

7. Counterparts. This Fourth Amendment may be executed by the parties hereto on any number of separate counterparts and all of said counterparts taken together shall be deemed to constitute one and the same instrument.

[SIGNATURE PAGES FOLLOW]

IN WITNESS WHEREOF, the parties hereto have caused their duly authorized officers to execute and deliver this Fourth Amendment as of the date first above written.

ALERE INC.
By:	/s/ David Teitel
	Name:	David Teitel
	Title:	CFO, VP & Treasurer
GENERAL ELECTRIC CAPITAL CORPORATION, as Lender and as Administrative Agent
By:	/s/ Ryan Guenin
	Name:	Ryan Guenin
	Title:	Duly Authorized Signatory

ACKNOWLEDGED AND AGREED:

ALERE HEALTH IMPROVEMENT COMPANY

ALERE HEALTH, LLC

ALERE HEALTHCARE OF ILLINOIS, INC.

ALERE HOME MONITORING, INC.

ALERE INTERNATIONAL HOLDING CORP.

ALERE NEWCO, INC.

ALERE NEWCO II, INC.

ALERE NORTH AMERICA, INC.

ALERE OF NEW YORK, INC.

ALERE SAN DIEGO, INC.

ALERE SCARBOROUGH, INC.

ALERE US HOLDINGS, LLC

ALERE WELLBEING, INC.

ALERE WELLOLOGY, INC.

ALERE WOMEN’S AND CHILDREN’S HEALTH, LLC

AMEDITECH INC.

BINAX, INC.

BIOSITE INCORPORATED

FIRST CHECK DIAGNOSTICS CORP.

FIRST CHECK ECOM, INC.

INNOVACON, INC.

INSTANT TECHNOLOGIES, INC.

INVERNESS MEDICAL, LLC

IVC INDUSTRIES, INC.

QUALITY ASSURED SERVICES, INC.

REDWOOD TOXICOLOGY LABORATORY, INC.

RMD NETWORKS, INC.

RTL HOLDINGS, INC.

SELFCARE TECHNOLOGY, INC.

SPDH, INC.

ZYCARE, INC.

By:	/s/ David A. Teitel
Name:	David A. Teitel
Title(respectively): Vice President & Treasurer, Vice President & Treasurer, Vice President, Finance & Treasurer, Vice President, Finance, President, President, President, Vice President, Finance, Vice President, Finance, Vice President, Finance, Vice President, Finance, President, Vice President, Finance & Treasurer, Vice President, Finance, Vice President, Finance, Chief Financial Officer & Treasurer, Vice President, Finance, Vice President, Finance, Vice President, Finance, Vice President, Vice President, Finance, Vice President, Finance, Vice President, Finance, President, Vice President, Finance, Vice President, Finance, Vice President, Finance & Treasurer, Vice President, Finance, Vice President, Finance, President, Chief Financial Officer and Treasurer

ALERE TOXICOLOGY SERVICES, INC.

LABORATORY SPECIALISTS OF AMERICA, INC.

By:	/s/ Ellen V. Chiniara
Name:	Ellen V. Chiniara

Title (respectively): Secretary, Secretary

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CEDAR FUNDING LTR.
By:	AEGON USA Investment Management, LLC
By:	/s/ Lisa Baltagi
Name:	Lisa Baltagi
Title:	Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
MALIBU CBNA LOAN FUNDING LLC
By:
By:	/s/ illegible
Name:
Title:

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ABCLO 2007-1, LTD.
By:	AllianceBernstein L.P.
By:	/s/ Michael Sohr
Name:	Michael Sohr
Title:	Senior Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ALLIANCEBERNSTEIN INSTITUTIONAL INVESTMENTS – HIGH YIELD LOAN PORTFOLIO
By:	AllianceBernstein L.P.
By:	/s/ Michael Sohr
Name:	Michael Sohr
Title:	Senior Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
AIB DEBT MANAGEMENT LIMITED
By:	/s/ Roisin O’Connell
Name:	Roison O’Connell
Title:	Senior Vice President, Investment Advisor to AIB Debt Management, Limited
By:	/s/ Joanne O’Driscoll
Name:	Joanne O’Driscoll
Title:	Senior Vice President, Investment Advisor to AIB Debt Management, Limited

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
AIMCO CLO, SERIES 2005-A
By:	/s/ Chris Goergen
Name:	Chris Goergen
Title:	Authorized Signatory
By:	/s/ Mark Cloghessy
Name:	Mark Cloghessy
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
AIMCO CLO, SERIES 2006-A
By:	/s/ Chris Goergen
Name:	Chris Goergen
Title:	Authorized Signatory
By:	/s/ Mark Cloghessy
Name:	Mark Cloghessy
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ALLSTATE LIFE INSURANCE COMPANY
By:	/s/ Chris Goergen
Name:	Chris Goergen
Title:	Authorized Signatory
By:	/s/ Mark Cloghessy
Name:	Mark Cloghessy
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
AMMC CLO IX, LIMITED
By:	American Money Management Corp., as Collateral Manager
By:	/s/ David P. Meyer
Name:	David P. Meyer
Title:	Senior Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
AMMC CLO X, LIMITED
By:	American Money Management Corp., as Collateral Manager
By:	/s/ David P. Meyer
Name:	David P. Meyer
Title:	Senior Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
AMMC CLO XI, LIMITED
By:	American Money Management Corp., as Collateral Manager
By:	/s/ David P. Meyer
Name:	David P. Meyer
Title:	Senior Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
AMMC CLO VII, LIMITED
By:	American Money Management Corp., as Collateral Manager
By:	/s/ David P. Meyer
Name:	David P. Meyer
Title:	Senior Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ACA CLO 2006-1 LTD
By:	Its Investment Advisor CVC Credit Partners, LLC
By:	/s/ Vincent Ingato
Name:	Vincent Ingato
Title:	MD/PM

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ACA CLO 2006-1 LTD
By:	Its Investment Advisor CVC Credit Partners, LLC
By:	/s/ Vincent Ingato
Name:	Vincent Ingato
Title:	MD/PM

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ACA CLO 2007-1 LTD
By:	Its Investment Advisor CVC Credit Partners, LLC
By:	/s/ Vincent Ingato
Name:	Vincent Ingato
Title:	MD/PM

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
APIDOS CDO I
By:	Its Investment Advisor CVC Credit Partners, LLC
By:	/s/ Vincent Ingato
Name:	Vincent Ingato
Title:	MD/PM

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
APIDOS CDO II
By:	Its Investment Advisor CVC Credit Partners, LLC
By:	/s/ Vincent Ingato
Name:	Vincent Ingato
Title:	MD/PM

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
APIDOS CDO III
By:	Its Investment Advisor CVC Credit Partners, LLC
By:	/s/ Vincent Ingato
Name:	Vincent Ingato
Title:	MD/PM

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
APIDOS CDO IV
By:	Its Investment Advisor CVC Credit Partners, LLC
By:	/s/ Vincent Ingato
Name:	Vincent Ingato
Title:	MD/PM

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
APIDOS CDO IV
By:	Its Investment Advisor CVC Credit Partners, LLC
By:	/s/ Vincent Ingato
Name:	Vincent Ingato
Title:	MD/PM

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
APIDOS CDO V
By:	Its Investment Advisor CVC Credit Partners, LLC
By:	/s/ Vincent Ingato
Name:	Vincent Ingato
Title:	MD/PM

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
APIDOS CINCO CDO
By:	Its Investment Advisor CVC Credit Partners, LLC
By:	/s/ Vincent Ingato
Name:	Vincent Ingato
Title:	MD/PM

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
APIDOS CLO IX
By:	Its Collateral Manager CVC Credit Partners, LLC
By:	/s/ Vincent Ingato
Name:	Vincent Ingato
Title:	MD/PM

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
APIDOS CLO VIII
By:	Its Collateral Manager CVC Credit Partners, LLC
By:	/s/ Vincent Ingato
Name:	Vincent Ingato
Title:	MD/PM

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
APIDOS CLO X
By:	Its Collateral Manager CVC Credit Partners, LLC
By:	/s/ Vincent Ingato
Name:	Vincent Ingato
Title:	MD/PM

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
APIDOS QUATTRO CDO
By:	Its Investment Advisor CVC Credit Partners, LLC
By:	/s/ Vincent Ingato
Name:	Vincent Ingato
Title:	MD/PM

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
SAN GABRIEL, CLO I LTD
By:	Its Investment Advisor CVC Credit Partners, LLC On behalf of Resource Capital Assets Management (RCAM)
By:	/s/ Vincent Ingato
Name:	Vincent Ingato
Title:	MD/PM

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
SHASTA CLO I LTD
By:	Its Investment Advisor CVC Credit Partners, LLC On behalf of Resource Capital Assets Management (RCAM)
By:	/s/ Vincent Ingato
Name:	Vincent Ingato
Title:	MD/PM

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
SIERRA CLO II LTD
By:	Its Investment Advisor CVC Credit Partners, LLC On behalf of Resource Capital Assets Management (RCAM)
By:	/s/ Vincent Ingato
Name:	Vincent Ingato
Title:	MD/PM

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ALM IV, LTD
By:	Apollo Credit Management (CLO), LLC as Collateral Manager
By:	/s/ Joe Moroney
Name:	Joe Moroney
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ALM LOAN FUNDER 2010-3, LTD
By:	Apollo Credit Management (CLO), LLC as Collateral Manager
By:	/s/ Joe Moroney
Name:	Joe Moroney
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ALM V, LTD
By:	Apollo Credit Management (CLO), LLC as Collateral Manager
By:	/s/ Joe Moroney
Name:	Joe Moroney
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ALM VI, LTD
By:	Apollo Credit Management (CLO), LLC as Collateral Manager
By:	/s/ Joe Moroney
Name:	Joe Moroney
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ALM VII, LTD
By:	Apollo Credit Management (CLO), LLC as Collateral Manager
By:	/s/ Joe Moroney
Name:	Joe Moroney
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
APIDOS QUATTRO CDO
By:	Its Investment Advisor CVC Credit Partners, LLC
By:	/s/ Vincent Ingato
Name:	Vincent Ingato
Title:	MD/PM

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
APPOLLO/PALMETTO LOAN PORTFOLIO, L.P.
By:	Apollo Credit Management II, L.P., its investment manager LLC as Collateral Manager
By:	Apollo Credit Management II, G.P., LLC Its general partner
By:	/s/ Joe Moroney
Name:	Joe Moroney
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CENT CDO 10 LIMITED
By:	Columbia Management Investment Advisers, LLC As Collateral Manager
By:	/s/ Robin C. Stancil
Name:	Robin C. Stancil
Title:	Assistant Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CENT CDO XI LIMITED
By:	Columbia Management Investment Advisers, LLC As Collateral Manager
By:	/s/ Robin C. Stancil
Name:	Robin C. Stancil
Title:	Assistant Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CENTURION CDO 8 LIMITED
By:	Columbia Management Investment Advisers, LLC As Collateral Manager
By:	/s/ Robin C. Stancil
Name:	Robin C. Stancil
Title:	Assistant Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CENTURION CDO 9 LIMITED
By:	Columbia Management Investment Advisers, LLC As Collateral Manager
By:	/s/ Robin C. Stancil
Name:	Robin C. Stancil
Title:	Assistant Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
DIVERSIFIED CREDIT PORTFOLIO LTD.
By:	Invesco Senior Secured Management, Inc. as Investment Adviser
By:	/s/ Kevin Egan
Name:	Kevin Egan
Title:	Authorized Individual

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
DOUBLE HAUL TRADING, LLC
By:	Sun Trust Bank, its Manager
By:	/s/ Douglas Weitz
Name:	Douglas Weitz
Title:	Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GULF STREAM – COMPASS CLO 2007, LTD.
By:	Gulf Stream Asset Management LLC As Collateral Manager
By:	/s/ Joe Moroney
Name:	Joe Moroney
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GULF STREAM – RASHINBAN CLO 2006-I, LTD.
By:	Gulf Stream Asset Management LLC As Collateral Manager
By:	/s/ Joe Moroney
Name:	Joe Moroney
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GULF STREAM – SEXTANT CLO 2007-1, LTD.
By:	Gulf Stream Asset Management LLC As Collateral Manager
By:	/s/ Joe Moroney
Name:	Joe Moroney
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
LEVERAGESOURCE V S.A.R.L.
By:	/s/ Laurent Ricci
Name:	Laurent Ricci
Title:	Class B Manager
By:	/s/ Joe Moroney
Name:	Joe Moroney
Title:	Class A Manager

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
LSR LOAN FUNDING LLC
By:	Citibank N.A.
By:	/s/ Tina Tran
Name:	Tina Tran
Title:	Associate Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
NEPTUNE FINANCE CCS, LTD.
By:	Gulf Stream Asset Management LLC As Collateral Manager
By:	/s/ Joe Moroney
Name:	Joe Moroney
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
TETON FUNDING, LLC
By:	SunTrust Bank, its Manager
By:	/s/ Douglas Weitz
Name:	Douglas Weitz
Title:	Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ARCH INVESTMENT HOLDINGS III LTD.
By:	PineBridge Investments LLC As Collateral Manager
By:	/s/ Steven Oh
Name:	Steven Oh
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ARES ENHANCED LOAN INVESTMENT STRATEGY II, LTD.
ARES Enhanced Loan Investment Strategy II, Ltd.
By:	ARES Enhanced Loan Management II, L.P., Its Portfolio Manager
By:	ARES Enhanced Loan II GP, LLC, Its General Partner
By:	/s/ John Eanes
Name:	John Eanes
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ARES ENHANCED LOAN INVESTMENT STRATEGY III, LTD.
ARES Enhanced Loan Investment Strategy III, Ltd.
By:	ARES Enhanced Loan Management III, L.P., Its Portfolio Manager
By:	ARES Enhanced Loan III GP, LLC, Its General Partner
By:	/s/ John Eanes
Name:	John Eanes
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ARES ENHANCED LOAN INVESTMENT STRATEGY IR, LTD.
ARES Enhanced Loan Investment Strategy IR Ltd.
By:	ARES Enhanced Loan Management IR, L.P., As Portfolio Manager
By:	ARES Enhanced Loan IR GP, LLC, Its General Partner
By:	/s/ John Eanes
Name:	John Eanes
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ARES ENHANCED LOAN INVESTMENT STRATEGY IR, LTD.
ARES Enhanced Loan Investment Strategy IR Ltd.
By:	ARES Enhanced Loan Management IR, L.P., As Portfolio Manager
By:	ARES Enhanced Loan IR GP LLC, Its General Partner
By:	/s/ John Eanes
Name:	John Eanes
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ARES IIIR/IVR CLO LTD.
ARES IIR/IVR CLO LTD.
By:	ARES CLO Management IIIR/IVR, L.P., Its Asset Manager
By:	ARES CLO Management IIIR/IVR, L., Its General Partner
By:	/s/ John Eanes
Name:	John Eanes
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ARES LOAN TRUST 2011
ARES Loan Trust 2011
By:	ARES Management LLC, Its Investment Manager
By:	/s/ John Eanes
Name:	John Eanes
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ARES NF CLO XIV LTD.
ARES NF CLO XIV Ltd.
By:	ARES NF CLO XIV Management, L.P., its collateral manager
By:	ARES NF CLO XIV Management LLC, its general partner
By:	/s/ John Eanes
Name:	John Eanes
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ARES NF CLO XV LTD.
ARES NF CLO XV Ltd.
By:	ARES NF CLO XV Management, L.P., its collateral manager
By:	ARES NF CLO XV Management LLC, its general partner
By:	/s/ John Eanes
Name:	John Eanes
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ARES SENIOR LOAN TRUST
ARES Senior Loan Trust
By:	ARES Senior Loan Trust Management, L.P., its Investment Manager
By:	ARES Senior Loan Trust Management, LLC, its General Partner
By:	/s/ John Eanes
Name:	John Eanes
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ARES SPC HOLDINGS, L.P.
ARES SPC Holdings, L.P.
By:	ARES SPC Holdings GP LLC, General Partner
By:	/s/ John Eanes
Name:	John Eanes
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ARES VIR CLO LTD.
ARES VIR CLO LTD.
By:	ARES CLO Management VIR, L.P., its Investment Manager
By:	ARES CLO Management VIR, L.P., its General Partner
By:	/s/ John Eanes
Name:	John Eanes
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ARES XI CLO LTD.
ARES XI CLO LTD.
By:	ARES CLO Management XI, L.P., Its Asset Manager
By:	ARES CLO GP XI, LLC, its General Partner
By:	/s/ John Eanes
Name:	John Eanes
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ARES XII CLO LTD.
ARES XII CLO Ltd.
By:	ARES CLO Management XII, L.P., Its Asset Manager
By:	ARES CLO GP XII, LLC, Its General Partner
By:	/s/ John Eanes
Name:	John Eanes
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ARES XVI CLO LTD.
ARES XVI CLO Ltd.
By:	ARES CLO Management XVI, L.P., Its Asset Manager
By:	ARES CLO GP XVI, LLC, Its General Partner
By:	/s/ John Eanes
Name:	John Eanes
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ARES XXI CLO LTD.
ARES XXI CLO Ltd.
By:	ARES CLO Management XXI, L.P., Its Investment Manager
By:	ARES CLO GP XXI, LLC, Its General Partner
By:	/s/ John Eanes
Name:	John Eanes
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ARES XXII CLO LTD.
ARES XXII CLO Ltd.
By:	ARES CLO Management XXII, L.P., Its Asset Manager
By:	ARES CLO GP XXII, LLC, Its General Partner
By:	/s/ John Eanes
Name:	John Eanes
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ARES XXIII CLO LTD.
ARES XXIII CLO Ltd.
By:	ARES CLO Management XXIII, L.P., Its Asset Manager
By:	ARES CLO GP XXIII, LLC, Its General Partner
By:	/s/ John Eanes
Name:	John Eanes
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ARES XXIV CLO LTD.
ARES XXIV CLO Ltd.
By:	ARES CLO Management XXIV, L.P., Its Asset Manager
By:	ARES CLO GP XXIV, LLC, Its General Partner
By:	/s/ John Eanes
Name:	John Eanes
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ARES XXV CLO LTD.
ARES XXV CLO Ltd.
By:	ARES CLO Management XXV, L.P., its Asset Manager
By:	ARES CLO GP XXV, LLC, its General Partner
By:	/s/ John Eanes
Name:	John Eanes
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CONFLUENT 2 LIMITED
Confluent 2 Limited
By:	ARES Private Account Management I, L.P., as Sub-Manager
By:	ARES Private Account Management I, G.P., LLC, Its General Partner
By:	/s/ John Eanes
Name:	John Eanes
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
FUTURE FUND BOARD OF GUARDIANS
Future Fund Board of Guardians
By:	ARES Enhanced Loan Investment Strategy Advisor IV, L.P., Its Investment Manager (On Behalf of the Elis IV Sub Account)
By:	ARES Enhanced Loan Investment Strategy Advisor IV GP, LLC, Its General Partner
By:	/s/ John Eanes
Name:	John Eanes
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GLOBAL LOAN OPPORTUNITY FUND B.V.
Global Loan Opportunity Fund B.V.
By:	ARES Management Limited, Its Portfolio Manager
By:	/s/ John Eanes
Name:	John Eanes
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
PPF NOMINEE 1 B.V.
PPF Nominee 1 B.V.
By:	ARES Management Limited, Its Portfolio Manager
By:	/s/ John Eanes
Name:	John Eanes
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
SEI INSTITUTIONAL INVESTMENTS TRUST – OPPORTUNISTIC INCOME FUND
SEI Institutional Investments Trust – Opportunistic Income Fund
By:	ARES Management LLC, as Portfolio Manager
By:	/s/ John Eanes
Name:	John Eanes
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
WELLPOINT, INC
Wellpoint, Inc
By:	ARES Management L.P., its Investment Manager
By:	ARES WLP Management GP, LLC, General Partner
By:	/s/ John Eanes
Name:	John Eanes
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
WELLPOINT, INCL
By:	Sankaty Advisors, LLC as Investment Manager
By:	/s/ Andrew Viens
Name:	Andrew Viens
Title:	Document Control Team

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
BLACK DIAMOND CLO 2005-2 LTD.
By:	Black Diamond CLO 2005-2 Adviser, L.L.C. As its Collateral Manager
By:	/s/ Steve Deckoff
Name:	Steve Deckoff
Title:	Managing Principal

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
BLACK DIAMOND CLO 2006-1 (CAYMAN) LTD.
By:	Black Diamond CLO 2006-1 Adviser, L.L.C. As its Collateral Manager
By:	/s/ Steve Deckoff
Name:	Steve Deckoff
Title:	Managing Principal

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
BLACK DIAMOND CLO 2012-1 LTD.
By:	Black Diamond CLO 2012-1 Adviser, L.L.C. As its Portfolio Manager
By:	/s/ Stephen H. Deckoff
Name:	Stephen H. Deckoff
Title:	Managing Principal

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GSC CAPITAL CORP. LOAN FUNDING 2005-1
By:	GSC Acquisition Holdings, L.L.C., as its Collateral Manager
By:	GSC MANAGER, LLC, in its capacity as Manager
By:	BLACK DIAMOND CAPITAL MANAGEMENT, L.L.C., in its capacity as Member
By:	/s/ Steve Deckoff
Name:	Steve Deckoff
Title:	Managing Principal

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GSC GROUP CDO FUND VIII, LIMITED
By:	GSC Acquisition Holdings, L.L.C., as its Collateral Manager
By:	GSC MANAGER, LLC, in its capacity as Manager
By:	BLACK DIAMOND CAPITAL MANAGEMENT, L.L.C., in its capacity as Member
By:	/s/ Steve Deckoff
Name:	Steve Deckoff
Title:	Managing Principal

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
BMO HARRIS FINANCING, INC.
By:	/s/ Phillip Ho
Name:	Phillip Ho
Title:	Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GALLATIN CLO III 2007-1, LTD
As Assignee
By:	UrsaMine Credit Advisors, LLC as its Collateral Manager
By:	/s/ Nick D. RosenZevay
Name:	Nick D. RosenZevay
Title:	President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CAPITALSOURCE BANK
By:	/s/ Audrey Yen
Name:	Audrey Yen
Title:	Senior Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CAPITALSOURCE BANK
By:	/s/ Audrey Yen
Name:	Audrey Yen
Title:	Senior Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CARLYLE ARNAGE CLO, LTD
By:	/s/ Linda Pace
Name:	Linda Pace
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CARLYLE AZURE CLO, LTD
By:	/s/ Linda Pace
Name:	Linda Pace
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CARLYLE BRISTOL CLO, LTD.
By:	/s/ Linda Pace
Name:	Linda Pace
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CARLYLE BRISTOL CLO, LTD.
By:	/s/ Linda Pace
Name:	Linda Pace
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CARLYLE DAYTONA CLO, LTD.
By:	/s/ Linda Pace
Name:	Linda Pace
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CARLYLE GLOBAL MARKET STRATEGIES CLO 2012-1, LTD.
By:	/s/ Linda Pace
Name:	Linda Pace
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CARLYLE HIGH YIELD PARTNERS IX, LTD.
By:	/s/ Linda Pace
Name:	Linda Pace
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CARLYLE HIGH YIELD PARTNERS VIII, LTD.
By:	/s/ Linda Pace
Name:	Linda Pace
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CARLYLE HIGH YIELD PARTNERS X, LTD.
By:	/s/ Linda Pace
Name:	Linda Pace
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CARLYLE MCLAREN CLO, LTD.
By:	/s/ Linda Pace
Name:	Linda Pace
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CARLYLE VEYRON CLO, LTD.
By:	/s/ Linda Pace
Name:	Linda Pace
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CENTRAL PARK CLO, LTD.
By:	GSO / Blackstone Debt Funds Management LLC as Collateral Manager
By:	/s/ Daniel H. Smith
Name:	Daniel H. Smith
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
FOOTHILL CLO I, LTD.
By:	/s/ Linda Pace
Name:	Linda Pace
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
MOUNTAIN CAPITAL CLO IV LTD.
By:	/s/ Linda Pace
Name:	Linda Pace
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
MOUNTAIN CAPITAL CLO V LTD.
By:	/s/ Linda Pace
Name:	Linda Pace
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
MOUNTAIN CAPITAL CLO VI LTD.
By:	/s/ Linda Pace
Name:	Linda Pace
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CIFC FUNDING 2006-I, LTD. CIFC FUNDING 2006-IB, LTD. CIFC FUNDING 2006-II, LTD. CIFC FUNDING 2007-I, LTD. CIFC FUNDING 2007-II, LTD. CIFC FUNDING 2007-III, LTD. CIFC FUNDING 2007-IV, LTD. CIFC FUNDING 2011-I, LTD. CIFC FUNDING 2012-I, LTD. CIFC FUNDING 2012-II, LTD. CIFC FUNDING 2012-III, LTD.
By:	CIFC Asset Management LLC, its Collateral Manager
By:	/s/ Robert Ranocchia
Name:	Robert Ranocchia
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CIFC FUNDING 2006-I, LTD. CIFC FUNDING 2006-IB, LTD. CIFC FUNDING 2006-II, LTD. CIFC FUNDING 2007-I, LTD. CIFC FUNDING 2007-II, LTD. CIFC FUNDING 2007-III, LTD. CIFC FUNDING 2007-IV, LTD. CIFC FUNDING 2011-I, LTD. CIFC FUNDING 2012-I, LTD. CIFC FUNDING 2012-II, LTD. CIFC FUNDING 2012-III, LTD.
By:	CIFC Asset Management LLC, its Collateral Manager
By:	/s/ Robert Ranocchia
Name:	Robert Ranocchia
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CIFC FUNDING 2006-I, LTD. CIFC FUNDING 2006-IB, LTD. CIFC FUNDING 2006-II, LTD. CIFC FUNDING 2007-I, LTD. CIFC FUNDING 2007-II, LTD. CIFC FUNDING 2007-III, LTD. CIFC FUNDING 2007-IV, LTD. CIFC FUNDING 2011-I, LTD. CIFC FUNDING 2012-I, LTD. CIFC FUNDING 2012-II, LTD. CIFC FUNDING 2012-III, LTD.
By:	CIFC Asset Management LLC, its Collateral Manager
By:	/s/ Robert Ranocchia
Name:	Robert Ranocchia
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CIFC FUNDING 2006-I, LTD. CIFC FUNDING 2006-IB, LTD. CIFC FUNDING 2006-II, LTD. CIFC FUNDING 2007-I, LTD. CIFC FUNDING 2007-II, LTD. CIFC FUNDING 2007-III, LTD. CIFC FUNDING 2007-IV, LTD. CIFC FUNDING 2011-I, LTD. CIFC FUNDING 2012-I, LTD. CIFC FUNDING 2012-II, LTD. CIFC FUNDING 2012-III, LTD.
By:	CIFC Asset Management LLC, its Collateral Manager
By:	/s/ Robert Ranocchia
Name:	Robert Ranocchia
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CIFC FUNDING 2006-I, LTD. CIFC FUNDING 2006-IB, LTD. CIFC FUNDING 2006-II, LTD. CIFC FUNDING 2007-I, LTD. CIFC FUNDING 2007-II, LTD. CIFC FUNDING 2007-III, LTD. CIFC FUNDING 2007-IV, LTD. CIFC FUNDING 2011-I, LTD. CIFC FUNDING 2012-I, LTD. CIFC FUNDING 2012-II, LTD. CIFC FUNDING 2012-III, LTD.
By:	CIFC Asset Management LLC, its Collateral Manager
By:	/s/ Robert Ranocchia
Name:	Robert Ranocchia
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CIFC FUNDING 2006-I, LTD. CIFC FUNDING 2006-IB, LTD. CIFC FUNDING 2006-II, LTD. CIFC FUNDING 2007-I, LTD. CIFC FUNDING 2007-II, LTD. CIFC FUNDING 2007-III, LTD. CIFC FUNDING 2007-IV, LTD. CIFC FUNDING 2011-I, LTD. CIFC FUNDING 2012-I, LTD. CIFC FUNDING 2012-II, LTD. CIFC FUNDING 2012-III, LTD.
By:	CIFC Asset Management LLC, its Collateral Manager
By:	/s/ Robert Ranocchia
Name:	Robert Ranocchia
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CIFC FUNDING 2006-I, LTD. CIFC FUNDING 2006-IB, LTD. CIFC FUNDING 2006-II, LTD. CIFC FUNDING 2007-I, LTD. CIFC FUNDING 2007-II, LTD. CIFC FUNDING 2007-III, LTD. CIFC FUNDING 2007-IV, LTD. CIFC FUNDING 2011-I, LTD. CIFC FUNDING 2012-I, LTD. CIFC FUNDING 2012-II, LTD. CIFC FUNDING 2012-III, LTD.
By:	CIFC Asset Management LLC, its Collateral Manager
By:	/s/ Robert Ranocchia
Name:	Robert Ranocchia
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CIFC FUNDING 2006-I, LTD. CIFC FUNDING 2006-IB, LTD. CIFC FUNDING 2006-II, LTD. CIFC FUNDING 2007-I, LTD. CIFC FUNDING 2007-II, LTD. CIFC FUNDING 2007-III, LTD. CIFC FUNDING 2007-IV, LTD. CIFC FUNDING 2011-I, LTD. CIFC FUNDING 2012-I, LTD. CIFC FUNDING 2012-II, LTD. CIFC FUNDING 2012-III, LTD.
By:	CIFC Asset Management LLC, its Collateral Manager
By:	/s/ Robert Ranocchia
Name:	Robert Ranocchia
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CIFC FUNDING 2006-I, LTD. CIFC FUNDING 2006-IB, LTD. CIFC FUNDING 2006-II, LTD. CIFC FUNDING 2007-I, LTD. CIFC FUNDING 2007-II, LTD. CIFC FUNDING 2007-III, LTD. CIFC FUNDING 2007-IV, LTD. CIFC FUNDING 2011-I, LTD. CIFC FUNDING 2012-I, LTD. CIFC FUNDING 2012-II, LTD. CIFC FUNDING 2012-III, LTD.
By:	CIFC Asset Management LLC, its Collateral Manager
By:	/s/ Robert Ranocchia
Name:	Robert Ranocchia
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CIFC FUNDING 2006-I, LTD. CIFC FUNDING 2006-IB, LTD. CIFC FUNDING 2006-II, LTD. CIFC FUNDING 2007-I, LTD. CIFC FUNDING 2007-II, LTD.- CIFC FUNDING 2007-III, LTD. CIFC FUNDING 2007-IV, LTD. CIFC FUNDING 2011-I, LTD. CIFC FUNDING 2012-I, LTD. CIFC FUNDING 2012-II, LTD. CIFC FUNDING 2012-III, LTD.
By:	CIFC Asset Management LLC, its Collateral Manager
By:	/s/ Robert Ranocchia
Name:	Robert Ranocchia
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CIFC FUNDING 2006-I, LTD. CIFC FUNDING 2006-IB, LTD. CIFC FUNDING 2006-II, LTD. CIFC FUNDING 2007-I, LTD. CIFC FUNDING 2007-II, LTD.- CIFC FUNDING 2007-III, LTD. CIFC FUNDING 2007-IV, LTD. CIFC FUNDING 2011-I, LTD. CIFC FUNDING 2012-I, LTD. CIFC FUNDING 2012-II, LTD. CIFC FUNDING 2012-III, LTD.
By:	CIFC Asset Management LLC, its Collateral Manager
By:	/s/ Robert Ranocchia
Name:	Robert Ranocchia
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
HEWETT’S ISLAND CLO V, LTD. HEWETT’S ISLAND CLO VI, LTD. PRIMUS CLO II, LTD.
By:	CypressTree Investment Management, LLC, it’s Collateral Manager
By:	/s/ Robert Ranocchia
Name:	Robert Ranocchia
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CIT BANK
By:	/s/ John Tracey
Name:	John Tracey
Title:	Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CIT CLO I LTD.
By:	CIT Asset Management LLC
By:	/s/ Roger M Burns
Name:	Roger M. Burns
Title:	President, CIT Asset Management

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CITIBANK N.A.
By:	/s/ Brian Blessing
Name:	Brian Blessing
Title:	Attorney-in-Fact

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CITIZENS BANK
By:	/s/ Todd A. Seehase
Name:	Todd A. Seehase
Title:	First Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CENT CDO 10 LIMITED
By:	Columbia Management Investment Advisers, LLC As Collateral Manager
By:	/s/ Robin C. Stancil
Name:	Robin C. Stancil
Title:	Assistant Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CENT CDO 12 LIMITED
By:	Columbia Management Investment Advisers, LLC As Collateral Manager
By:	/s/ Robin C. Stancil
Name:	Robin C. Stancil
Title:	Assistant Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CENT CDO 14 LIMITED
By:	Columbia Management Investment Advisers, LLC As Collateral Manager
By:	/s/ Robin C. Stancil
Name:	Robin C. Stancil
Title:	Assistant Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CENT CDO 15 LIMITED
By:	Columbia Management Investment Advisers, LLC As Collateral Manager
By:	/s/ Robin C. Stancil
Name:	Robin C. Stancil
Title:	Assistant Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CENT CDO XI LIMITED
By:	Columbia Management Investment Advisers, LLC As Collateral Manager
By:	/s/ Robin C. Stancil
Name:	Robin C. Stancil
Title:	Assistant Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CENTURION CDO 9 LIMITED
By:	Columbia Management Investment Advisers, LLC As Collateral Manager
By:	/s/ Robin C. Stancil
Name:	Robin C. Stancil
Title:	Assistant Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
COLUMBIA FLOATING RATE FUND, A SERIES OF COLUMBIA FUNDS SERIES TRUST II
By:	/s/ Robin C. Stancil
Name:	Robin C. Stancil
Title:	Assistant Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
COLUMBIA STRATEGIC INCOME FUND, A SERIES OF COLUMBIA FUNDS SERIES TRUST II
By:	/s/ Robin C. Stancil
Name:	Robin C. Stancil
Title:	Assistant Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
COLUMBIA VARIABLE PORTFOLIO – STRATEGIC INCOME FUND, A SERIES OF COLUMBIA FUNDS VARIABLE INSURANCE TRUST
By:	/s/ Robin C. Stancil
Name:	Robin C. Stancil
Title:	Assistant Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
COLUMBIA FLOATING RATE FUND, A SERIES OF COLUMBIA FUNDS SERIES TRUST II
By:	/s/ Robin C. Stancil
Name:	Robin C. Stancil
Title:	Assistant Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
RIVERSOURCE BOND SERIES, INC.
By:	/s/ Scott R. Plummer
Name:	Scott R. Plummer
Title:	Secretary

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
RIVERSOURCE LIFE INSURANCE COMPANY
By:	/s/ Robin C. Stancil
Name:	Robin C. Stancil
Title:	Assistant Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CRÉDIT INDUSTRIEL ET COMMERCIAL
By:	/s/ Marcus Edward
Name:	Marcus Edward
Title:	Managing Director
By:
By:	/s/ Brian O’Leary
Name:	Brian O’Leary
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
LAFAYETTE CLO I LTD
By:	/s/ Marcus Edward
Name:	Marcus Edward
Title:	Managing Director
By:
By:	/s/ Brian O’Leary
Name:	Brian O’Leary
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
THE CITY OF NEW YORK GROUP TRUST
By:	Invesco Senior Secured Management, Inc. as Investment Manager
By:	/s/ Kevin Egan
Name:	Kevin Egan
Title:	Authorized Individual

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH
By:	/s/ Ari Bruger
Name:	Ari Bruger
Title:	Vice President
By:
By:	/s/ Tyler R. Smith
Name:	Tyler R. Smith
Title:	Associate

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GANNETT PEAK CLO I, LTD.
By:	THL Credit Senior Loan Strategies LLC, as Manager
By:	/s/ illegible
Name:	LandAmend LLC
Title:	Administrator

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ATRIUM V
By:	Credit Suisse Asset Management, LLC, as collateral manager
By:	/s/ Thomas Flannery
Name:	Thomas Flannery
Title:

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
AUSTRALIANSUPER
By:	Credit Suisse Asset Management, LLC, as sub-advisor to Bentham Asset Manager Pty Ltd. in its capacity as agent of and investment manager for AustralianSuper Pty Ltd. In its capacity as trustee of AustralianSuper
By:	/s/ Thomas Flannery
Name:	Thomas Flannery
Title:

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
BENTHAM WHOLESALE SYNDICATED LOAN FUND
By:	Credit Suisse Asset Management, LLC, as agent (sub-advisor) for Challenger Investment Services Limited, the Responsible Entity for Bentham Wholesale Syndicated Loan Fund
By:	/s/ Thomas Flannery
Name:	Thomas Flannery
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CASTLE GARDEN FUNDING
By:	/s/ Thomas Flannery
Name:	Thomas Flannery
Title:

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
MADISON PARK FUNDING II, LTD.
By:	Credit Suisse Asset Management, LLC, as collateral manager
By:	/s/ Thomas Flannery
Name:	Thomas Flannery
Title:

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
MADISON PARK FUNDING III, LTD.
By:	Credit Suisse Asset Management, LLC, as collateral manager
By:	/s/ Thomas Flannery
Name:	Thomas Flannery
Title:

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
MADISON PARK FUNDING V, LTD.
By:	Credit Suisse Asset Management, LLC, as collateral manager
By:	/s/ Thomas Flannery
Name:	Thomas Flannery
Title:

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
MADISON PARK FUNDING VI, LTD.
By:	Credit Suisse Asset Management, LLC, as collateral manager
By:	/s/ Thomas Flannery
Name:	Thomas Flannery
Title:

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
QUALCOMM GLOBAL TRADING PTE. LTD.
By:	Credit Suisse Asset Management, LLC, as investment manager
By:	/s/ Thomas Flannery
Name:	Thomas Flannery
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
WEST CLO 2012-1 LTD.
By:	/s/ Joanna Willars
Name:	Joanna Willars
Title:	Vice President, Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CIT BANK
By:	/s/ John Tracey
Name:	John Tracey
Title:	Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
BRIDGEPORT CLO LTD. SCHILLER PARK CLO LTD. BURR RIDGE CLO PLUS LTD. BRIDGEPORT CLO II LTD.
By:	Deerfield Capital Management LLC, its Collateral Manager
By:	/s/ Robert Ranocchia
Name:	Robert Ranocchia
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
BRIDGEPORT CLO LTD. SCHILLER PARK CLO LTD. BURR RIDGE CLO PLUS LTD. BRIDGEPORT CLO II LTD.
By:	Deerfield Capital Management LLC, its Collateral Manager
By:	/s/ Robert Ranocchia
Name:	Robert Ranocchia
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
BRIDGEPORT CLO LTD. SCHILLER PARK CLO LTD. BURR RIDGE CLO PLUS LTD. BRIDGEPORT CLO II LTD.
By:	Deerfield Capital Management LLC, its Collateral Manager
By:	/s/ Robert Ranocchia
Name:	Robert Ranocchia
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
COLUMBUS PARK CDO LTD.
By:	GSO / Blackstone Debt Funds Management LLC as Portfolio Manager
By:	/s/ Daniel H. Smith
Name:	Daniel H. Smith
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
COLUMBUSNOVA CLO LTD. 2006-I COLUMBUSNOVA CLO LTD. 2006-II COLUMBUSNOVA CLO LTD. 2007-I COLUMBUSNOVA CLO IV LTD. 2007-II
By:	Columbus Nova Credit Investments Management, LLC, its Collateral Manager
By:	/s/ Robert Ranocchia
Name:	Robert Ranocchia
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
COLUMBUSNOVA CLO LTD. 2006-I COLUMBUSNOVA CLO LTD. 2006-II COLUMBUSNOVA CLO LTD. 2007-I COLUMBUSNOVA CLO IV LTD. 2007-II
By:	Columbus Nova Credit Investments Management, LLC, its Collateral Manager
By:	/s/ Robert Ranocchia
Name:	Robert Ranocchia
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
COLUMBUSNOVA CLO LTD. 2006-I COLUMBUSNOVA CLO LTD. 2006-II COLUMBUSNOVA CLO LTD. 2007-I COLUMBUSNOVA CLO IV LTD. 2007-II
By:	Columbus Nova Credit Investments Management, LLC, its Collateral Manager
By:	/s/ Robert Ranocchia
Name:	Robert Ranocchia
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
HEWETT’S ISLAND CLO I-R, LTS
By:	Acis Capital Management, LP, its Collateral Manager Acis Capital Management, GP, LLC, its general partner
By:	/s/ Carter Chism
Name:	Carter Chism
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
HEWETT’S ISLAND CLO V, LTD HEWETT’S ISLAND CLO VI, LTD. PRIMUS CLO II, LTD.
By:	CypressTree Investment Management, LLC, its Collateral Manager
By:	/s/ Robert Ranocchia
Name:	Robert Ranocchia
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
HEWETT’S ISLAND CLO V, LTD HEWETT’S ISLAND CLO VI, LTD. PRIMUS CLO II, LTD.
By:	CypressTree Investment Management, LLC, its Collateral Manager
By:	/s/ Robert Ranocchia
Name:	Robert Ranocchia
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
HEWETT’S ISLAND CLO V, LTD HEWETT’S ISLAND CLO VI, LTD. PRIMUS CLO II, LTD.
By:	CypressTree Investment Management, LLC, its Collateral Manager
By:	/s/ Robert Ranocchia
Name:	Robert Ranocchia
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
BRIDGEPORT CLO LTD. SCHILLER PARK CLO LTD. BURR RIDGE CLO PLUS LTD. BRIDGEPORT CLO II LTD.
By:	Deerfield Capital Management LLC, its Collateral Manager
By:	/s/ Robert Ranocchia
Name:	Robert Ranocchia
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
DENALI CAPITAL CLO V, LTD.
By:	Denali Capital LLC, managing member of DC Funding Partners LLC, portfolio manager
By:	/s/ Kelli C. Marti
Name:	Kelli Marti
Title:	Senior Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
I
By:	Denali Capital LLC, managing member of DC Funding Partners LLC, collateral manager
By:	/s/ Kelli C. Marti
Name:	Kelli Marti
Title:	Senior Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
DENALI CAPITAL CLO VII, LTD.
By:	Denali Capital LLC, managing member of DC Funding Partners LLC, portfolio manager
By:	/s/ Kelli C. Marti
Name:	Kelli Marti
Title:	Senior Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
SPRING ROAD CLO 2007-1, LTD.
By:	Denali Capital LLC, managing member of DC Funding Partners LLC, Collateral Manager
By:	/s/ Kelli C. Marti
Name:	Kelli Marti
Title:	Senior Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
DEUTSCHE BANK AG NEW YORK BRANCH.
By:	DB Services New Jersey, Inc.
By:	/s/ Andrew Mac Donald
Name:	Andrew Mac Donald
Title:	Associate
By:
By:	/s/ Angeline Quintana
Name:	Angeline Quintana
Title:	Assistant Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
DNB BANK ASA, GRAND CAYMAN BRANCH
By:	/s/ Geshu Sugandh
Name:	Geshu Sugandh
Title:	Vice President
By:
By:	/s/ Bjorn E. Hammerstad
Name:	Bjorn Erik Hammerstad
Title:	Senior Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
EAST WEST BANK
By:	/s/ Andrew Maria
Name:	Andrew Maria
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
COLUMBIA FUNDS VARIABLE SERIES TRUST II- VARIABLE PORTFOLIO- EATON VANCE FLOATING-RATE INCOME FUND
By:	Eaton Vance Management as Investment Sub-Advisor
By:	/s/ Michael B. Botthof
Name:	Michael B. Botthof
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
EATON VANCE CDO IX LTD.
By:	Eaton Vance Management as Investment Advisor
By:	/s/ Michael B. Botthof
Name:	Michael B. Botthof
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
EATON VANCE CDO VII PLC.
By:	Eaton Vance Management as Interim Investment Advisor
By:	/s/ Michael B. Botthof
Name:	Michael B. Botthof
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
EATON VANCE CDO VIII LTD.
By:	Eaton Vance Management as Investment Advisor
By:	/s/ Michael B. Botthof
Name:	Michael B. Botthof
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
EATON VANCE CDO X PLC
By:	Eaton Vance Management as Investment Advisor
By:	/s/ Michael B. Botthof
Name:	Michael B. Botthof
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
EATON VANCE FLOATING-RATE INCOME TRUST
By:	Eaton Vance Management as Investment Advisor
By:	/s/ Michael B. Botthof
Name:	Michael B. Botthof
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
EATON VANCE INSTITUTIONAL SENIOR LOAN FUND
By:	Eaton Vance Management as Investment Advisor
By:	/s/ Michael B. Botthof
Name:	Michael B. Botthof
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
EATON VANCE INTERNATIONAL (CAYMAN ISLANDS) FLOATING-RATE INCOME PORTFOLIO
By:	Eaton Vance Management as Investment Advisor
By:	/s/ Michael B. Botthof
Name:	Michael B. Botthof
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
EATON VANCE LIMITED DURATION INCOME FUND
By:	Eaton Vance Management as Investment Advisor
By:	/s/ Michael B. Botthof
Name:	Michael B. Botthof
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
EATON VANCE SENIOR FLOATING-RATE TRUST
By:	Eaton Vance Management as Investment Advisor
By:	/s/ Michael B. Botthof
Name:	Michael B. Botthof
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
EATON VANCE SENIOR INCOME TRUST
By:	Eaton Vance Management as Investment Advisor
By:	/s/ Michael B. Botthof
Name:	Michael B. Botthof
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
EATON VANCE SHORT DURATION DIVERSIFIED INCOME FUND
By:	Eaton Vance Management as Investment Advisor
By:	/s/ Michael B. Botthof
Name:	Michael B. Botthof
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
EATON VANCE VT FLOATING-RATE INCOME FUND
By:	Eaton Vance Management as Investment Advisor
By:	/s/ Michael B. Botthof
Name:	Michael B. Botthof
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GRAYSON & CO.
By:	Boston Management and Research as Investment Advisor
By:	/s/ Michael B. Botthof
Name:	Michael B. Botthof
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GRAYSON CLO, LTD.
By:	Highland Capital Management, L.P. As Collateral Manager
By:	/s/ Carter Chism
Name:	Carter Chism
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
INNOVATION TRUST 2009
By:	Eaton Vance Management as Investment Advisor
By:	/s/ Michael B. Botthof
Name:	Michael B. Botthof
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
MET INVESTORS SERIES TRUST - MET/EATON VANCE FLOATING RATE PORTFOLIO
By:	Eaton Vance Management as Investment Sub-Advisor
By:	/s/ Michael B. Botthof
Name:	Michael B. Botthof
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
PACIFIC LIFE FUNDS - PL FLOATING RATE LOAN FUND
By:	Eaton Vance Management as Investment Sub-Advisor
By:	/s/ Michael B. Botthof
Name:	Michael B. Botthof
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
PACIFIC SELECT FUND FLOATING RATE LOAN PORTFOLIO
By:	Eaton Vance Management as Investment Sub-Advisor
By:	/s/ Michael B. Botthof
Name:	Michael B. Botthof
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
COLUMBIA FUNDS VARIABLE SERIES TRUST II - VARIABLE PORTFOLIO - EATON VANCE FLOATING INCOME FUND
By:	Eaton Vance Management as Investment Sub-Advisor
By:	/s/ Michael B. Botthof
Name:	Michael B. Botthof
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
EATON VANCE CDO X PLC
By:	Eaton Vance Management as Investment Advisor
By:	/s/ Michael B. Botthof
Name:	Michael B. Botthof
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
EATON VANCE FLOATING-RATE INCOME TRUST
By:	Eaton Vance Management as Investment Advisor
By:	/s/ Michael B. Botthof
Name:	Michael B. Botthof
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
EATON VANCE INSTITUTIONAL SENIOR LOAN FUND
By:	Eaton Vance Management as Investment Advisor
By:	/s/ Michael B. Botthof
Name:	Michael B. Botthof
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
EATON VANCE INTERNATIONAL (CAYMAN ISLANDS) FLOATING-RATE INCOME PORTFOLIO
By:	Eaton Vance Management as Investment Advisor
By:	/s/ Michael B. Botthof
Name:	Michael B. Botthof
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
EATON VANCE LIMITED DURATION INCOME FUND
By:	Eaton Vance Management as Investment Advisor
By:	/s/ Michael B. Botthof
Name:	Michael B. Botthof
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
EATON VANCE SENIOR FLOATING-RATE TRUST
By:	Eaton Vance Management as Investment Advisor
By:	/s/ Michael B. Botthof
Name:	Michael B. Botthof
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
EATON VANCE SENIOR INCOME TRUST
By:	Eaton Vance Management as Investment Advisor
By:	/s/ Michael B. Botthof
Name:	Michael B. Botthof
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
EATON VANCE SHORT DURATION DIVERSIFIED INCOME FUND
By:	Eaton Vance Management as Investment Advisor
By:	/s/ Michael B. Botthof
Name:	Michael B. Botthof
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
EATON VANCE VT FLOATING-RATE INCOME FUND
By:	Eaton Vance Management as Investment Advisor
By:	/s/ Michael B. Botthof
Name:	Michael B. Botthof
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GRAYSON & CO.
By:	Boston Management and Research as Investment Advisor
By:	/s/ Michael B. Botthof
Name:	Michael B. Botthof
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GRAYSON CLO, LTD.
By:	Highland Capital Management, L.P. As Collateral Manager
By:	/s/ Carter Chism
Name:	Carter Chism
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
INNOVATION TRUST 2009
By:	Eaton Vance Management as Investment Advisor
By:	/s/ Michael B. Botthof
Name:	Michael B. Botthof
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
MET INVESTORS SERIES TRUST - MET/EATON VANCE FLOATING RATE PORTFOLIO
By:	Eaton Vance Management as Investment Sub-Advisor
By:	/s/ Michael B. Botthof
Name:	Michael B. Botthof
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
PACIFIC LIFE FUNDS - PL FLOATING RATE LOAN FUND
By:	Eaton Vance Management as Investment Sub-Advisor
By:	/s/ Michael B. Botthof
Name:	Michael B. Botthof
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
PACIFIC SELECT FUND FLOATING RATE LOAN PORTFOLIO
By:	Eaton Vance Management as Investment Sub-Advisor
By:	/s/ Michael B. Botthof
Name:	Michael B. Botthof
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
COLUMBIA FUNDS VARIABLE SERIES TRUST II - VARIABLE PORTFOLIO - EATON VANCE FLOATING INCOME FUND
By:	Eaton Vance Management as Investment Sub-Advisor
By:	/s/ Michael B. Botthof
Name:	Michael B. Botthof
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
SENIOR DEBT PORTFOLIO
By:	Boston Management and Research as Investment Advisor
By:	/s/ Michael B. Botthof
Name:	Michael B. Botthof
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
AVERY STREET CLO, LTD.
By:
By:	/s/ S. D’Orsi
Name:	Scott D’Orsi
Title:	Portfolio Manager

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
EMERSON PLACE CLO, LTD.
By:
By:	/s/ S. D’Orsi
Name:	Scott D’Orsi
Title:	Portfolio Manager

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
LIME STREET CLO, LTD.
By:
By:	/s/ S. D’Orsi
Name:	Scott D’Orsi
Title:	Portfolio Manager

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
FIDELITY ADVISOR SERIES I: FIDELITY ADVISOR FLOATING RATE HIGH INCOME FUND
By:
By:	/s/ Stacie M. Smith
Name:	Stacie M. Smith
Title:	Deputy Treasurer

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ADVANCED SERIES TRUST - AST FIRST TRUST BALANCED TARGET PORTFOLIO
By:	First Trust Advisors L.P., its investment manager
By:	/s/ Scott Fries
Name:	Scott Fries
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ADVANCED SERIES TRUST - AST FIRST TRUST CAPITAL APPRECIATION TARGET PORTFOLIO
By:	First Trust Advisors L.P., its investment manager
By:	/s/ Scott Fries
Name:	Scott Fries
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
FIRST TRUST SENIOR FLOATING RATE INCOME FUND II
By:	First Trust Advisors L.P., its investment manager
By:	/s/ Scott Fries
Name:	Scott Fries
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ADVANCED SERIES TRUST - AST FIRST TRUST BALANCED TARGET PORTFOLIO
By:	First Trust Advisors L.P., its investment manager
By:	/s/ Scott Fries
Name:	Scott Fries
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
FIRST TRUST SENIOR FLOATING RATE INCOME FUND II
By:	First Trust Advisors L.P., its investment manager
By:	/s/ Scott Fries
Name:	Scott Fries
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
FRANKLIN CLO V, LTD.
By:	Franklin Advisers, Inc. as Collateral Manager
By:	/s/ David Ardini
Name:	David Ardini
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
FRANKLIN INVESTORS SECURITIES TRUST - FRANKLIN FLOATING RATE DAILY ACCESS FUND.
By:
By:	/s/ Madeline Lam
Name:	Madeline Lam
Title:	Asst. Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
FRANKLIN FLOATING RATE MASTER TRUST - FRANKLIN FLOATING RATE MASTER SERIES
By:
By:	/s/ Madeline Lam
Name:	Madeline Lam
Title:	Asst. Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
FRANKLIN TEMPLETON LIMITED DURATION INCOME TRUST.
By:
By:	/s/ Madeline Lam
Name:	Madeline Lam
Title:	Asst. Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
FRANKLIN TEMPLETON SERIES II FUNDS - FRANKLIN FLOATING RATE II FUND
By:
By:	/s/ Madeline Lam
Name:	Madeline Lam
Title:	Asst. Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GE CAPITAL BANK, FORMERLY KNOWN AS, GE CAPITAL FINANCIAL INC.
By:
By:	/s/ Jeffrey Thomas
Name:	Jeffrey Thomas
Title:	Duly Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GENERAL ELECTRIC CAPITAL CORPORATION, AS LENDER AND AS ADMINISTRATIVE AGENT
By:
By:	/s/ Ryan Guenin
Name:	Ryan Guenin
Title:	Duly Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GOLDMAN SACHS BANK USA
By:
By:	/s/ Michelle Latzoni
Name:	Michelle Latzoni
Title:	Authorized Signature

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GOLUB CAPITAL PARTNERS CLO 11, LTD
By:	GC Advisors LLC, as agent
By:	/s/ Christina Jamieson
Name:	Christina Jamieson
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GOLUB CAPITAL PARTNERS CLO 14, LTD
By:	GC Advisors LLC, as agent
By:	/s/ Christina Jamieson
Name:	Christina Jamieson
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CALLIDUS DEBT PARTNERS CLO FUND IV, LTD.
By:	GSO/Blackstone Debt Funds Management LLC as Collateral Manager
By:	/s/ Daniel H. Smith
Name:	Daniel H. Smith
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
FINN SQUARE CLO, LTD.
By:	GSO/Blackstone Debt Funds Management LLC as Collateral Manager
By:	/s/ Daniel H. Smith
Name:	Daniel H. Smith
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GALE FORCE 3 CLO, LTD..
By:	GSO/BLACKSTONE Debt Funds Management LLC as Collateral Manager
By:	/s/ Daniel H. Smith
Name:	Daniel H. Smith
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GRAMERCY PARK CLO LTD..
By:	GSO/Blackstone Debt Funds Management LLC as Collateral Manager
By:	/s/ Daniel H. Smith
Name:	Daniel H. Smith
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GSO JUPITER LOAN TRUST.
By:	GSO Capital Advisors LLC, as its Investment Advisor
By:	/s/ Daniel H. Smith
Name:	Daniel H. Smith
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GSO LOAN TRUST 2010
By:	GSO Capital Advisors LLC, as its Investment Advisor
By:	/s/ Daniel H. Smith
Name:	Daniel H. Smith
Title:	Authorized Signatory

[start of pt 5]

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GSO PALMETTO LIQUIDITY FUND LLC
By:	GSO/Blackstone Debt Funds Management LLC as Investment Manager
By:	/s/ Christopher Sullivan
Name:	Chris Sullivan
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
MARINE PARK CLO LTD.
By:	GSO/Blackstone Debt Funds Management LLC as Collateral Manager
By:	/s/ Dan H Smith
Name:	Daniel H. Smith
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
OPTUMHEALTH BANK, INC.
By:	GSO Capital Advisors LLC as Manager
By:	/s/ Dan H Smith
Name:	Daniel H. Smith
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
SSD LOAN FUNDING LLC
By:	Citibank, N.A.
By:	/s/ Tina Tan
Name:	Tina Tran
Title:	Associate Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
SSOMF LOAN FUNDING LLC
By:	Citibank, N.A.
By:	/s/ Tina Tan
Name:	Tina Tran
Title:	Associate Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
SUNSUPER POOLED SUPERANNUATION TRUST
By:	GSO Capital Partners LP, its Investment Manager
By:	/s/ Dan H Smith
Name:	Daniel H. Smith
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GULF STREAM - COMPASS CLO 2007, LTD.
By:	Gulf Stream Asset Management LLC As Collateral Manager
By:	/s/ Joe Moroney
Name:	Joe Moroney
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GULF STREAM - RASHINBAN CLO 2006-I, LTD.
By:	Gulf Stream Asset Management LLC As Collateral Manager
By:	/s/ Joe Moroney
Name:	Joe Moroney
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GULF STREAM - SEXTANT CLO 2007-1, LTD.
By:	Gulf Stream Asset Management LLC As Collateral Manager
By:	/s/ Joe Moroney
Name:	Joe Moroney
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
NEPTUNE FINANCE CCS, LTD.
By:	Gulf Stream Asset Management LLC As Collateral Manager
By:	/s/ Joe Moroney
Name:	Joe Moroney
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
WHITEHORSE VI, LTD
By:	H.I.G. WhiteHorse Capital, LLC As: collateral manager
By:	/s/ Richard Siegel
Name:	Richard Siegel
Title:	Authorized Officer

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
HALCYON STRUCTURED ASSET MANAGEMENT LONG SECURED/SHORT UNSECURED CLO 2006-1 LTD. HALCYON STRUCTURED ASSET MANAGEMENT LONG SECURED/SHORT UNSECURED 2007-2 LTD. HALCYON LOAN INVESTORS CLO 1 LTD. HALCYON LOAN ADVISORS FUNDING 2012-1 LTD. BACCHUS (U.S.) 2006-1 LTD.
By:	/s/ illegible
Name:
Title:

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
HALCYON STRUCTURED ASSET MANAGEMENT LONG SECURED/SHORT UNSECURED CLO 2006-1 LTD. HALCYON STRUCTURED ASSET MANAGEMENT LONG SECURED/SHORT UNSECURED 2007-2 LTD. HALCYON LOAN INVESTORS CLO 1 LTD. HALCYON LOAN ADVISORS FUNDING 2012-1 LTD. BACCHUS (U.S.) 2006-1 LTD.
By:
By:	/s/ illegible
Name:
Title:

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
HALCYON STRUCTURED ASSET MANAGEMENT LONG SECURED/SHORT UNSECURED CLO 2006-1 LTD. HALCYON STRUCTURED ASSET MANAGEMENT LONG SECURED/SHORT UNSECURED 2007-2 LTD. HALCYON LOAN INVESTORS CLO 1 LTD. HALCYON LOAN ADVISORS FUNDING 2012-1 LTD. BACCHUS (U.S.) 2006-1 LTD.
By:
By:	/s/ illegible
Name:
Title:

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
HALCYON STRUCTURED ASSET MANAGEMENT LONG SECURED/SHORT UNSECURED CLO 2006-1 LTD. HALCYON STRUCTURED ASSET MANAGEMENT LONG SECURED/SHORT UNSECURED 2007-2 LTD. HALCYON LOAN INVESTORS CLO 1 LTD. HALCYON LOAN ADVISORS FUNDING 2012-1 LTD. BACCHUS (U.S.) 2006-1 LTD.
By:
By:	/s/ illegible
Name:
Title:

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
HALCYON STRUCTURED ASSET MANAGEMENT LONG SECURED/SHORT UNSECURED CLO 2006-1 LTD. HALCYON STRUCTURED ASSET MANAGEMENT LONG SECURED/SHORT UNSECURED 2007-2 LTD. HALCYON LOAN INVESTORS CLO 1 LTD. HALCYON LOAN ADVISORS FUNDING 2012-1 LTD. BACCHUS (U.S.) 2006-1 LTD.
By:
By:	/s/ illegible
Name:
Title:

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
HARCH CLO II, LIMITED
By:
By:	/s/ Joseph W. Harch
Name:	Joseph Harch
Title:	Chairman

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
HARCH CLO III, LIMITED
By:
By:	/s/ Joseph W. Harch
Name:	Joseph Harch
Title:	Chairman

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
EACH OF THE PERSONS LISTED ON ANNEX A, SEVERALLY BUT NOT JOINTLY, AS A LENDER
By:	Wellington Management Company, LLP, as its Investment Adviser
By:	/s/ Steven M. Hoffman
Name:	Steven M. Hoffman
Title:	Vice President and Counsel

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
HARTFORD LIFE INSURANCE COMPANY
By:	Hartford Investment Management Company - Agent and Attorney-in-Fact
By:	/s/ Mark Midura
Name:	Mark Midura
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
EACH OF THE PERSONS LISTED ON ANNEX A, SEVERALLY BUT NOT JOINTLY, AS A LENDER
By:	Wellington Management Company, LLP, as its Investment Adviser
By:	/s/ Steven M. Hoffman
Name:	Steven M. Hoffman
Title:	Vice President and Counsel

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
VIRTUS MULTI-SECTOR SHORT TERM BOND FUND
By:
By:	/s/ Kyle Jennings
Name:	Kyle Jennings
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ABERDEEN LOAN FUNDING, LTD
By:	Highland Capital Management, L.P. As Collateral Manager
By:	/s/ Carter Chism
Name:	Carter Chism
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
BRENTWOOD CLO, LTD.
By:	Highland Capital Management, L.P. As Collateral Manager
By:	/s/ Carter Chism
Name:	Carter Chism
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
BRENTWOOD CLO, LTD.
By:	Highland Capital Management, L.P. As Collateral Manager
By:	/s/ Carter Chism
Name:	Carter Chism
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
EASTLAND CLO, LTD.
By:	Highland Capital Management, L.P. As Collateral Manager
By:	/s/ Carter Chism
Name:	Carter Chism
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GLENEAGLES CLO LTD.
By:	Highland Capital Management, L.P. As Collateral Manager
By:	/s/ Carter Chism
Name:	Carter Chism
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GRAYSON CLO, LTD.
By:	Highland Capital Management, L.P. As Collateral Manager
By:	/s/ Carter Chism
Name:	Carter Chism
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GREENBRIAR CLO, LTD.
By:	Highland Capital Management, L.P. As Collateral Manager
By:	/s/ Carter Chism
Name:	Carter Chism
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
HEWETT’S ISLAND CLO I-R, LTD.
By:	Acis Capital Management, LP, its Collateral Manager Acis Capital Management GP, LLC, its general partner
By:	/s/ Carter Chism
Name:	Carter Chism
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
HIGHLAND CREDIT OPPORTUNITIES CDO, LTD.
By:	Highland Capital Management, L.P. As Collateral Manager
By:	/s/ Carter Chism
Name:	Carter Chism
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
LIBERTY CLO, LTD.
By:	Highland Capital Management, L.P. As Collateral Manager
By:	/s/ Carter Chism
Name:	Carter Chism
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
RED RIVER CLO, LTD
By:	Highland Capital Management, L.P. As Collateral Manager
By:	/s/ Carter Chism
Name:	Carter Chism
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ROCKWALL CDO II LTD.
By:	Highland Capital Management, L.P. As Collateral Manager
By:	/s/ Carter Chism
Name:	Carter Chism
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ROCKWALL CDO LTD
By:	Highland Capital Management, L.P. As Collateral Manager
By:	/s/ Carter Chism
Name:	Carter Chism
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
STRATFORD CLO, LTD.
By:	Highland Capital Management, L.P. As Collateral Manager
By:	/s/ Carter Chism
Name:	Carter Chism
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
WELLS FARGO PRINCIPAL LENDING, LLC
By:
By:	/s/ Jeff Nikorah
Name:	Jeff Nikorah
Title:	Executive Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
WESTCHESTER CLO, LTD.
By:	Highland Capital Management, L.P. As Collateral Manager
By:	/s/ Carter Chism
Name:	Carter Chism
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CFS WHOLESALE GLOBAL CORPORATE DEBT FUND
By:
By:	/s/ Daniel Brennand
Name:	Daniel Brennand
Title:	Vice-President, Monegy Inc. (Fund Manager)

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
HSBC BANK PLC
By:
By:	/s/ Mike
Name:	Mike
Title:	Corporate Banking Manager

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
HSBC BANK USA, NATIONAL ASSOCIATION
By:
By:	/s/ David A. Carroll
Name:	David A. Carroll
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
HUDSON CANYON FUNDING II SUBSIDIARY HOLDING COMPANY II, LLC
By:	Invesco Senior Secured Management, Inc. as Collateral Manager and Attorney in Fact
By:	/s/ Kevin Egan
Name:	Kevin Egan
Title:	Authorized Individual

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
IBM PERSONAL PENSION PLAN TRUST
By:	ING Investment Management Co., as its investment manager
By:	/s/ Jason Almiro
Name:	Jason Almiro
Title:	Analyst

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ING (L) FLEX - SENIOR LOANS
By:	ING Investment Management Co., as its investment manager
By:	/s/ Jason Almiro
Name:	Jason Almiro
Title:	Analyst

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ING IM CLO 2012-2, LTD.
By:	ING Alternative Asset Management LLC, as its investment manager
By:	/s/ Jason Almiro
Name:	Jason Almiro
Title:	Analyst

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ING IM CLO 2012-3, LTD
By:	ING Alternative Asset Management LLC, as its investment manager
By:	/s/ Jason Almiro
Name:	Jason Almiro
Title:	Analyst

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ING IM CLO 2012-4, LTD.
By:	ING Alternative Asset Management LLC, as its investment manager
By:	/s/ Jason Almiro
Name:	Jason Almiro
Title:	Analyst

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ING INVESTMENT MANAGEMENT CLO I, LTD.
By:	ING Investment Management Co., as its investment manager
By:	/s/ Jason Almiro
Name:	Jason Almiro
Title:	Analyst

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ING INVESTMENT MANAGEMENT CLO II, LTD.
By:	ING Alternative Asset Management LLC, as its investment manager
By:	/s/ Jason Almiro
Name:	Jason Almiro
Title:	Analyst

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ING INVESTMENT MANAGEMENT CLO III, LTD.
By:	ING Alternative Asset Management LLC, as its investment manager
By:	/s/ Jason Almiro
Name:	Jason Almiro
Title:	Analyst

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ING INVESTMENT MANAGEMENT CLO IV, LTD.
By:	ING Alternative Asset Management LLC, as its investment manager
By:	/s/ Jason Almiro
Name:	Jason Almiro
Title:	Analyst

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ING INVESTMENT MANAGEMENT CLO V, LTD.
By:	ING Alternative Asset Management LLC, as its investment manager
By:	/s/ Jason Almiro
Name:	Jason Almiro
Title:	Analyst

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ING LIFE INSURANCE AND ANNUITY COMPANY
By:	Prudential Investment Management, Inc., as Investment Advisor
By:	/s/ Joseph Lemanowicz
Name:	Joseph Lemanowicz
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ISL LOAN TRUST
By:	ING Investment Management Co., as its investment advisor
By:	/s/ Jason Almiro
Name:	Jason Almiro
Title:	Analyst

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
PHOENIX CLO I,, LTD.
By:	ING Alternative Asset Management LLC, as its investment manager
By:	/s/ Jason Almiro
Name:	Jason Almiro
Title:	Analyst

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
PHOENIX CLO II, LTD.
By:	ING Alternative Asset Management LLC, as its investment manager
By:	/s/ Jason Almiro
Name:	Jason Almiro
Title:	Analyst

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
PHOENIX CLO III, LTD.
By:	ING Alternative Asset Management LLC, as its investment manager
By:	/s/ Jason Almiro
Name:	Jason Almiro
Title:	Analyst

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
AVALON IV CAPITAL, LTD.
By:	Invesco Senior Secured Management, Inc. as Asset Manager
By:	/s/ Kevin Egan
Name:	Kevin Egan
Title:	Authorized Individual

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
BELHURST CLO LTD.
By:	Invesco Senior Secured Management, Inc. as Collateral Manager
By:	/s/ Kevin Egan
Name:	Kevin Egan
Title:	Authorized Individual

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CHILDREN’S HEALTHCARE OF ATLANTA, INC.
By:	Invesco Senior Secured Management, Inc. as Investment Manager
By:	/s/ Kevin Egan
Name:	Kevin Egan
Title:	Authorized Individual

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CEDAR FUNDING LTD.
By:	ARGON USA Investment Management, LLC
By:	/s/ Lisa Baltagi
Name:	Lisa Baltagi
Title:	Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CONFLUENT 2 LIMITED
By:	ARES PRIVATE ACCOUNT MANAGEMENT I, L.P., AS SUB-MANAGER
By:	/s/ John Eanes
Name:	John Eanes
Title:	Vice President
CONFLUENT 2 LIMITED
By:	ARES PRIVATE ACCOUNT MANAGEMENT I GP, LLC, ITS GENERAL PARTNER
By:	/s/John Eanes
Name:	John Eanes
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CONFLUENT 3 LIMITED
By:	Invesco Senior Secured Management, Inc. as Investment Manager
By:	/s/ Kevin Egan
Name:	Kevin Egan
Title:	Authorized Individual

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
DIVERSIFIED CREDIT PORTFOLIO LTD.
By:	Invesco Senior Secured Management, Inc. as Investment Adviser
By:	/s/ Kevin Egan
Name:	Kevin Egan
Title:	Authorized Individual

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
INVESCO FLOATING RATE FUND
By:	Invesco Senior Secured Management, Inc. as Sub-Adviser
By:	/s/ Kevin Egan
Name:	Kevin Egan
Title:	Authorized Individual

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
INVESCO SENIOR INCOME TRUST
By:	Invesco Senior Secured Management, Inc. as Sub-advisor
By:	/s/ Kevin Egan
Name:	Kevin Egan
Title:	Authorized Individual

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
INVESCO ZODIAC FUNDS - INVESCO US SENIOR LOAN FUND
By:	Invesco Management S.A. As Investment Manager
By:	/s/ Kevin Egan
Name:	Kevin Egan
Title:	Authorized Individual

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
INVESCO SENIOR LOAN FUND
By:	Invesco Senior Secured Management, Inc. as Sub-advisor
By:	/s/ Kevin Egan
Name:	Kevin Egan
Title:	Authorized Individual

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
LIMEROCK CLO I
By:	Invesco Senior Secured Management, Inc. as Investment Manager
By:	/s/ Kevin Egan
Name:	Kevin Egan
Title:	Authorized Individual

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
MAREA CLO, LTD.
By:	Invesco Senior Secured Management, Inc. as Collateral Manager
By:	/s/ Kevin Egan
Name:	Kevin Egan
Title:	Authorized Individual

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
MORGAN STANLEY INVESTMENT MANAGEMENT CROTON, LTD.
By:	Invesco Senior Secured Management, Inc. as Collateral Manager
By:	/s/ Kevin Egan
Name:	Kevin Egan
Title:	Authorized Individual

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
MSIM PECONIC BAY, LTD.
By:	Invesco Senior Secured Management, Inc. as Collateral Manager
By:	/s/ Kevin Egan
Name:	Kevin Egan
Title:	Authorized Individual

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
NAUTIQUE FUNDING LTD
By:	Invesco Senior Secured Management, Inc. as Collateral Manager
By:	/s/ Kevin Egan
Name:	Kevin Egan
Title:	Authorized Individual

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
QUALCOMM GLOBAL TRADING PTE. LTD.
By:	Invesco Senior Secured Management, Inc. as
	Investment Manager
By:	/s/ Kevin Egan
Name:	Kevin Egan
Title:	Authorized Individual

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
SANKATY SENIOR LOAN FUND, L.P.
By:	/s/ Andrew S. Viens
Name:	Andrew S. Viens
Title:	Sr. Vice President of Operations

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
WASATCH CLO LTD
By:	Invesco Senior Secured Management, Inc. as
	Portfolio Manager
By:	/s/ Kevin Egan
Name:	Kevin Egan
Title:	Authorized Individual

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
AIB DEBT MANAGEMENT LIMITED
By:	/s/ Roisin O’Connell
Name:	Roisin O’Connell
Title:	Senior Vice President Investment Advisor to AIB Debt Management Limited
AIB DEBT MANAGEMENT LIMITED
By:	/s/ Joanne O’Driscoll
Name:	Joanne O’Driscoll
Title:	Vice President Investment Advisor to AIB Debt Management Limited

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
JEFFERIES FINANCE LLC
By:	/s/ J. Paul McDonnell
Name:	J. Paul McDonnell
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
JEFFERIES GROUP LLC
By:	/s/ William McLoughlin
Name:	William McLoughlin
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
JEFFERIES LEVERAGED CREDIT PRODUCTS, LLC
By:	/s/ Paul J. Loomis
Name:	Paul J. Loomis
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
JFIN CAPITAL LLC
By:	/s/ J. Paul McDonnell
Name:	J. Paul McDonnell
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
JFIN CLO 2007 LTD
By:	Jefferies Finance LLC, as Collateral Manager
By:	/s/ J. Paul McDonnell
Name:	J. Paul McDonnell
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
JFIN CLO 2012 LTD
By:	Jefferies Finance LLC, as Portfolio Manager
By:	/s/ J. Paul McDonnell
Name:	J. Paul McDonnell
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
JFIN FUNDING III LLC
By:	/s/ J. Paul McDonnell
Name:	J. Paul McDonnell
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
COMMUNITY INSURANCE COMPANY
By:	ARES WLP MANAGEMENT, L.P., ITS INVESTMENT MANAGER
By:	/s/ John Eanes
Name:	John Eanes
Title:	Vice President
COMMUNITY INSURANCE COMPANY
By:	ARES WLP MANAGEMENT, GP, LLC, ITS GENERAL PARTNER
By:	/s/ John Eanes
Name:	John Eanes
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
JMP CREDIT ADVISORS CLO I LTD.
By:	Cratos CDO Management, LLC As Attorney-in-Fact
By:	/s/ Ronald J. Banks
Name:	Ronald J. Banks
Title:	Managing Director
JMP CREDIT ADVISORS CLO I LTD.
By:	JMP Credit Advisors LLC, Its Manager
By:	/s/ Ronald J. Banks
Name:	Ronald J. Banks
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
KATONAH VII CLO LTD.
By:	/s/ Dominick J. Mazzitelli
Name:	Dominick J. Mazzitelli
Title:	President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
KATONAH VIII CLO LTD.
By:	/s/ Dominick J. Mazzitelli
Name:	Dominick J. Mazzitelli
Title:	President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
KATONAH X CLO LTD.
By:	/s/ Dominick J. Mazzitelli
Name:	Dominick J. Mazzitelli
Title:	President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
KKR FINANCIAL CLO 2007-1, LTD.
By:	/s/ Jeffrey Smith
Name:	Jeffrey Smith
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
HEWETT’S ISLAND CLO IV, Ltd.
By:	LCM Asset Management LLC As Collateral Manager
By:	/s/ Sophie A. Venon
Name:	Sophie A. Venon
Title:

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
LCM III, Ltd.
By:	LCM Asset Management LLC As Collateral Manager
By:	/s/ Sophie A. Venon
Name:	Sophie A. Venon
Title:

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
LCM IV, Ltd.
By:	LCM Asset Management LLC As Collateral Manager
By:	/s/ Sophie A. Venon
Name:	Sophie A. Venon
Title:

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
LCM IX LIMITED PARTNERSHIP
By:	LCM Asset Management LLC As Collateral Manager
By:	/s/ Sophie A. Venon
Name:	Sophie A. Venon
Title:

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
LCM V, LTD.
By:	LCM Asset Management LLC As Collateral Manager
By:	/s/ Sophie A. Venon
Name:	Sophie A. Venon
Title:

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
LCM VI, LTD.
By:	LCM Asset Management LLC As Collateral Manager
By:	/s/ Sophie A. Venon
Name:	Sophie A. Venon
Title:

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
LCM VIII LIMITED PARTNERSHIP
By:	LCM Asset Management LLC As Collateral Manager
By:	/s/ Sophie A. Venon
Name:	Sophie A. Venon
Title:

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
LCM X LIMITED PARTNERSHIP
By:	LCM Asset Management LLC As Collateral Manager
By:	/s/ Sophie A. Venon
Name:	Sophie A. Venon
Title:

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
LCM XI LIMITED PARTNERSHIP
By:	LCM Asset Management LLC As Collateral Manager
By:	/s/ Sophie A. Venon
Name:	Sophie A. Venon
Title:

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
LCM XII LIMITED PARTNERSHIP
By:	LCM Asset Management LLC As Collateral Manager
By:	/s/ Sophie A. Venon
Name:	Sophie A. Venon
Title:

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
APOSTLE LOOMIS SAYLES CREDIT OPPORTUNITIES FUND, As Lender
By:	Loomis, Sayles & Company, L.P., Its Investment Manager
By:	/s/ Mary McCarthy
Name:	Mary McCarthy
Title:	Vice President
APOSTLE LOOMIS SAYLES CREDIT OPPORTUNITIES FUND, As Lender
By:	Loomis, Sayles & Company, Incorporated, Its General Partner
By:	/s/ Mary McCarthy
Name:	Mary McCarthy
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
APOSTLE LOOMIS SAYLES SENIOR LOAN FUND, AS LENDER
By:	Loomis, Sayles & Company, L.P., Its Investment Manager
By:	/s/ Mary McCarthy
Name:	Mary McCarthy
Title:	Vice President
APOSTLE LOOMIS SAYLES CREDIT OPPORTUNITIES FUND, AS LENDER
By:	Loomis, Sayles & Company, Incorporated, Its General Partner
By:	/s/ Mary McCarthy
Name:	Mary McCarthy
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CONFLUENT 4 LIMITED
By:	Loomis, Sayles & Company, L.P. As Sub-Manager
By:	/s/ Mary McCarthy
Name:	Mary McCarthy
Title:	Vice President
CONFLUENT 4 LIMITED
By:	Loomis, Sayles & Company, Incorporated Its General Partner
By:	/s/ Mary McCarthy
Name:	Mary McCarthy
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
LOOMIS SAYLES CLO I, LTD.
By:	Loomis, Sayles & Company, L.P. Its Collateral Manager
By:	/s/ Mary McCarthy
Name:	Mary McCarthy
Title:	Vice President
LOOMIS SAYLES CLO I, LTD.
By:	Loomis Sayles & Company, Incorporated Its General Partner
By:	/s/ Mary McCarthy
Name:	Mary McCarthy
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
THE LOOMIS SAYLES SENIOR LOAN FUND, LLC.
By:	Loomis, Sayles & Company, L.P. Its Managing Member
By:	/s/ Mary McCarthy
Name:	Mary McCarthy
Title:	Vice President
THE LOOMIS SAYLES SENIOR LOAN FUND, LLC.
By:	Loomis, Sayles & Company, Incorporated Its General Partner
By:	/s/ Mary McCarthy
Name:	Mary McCarthy
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
NEW YORK LIFE INSURANCE COMPANY (GUARANTEED PRODUCTS)
By:	MacKay Shields LLC, As Investment Adviser and not individually
By:	/s/ Dan Roberts
Name:	Dan Roberts
Title:	Senior Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
NEW YORK LIFE INSURANCE COMPANY, GP – PORTABLE ALPHA
By:	MacKay Shield LLC, As Investment Adviser and not individually
By:	/s/ Dan Roberts
Name:	Dan Roberts
Title:	Senior Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
MALIBU CBNA LOAN FUNDING LLC
By:
By:	/s/ Adam Kalsur
Name:	Adam Kalsur
Title:	Attorney

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
JERSEY STREET CLO, LTD.
By:	Collateral Manager, Massachusetts Financial Services Company
By:	/s/ David J. [illegible]
Name:
Title:	As authorized representative and not individually

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
MARLBOROUGH STREET CLO, LTD.
By:	Collateral Manager, Massachusetts Financial Services Company
By:	/s/ David J. [illegible]
Name:
Title:	As authorized representative and not individually

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GANNETT PEAK CLO I, LTD.
By:	THL Credit Senior Loan Strategies LLC, as Manager
By:	/s/ Kathleen Adam
Name:	Kathleen Adam LendAmend LLC
Title:	Administrator

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
WIND RIVER CLO II – TATE INVESTORS, LTD.
By:	THL Credit Senior Loan Strategies LLC, as Manager
By:	/s/ Kathleen Adam
Name:	Kathleen Adam LendAmend LLC
Title:	Administrator

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
VENTURE IX CDO, LIMITED
By:	Its investment advisor, MJX Asset Management, LLC
By:	/s/ Martin E. Davey
Name:	Martin E. Davey
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
VENTURE V CDO LIMITED
By:	Its investment advisor, MJX Asset Management, LLC
By:	/s/ Martin E. Davey
Name:	Martin E. Davey
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
VENTURE VI CDO LIMITED
By:	Its investment advisor, MJX Asset Management, LLC
By:	/s/ Martin E. Davey
Name:	Martin E. Davey
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
VENTURE VII CDO LIMITED
By:	Its investment advisor, MJX Asset Management, LLC
By:	/s/ Martin E. Davey
Name:	Martin E. Davey
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
VENTURE VIII CDO, LIMITED
By:	Its investment advisor, MJX Asset Management, LLC
By:	/s/ Martin E. Davey
Name:	Martin E. Davey
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
VENTURE X CLO, LIMITED
By:	Its investment advisor, MJX Asset Management, LLC
By:	/s/ Martin E. Davey
Name:	Martin E. Davey
Title:	Senior Portfolio Manager

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
VENTURE XI CLO, LIMITED
By:	Its investment advisor, MJX Asset Management, LLC
By:	/s/ Martin E. Davey
Name:	Martin E. Davey
Title:	Senior Portfolio Manager

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
VENTURE XII CLO, LIMITED
By:	Its investment advisor MJX Asset Management LLC
By:	/s/ Martin E. Davey
Name:	Martin E. Davey
Title:	Senior Portfolio Manager

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
MC FUNDING, LTD
By:	Monroe Capital Management, LLC, as Collateral Manager
By:	/s/ Matthew R. Lane
Name:	Matthew R. Lane
Title:	Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
NOB HILL CLO LIMITED
By:
By:	/s/ Kyle Jennings
Name:	Kyle Jennings
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
VIRTUS SENIOR FLOATING RATE FUND
By:
By:	/s/ Kyle Jennings
Name:	Kyle Jennings
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ACE TEMPEST REINSURANCE LTD.
By:	Oaktree Capital Management, L.P. Its: Investment Manager
By:	/s/ Francoise Giacalone
Name:	Francoise Giacalone
Title:	Managing Director
By:
By:	/s/ Desmund Shirazi
Name:	Desmund Shirazi
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ARCH INVESTMENT HOLDINGS IV LTD.
By:	Oaktree Capital Management, L.P. Its: Investment Manager
By:	/s/ Francoise Giacalone
Name:	Francoise Giacalone
Title:	Managing Director
By:
By:	/s/ Desmund Shirazi
Name:	Desmund Shirazi
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
OAKTREE SENIOR LOAN FUND, L.P.
By:	Oaktree Senior Loan Fund GP, L.P. Its: General Partner, By: Oaktree Fund GP IIA, LLC Its: General Partner, By: Oaktree Fund GP II, L.P. Its; Managing Member
By:	/s/ Francoise Giacalone
Name:	Francoise Giacalone
Title:	Authorized Signatory
By:
By:	/s/ Desmund Shirazi
Name:	Desmund Shirazi
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
THE PUBLIC EDUCATION EMPLOYEE RETIREMENT SYSTEM OF MISSOURI
By:	Oaktree Capital Management, L.P. Its: Investment Manager
By:	/s/ Francoise Giacalone
Name:	Francoise Giacalone
Title:	Managing Director
By:
By:	/s/ Desmund Shirazi
Name:	Desmund Shirazi
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
THE PUBLIC SCHOOL RETIREMENT SYSTEM OF MISSOURI
By:	Oaktree Capital Management, L.P. Its: Investment Manager
By:	/s/ Francoise Giacalone
Name:	Francoise Giacalone
Title:	Managing Director
By:
By:	/s/ Desmund Shirazi
Name:	Desmund Shirazi
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
HAMLET II, LTD.
By:	Octagon Credit Investors, LLC as Portfolio Manager
By:	/s/ Lauren Basmadjian
Name:	Lauren Basmadjian
Title:	Portfolio Manager

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
OCP CLO 2012-2, LTD.
By:	Onex Credit Partners, LLC, as Collateral Manager
By:	/s/ Paul Travers
Name:	Paul Travers
Title:	Portfolio Manager

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
OCTAGON DELAWARE TRUST 2011
By:	Octagon Credit Investors, LLC as Portfolio Manager
By:	/s/ Lauren Basmadjina
Name:	Lauren Basmadjian
Title:	Portfolio Manager

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
OCTAGON INVESTMENT PARTNERS IX, LTD.
By:	Octagon Credit Investors, LLC as Manager
By:	/s/ Lauren Basmadjian
Name:	Lauren Basmadjian
Title:	Portfolio Manager

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
OCTAGON INVESTMENT PARTNERS V, LTD.
By:	Octagon Credit Investors, LLC as Portfolio Manager
By:	/s/ Lauren Basmadjian
Name:	Lauren Basmadjian
Title:	Portfolio Manager

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
OCTAGON INVESTMENT PARTNERS VIII, LTD
By:	Octagon Credit Investors, LLC as collateral manager
By:	/s/ Lauren Basmadjian
Name:	Lauren Basmadjian
Title:	Portfolio Manager

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
OCTAGON INVESTMENT PARTNERS X, LTD.
By:	Octagon Credit Investors, LLC as Collateral Manager
By:	/s/ Lauren Basmadjian
Name:	Lauren Basmadjian
Title:	Portfolio Manager

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
OCTAGON INVESTMENT PARTNERS XI, LTD.
By:	Octagon Credit Investors, LLC as Collateral Manager
By:	/s/ Lauren Basmadjian
Name:	Lauren Basmadjian
Title:	Portfolio Manager

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
OCTAGON INVESTMENT PARTNERS XIV, LTD.
By:	Octagon Credit Investors, LLC as Collateral Manager
By:	/s/ Lauren Basmadjian
Name:	Lauren Basmadjian
Title:	Portfolio Manager

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
OCTAGON PAUL CREDIT FUND SERIES I, LTD.
By:	Octagon Credit Investors, LLC as Portfolio Manager
By:	/s/ Lauren Basmadjian
Name:	Lauren Basmadjian
Title:	Portfolio Manager

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
WESTCHESTER CLO, LTD.
By:	Highland Capital Management, L.P. As Collateral Manager
By:	/s/ Carter Chism
Name:	Carter Chism
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
OCP CLO 2012-1, LTD.
By:	Onex Credit Partners, LLC , as Portfolio Manager
By:	/s/ Paul Travers
Name:	Paul Travers
Title:	Portfolio Manager

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
OCP CLO 2012-2, LTD.
By:	Onex Credit Partners, LLC, as Collateral Manager
By:	/s/ Paul Travers
Name:	Paul Travers
Title:	Portfolio Manager

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
OCTAGON DELAWARE TRUST 2011
By:	Octagon Credit Investors, LLC as Portfolio Manager
By:	/s/ Lauren Basmadjian
Name:	Lauren Basmadjian
Title:	Portfolio Manager

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
HARBOURVIEW CLO 2006-I
By:	Brown Brothers Harriman & Co, acting as agent for OppenheimerFunds, Inc.
By:	/s/ Jason Reuter
Name:	Jason Reuter
Title:	AVP

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
OPPENHEIMER MASTER LOAN FUND, LLC
By:	Brown Brothers Harriman & Co, acting as agent for OppenheimerFunds, Inc.
By:	/s/ Jason Reuter
Name:	Jason Reuter
Title:	AVP

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
OPPENHEIMER SENIOR FLOATING RATE FUND
By:	Brown Brothers Harriman & Co. acting as agent for OppenheimerFunds, Inc.
By:	/s/ Jason Reuter
Name:	Jason Reuter
Title:	AVP

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
OPPENHEIMER SENIOR FLOATING RATE FUND
By:	Brown Brothers Harriman & Co acting as agent for OppenheimerFunds, Inc.
By:	/s/ Jason Reuter
Name:	Jason Reuter
Title:	AVP

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
OFSI FUND III, LTD.
By:	Orchard First Source Capital, Inc. its: attorney in fact
By:	/s/ Ken A. Brown
Name:	Ken A. Brown
Title:	Duly Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
FIRE AND POLICE PENSION FUND, SAN ANTONIO
By:	PineBridge Investments LLC Its Investment Manager
By:	/s/ Steven Oh
Name:	Steven Oh
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GALAXY V CLO, LTD
By:	PineBridge Investments LLC Its Collateral Manager
By:	/s/ Steven Oh
Name:	Steven Oh
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GALAXY VI CLO, LTD
By:	PineBridge Investments LLC Its Collateral Manager
By:	/s/ Steven Oh
Name:	Steven Oh
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GALAXY VII CLO, LTD
By:	PineBridge Investments LLC Its Collateral Manager
By:	/s/ Steven Oh
Name:	Steven Oh
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GALAXY VIII CLO, LTD
By:	PineBridge Investments LLC Its Collateral Manager
By:	/s/ Steven Oh
Name:	Steven Oh
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GALAXY X CLO, LTD
By:	PineBridge Investments LLC Its Collateral Manager
By:	/s/ Steven Oh
Name:	Steven Oh
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GALAXY XI CLO, LTD.
By:	PineBridge Investments LLC As Collateral Manager
By:	/s/ Steven Oh
Name:	Steven Oh
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GALAXY XII CLO, LTD.
By:	PineBridge Investments LLC As Collateral Manager
By:	/s/ Steven Oh
Name:	Steven Oh
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
SATURN CLO, LTD.
By:	PineBridge Investments LLC Its Collateral Manager
By:	/s/ Steven Oh
Name:	Steven Oh
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
VALIDUS REINSURANCE LTD.
By:	PineBridge Investments LLC Its Investment Manager
By:	/s/ Steven Oh
Name:	Steven Oh
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
Pioneer Floating Rate Trust
Pioneer Diversified High Income Trust
By:	Pioneer Investment Management, Inc., As adviser to each Lender above
By:	/s/ Margaret C. Begley
Name:	Margaret C. Begley
Title:	Secretary and Associate General Counsel

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
Pioneer Floating Rate Trust
Pioneer Diversified High Income Trust
By:	Pioneer Investment Management, Inc., As adviser to each Lender above
By:	/s/ Margaret C. Begley
Name:	Margaret C. Begley
Title:	Secretary and Associate General Counsel

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
JNL/PPM America Floating Rate Income Fund, a series of the JNL Series Trust
By:	/s/ David C. Wagner
	PPM America, Inc., as sub-adviser
Name:	David C. Wagner
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
PPM GRAYHAWK CLO, LTD.
By:	/s/ David C. Wagner
	PPM America, Inc., as Collateral Manager
Name:	David C. Wagner
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ROSEDALE CLO LTD.
By:	Princeton Advisory Group, Inc. The Collateral Manager
By:	/s/ Paul P. Malecki
Name:	Paul P. Malecki
Title:	Senior Portfolio Manager
	Princeton Advisory Group, Inc.

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ADVANCED SERIES TRUST - AST PRUDENTIAL CORE BOND PORTFOLIO
By:	Prudential Investment Management, Inc., As Investment Advisor
By:	/s/ Joseph Lemanowicz
Name:	Joseph Lemanowicz
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
DOUBLE HAUL TRADING, LLC.
By:	SunTrust Bank, its Manager
By:	/s/ Douglas Weltz
Name:	Douglas Weltz
Title:	Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
DRYDEN XI - LEVERAGED LOAN CDO 2006
By:	Prudential Investment Management, Inc., as Collateral Manager
By:	/s/ Joseph Lemanowicz
Name:	Joseph Lemanowicz
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
DRYDEN XVIII LEVERAGED LOAN 2007 LTD.
By:	Prudential Investment Management, Inc., as Collateral Manager
By:	/s/ Joseph Lemanowicz
Name:	Joseph Lemanowicz
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
DRYDEN XVI - LEVERAGED LOAN CDO 2006
By:	Prudential Investment Management, Inc., as Collateral Manager
By:	/s/ Joseph Lemanowicz
Name:	Joseph Lemanowicz
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
DRYDEN XXI LEVERAGED LOAN CDO LLC
By:	Prudential Investment Management, Inc., as Collateral Manager
By:	/s/ Joseph Lemanowicz
Name:	Joseph Lemanowicz
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
DRYDEN XXII SENIOR LOAN FUND
By:	Prudential Investment Management, Inc., as Collateral Manager
By:	/s/ Joseph Lemanowicz
Name:	Joseph Lemanowicz
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
DRYDEN XXIII SENIOR LOAN FUND
By:	Prudential Investment Management, Inc., as Collateral Manager
By:	/s/ Joseph Lemanowicz
Name:	Joseph Lemanowicz
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
DRYDEN XXIV SENIOR LOAN FUND
By:	Prudential Investment Management, Inc., as Collateral Manager
By:	/s/ Joseph Lemanowicz
Name:	Joseph Lemanowicz
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
DRYDEN XXV SENIOR LOAN FUND
By:	Prudential Investment Management, Inc., as Collateral Manager
By:	/s/ Joseph Lemanowicz
Name:	Joseph Lemanowicz
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GATEWAY CLO LIMITED
By:	Prudential Investment Management, Inc., as Collateral Manager
By:	/s/ Joseph Lemanowicz
Name:	Joseph Lemanowicz
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
PRAMERICA FIXED INCOME FUNDS PLC - ABSOLUTE TOTAL RETURN FUND
By:	Pramerica Investment Management, a trading name of Prudential Investment Management, Inc., as Investment Manager
By:	/s/ Joseph Lemanowicz
Name:	Joseph Lemanowicz
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
PRUDENTIAL BANK LOAN FUND OF THE PRUDENTIAL TRUST COMPANY COLLECTIVE TRUST
By:	Prudential Investment Management, Inc., An Investment Advisor
By:	/s/ Joseph Lemanowicz
Name:	Joseph Lemanowicz
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
PRUDENTIAL GLOBAL TOTAL RETURN FUND
By:	Prudential Investment Management, Inc., as Investment Advisor
By:	/s/ Joseph Lemanowicz
Name:	Joseph Lemanowicz
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
PRUDENTIAL INVESTMENT PORTFOLIOS 9 - PRUDENTIAL ABSOLUTE RETURN BOND FUND
By:	Prudential Investment Management, Inc., as Investment Advisor
By:	/s/ Joseph Lemanowicz
Name:	Joseph Lemanowicz
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
PRUDENTIAL INVESTMENT PORTFOLIOS, INC. 14 - PRUDENTIAL FLOATING RATE INCOME FUND
By:	Prudential Investment Management, Inc., as Investment Advisor
By:	/s/ Joseph Lemanowicz
Name:	Joseph Lemanowicz
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
THE PRUDENTIAL SERIES FUND - DIVERSIFIED BOND PORTFOLIO
By:	Prudential Investment Management, Inc., As Investment Advisor
By:	/s/ Joseph Lemanowicz
Name:	Joseph Lemanowicz
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
PRUDENTIAL TOTAL RETURN BOND FUND, INC.
By:	Prudential Investment Management, Inc., as Investment Advisor
By:	/s/ Joseph Lemanowicz
Name:	Joseph Lemanowicz
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
SPECIALIZED INVESTMENT MANAGEMENT SICAV - SIF CORPORATE LOAN MASTER FUND
By:	Zaisgroup International LLP, as Investment Advisor
By:	Pramerica Investment Management Limited, as Portfolio Advisor
By:	Pramerica Investment Management (a trading name of Prudential Investment Management, Inc.) as Sub-Advisor
By:	/s/ Joseph Lemanowicz
Name:	Joseph Lemanowicz
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
RAYMOND JAMES BANK, N.A.
By:	/s/ Alexander L. Rody
Name:	Alexander L. Rody
Title:	Senior Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
RBS CITIZENS, N.A.
By:	/s/ Donald A. Wright
Name:	Donald A. Wright
Title:	SVP

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
ROYAL BANK OF CANADA, AS LENDER
By:	/s/ Dean Sas
Name:	Dean Sas
Title:	Authorized Signatory

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
CHATHAM LIGHT II CLO, LIMITED
By:	Sankaty Advisors, LLC as Collateral Manager
By:	/s/ Andrew S. Viens
Name:	Andrew S. Viens
Title:	Sr. Vice President of Operations

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
QUANTAS SUPERANNUATION PLAN
By:	Sankaty Advisors, LLC as Investment Manager
By:	/s/ Andrew S. Viens
Name:	Andrew S. Viens
Title:	Sr. Vice President of Operations

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
RACE POINT III CLO
By:	Sankaty Advisors, LLC as Collateral Manager
By:	/s/ Andrew S. Viens
Name:	Andrew S. Viens
Title:	Sr. Vice President of Operations

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
RACE POINT IV CLO, LTD.
By:	Sankaty Advisors, LLC as Collateral Manager
By:	/s/ Andrew S. Viens
Name:	Andrew S. Viens
Title:	Sr. Vice President of Operations

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
RACE POINT V CLO, LIMITED
By:	Sankaty Advisors, LLC, its Asset Manager
By:	/s/ Andrew S. Viens
Name:	Andrew S. Viens
Title:	Sr. Vice President of Operations

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
RACE POINT VI CLO, LTD.
By:	Sankaty Advisors, LLC, as Asset Manager
By:	/s/ Andrew S. Viens
Name:	Andrew S. Viens
Title:	Sr. Vice President of Operations

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
RACE POINT VII CLO, LIMITED
By:	Sankaty Advisors, LLC as Portfolio Manager
By:	/s/ Andrew S. Viens
Name:	Andrew S. Viens
Title:	Sr. Vice President of Operations

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
SAN GABRIEL CLO I LTD.
By:	Its Investment Advisor CVC Credit Partners, LLC On behalf of Resource Capital Asset Management (RCAM)
By:	/s/ Vincent Ingato
Name:	Vincent Ingato
Title:	MD/PM

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
SANKATY SENIOR LOAN FUND, L.P.
By:	Sankaty Senior Loan Fund, L.P.
By:	/s/ Andrew S. Viens
Name:	Andrew S. Viens
Title:	Sr. Vice President of Operations

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
WELLPOINT, INC.
By:	Sankaty Advisors, LLC as Investment Manager
By:	/s/ Andrew S. Viens
Name:	Andrew S. Viens
Title:	Document Control Team

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GSC INVESTMENT CORP CLO 2007 LTD
By:	/s/ Tom Inglesby
Name:	Tom Inglesby
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
SARATOGA CLO I, LIMITED
By:	Invesco Senior Secured Management, Inc., as Asset Manager
By:	/s/ Kevin Egan
Name:	Kevin Egan
Title:	Authorized Individual

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
SUMITOMO MITSUI TRUST BANK, LIMITED, NEW YORK BRANCY
By:	/s/ Albert C. Tew II
Name:	Albert C. Tew II
Title:	Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
SUNTRUST BANK
By:	/s/ John Cappellari
Name:	John Cappellari
Title:	Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
SUNTRUST BANK
By:	/s/ John Cappellari
Name:	John Cappellari
Title:	Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GRANT GROVE CLO, LTD.
By:	Tall Tree Investment Management, LLC, as Collateral Manager
By:	/s/ Michael J. Starshak, Jr.
Name:	Michael J. Starshak, Jr.
Title:	Officer

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
MUIR GROVE CLO, LTD.
By:	Tall Tree Investment Management, LLC, as Collateral Manager
By:	/s/ Michael J. Starshak
Name:	Michael J. Starshak
Title:	Officer

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
MUIR GROVE CLO, LTD.
By:	Tall Tree Investment Management, LLC, as Collateral Manager
By:	/s/ Michael J. Starshak
Name:	Michael J. Starshak
Title:	Officer

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
T2 INCOME FUND CLO I, LTD., AS LENDER
By:	T2 Advisers, LLC,
	As Collateral Manager
By:	/s/ Saul Rosenthal
Name:	Saul Rosenthal
Title:	President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
TRIMARAN CLO VI LTD.
By:	Trimaran Advisors LLC
By:	/s/ Dominick J. Mazzitelli
Name:	Dominick J. Mazzitelli
Title:	President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GALLATIN CLO II 2005- 1, LTD
By:	UrsaMine Credit Advisors, LLC, as its Collateral Manager
By:	/s/ Niall D. Rosenzweig
Name:	Niall D. Rosenzweig
Title:	President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GALLATIN CLO III 2007- 1, LTD As Assignee
By:	UrsaMine Credit Advisors, LLC, as its Collateral Manager
By:	/s/ Niall D. Rosenzweig
Name:	Niall D. Rosenzweig
Title:	President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
GALLATIN CLO IV 2012- 1, LTD As Assignee
By:	MP Senior Credit Partners L.P., as its Collateral Manager
By:	/s/ Niall D. Rosenzweig
Name:	Niall D. Rosenzweig
Title:	President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
Each Of The Persons Listed On Annex A, Severally But Not Jointly, As a Lender
By:	Wellington Management Company, LLP, as its Investment Adviser
By:	/s/ Steven M. Hoffman
Name:	Steven M. Hoffman
Title:	Vice President and Counsel

ANNEX A

The Hartford Floating Rate Fund

The Hartford Floating Rate High Income Fund

The Hartford Short Duration Fund

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
Each Of The Persons Listed On Annex A, Severally But Not Jointly, As a Lender
By:	Wellington Management Company, LLP, as its Investment Adviser
By:	/s/ Steven M. Hoffman
Name:	Steven M. Hoffman
Title:	Vice President and Counsel

ANNEX A

The Hartford Floating Rate Fund

The Hartford Floating Rate High Income Fund

The Hartford Short Duration Fund

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
FOOTHILL CLO I, LTD.
By:	/s/ Linda Pace
Name:	Linda Pace
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
VIRTUS SENIOR FLOATING RATE FUND
By:	/s/ Kyle Jennings
Name:	Kyle Jennings
Title:	Managing Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
WELLS FARGO BANK, NATIONAL ASSOCIATION, As A Lender And Holder Of $992,462.32 Of Term Loans On Its Loan Trading Desk
By:	/s/ P. Jeffrey Huth
Name:	P. Jeffrey Huth
Title:	Director

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
WELLS FARO PRINCIPAL LENDING, LLC
By:	/s/ Jeff Nikora
Name:	Jeff Nikora
Title:	Executive Vice President

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
OCEAN TRAILS CLO I
By:	West Gate Horizons Advisors LLC, as Investment Manager
By:	/s/ Helen Rhee
Name:	Helen Rhee
Title:	Senior Analyst

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
OCEAN TRAILS CLO II
By:	West Gate Horizons Advisors LLC, as Investment Manager
By:	/s/ Helen Rhee
Name:	Helen Rhee
Title:	Senior Analyst

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
WG HORIZONS CLO I
By:	West Gate Horizons Advisors LLC, as Investment Manager
By:	/s/ Helen Rhee
Name:	Helen Rhee
Title:	Senior Analyst

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
OCEAN TRAILS CLO I
By:	West Gate Horizons Advisors LLC, as Investment Manager
By:	/s/ Helen Rhee
Name:	Helen Rhee
Title:	Senior Analyst

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
WG HORIZONS CLO I
By:	West Gate Horizons Advisors LLC, as Investment Manager
By:	/s/ Helen Rhee
Name:	Helen Rhee
Title:	Senior Analyst

SIGNATURE PAGE TO THE FOURTH AMENDMENT TO CREDIT AGREEMENT, DATED AS OF THE DATE FIRST WRITTEN ABOVE, AMONG ALERE INC., THE LENDERS PARTY THERETO AND GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
WHITEHORSE III, LTD
By:	WhiteHorse Capital Partners, LP As Collateral Manager
By:	WhiteRock Asset Advisor, LLC, its GP
By:	/s/ Jay Carvell
Name:	Jay Carvell
Title:	Manager

EX-31.1

EXHIBIT 31.1

CERTIFICATION

I, Ron Zwanziger, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Alere Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 9, 2013	/s/ Ron Zwanziger
	Ron Zwanziger Chairman, President and Chief Executive Officer

EX-31.2

EXHIBIT 31.2

CERTIFICATION

I, David Teitel, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Alere Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 9, 2013	/s/ David Teitel
	David Teitel Chief Financial Officer

EX-32.1

Exhibit 32.1

Certification Pursuant to

18 U.S.C. Section 1350,

as Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

Each of the undersigned officers of Alere Inc. (the “Company”) hereby certifies, to his knowledge, that the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 30, 2013 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. This certification is being furnished as an exhibit to the Report pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. This certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except to the extent that the Company specifically incorporates this certification by reference.

Date: May 9, 2013	/s/ Ron Zwanziger
	Ron Zwanziger Chief Executive Officer
Date: May 9, 2013	/s/ David Teitel
	David Teitel Chief Financial Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signatures that appear in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

XML

Financial Information by Segment (Tables)

3 Months Ended

Mar. 31, 2013

Segment Reporting [Abstract]

Performance of Our Operating Segments Based on Revenue and Operating Income (Loss)

We evaluate performance of our operating segments based on revenue and operating income (loss). Segment information for the three months ended March 31, 2013 and 2012 is as follows (in thousands):

	Professional Diagnostics		Health Information Solutions			Consumer Diagnostics		Corporate and Other			Total
Three Months Ended March 31, 2013:
Net revenue	$	582,492	$	134,207		$	22,550	$	—		$	739,249
Operating income (loss)	$	59,840	$	(13,893	)	$	2,280	$	(17,738	)	$	30,489
Depreciation and amortization	$	82,794	$	20,737		$	1,153	$	286		$	104,970
Non-cash charge associated with acquired inventory	$	461	$	—		$	—	$	—		$	461
Restructuring charge	$	1,389	$	2,503		$	—	$	—		$	3,892
Stock-based compensation	$	—	$	—		$	—	$	4,123		$	4,123
Three Months Ended March 31, 2012:
Net revenue	$	518,357	$	130,784		$	21,988	$	—		$	671,129
Operating income (loss)	$	70,179	$	(19,356	)	$	365	$	(16,130	)	$	35,058
Depreciation and amortization	$	77,467	$	23,774		$	1,259	$	221		$	102,721
Non-cash charge associated with acquired inventory	$	4,681	$	—		$	—	$	—		$	4,681
Restructuring charge	$	4,794	$	717		$	—	$	17		$	5,528
Stock-based compensation	$	—	$	—		$	—	$	3,874		$	3,874
Assets:
As of March 31, 2013	$	6,414,701	$	608,161		$	175,285	$	50,328		$	7,248,475
As of December 31, 2012	$	6,214,847	$	593,172		$	192,748	$	67,161		$	7,067,928

Summary of Company's Net Revenue from Professional Diagnostics and Health Information Solutions Reporting Segments by Groups of Similar Products and Services

The following tables summarize our net revenue from the professional diagnostics and health information solutions reporting segments by groups of similar products and services for the three months ended March 31, 2013 and 2012 (in thousands):

	Three Months Ended March 31,
Professional Diagnostics Segment	2013		2012
Cardiology	$	114,933	$	138,826
Infectious disease		189,844		151,016
Toxicology		149,049		121,740
Diabetes		50,083		28,161
Other		74,719		75,706
Net product sales and services revenue		578,628		515,449
License and royalty revenue		3,864		2,908
Professional diagnostics net revenue	$	582,492	$	518,357
	Three Months Ended March 31,
Health Information Solutions Segment	2013		2012
Disease and case management	$	54,126	$	53,380
Wellness		26,300		27,026
Women’s & children’s health		29,080		29,771
Patient self-testing services		24,701		20,607
Health information solutions net revenue	$	134,207	$	130,784

XML

Business Combinations - IIntangible Assets Acquired and their Respective Fair Values and Weighted-Average Useful Lives (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended	12 Months Ended
	Mar. 31, 2013	Dec. 31, 2012
Acquired Finite And Indefinite Lived Intangible Assets [Line Items]
Total intangible assets	$ 173,860	$ 325,223
Weighted-average Useful Life	0 years	0 years
In-process research and development [Member]
Acquired Finite And Indefinite Lived Intangible Assets [Line Items]
Acquired indefinite-lived intangible asset, amount	24,200	4,900
Epocal [Member]
Acquired Finite And Indefinite Lived Intangible Assets [Line Items]
Total intangible assets	164,400
Epocal [Member] | In-process research and development [Member]
Acquired Finite And Indefinite Lived Intangible Assets [Line Items]
Acquired indefinite-lived intangible asset, amount	24,200
Mega Medika [Member]
Acquired Finite And Indefinite Lived Intangible Assets [Line Items]
Total intangible assets	9,460
Mega Medika [Member] | In-process research and development [Member]
Acquired Finite And Indefinite Lived Intangible Assets [Line Items]
Acquired indefinite-lived intangible asset, amount
Core technology and patents [Member]
Acquired Finite And Indefinite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible asset, amount	119,700	148,103
Weighted-average Useful Life	20 years	18 years 8 months 12 days
Core technology and patents [Member] | Epocal [Member]
Acquired Finite And Indefinite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible asset, amount	119,700
Core technology and patents [Member] | Mega Medika [Member]
Acquired Finite And Indefinite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible asset, amount
Trademarks and trade names [Member]
Acquired Finite And Indefinite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible asset, amount	20,500	19,390
Weighted-average Useful Life	19 years 2 months 12 days	18 years 3 months 18 days
Trademarks and trade names [Member] | Epocal [Member]
Acquired Finite And Indefinite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible asset, amount	20,500
Trademarks and trade names [Member] | Mega Medika [Member]
Acquired Finite And Indefinite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible asset, amount
Customer relationships [Member]
Acquired Finite And Indefinite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible asset, amount	9,460	136,485
Weighted-average Useful Life	21 years	18 years 1 month 6 days
Customer relationships [Member] | Epocal [Member]
Acquired Finite And Indefinite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible asset, amount
Customer relationships [Member] | Mega Medika [Member]
Acquired Finite And Indefinite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible asset, amount	9,460
Non-competition agreements [Member]
Acquired Finite And Indefinite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible asset, amount		1,118
Weighted-average Useful Life		5 years 1 month 6 days
Other [Member]
Acquired Finite And Indefinite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible asset, amount		$ 15,227
Weighted-average Useful Life		9 years 2 months 12 days

XML

Net Income (Loss) per Common Share - Potential Dilutive Securities Not Included in Calculation of Diluted Net Income (Loss) per Common Share (Detail) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	23,668	23,605
Options to purchase common stock [Member]
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	9,987	9,776
Warrants [Member]
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	4	152
Convertible shares related to 3% convertible senior subordinated notes [Member]
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	3,411	3,411
Subordinated convertible promissory notes [Member]
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	27	27
Convertible preferred stock series B [Member]
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	10,239	10,239

XML

Related Party Transactions - Additional Information (Detail) (USD $)	3 Months Ended			3 Months Ended					12 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Dec. 31, 2012	Mar. 31, 2013 Sales revenue services [Member]	Mar. 31, 2012 Sales revenue services [Member]	Mar. 31, 2013 Sales revenue goods [Member]	Mar. 31, 2012 Sales revenue goods [Member]	Mar. 31, 2013 Swiss Precision Diagnostics [Member]	Dec. 31, 2012 Swiss Precision Diagnostics [Member]	May 31, 2007 Swiss Precision Diagnostics [Member]
Related Party Transaction [Line Items]
Joint venture ownership percentage with P&G										50.00%
Net receivable to joint venture	$ 600,000		$ 2,300,000
Restructuring charges	3,992,000	5,528,000						1,500,000	1,600,000
Long-term receivables cost related to restructuring plan	13,700,000		14,600,000
Customer receivables associated with revenue earned after SPD was completed have been classified as other receivables	8,900,000		6,900,000
Revenue from joint venture				17,100,000	17,100,000	300,000	300,000
Trade receivables from joint venture	8,700,000		7,300,000
Trade payable to joint venture	15,700,000		21,300,000
Cash (return of investment) from SPD	$ 10,800,000	$ 6,100,000

XML

Restructuring Plans - Aggregate Charges Associated with Restructuring Plans Recorded in Operating Income (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 3,992	$ 5,528
Cost of net revenue [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	623	964
Research and development [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges		624
Sales and marketing [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	1,099	827
General and administrative [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	2,170	3,113
Operating expenses [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	3,892	5,528
Interest expense [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	55	60
Total charges [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 3,947	$ 5,588

XML

Guarantor Financial Information - Consolidating Statement of Operations (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Condensed Financial Statements, Captions [Line Items]
Net product sales	$ 508,276	$ 475,787
Services revenue	226,909	192,434
Net product sales and services revenue	735,185	668,221
License and royalty revenue	4,064	2,908
Net revenue	739,249	671,129
Cost of net product sales	253,078	225,554
Cost of services revenue	120,158	90,860
Cost of net product sales and services revenue	373,236	316,414
Cost of license and royalty revenue	1,756	1,644
Cost of net revenue	374,992	318,058
Gross profit (loss)	364,257	353,071
Operating expenses:
Research and development	41,454	39,000
Sales and marketing	156,456	158,578
General and administrative	135,858	120,435
Total operating expenses	333,768	318,013
Operating income (loss)	30,489	35,058
Interest expense, including amortization of original issue discounts and deferred financing costs	(57,399)	(50,727)
Other income (expense), net	(470)	11,831
Income (loss) before provision (benefit) for income taxes	(27,380)	(3,838)
Provision (benefit) for income taxes	(36,871)	(1,455)
Income (loss) before equity earnings of unconsolidated entities, net of tax	9,491	(2,383)
Equity in earnings (losses) of subsidiaries, net of tax
Equity earnings of unconsolidated entities, net of tax	2,934	3,412
Net income	12,425	1,029
Less: Net loss attributable to non-controlling interests	(25)	(185)
Net income attributable to Alere Inc. and Subsidiaries	12,450	1,214
Preferred stock dividends	(5,250)	(5,309)
Net income (loss) available to common stockholders	7,200	(4,095)
Issuer [Member]
Condensed Financial Statements, Captions [Line Items]
Net product sales
Services revenue
Net product sales and services revenue
License and royalty revenue
Net revenue
Cost of net product sales	948	850
Cost of services revenue
Cost of net product sales and services revenue	948	850
Cost of license and royalty revenue
Cost of net revenue	948	850
Gross profit (loss)	(948)	(850)
Operating expenses:
Research and development	4,423	5,196
Sales and marketing	1,392	1,057
General and administrative	14,027	11,631
Total operating expenses	19,842	17,884
Operating income (loss)	(20,790)	(18,734)
Interest expense, including amortization of original issue discounts and deferred financing costs	(56,858)	(49,716)
Other income (expense), net	4,770	(8,074)
Income (loss) before provision (benefit) for income taxes	(72,878)	(76,524)
Provision (benefit) for income taxes	(62,811)	(26,998)
Income (loss) before equity earnings of unconsolidated entities, net of tax	(10,067)	(49,526)
Equity in earnings (losses) of subsidiaries, net of tax	22,244	49,895
Equity earnings of unconsolidated entities, net of tax	248	660
Net income	12,425	1,029
Less: Net loss attributable to non-controlling interests
Net income attributable to Alere Inc. and Subsidiaries	12,425	1,029
Preferred stock dividends	(5,250)	(5,309)
Net income (loss) available to common stockholders	7,175	(4,280)
Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net product sales	233,493	223,417
Services revenue	206,171	176,715
Net product sales and services revenue	439,664	400,132
License and royalty revenue	3,035	4,304
Net revenue	442,699	404,436
Cost of net product sales	120,594	106,202
Cost of services revenue	115,611	83,643
Cost of net product sales and services revenue	236,205	189,845
Cost of license and royalty revenue	17	5
Cost of net revenue	236,222	189,850
Gross profit (loss)	206,477	214,586
Operating expenses:
Research and development	17,380	17,482
Sales and marketing	82,838	86,337
General and administrative	64,983	64,644
Total operating expenses	165,201	168,463
Operating income (loss)	41,276	46,123
Interest expense, including amortization of original issue discounts and deferred financing costs	(7,021)	(11,067)
Other income (expense), net	6,259	9,428
Income (loss) before provision (benefit) for income taxes	40,514	44,484
Provision (benefit) for income taxes	17,926	16,782
Income (loss) before equity earnings of unconsolidated entities, net of tax	22,588	27,702
Equity in earnings (losses) of subsidiaries, net of tax	(614)	(348)
Equity earnings of unconsolidated entities, net of tax
Net income	21,974	27,354
Less: Net loss attributable to non-controlling interests
Net income attributable to Alere Inc. and Subsidiaries	21,974	27,354
Preferred stock dividends
Net income (loss) available to common stockholders	21,974	27,354
Non-Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net product sales	320,897	285,599
Services revenue	20,738	15,719
Net product sales and services revenue	341,635	301,318
License and royalty revenue	3,533	2,546
Net revenue	345,168	303,864
Cost of net product sales	173,216	151,598
Cost of services revenue	8,502	7,217
Cost of net product sales and services revenue	181,718	158,815
Cost of license and royalty revenue	4,243	5,581
Cost of net revenue	185,961	164,396
Gross profit (loss)	159,207	139,468
Operating expenses:
Research and development	19,651	16,322
Sales and marketing	72,226	71,184
General and administrative	56,848	44,160
Total operating expenses	148,725	131,666
Operating income (loss)	10,482	7,802
Interest expense, including amortization of original issue discounts and deferred financing costs	(3,417)	(3,254)
Other income (expense), net	(1,603)	23,787
Income (loss) before provision (benefit) for income taxes	5,462	28,335
Provision (benefit) for income taxes	8,127	8,690
Income (loss) before equity earnings of unconsolidated entities, net of tax	(2,665)	19,645
Equity in earnings (losses) of subsidiaries, net of tax
Equity earnings of unconsolidated entities, net of tax	2,688	2,736
Net income	23	22,381
Less: Net loss attributable to non-controlling interests	(25)	(185)
Net income attributable to Alere Inc. and Subsidiaries	48	22,566
Preferred stock dividends
Net income (loss) available to common stockholders	48	22,566
Eliminations [Member]
Condensed Financial Statements, Captions [Line Items]
Net product sales	(46,114)	(33,229)
Services revenue
Net product sales and services revenue	(46,114)	(33,229)
License and royalty revenue	(2,504)	(3,942)
Net revenue	(48,618)	(37,171)
Cost of net product sales	(41,680)	(33,096)
Cost of services revenue	(3,955)
Cost of net product sales and services revenue	(45,635)	(33,096)
Cost of license and royalty revenue	(2,504)	(3,942)
Cost of net revenue	(48,139)	(37,038)
Gross profit (loss)	(479)	(133)
Operating expenses:
Research and development
Sales and marketing
General and administrative
Total operating expenses
Operating income (loss)	(479)	(133)
Interest expense, including amortization of original issue discounts and deferred financing costs	9,897	13,310
Other income (expense), net	(9,896)	(13,310)
Income (loss) before provision (benefit) for income taxes	(478)	(133)
Provision (benefit) for income taxes	(113)	71
Income (loss) before equity earnings of unconsolidated entities, net of tax	(365)	(204)
Equity in earnings (losses) of subsidiaries, net of tax	(21,630)	(49,547)
Equity earnings of unconsolidated entities, net of tax	(2)	16
Net income	(21,997)	(49,735)
Less: Net loss attributable to non-controlling interests
Net income attributable to Alere Inc. and Subsidiaries	(21,997)	(49,735)
Preferred stock dividends
Net income (loss) available to common stockholders	$ (21,997)	$ (49,735)

XML

Stock-based Compensation - Stock-Based Compensation Expense (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$ 4,123	$ 3,874
Benefit for income taxes	(862)	(541)
Stock-based compensation, net of tax	3,261	3,333
Cost of net revenue [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	232	269
Research and development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	747	771
Sales and marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	716	917
General and administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$ 2,428	$ 1,917

XML

Business Combinations (Tables)

3 Months Ended

Mar. 31, 2013

Business Combinations [Abstract]

Preliminary Fair Values of Net Assets Acquired for Acquisitions

A summary of the preliminary fair values of the net assets acquired for the acquisitions consummated in 2013 is as follows (in thousands):

	Epocal		Mega Medika		Total
Current assets(1)	$	11,935	$	1,142	$	13,077
Property, plant and equipment		1,267		229		1,496
Goodwill		99,519		655		100,174
Intangible assets		164,400		9,460		173,860
Other non-current assets		17,610		—		17,610
Total assets acquired		294,731		11,486		306,217
Current liabilities		2,543		549		3,092
Non-current liabilities		43,727		211		43,938
Total liabilities assumed		46,270		760		47,030
Net assets acquired		248,461		10,726		259,187
Less:
Contingent consideration		75,000		295		75,295
Cash paid	$	173,461	$	10,431	$	183,892

⁽¹⁾  Includes approximately $2.6 million of acquired cash.

A summary of the preliminary fair values of the net assets acquired for the acquisitions consummated in 2012 is as follows (in thousands):

Current assets(1)	$	46,041
Property, plant and equipment		9,029
Goodwill		259,231
Intangible assets		325,223
Other non-current assets		629
Total assets acquired		640,153
Current liabilities		28,802
Non-current liabilities		116,580
Total liabilities assumed		145,382
Net assets acquired		494,771
Less:
Contingent consideration		75,620
Cash paid	$	419,151

⁽¹⁾  Includes approximately $3.8 million of acquired cash.

Intangible Assets Acquired and their Respective Fair Values and Weighted-Average Useful Lives

The following are the intangible assets acquired and their respective fair values and weighted-average useful lives (dollars in thousands):

	Epocal		Mega Medika		Total		Weighted- average Useful Life
Core technology and patents	$	119,700	$	—	$	119,700		20.0 years
Trademarks and trade names		20,500		—		20,500		19.2 years
Customer relationships		—		9,460		9,460		21.0 years
In-process research and development		24,200		—		24,200		N/A
Total intangible assets	$	164,400	$	9,460	$	173,860

The following are the intangible assets acquired and their respective fair values and weighted-average useful lives (dollars in thousands):

	Amount		Weighted- average Useful Life
Core technology and patents	$	148,103		18.7 years
Trademarks and trade names		19,390		18.3 years
Customer relationships		136,485		18.1 years
Non-competition agreements		1,118		5.1 years
Other		15,227		9.2 years
In-process research and development		4,900		N/A
Total intangible assets	$	325,223

XML

Guarantor Financial Information - Consolidating Statement of Comprehensive Income (Loss) (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Condensed Financial Statements, Captions [Line Items]
Net income	$ 12,425	$ 1,029
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment	(75,355)	35,939
Unrealized gains on available for sale securities		431
Unrealized gains on hedging instruments	11	1,107
Minimum pension liability adjustment	605	(165)
Other comprehensive income (loss), before tax	(74,739)	37,312
Income tax provision (benefit) related to items of other comprehensive income (loss)		(41)
Other comprehensive income (loss), net of tax	(74,739)	37,353
Comprehensive income (loss)	(62,314)	38,382
Less: Comprehensive loss attributable to non-controlling interests	(25)	(185)
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	(62,289)	38,567
Issuer [Member]
Condensed Financial Statements, Captions [Line Items]
Net income	12,425	1,029
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment	(201)	329
Unrealized gains on available for sale securities		429
Unrealized gains on hedging instruments		17
Minimum pension liability adjustment
Other comprehensive income (loss), before tax	(201)	775
Income tax provision (benefit) related to items of other comprehensive income (loss)
Other comprehensive income (loss), net of tax	(201)	775
Comprehensive income (loss)	12,224	1,804
Less: Comprehensive loss attributable to non-controlling interests
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	12,224	1,804
Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net income	21,974	27,354
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment		(306)
Unrealized gains on available for sale securities		2
Unrealized gains on hedging instruments
Minimum pension liability adjustment
Other comprehensive income (loss), before tax		(304)
Income tax provision (benefit) related to items of other comprehensive income (loss)
Other comprehensive income (loss), net of tax		(304)
Comprehensive income (loss)	21,974	27,050
Less: Comprehensive loss attributable to non-controlling interests
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	21,974	27,050
Non-Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net income	23	22,381
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment	(75,154)	35,251
Unrealized gains on hedging instruments	11	1,090
Minimum pension liability adjustment	605	(165)
Other comprehensive income (loss), before tax	(74,538)	36,176
Income tax provision (benefit) related to items of other comprehensive income (loss)		(41)
Other comprehensive income (loss), net of tax	(74,538)	36,217
Comprehensive income (loss)	(74,515)	58,598
Less: Comprehensive loss attributable to non-controlling interests	(25)	(185)
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	(74,490)	58,783
Eliminations [Member]
Condensed Financial Statements, Captions [Line Items]
Net income	(21,997)	(49,735)
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment		665
Unrealized gains on hedging instruments
Minimum pension liability adjustment
Other comprehensive income (loss), before tax		665
Income tax provision (benefit) related to items of other comprehensive income (loss)
Other comprehensive income (loss), net of tax		665
Comprehensive income (loss)	(21,997)	(49,070)
Less: Comprehensive loss attributable to non-controlling interests
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	$ (21,997)	$ (49,070)

XML

Material Contingencies - Additional Information (Detail)			3 Months Ended		3 Months Ended
	Mar. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)	Mar. 31, 2013 Epocal [Member] USD ($)	Feb. 01, 2013 Epocal [Member] USD ($)	Mar. 31, 2013 Accordant [Member] USD ($)	Dec. 31, 2012 Accordant [Member] USD ($)	Mar. 31, 2013 Branan [Member] USD ($)	Dec. 31, 2012 Branan [Member] USD ($)	Mar. 31, 2013 ROAR [Member] USD ($)	Mar. 31, 2013 ROAR [Member] GBP (£)
Business Acquisition, Contingent Consideration [Line Items]
Payable contingent cash consideration remaining			$ 90,500,000			$ 4,500,000		$ 2,000,000
Earn-out cash paid	183,892,000	419,151,000	173,461,000	173,500,000	1,500,000
Payments in installments during the second quarter					1,500,000
Payments in installments during the third quarter					1,500,000
Incremental accrual							1,000,000
Maximum remaining amount of earn-out payments							2,000,000		14,400,000	9,500,000
Cash paid on the day of acquisition			15,000,000
Maximum amount of management incentive payments			9,400,000
Accrued earn-out payments									$ 1,500,000	£ 1,000,000

XML

Restructuring Plans - Additional Information (Detail) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2013
Restructuring Cost and Reserve [Line Items]
Restructuring reserve accrued expenses and other current liabilities	$ 5.4
Restructuring reserve other long-term liabilities	1.0
2013 Restructuring Plans [Member] | Professional Diagnostics Business Segment [Member]
Restructuring Cost and Reserve [Line Items]
Cash charges remain unpaid	1.4
Additional costs	0.1
2012 Restructuring Plans [Member] | Professional Diagnostics Business Segment [Member]
Restructuring Cost and Reserve [Line Items]
Additional costs	3.8
2012 Restructuring Plans [Member] | Health Information Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Additional costs	3.7
2011, 2010 and 2008 Restructuring Plans [Member] | Professional Diagnostics Business Segment [Member]
Restructuring Cost and Reserve [Line Items]
Additional costs	1.6
2011, 2010 and 2008 Restructuring Plans [Member] | Health Information Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Cash charges remain unpaid	$ 2.6

XML

Equity Investments - Financial Information for SPD and Techlab on Combined Condensed Balance Sheets (Detail) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2013	Dec. 31, 2012
Equity Method Investments And Joint Ventures [Abstract]
Current assets	$ 65,835	$ 79,842
Non-current assets	37,603	38,991
Total assets	103,438	118,833
Current liabilities	32,950	45,084
Non-current liabilities	6,986	6,791
Total liabilities	$ 39,936	$ 51,875

XML

Guarantor Financial Information - Consolidating Statement Of Cash Flows (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Cash Flows from Operating Activities:
Net income	$ 12,425	$ 1,029
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Equity in earnings (losses) of subsidiaries, net of tax
Non-cash interest expense, including amortization of original issue discounts and write-off of deferred financing costs	5,217	5,278
Depreciation and amortization	104,970	102,721
Non-cash charges for sale of inventories revalued at the date of acquisition	461	4,681
Non-cash stock-based compensation expense	4,123	3,874
Impairment of inventory		5
Impairment of long-lived assets		134
(Gain) loss on sale of fixed assets	172	566
Equity earnings of unconsolidated entities, net of tax	(2,934)	(3,412)
Deferred income taxes	(50,907)	(13,752)
Other non-cash items	1,941
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net	(20,167)	(12,942)
Inventories, net	(17,171)	9,351
Prepaid expenses and other current assets	(5,833)	3,521
Accounts payable	(1,988)	(17,806)
Accrued expenses and other current liabilities	39,957	3,985
Other non-current liabilities	795	14,697
Intercompany payable (receivable)
Net cash provided by (used in) operating activities	71,061	101,930
Cash Flows from Investing Activities:
Decrease (increase) in restricted cash	(8,573)	6,302
Purchases of property, plant and equipment	(36,105)	(30,385)
Proceeds from sale of property, plant and equipment	1,143	527
Cash paid for acquisitions, net of cash acquired	(158,421)	(38,008)
Cash received from equity method investments	10,771	6,066
Cash received (paid) for marketable securities		(2)
Increase in other assets	(5,569)	(8,554)
Net cash used in investing activities	(196,754)	(64,054)
Cash Flows from Financing Activities:
Cash paid for financing costs	(1,427)	(1,876)
Cash paid for contingent purchase price consideration	(19,098)	(48)
Proceeds from issuance of common stock, net of issuance costs	6,135	7,674
Proceeds from issuance of long-term debt	10,053	199,141
Payments on long-term debt	(19,638)	(16,911)
Net proceeds (payments) under revolving credit facilities	162,483	1,339
Payments on short-term debt		(6,240)
Cash paid for dividends	(5,323)	(5,323)
Excess tax benefits on exercised stock options	104	148
Principal payments on capital lease obligations	(1,721)	(1,720)
Net cash provided by (used in) financing activities	131,568	176,184
Foreign exchange effect on cash and cash equivalents	(6,988)	864
Net increase (decrease) in cash and cash equivalents	(1,113)	214,924
Cash and cash equivalents, beginning of period	328,346	299,173
Cash and cash equivalents, end of period	327,233	514,097
Issuer [Member]
Cash Flows from Operating Activities:
Net income	12,425	1,029
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Equity in earnings (losses) of subsidiaries, net of tax	(22,244)	(49,895)
Non-cash interest expense, including amortization of original issue discounts and write-off of deferred financing costs	5,153	5,219
Depreciation and amortization	1,287	2,074
Non-cash charges for sale of inventories revalued at the date of acquisition
Non-cash stock-based compensation expense	1,660	1,007
Impairment of inventory
Impairment of long-lived assets
(Gain) loss on sale of fixed assets
Equity earnings of unconsolidated entities, net of tax	(248)	(660)
Deferred income taxes	(30,889)	(11,105)
Other non-cash items	(762)
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net
Inventories, net
Prepaid expenses and other current assets	(473,927)	10,526
Accounts payable	(604)	(863)
Accrued expenses and other current liabilities	478,082	(14,901)
Other non-current liabilities	(126)	4,309
Intercompany payable (receivable)	63,473	131,413
Net cash provided by (used in) operating activities	33,280	78,153
Cash Flows from Investing Activities:
Decrease (increase) in restricted cash	(7,933)
Purchases of property, plant and equipment	(37)	(4)
Proceeds from sale of property, plant and equipment
Cash paid for acquisitions, net of cash acquired	(151,372)	(22,500)
Cash received from equity method investments
Cash received (paid) for marketable securities
Increase in other assets	(3,210)	(6,144)
Net cash used in investing activities	(162,552)	(28,648)
Cash Flows from Financing Activities:
Cash paid for financing costs	(1,427)	(1,876)
Cash paid for contingent purchase price consideration	(19,098)	(48)
Proceeds from issuance of common stock, net of issuance costs	6,135	7,674
Proceeds from issuance of long-term debt		198,000
Payments on long-term debt	(16,845)	(10,750)
Net proceeds (payments) under revolving credit facilities	170,000
Payments on short-term debt		(6,240)
Cash paid for dividends	(5,323)	(5,323)
Excess tax benefits on exercised stock options	71	98
Principal payments on capital lease obligations
Net cash provided by (used in) financing activities	133,513	181,535
Foreign exchange effect on cash and cash equivalents	762	(429)
Net increase (decrease) in cash and cash equivalents	5,003	230,611
Cash and cash equivalents, beginning of period	3,623	12,451
Cash and cash equivalents, end of period	8,626	243,062
Guarantor Subsidiaries [Member]
Cash Flows from Operating Activities:
Net income	21,974	27,354
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Equity in earnings (losses) of subsidiaries, net of tax	614	348
Non-cash interest expense, including amortization of original issue discounts and write-off of deferred financing costs	55	59
Depreciation and amortization	61,956	63,363
Non-cash charges for sale of inventories revalued at the date of acquisition		1,400
Non-cash stock-based compensation expense	1,096	1,377
Impairment of inventory		5
Impairment of long-lived assets		134
(Gain) loss on sale of fixed assets	227	508
Equity earnings of unconsolidated entities, net of tax
Deferred income taxes	(10,300)	(614)
Other non-cash items	275
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net	(1,722)	(4,605)
Inventories, net	(10,475)	13,349
Prepaid expenses and other current assets	413,773	(4,386)
Accounts payable	(7,960)	(4,101)
Accrued expenses and other current liabilities	(387,332)	34,232
Other non-current liabilities	(2,946)	(10,015)
Intercompany payable (receivable)	(80,252)	(128,235)
Net cash provided by (used in) operating activities	(1,017)	(9,827)
Cash Flows from Investing Activities:
Decrease (increase) in restricted cash	(630)
Purchases of property, plant and equipment	(14,354)	(17,375)
Proceeds from sale of property, plant and equipment	2,106	201
Cash paid for acquisitions, net of cash acquired
Cash received from equity method investments
Cash received (paid) for marketable securities		(2)
Increase in other assets	(928)	(397)
Net cash used in investing activities	(13,806)	(17,573)
Cash Flows from Financing Activities:
Cash paid for financing costs
Cash paid for contingent purchase price consideration
Proceeds from issuance of common stock, net of issuance costs
Proceeds from issuance of long-term debt	1,007	951
Payments on long-term debt	(445)	(656)
Net proceeds (payments) under revolving credit facilities		(2)
Payments on short-term debt
Cash paid for dividends
Excess tax benefits on exercised stock options	17	48
Principal payments on capital lease obligations	(814)	(502)
Net cash provided by (used in) financing activities	(235)	(161)
Foreign exchange effect on cash and cash equivalents	16	73
Net increase (decrease) in cash and cash equivalents	(15,042)	(27,488)
Cash and cash equivalents, beginning of period	67,449	95,212
Cash and cash equivalents, end of period	52,407	67,724
Non-Guarantor Subsidiaries [Member]
Cash Flows from Operating Activities:
Net income	23	22,381
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Equity in earnings (losses) of subsidiaries, net of tax
Non-cash interest expense, including amortization of original issue discounts and write-off of deferred financing costs	9
Depreciation and amortization	41,756	37,345
Non-cash charges for sale of inventories revalued at the date of acquisition	461	3,281
Non-cash stock-based compensation expense	1,367	1,490
Impairment of inventory
Impairment of long-lived assets
(Gain) loss on sale of fixed assets	(55)	58
Equity earnings of unconsolidated entities, net of tax	(2,688)	(2,736)
Deferred income taxes	(9,605)	(2,033)
Other non-cash items	2,428
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net	(18,455)	(8,337)
Inventories, net	(7,271)	(3,733)
Prepaid expenses and other current assets	35,134	(2,619)
Accounts payable	6,576	(12,842)
Accrued expenses and other current liabilities	(31,606)	(15,346)
Other non-current liabilities	3,867	20,332
Intercompany payable (receivable)	16,779	(3,178)
Net cash provided by (used in) operating activities	38,730	34,063
Cash Flows from Investing Activities:
Decrease (increase) in restricted cash	(10)	6,302
Purchases of property, plant and equipment	(26,736)	(13,465)
Proceeds from sale of property, plant and equipment	4,085	326
Cash paid for acquisitions, net of cash acquired	(7,049)	(15,508)
Cash received from equity method investments	10,771	6,066
Cash received (paid) for marketable securities
Increase in other assets	(1,431)	(2,013)
Net cash used in investing activities	(20,370)	(18,292)
Cash Flows from Financing Activities:
Cash paid for financing costs
Cash paid for contingent purchase price consideration
Proceeds from issuance of common stock, net of issuance costs
Proceeds from issuance of long-term debt	9,046	190
Payments on long-term debt	(2,348)	(5,505)
Net proceeds (payments) under revolving credit facilities	(7,517)	1,341
Payments on short-term debt
Cash paid for dividends
Excess tax benefits on exercised stock options	16	2
Principal payments on capital lease obligations	(907)	(1,218)
Net cash provided by (used in) financing activities	(1,710)	(5,190)
Foreign exchange effect on cash and cash equivalents	(7,724)	1,220
Net increase (decrease) in cash and cash equivalents	8,926	11,801
Cash and cash equivalents, beginning of period	257,274	191,510
Cash and cash equivalents, end of period	266,200	203,311
Eliminations [Member]
Cash Flows from Operating Activities:
Net income	(21,997)	(49,735)
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Equity in earnings (losses) of subsidiaries, net of tax	21,630	49,547
Non-cash interest expense, including amortization of original issue discounts and write-off of deferred financing costs
Depreciation and amortization	(29)	(61)
Non-cash charges for sale of inventories revalued at the date of acquisition
Non-cash stock-based compensation expense
Impairment of inventory
Impairment of long-lived assets
(Gain) loss on sale of fixed assets
Equity earnings of unconsolidated entities, net of tax	2	(16)
Deferred income taxes	(113)
Other non-cash items
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net
Inventories, net	575	(265)
Prepaid expenses and other current assets	19,187
Accounts payable
Accrued expenses and other current liabilities	(19,187)
Other non-current liabilities		71
Intercompany payable (receivable)
Net cash provided by (used in) operating activities	68	(459)
Cash Flows from Investing Activities:
Decrease (increase) in restricted cash
Purchases of property, plant and equipment	5,022	459
Proceeds from sale of property, plant and equipment	(5,048)
Cash paid for acquisitions, net of cash acquired
Cash received from equity method investments
Cash received (paid) for marketable securities
Increase in other assets
Net cash used in investing activities	(26)	459
Cash Flows from Financing Activities:
Cash paid for financing costs
Cash paid for contingent purchase price consideration
Proceeds from issuance of common stock, net of issuance costs
Proceeds from issuance of long-term debt
Payments on long-term debt
Net proceeds (payments) under revolving credit facilities
Payments on short-term debt
Cash paid for dividends
Excess tax benefits on exercised stock options
Principal payments on capital lease obligations
Net cash provided by (used in) financing activities
Foreign exchange effect on cash and cash equivalents	(42)
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period

XML

Guarantor Financial Information - Additional Information (Detail)	Mar. 31, 2013	Dec. 31, 2012
7.25% Senior notes [Member]
Debt Instrument [Line Items]
Interest rate of debt instrument	7.25%	7.25%
8.625% Senior subordinated notes [Member]
Debt Instrument [Line Items]
Interest rate of debt instrument	8.625%	8.625%
9% Senior subordinated notes [Member]
Debt Instrument [Line Items]
Interest rate of debt instrument	9.00%	9.00%

XML

Related Party Transactions - Related Party Balances with SPD within Consolidated Balance Sheets (Detail) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2013	Dec. 31, 2012
Related Party Transaction [Line Items]
Accounts receivable, net of allowances	$ 540,093	$ 524,332
Prepaid expenses and other current assets	167,346	145,236
Deferred financing costs, net, and other non-current assets	99,300	108,857
Accounts payable	166,012	169,974
Related party transaction [Member]
Related Party Transaction [Line Items]
Accounts receivable, net of allowances	8,667	7,317
Prepaid expenses and other current assets	9,425	9,161
Deferred financing costs, net, and other non-current assets	13,665	14,629
Accounts payable	$ 15,676	$ 21,258

XML

Equity Investments

3 Months Ended

Mar. 31, 2013

Equity Method Investments And Joint Ventures [Abstract]

Equity Investments

(19) Equity Investments

We account for the results from our equity investments under the equity method of accounting in accordance with ASC 323, Investments — Equity Method and Joint Ventures, based on the percentage of our ownership interest in the business. Our equity investments primarily include the following:

(a) SPD

In May 2007, we completed the formation of SPD, our 50/50 joint venture with P&G for the development, manufacturing, marketing and sale of existing and to-be-developed consumer diagnostic products, outside the cardiology, diabetes and oral care fields. Upon completion of the arrangement to form SPD, we ceased to consolidate the operating results of our consumer diagnostics business related to SPD. For the three months ended March 31, 2013 and 2012, we recorded earnings of $2.5 million and $2.8 million, respectively, in equity earnings of unconsolidated entities, net of tax, in our accompanying Consolidated Statements of Operations, which represented our 50% share of SPD’s net income for the respective periods.

(b) TechLab

In May 2006, we acquired 49% of TechLab, Inc., or TechLab, a privately-held developer, manufacturer and distributor of rapid non-invasive intestinal diagnostics tests in the areas of intestinal inflammation, antibiotic-associated diarrhea and parasitology. For the three months ended March 31, 2013 and 2012, we recorded earnings of $0.2 million and $0.7 million, respectively, in equity earnings of unconsolidated entities, net of tax, in our accompanying Consolidated Statements of Operations, which represented our minority share of TechLab’s net income for the respective periods.

Summarized financial information for SPD and TechLab on a combined basis is as follows (in thousands):

	Three Months Ended March 31,
Combined Condensed Results of Operations:	2013		2012
Net revenue	$	49,155	$	52,525
Gross profit	$	37,113	$	35,179
Net income after taxes	$	5,577	$	6,993
Combined Condensed Balance Sheet:	March 31, 2013		December 31, 2012
Current assets	$	65,835	$	79,842
Non-current assets		37,603		38,991
Total assets	$	103,438	$	118,833
Current liabilities	$	32,950	$	45,084
Non-current liabilities		6,986		6,791
Total liabilities	$	39,936	$	51,875

XML

Stockholders' Equity and Non-controlling Interests - Summary of Changes in Stockholders' Equity and Non-controlling Interests Comprising Total Equity (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Equity And Noncontrolling Interests [Line Items]
Equity, beginning of period	$ 2,182,704	$ 2,231,574
Exercise of common stock options, warrants and shares issued under employee stock purchase plan	6,135	7,674
Preferred stock dividends	(5,323)	(5,323)
Stock-based compensation related to grants of common stock options	4,123	3,874
Excess tax benefits on exercised stock options	(422)	104
Net income (loss)	12,425	1,029
Total other comprehensive income (loss)	(74,739)	37,353
Equity, end of period	2,124,903	2,276,333
Issuer [Member]
Equity And Noncontrolling Interests [Line Items]
Equity, beginning of period	2,180,422	2,229,234
Exercise of common stock options, warrants and shares issued under employee stock purchase plan	6,135	7,674
Preferred stock dividends	(5,323)	(5,323)
Stock-based compensation related to grants of common stock options	4,123	3,874
Excess tax benefits on exercised stock options	(422)	104
Net income (loss)	12,450	1,214
Total other comprehensive income (loss)	(74,739)	37,353
Equity, end of period	2,122,646	2,274,130
Non-controlling Interests [Member]
Equity And Noncontrolling Interests [Line Items]
Equity, beginning of period	2,282	2,340
Exercise of common stock options, warrants and shares issued under employee stock purchase plan
Preferred stock dividends
Stock-based compensation related to grants of common stock options
Excess tax benefits on exercised stock options
Net income (loss)	(25)	(137)
Total other comprehensive income (loss)
Equity, end of period	$ 2,257	$ 2,203

XML

Guarantor Financial Information (Tables)

3 Months Ended

Mar. 31, 2013

Text Block [Abstract]

Consolidating Statement of Operations

CONSOLIDATING STATEMENT OF OPERATIONS

For the Three Months Ended March 31, 2013

(in thousands)

	Issuer			Guarantor Subsidiaries			Non- Guarantor Subsidiaries			Eliminations			Consolidated
Net product sales	$	—		$	233,493		$	320,897		$	(46,114	)	$	508,276
Services revenue		—			206,171			20,738			—			226,909
Net product sales and services revenue		—			439,664			341,635			(46,114	)		735,185
License and royalty revenue		—			3,035			3,533			(2,504	)		4,064
Net revenue		—			442,699			345,168			(48,618	)		739,249
Cost of net product sales		948			120,594			173,216			(41,680	)		253,078
Cost of services revenue		—			115,611			8,502			(3,955	)		120,158
Cost of net product sales and services revenue		948			236,205			181,718			(45,635	)		373,236
Cost of license and royalty revenue		—			17			4,243			(2,504	)		1,756
Cost of net revenue		948			236,222			185,961			(48,139	)		374,992
Gross profit (loss)		(948	)		206,477			159,207			(479	)		364,257
Operating expenses:
Research and development		4,423			17,380			19,651			—			41,454
Sales and marketing		1,392			82,838			72,226			—			156,456
General and administrative		14,027			64,983			56,848			—			135,858
Total operating expenses		19,842			165,201			148,725			—			333,768
Operating income (loss)		(20,790	)		41,276			10,482			(479	)		30,489
Interest expense, including amortization of original issue discounts and deferred financing costs		(56,858	)		(7,021	)		(3,417	)		9,897			(57,399	)
Other income (expense), net		4,770			6,259			(1,603	)		(9,896	)		(470	)
Income (loss) before provision (benefit) for income taxes		(72,878	)		40,514			5,462			(478	)		(27,380	)
Provision (benefit) for income taxes		(62,811	)		17,926			8,127			(113	)		(36,871	)
Income (loss) before equity earnings of unconsolidated entities, net of tax		(10,067	)		22,588			(2,665	)		(365	)		9,491
Equity in earnings (losses) of subsidiaries, net of tax		22,244			(614	)		—			(21,630	)		—
Equity earnings of unconsolidated entities, net of tax		248			—			2,688			(2	)		2,934
Net income		12,425			21,974			23			(21,997	)		12,425
Less: Net loss attributable to non-controlling interests		—			—			(25	)		—			(25	)
Net income attributable to Alere Inc. and Subsidiaries		12,425			21,974			48			(21,997	)		12,450
Preferred stock dividends		(5,250	)		—			—			—			(5,250	)
Net income available to common stockholders	$	7,175		$	21,974		$	48		$	(21,997	)	$	7,200

CONSOLIDATING STATEMENT OF OPERATIONS

For the Three Months Ended March 31, 2012

(in thousands)

	Issuer			Guarantor Subsidiaries			Non- Guarantor Subsidiaries			Eliminations			Consolidated
Net product sales	$	—		$	223,417		$	285,599		$	(33,229	)	$	475,787
Services revenue		—			176,715			15,719			—			192,434
Net product sales and services revenue		—			400,132			301,318			(33,229	)		668,221
License and royalty revenue		—			4,304			2,546			(3,942	)		2,908
Net revenue		—			404,436			303,864			(37,171	)		671,129
Cost of net product sales		850			106,202			151,598			(33,096	)		225,554
Cost of services revenue		—			83,643			7,217			—			90,860
Cost of net product sales and services revenue		850			189,845			158,815			(33,096	)		316,414
Cost of license and royalty revenue		—			5			5,581			(3,942	)		1,644
Cost of net revenue		850			189,850			164,396			(37,038	)		318,058
Gross profit (loss)		(850	)		214,586			139,468			(133	)		353,071
Operating expenses:
Research and development		5,196			17,482			16,322			—			39,000
Sales and marketing		1,057			86,337			71,184			—			158,578
General and administrative		11,631			64,644			44,160			—			120,435
Total operating expenses		17,884			168,463			131,666			—			318,013
Operating income (loss)		(18,734	)		46,123			7,802			(133	)		35,058
Interest expense, including amortization of original issue discounts and deferred financing costs		(49,716	)		(11,067	)		(3,254	)		13,310			(50,727	)
Other income (expense), net		(8,074	)		9,428			23,787			(13,310	)		11,831
Income (loss) before provision (benefit) for income taxes		(76,524	)		44,484			28,335			(133	)		(3,838	)
Provision (benefit) for income taxes		(26,998	)		16,782			8,690			71			(1,455	)
Income (loss) before equity earnings of unconsolidated entities, net of tax		(49,526	)		27,702			19,645			(204	)		(2,383	)
Equity in earnings (losses) of subsidiaries, net of tax		49,895			(348	)		—			(49,547	)		—
Equity earnings of unconsolidated entities, net of tax		660			—			2,736			16			3,412
Net income		1,029			27,354			22,381			(49,735	)		1,029
Less: Net loss attributable to non-controlling interests		—			—			(185	)		—			(185	)
Net income attributable to Alere Inc. and Subsidiaries		1,029			27,354			22,566			(49,735	)		1,214
Preferred stock dividends		(5,309	)		—			—			—			(5,309	)
Net income (loss) available to common stockholders	$	(4,280	)	$	27,354		$	22,566		$	(49,735	)	$	(4,095	)

Consolidating Statement of Comprehensive Income (Loss)

CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS)

For the Three Months Ended March 31, 2013

(in thousands)

	Issuer			Guarantor Subsidiaries		Non-Guarantor Subsidiaries			Eliminations			Consolidated
Net income	$	12,425		$	21,974	$	23		$	(21,997	)	$	12,425
Other comprehensive loss, before tax:
Changes in cumulative translation adjustment		(201	)		—		(75,154	)		—			(75,355	)
Unrealized gains on hedging instruments		—			—		11			—			11
Minimum pension liability adjustment		—			—		605			—			605
Other comprehensive loss, before tax		(201	)		—		(74,538	)		—			(74,739	)
Income tax provision (benefit) related to items of other comprehensive loss		—			—		—			—			—
Other comprehensive loss, net of tax		(201	)		—		(74,538	)		—			(74,739	)
Comprehensive income (loss)		12,224			21,974		(74,515	)		(21,997	)		(62,314	)
Less: Comprehensive loss attributable to non-controlling interests		—			—		(25	)		—			(25	)
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	$	12,224		$	21,974	$	(74,490	)	$	(21,997	)	$	(62,289	)

CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

For the Three Months Ended March 31, 2012

(in thousands)

	Issuer		Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations			Consolidated
Net income	$	1,029	$	27,354		$	22,381		$	(49,735	)	$	1,029
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment		329		(306	)		35,251			665			35,939
Unrealized gains on available for sale securities		429		2			—			—			431
Unrealized gains on hedging instruments		17		—			1,090			—			1,107
Minimum pension liability adjustment		—		—			(165	)		—			(165	)
Other comprehensive income (loss), before tax		775		(304	)		36,176			665			37,312
Income tax benefit related to items of other comprehensive income		—		—			(41	)		—			(41	)
Other comprehensive income (loss), net of tax		775		(304	)		36,217			665			37,353
Comprehensive income		1,804		27,050			58,598			(49,070	)		38,382
Less: Comprehensive loss attributable to non-controlling interests		—		—			(185	)		—			(185	)
Comprehensive income attributable to Alere Inc. and Subsidiaries	$	1,804	$	27,050		$	58,783		$	(49,070	)	$	38,567

Consolidating Balance Sheet

CONSOLIDATING BALANCE SHEET

March 31, 2013

(in thousands)

	Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations			Consolidated
ASSETS
Current assets:
Cash and cash equivalents	$	8,626		$	52,407		$	266,200		$	—		$	327,233
Restricted cash		7,933			2,309			1,407			—			11,649
Marketable securities		—			771			113			—			884
Accounts receivable, net of allowances		—			242,772			297,321			—			540,093
Inventories, net		—			147,580			209,509			(20,647	)		336,442
Deferred tax assets		32,145			37,079			11,367			2,939			83,530
Prepaid expenses and other current assets		453,291			(315,140	)		29,231			(36	)		167,346
Intercompany receivables		312,349			603,711			64,077			(980,137	)		—
Total current assets		814,344			771,489			879,225			(997,881	)		1,467,177
Property, plant and equipment, net		2,387			290,253			236,980			(456	)		529,164
Goodwill		—			1,820,992			1,295,865			—			3,116,857
Other intangible assets with indefinite lives		—			13,900			44,493			—			58,393
Finite-lived intangible assets, net		10,927			1,092,551			771,158			—			1,874,636
Deferred financing costs, net and other non-current assets		69,133			10,357			19,881			(71	)		99,300
Investments in subsidiaries		4,345,418			353,666			(67,215	)		(4,631,869	)		—
Investments in unconsolidated entities		34,384			—			48,363			11,548			94,295
Deferred tax assets		—			—			8,653			—			8,653
Intercompany notes receivable		1,672,676			752,565			64,766			(2,490,007	)		—
Total assets	$	6,949,269		$	5,105,773		$	3,302,169		$	(8,108,736	)	$	7,248,475
LIABILITIES AND EQUITY
Current liabilities:
Current portion of long-term debt	$	45,000		$	985		$	6,225		$	—		$	52,210
Current portion of capital lease obligations		—			3,207			2,939			—			6,146
Accounts payable		7,390			67,623			90,999			—			166,012
Accrued expenses and other current liabilities		84,912			199,618			186,418			(29	)		470,919
Intercompany payables		584,562			133,102			262,472			(980,136	)		—
Total current liabilities		721,864			404,535			549,053			(980,165	)		695,287
Long-term liabilities:
Long-term debt, net of current portion		3,770,784			299			17,759			—			3,788,842
Capital lease obligations, net of current portion		—			4,845			6,770			—			11,615
Deferred tax liabilities		(15,907	)		319,914			111,497			(52	)		415,452
Other long-term liabilities		18,099			69,963			124,385			(71	)		212,376
Intercompany notes payables		331,783			1,602,374			555,850			(2,490,007	)		—
Total long-term liabilities		4,104,759			1,997,395			816,261			(2,490,130	)		4,428,285
Stockholders’ equity		2,122,646			2,703,843			1,934,598			(4,638,441	)		2,122,646
Non-controlling interests		—			—			2,257			—			2,257
Total equity		2,122,646			2,703,843			1,936,855			(4,638,441	)		2,124,903
Total liabilities and equity	$	6,949,269		$	5,105,773		$	3,302,169		$	(8,108,736	)	$	7,248,475

CONSOLIDATING BALANCE SHEET

December 31, 2012

(in thousands)

	Issuer			Guarantor Subsidiaries		Non-Guarantor Subsidiaries			Eliminations			Consolidated
ASSETS
Current assets:
Cash and cash equivalents	$	3,623		$	67,449	$	257,274		$	—		$	328,346
Restricted cash		—			1,680		1,396			—			3,076
Marketable securities		—			787		117			—			904
Accounts receivable, net of allowances		—			241,050		283,282			—			524,332
Inventories, net		—			142,413		203,230			(8,522	)		337,121
Deferred tax assets		12,193			39,601		13,138			2,790			67,722
Prepaid expenses and other current assets		(20,636	)		99,271		66,634			(33	)		145,236
Intercompany receivables		298,812			1,254,727		55,847			(1,609,386	)		—
Total current assets		293,992			1,846,978		880,918			(1,615,151	)		1,406,737
Property, plant and equipment, net		2,679			293,260		239,082			(552	)		534,469
Goodwill		—			1,820,438		1,227,967			—			3,048,405
Other intangible assets with indefinite lives		—			14,600		21,851			—			36,451
Finite-lived intangible assets, net		24,701			1,132,656		676,868			—			1,834,225
Deferred financing costs, net and other non-current assets		78,522			10,341		20,065			(71	)		108,857
Investments in subsidiaries		4,114,478			358,088		(67,799	)		(4,404,767	)		—
Investments in unconsolidated entities		33,979			—		56,512			—			90,491
Deferred tax assets		—			782		7,511			—			8,293
Intercompany notes receivable		1,724,650			722,552		1,278			(2,448,480	)		—
Total assets	$	6,273,001		$	6,199,695	$	3,064,253		$	(8,469,021	)	$	7,067,928
LIABILITIES AND EQUITY
Current liabilities:
Current portion of long-term debt	$	45,000		$	349	$	14,883		$	—		$	60,232
Current portion of capital lease obligations		—			3,209		3,475			—			6,684
Accounts payable		7,993			76,256		85,725			—			169,974
Accrued expenses and other current liabilities		(388,830	)		586,116		214,659			(26	)		411,919
Intercompany payables		557,578			806,507		245,300			(1,609,385	)		—
Total current liabilities		221,741			1,472,437		564,042			(1,609,411	)		648,809
Long-term liabilities:
Long-term debt, net of current portion		3,617,068			374		11,233			—			3,628,675
Capital lease obligations, net of current portion		—			5,412		7,505			—			12,917
Deferred tax liabilities		(5,329	)		333,388		100,216			(87	)		428,188
Other long-term liabilities		17,678			72,890		76,138			(71	)		166,635
Intercompany notes payables		241,421			1,630,376		576,684			(2,448,481	)		—
Total long-term liabilities		3,870,838			2,042,440		771,776			(2,448,639	)		4,236,415
Stockholders’ equity		2,180,422			2,684,818		1,726,153			(4,410,971	)		2,180,422
Non-controlling interests		—			—		2,282			—			2,282
Total equity		2,180,422			2,684,818		1,728,435			(4,410,971	)		2,182,704
Total liabilities and equity	$	6,273,001		$	6,199,695	$	3,064,253		$	(8,469,021	)	$	7,067,928

Consolidating Statement of Cash Flows

CONSOLIDATING STATEMENT OF CASH FLOWS

For the Three Months Ended March 31, 2013

(in thousands)

	Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations			Consolidated
Cash Flows from Operating Activities:
Net income	$	12,425		$	21,974		$	23		$	(21,997	)	$	12,425
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Equity in earnings (losses) of subsidiaries, net of tax		(22,244	)		614			—			21,630			—
Non-cash interest expense, including amortization of original issue discounts and write-off of deferred financing costs		5,153			55			9			—			5,217
Depreciation and amortization		1,287			61,956			41,756			(29	)		104,970
Non-cash charges for sale of inventories revalued at the date of acquisition		—			—			461			—			461
Non-cash stock-based compensation expense		1,660			1,096			1,367			—			4,123
(Gain) loss on sale of fixed assets		—			227			(55	)		—			172
Equity earnings of unconsolidated entities, net of tax		(248	)		—			(2,688	)		2			(2,934	)
Deferred income taxes		(30,889	)		(10,300	)		(9,605	)		(113	)		(50,907	)
Other non-cash items		(762	)		275			2,428			—			1,941
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net		—			(1,722	)		(18,445	)		—			(20,167	)
Inventories, net		—			(10,475	)		(7,271	)		575			(17,171	)
Prepaid expenses and other current assets		(473,927	)		413,773			35,134			19,187			(5,833	)
Accounts payable		(604	)		(7,960	)		6,576			—			(1,988	)
Accrued expenses and other current liabilities		478,082			(387,332	)		(31,606	)		(19,187	)		39,957
Other non-current liabilities		(126	)		(2,946	)		3,867			—			795
Intercompany payable (receivable)		63,473			(80,252	)		16,779			—			—
Net cash provided by (used in) operating activities		33,280			(1,017	)		38,730			68			71,061
Cash Flows from Investing Activities:
Increase in restricted cash		(7,933	)		(630	)		(10	)		—			(8,573	)
Purchases of property, plant and equipment		(37	)		(14,354	)		(26,736	)		5,022			(36,105	)
Proceeds from sale of property, plant and equipment		—			2,106			4,085			(5,048	)		1,143
Cash paid for acquisitions, net of cash acquired		(151,372	)		—			(7,049	)		—			(158,421	)
Cash received from equity method investments		—			—			10,771			—			10,771
Increase in other assets		(3,210	)		(928	)		(1,431	)		—			(5,569	)
Net cash used in investing activities		(162,552	)		(13,806	)		(20,370	)		(26	)		(196,754	)
Cash Flows from Financing Activities:
Cash paid for financing costs		(1,427	)		—			—			—			(1,427	)
Cash paid for contingent purchase price consideration		(19,098	)		—			—			—			(19,098	)
Proceeds from issuance of common stock, net of issuance costs		6,135			—			—			—			6,135
Proceeds from issuance of long-term debt		—			1,007			9,046			—			10,053
Payments on long-term debt		(16,845	)		(445	)		(2,348	)		—			(19,638	)
Net proceeds (payments) under revolving credit facilities		170,000			—			(7,517	)		—			162,483
Cash paid for dividends		(5,323	)		—			—			—			(5,323	)
Excess tax benefits on exercised stock options		71			17			16			—			104
Principal payments on capital lease obligations		—			(814	)		(907	)		—			(1,721	)
Net cash provided by (used in) financing activities		133,513			(235	)		(1,710	)		—			131,568
Foreign exchange effect on cash and cash equivalents		762			16			(7,724	)		(42	)		(6,988	)
Net increase (decrease) in cash and cash equivalents		5,003			(15,042	)		8,926			—			(1,113	)
Cash and cash equivalents, beginning of period		3,623			67,449			257,274			—			328,346
Cash and cash equivalents, end of period	$	8,626		$	52,407		$	266,200		$	—		$	327,233

CONSOLIDATING STATEMENT OF CASH FLOWS

For the Three Months Ended March 31, 2012

(in thousands)

	Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations			Consolidated
Cash Flows from Operating Activities:
Net income	$	1,029		$	27,354		$	22,381			$(49,735)		$	1,029
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Equity in earnings (losses) of subsidiaries, net of tax		(49,895	)		348			—			49,547			—
Non-cash interest expense, including amortization of original issue discounts and write-off of deferred financing costs		5,219			59			—			—			5,278
Depreciation and amortization		2,074			63,363			37,345			(61	)		102,721
Non-cash charges for sale of inventories revalued at the date of acquisition		—			1,400			3,281			—			4,681
Non-cash stock-based compensation expense		1,007			1,377			1,490			—			3,874
Impairment of inventory		—			5			—			—			5
Impairment of long-lived assets		—			134			—			—			134
Loss on sale of fixed assets		—			508			58			—			566
Equity earnings of unconsolidated entities, net of tax		(660	)		—			(2,736	)		(16	)		(3,412	)
Deferred income taxes		(11,105	)		(614	)		(2,033	)		—			(13,752	)
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net		—			(4,605	)		(8,337	)		—			(12,942	)
Inventories, net		—			13,349			(3,733	)		(265	)		9,351
Prepaid expenses and other current assets		10,526			(4,386	)		(2,619	)		—			3,521
Accounts payable		(863	)		(4,101	)		(12,842	)		—			(17,806	)
Accrued expenses and other current liabilities		(14,901	)		34,232			(15,346	)		—			3,985
Other non-current liabilities		4,309			(10,015	)		20,332			71			14,697
Intercompany payable (receivable)		131,413			(128,235	)		(3,178	)		—			—
Net cash provided by (used in) operating activities		78,153			(9,827	)		34,063			(459	)		101,930
Cash Flows from Investing Activities:
Decrease in restricted cash		—			—			6,302			—			6,302
Purchases of property, plant and equipment		(4	)		(17,375	)		(13,465	)		459			(30,385	)
Proceeds from sale of property, plant and equipment		—			201			326			—			527
Cash paid for acquisitions, net of cash acquired		(22,500	)		—			(15,508	)		—			(38,008	)
Cash received from equity method investments		—			—			6,066			—			6,066
Cash paid for marketable securities		—			(2	)		—			—			(2	)
Increase in other assets		(6,144	)		(397	)		(2,013	)		—			(8,554	)
Net cash used in investing activities		(28,648	)		(17,573	)		(18,292	)		459			(64,054	)
Cash Flows from Financing Activities:
Cash paid for financing costs		(1,876	)		—			—			—			(1,876	)
Cash paid for contingent purchase price consideration		(48	)		—			—			—			(48	)
Proceeds from issuance of common stock, net of issuance costs		7,674			—			—			—			7,674
Proceeds from issuance of long-term debt		198,000			951			190			—			199,141
Payments on long-term debt		(10,750	)		(656	)		(5,505	)		—			(16,911	)
Net proceeds under revolving credit facilities		—			(2	)		1,341			—			1,339
Payments on short-term debt		(6,240	)		—			—			—			(6,240	)
Cash paid for dividends		(5,323	)		—			—			—			(5,323	)
Excess tax benefits on exercised stock options		98			48			2			—			148
Principal payments on capital lease obligations		—			(502	)		(1,218	)		—			(1,720	)
Net cash provided by (used in) financing activities		181,535			(161	)		(5,190	)		—			176,184
Foreign exchange effect on cash and cash equivalents		(429	)		73			1,220			—			864
Net increase (decrease) in cash and cash equivalents		230,611			(27,488	)		11,801			—			214,924
Cash and cash equivalents, beginning of period		12,451			95,212			191,510			—			299,173
Cash and cash equivalents, end of period	$	243,062		$	67,724		$	203,311		$	—		$	514,097

XML

Equity Investments - Financial Information for SPD and Techlab on Combined Condensed Results of Operations (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Equity Method Investments And Joint Ventures [Abstract]
Net revenue	$ 49,155	$ 52,525
Gross profit	37,113	35,179
Net income after taxes	$ 5,577	$ 6,993

XML

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2013

Fair Value Disclosures [Abstract]

Fair Value Assets and Liabilities Measured on Recurring Basis, Valuation Techniques

The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2013 and December 31, 2012, and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value (in thousands):

Description	March 31,  2013		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Unobservable Inputs (Level 3)
Assets:
Marketable securities	$	884	$	884	$	—	$	—
Total assets	$	884	$	884	$	—	$	—
Liabilities:
Contingent consideration obligations (1)	$	240,604	$	—	$	—	$	240,604
Total liabilities	$	240,604	$	—	$	—	$	240,604
Description	December 31, 2012		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Unobservable Inputs (Level 3)
Assets:
Marketable securities	$	904	$	904	$	—	$	—
Total assets	$	904	$	904	$	—	$	—
Liabilities:
Contingent consideration obligations (1)	$	176,172	$	—	$	—	$	176,172
Total liabilities	$	176,172	$	—	$	—	$	176,172

⁽¹⁾  We determine the fair value of the contingent consideration obligations based on a probability-weighted approach derived from earn-out criteria estimates and a probability assessment with respect to the likelihood of achieving the various earn-out criteria. The measurement is based upon significant inputs not observable in the market. Significant increases or decreases in any of these inputs could result in a significantly higher or lower fair value measurement. Changes in the fair value of these contingent consideration obligations are recorded as income or expense within operating income in our Consolidated Statements of Operations.

Changes in Fair Value of Contingent Consideration Obligations

Changes in the fair value of our Level 3 contingent consideration obligations during the three months ended March 31, 2013 were as follows (in thousands):

Fair value of contingent consideration obligations, January 1, 2013	$	176,172
Acquisition date fair value of contingent consideration obligations recorded		75,295
Foreign currency		(557	)
Payments		(21,323	)
Present value accretion		3,474
Adjustments, net (income) expense		7,543
Fair value of contingent consideration obligations, March 31, 2013	$	240,604

XML

Business Combinations - Preliminary Fair Values of Net Assets Acquired for Acquisitions (Detail) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2013	Dec. 31, 2012	Mar. 31, 2013 Epocal [Member]	Feb. 01, 2013 Epocal [Member]	Mar. 31, 2013 Mega Medika [Member]	Jan. 07, 2013 Mega Medika [Member]
Business Acquisition [Line Items]
Current assets	$ 13,077	$ 46,041	$ 11,935		$ 1,142
Property, plant and equipment	1,496	9,029	1,267		229
Goodwill	100,174	259,231	99,519		655
Intangible assets	173,860	325,223	164,400		9,460
Other non-current assets	17,610	629	17,610
Total assets acquired	306,217	640,153	294,731		11,486
Current liabilities	3,092	28,802	2,543		549
Non-current liabilities	43,938	116,580	43,727		211
Total liabilities assumed	47,030	145,382	46,270		760
Net assets acquired	259,187	494,771	248,461		10,726
Contingent consideration	75,295	75,620	75,000	75,000	295	300
Cash paid	$ 183,892	$ 419,151	$ 173,461	$ 173,500	$ 10,431	$ 10,400

XML

Defined Benefit Pension Plan - Net Periodic Benefit Costs (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Compensation And Retirement Disclosure [Abstract]
Service cost
Interest cost	182	198
Expected return on plan assets	(156)	(152)
Amortization of prior service cost	103	104
Realized losses
Net periodic benefit cost	$ 129	$ 150

XML

Long-term Debt - Long-Term Debt Interest Expense (Parenthetical) (Detail) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Debt Disclosure [Abstract]
Amortization fee	$ 1.0	$ 1.3

XML

Net Income (Loss) per Common Share - Computation of Basic and Diluted Net Income (Loss) per Common Share (Detail) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Numerator:
Net income	$ 12,425	$ 1,029
Preferred stock dividends	(5,250)	(5,309)
Less: Net loss attributable to non-controlling interest	(25)	(185)
Net income (loss) available to common stockholders	$ 7,200	$ (4,095)
Denominator:
Weighted-average common shares outstanding-basic	81,199	80,240
Effect of dilutive securities:
Stock options	101
Weighted-average common shares outstanding-diluted	81,300	80,240
Basic net income (loss) per common share attributable to Alere Inc. and Subsidiaries	$ 0.09	$ (0.05)
Diluted net income (loss) per common share attributable to Alere Inc. and Subsidiaries	$ 0.09	$ (0.05)

XML

Inventories

3 Months Ended

Mar. 31, 2013

Inventory Disclosure [Abstract]

Inventories

(3) Inventories

Inventories are stated at the lower of cost (first in, first out) or market and are comprised of the following (in thousands):

	March 31, 2013		December 31, 2012
Raw materials	$	101,477	$	99,498
Work-in-process		82,574		89,895
Finished goods		152,391		147,728
	$	336,442	$	337,121

XML

Long-Term Debt - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2013	Mar. 22, 2013
Debt Instrument [Line Items]
Percentage of principal to be paid as premium	1.00%
Secured credit facility [Member]
Debt Instrument [Line Items]
Basis point reductions in interest rate margins		0.50%
Floor rate applicable to term loans based on Eurodollar rate	1.00%
Minimum [Member] | Secured credit facility [Member]
Debt Instrument [Line Items]
Consolidated secured leverage ratio, Base Rate		2.00%
Consolidated secured leverage ratio, Eurodollar Rate		3.00%
Maximum [Member] | Secured credit facility [Member]
Debt Instrument [Line Items]
Consolidated secured leverage ratio, Base Rate		2.75%
Consolidated secured leverage ratio, Eurodollar Rate		3.75%

XML

Cash and Cash Equivalents - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2013
Cash And Cash Equivalents [Abstract]
Cash investment maturity period	Three months or less

XML

Inventories (Tables)

3 Months Ended

Mar. 31, 2013

Inventory Disclosure [Abstract]

Inventories are Stated at the Lower of Cost (First in, First out) or Market

Inventories are stated at the lower of cost (first in, first out) or market and are comprised of the following (in thousands):

	March 31, 2013		December 31, 2012
Raw materials	$	101,477	$	99,498
Work-in-process		82,574		89,895
Finished goods		152,391		147,728
	$	336,442	$	337,121

XML

Recent Accounting Pronouncements (Policies)

3 Months Ended

Mar. 31, 2013

Accounting Changes And Error Corrections [Abstract]

Intangibles - Goodwill and Other

Recently Adopted Standards

Effective January 1, 2013, we adopted ASU No. 2012-02, Intangibles —   Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment, or ASU 2012-02. ASU 2012-02 allows an entity the option to first assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that the indefinite-lived intangible asset is impaired. If an entity concludes that it is not more likely than not that the indefinite-lived intangible asset is impaired, then the entity is not required to take further action. However, if an entity concludes otherwise, then it is required to determine the fair value of the indefinite-lived intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying amount. An entity also has the option to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to performing the quantitative impairment test. An entity will be able to resume performing the qualitative assessment in any subsequent period. The adoption of this standard is not expected to have an impact on our financial position, results of operations, comprehensive income or cash flows.

XML

Restructuring Plans - Restructuring Activities Related to Restructuring Plans (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		63 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 3,992	$ 5,528
Severance-related costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	3,033
Facility and transition costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	904
Other exit costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	55
2013 Restructuring Plans [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	915
2013 Restructuring Plans [Member] | Severance-related costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	902
2013 Restructuring Plans [Member] | Facility and transition costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	13
Professional Diagnostics Business Segment [Member] | 2013 Restructuring Plans [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	846
Professional Diagnostics Business Segment [Member] | 2013 Restructuring Plans [Member] | Severance-related costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	833
Professional Diagnostics Business Segment [Member] | 2013 Restructuring Plans [Member] | Facility and transition costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	13
Professional Diagnostics Business Segment [Member] | 2012 Restructuring Plans [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	125	1,973	5,280
Professional Diagnostics Business Segment [Member] | 2012 Restructuring Plans [Member] | Severance-related costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	62	1,973	4,794
Professional Diagnostics Business Segment [Member] | 2012 Restructuring Plans [Member] | Facility and transition costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	63		182
Professional Diagnostics Business Segment [Member] | 2012 Restructuring Plans [Member] | Cash charges (recoveries) [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	125	1,973	4,976
Professional Diagnostics Business Segment [Member] | 2012 Restructuring Plans [Member] | Fixed asset and inventory impairments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges			304
Professional Diagnostics Business Segment [Member] | 2011, 2010 and 2008 Restructuring Plans [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	435	2,841	34,447
Professional Diagnostics Business Segment [Member] | 2011, 2010 and 2008 Restructuring Plans [Member] | Severance-related costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	250	1,965	19,963
Professional Diagnostics Business Segment [Member] | 2011, 2010 and 2008 Restructuring Plans [Member] | Facility and transition costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	169	723	7,396
Professional Diagnostics Business Segment [Member] | 2011, 2010 and 2008 Restructuring Plans [Member] | Other exit costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	16	19	714
Professional Diagnostics Business Segment [Member] | 2011, 2010 and 2008 Restructuring Plans [Member] | Cash charges (recoveries) [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	435	2,707	28,073
Professional Diagnostics Business Segment [Member] | 2011, 2010 and 2008 Restructuring Plans [Member] | Fixed asset and inventory impairments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges		134	6,374
Health Information Solutions [Member] | 2013 Restructuring Plans [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	69
Health Information Solutions [Member] | 2013 Restructuring Plans [Member] | Severance-related costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	69
Health Information Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	2,503	717
Health Information Solutions [Member] | 2012 Restructuring Plans [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	2,453	802	12,393
Health Information Solutions [Member] | 2012 Restructuring Plans [Member] | Severance-related costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	1,819	797	4,864
Health Information Solutions [Member] | 2012 Restructuring Plans [Member] | Facility and transition costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	659		1,893
Health Information Solutions [Member] | 2012 Restructuring Plans [Member] | Other exit costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	20		35
Health Information Solutions [Member] | 2012 Restructuring Plans [Member] | Cash charges (recoveries) [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	2,498	797	6,792
Health Information Solutions [Member] | 2012 Restructuring Plans [Member] | Fixed asset and inventory impairments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges			2,689
Health Information Solutions [Member] | 2012 Restructuring Plans [Member] | Intangible asset impairments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges		5	2,988
Health Information Solutions [Member] | 2012 Restructuring Plans [Member] | Other non-cash charges (recoveries) [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	(45)		(76)
Health Information Solutions [Member] | 2011, 2010 and 2008 Restructuring Plans [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	19	(45)	20,252
Health Information Solutions [Member] | 2011, 2010 and 2008 Restructuring Plans [Member] | Severance-related costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges			6,901
Health Information Solutions [Member] | 2011, 2010 and 2008 Restructuring Plans [Member] | Facility and transition costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges		(86)	8,010
Health Information Solutions [Member] | 2011, 2010 and 2008 Restructuring Plans [Member] | Other exit costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	19	41	531
Health Information Solutions [Member] | 2011, 2010 and 2008 Restructuring Plans [Member] | Cash charges (recoveries) [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	19	(45)	15,442
Health Information Solutions [Member] | 2011, 2010 and 2008 Restructuring Plans [Member] | Fixed asset and inventory impairments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges			1,114
Health Information Solutions [Member] | 2011, 2010 and 2008 Restructuring Plans [Member] | Intangible asset impairments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges			2,935
Health Information Solutions [Member] | 2011, 2010 and 2008 Restructuring Plans [Member] | Other non-cash charges (recoveries) [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges			761
Corporate and Other [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges		17
Corporate and Other [Member] | 2011, 2010 and 2008 Restructuring Plans [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges		17	1,193
Corporate and Other [Member] | 2011, 2010 and 2008 Restructuring Plans [Member] | Severance-related costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges		17	1,190
Corporate and Other [Member] | 2011, 2010 and 2008 Restructuring Plans [Member] | Cash charges (recoveries) [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges		17	1,190
Corporate and Other [Member] | 2011, 2010 and 2008 Restructuring Plans [Member] | Fixed asset and inventory impairments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges			$ 3

XML

Inventories - Inventories are Stated at the Lower of Cost (First in, First out) or Market (Detail) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2013	Dec. 31, 2012
Inventory Disclosure [Abstract]
Raw materials	$ 101,477	$ 99,498
Work-in-process	82,574	89,895
Finished goods	152,391	147,728
Inventories, net	$ 336,442	$ 337,121

XML

Stock-based Compensation (Tables)

3 Months Ended

Mar. 31, 2013

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation Expense

We recorded stock-based compensation expense in our Consolidated Statements of Operations for the three months ended March 31, 2013 and 2012, respectively, as follows (in thousands):

	Three Months Ended March 31,
	2013			2012
Cost of net revenue	$	232		$	269
Research and development		747			771
Sales and marketing		716			917
General and administrative		2,428			1,917
		4,123			3,874
Benefit for income taxes		(862	)		(541	)
	$	3,261		$	3,333

XML

Net Income (Loss) per Common Share (Tables)

3 Months Ended

Mar. 31, 2013

Earnings Per Share [Abstract]

Computation of Basic and Diluted Net Income (Loss) per Common Share

The following table sets forth the computation of basic and diluted net income (loss) per common share for the three months ended March 31, 2013 and 2012 (in thousands, except per share data):

	Three Months Ended March 31,
	2013			2012
Numerator:
Net income	$	12,425		$	1,029
Preferred stock dividends		(5,250	)		(5,309	)
Less: Net loss attributable to non-controlling interest		(25	)		(185	)
Net income (loss) available to common stockholders	$	7,200		$	(4,095	)
Denominator:
Weighted-average common shares outstanding—basic		81,199			80,240
Effect of dilutive securities:
Stock options		101			—
Weighted-average common shares outstanding—diluted		81,300			80,240
Basic net income (loss) per common share attributable to Alere Inc. and Subsidiaries	$	0.09		$	(0.05	)
Diluted net income (loss) per common share attributable to Alere Inc. and Subsidiaries	$	0.09		$	(0.05	)

Potential Dilutive Securities Not Included in Calculation of Diluted Net Income (Loss) per Common Share

The following potential dilutive securities were not included in the calculation of diluted net income (loss) per common share because the inclusion thereof would be antidilutive (in thousands):

	Three Months Ended March 31,
	2013		2012
Denominator:
Options to purchase shares of common stock		9,987		9,776
Warrants		4		152
Conversion shares related to 3% convertible senior subordinated notes		3,411		3,411
Conversion shares related to subordinated convertible promissory notes		27		27
Conversion shares related to Series B convertible preferred stock		10,239		10,239
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding		23,668		23,605

XML

Cash and Cash Equivalents

3 Months Ended

Mar. 31, 2013

Cash And Cash Equivalents [Abstract]

Cash and Cash Equivalents

(2) Cash and Cash Equivalents

We consider all highly-liquid cash investments with original maturities of three months or less at the date of acquisition to be cash equivalents. At March 31, 2013, our cash equivalents consisted of money market funds.

XML

Stockholders' Equity and Non-controlling Interests (Tables)

3 Months Ended

Mar. 31, 2013

Equity [Abstract]

Summary of Changes in Stockholders' Equity and Non-controlling Interests Comprising Total Equity

A summary of the changes in stockholders’ equity and non-controlling interests comprising total equity for the three months ended March 31, 2013 and 2012 is provided below (in thousands):

	Three Months Ended March 31,
	2013									2012
	Total Stockholders’ Equity			Non- controlling Interests			Total Equity			Total Stockholders’ Equity			Non- controlling Interests			Total Equity
Equity, beginning of period	$	2,180,422		$	2,282		$	2,182,704		$	2,229,234		$	2,340		$	2,231,574
Exercise of common stock options, warrants and shares issued under employee stock purchase plan		6,135			—			6,135			7,674			—			7,674
Preferred stock dividends		(5,323	)		—			(5,323	)		(5,323	)		—			(5,323	)
Stock-based compensation related to grants of common stock options		4,123			—			4,123			3,874			—			3,874
Excess tax benefits on exercised stock options		(422	)		—			(422	)		104			—			104
Net income (loss)		12,450			(25	)		12,425			1,214			(137	)		1,077
Total other comprehensive income (loss)		(74,739	)		—			(74,739	)		37,353			—			37,353
Equity, end of period	$	2,122,646		$	2,257		$	2,124,903		$	2,274,130		$	2,203		$	2,276,333

XML

Related Party Transactions (Tables)

3 Months Ended

Mar. 31, 2013

Related Party Transactions [Abstract]

Related Party Balances with SPD within Consolidated Balance Sheets

The following table summarizes our related party balances with SPD within our Consolidated Balance Sheets (in thousands):

Balance Sheet Caption	March 31, 2013		December 31, 2012
Accounts receivable, net of allowances	$	8,667	$	7,317
Prepaid expenses and other current assets	$	9,425	$	9,161
Deferred financing costs, net, and other non-current assets	$	13,665	$	14,629
Accounts payable	$	15,676	$	21,258

XML

Business Combinations - Preliminary Fair Values of Net Assets Acquired for Acquisitions (Parenthetical) (Detail) (USD $) In Millions, unless otherwise specified	Mar. 31, 2013	Dec. 31, 2012
Business Combinations [Abstract]
Cash acquired	$ 2.6	$ 3.8

XML

Other Arrangements - Additional Information (Detail) (USD $) In Millions, unless otherwise specified	1 Months Ended	3 Months Ended
	Feb. 19, 2013	Mar. 31, 2013
Gates Foundation [Member]
Agreements [Line Items]
Revenue from grant awarded	$ 21.6
Cash received from grant-related funding		7.9
Qualified expenditures		0.5
Gates Loan Agreement [Member]
Agreements [Line Items]
Aggregate principal amount of subordinated term loan	$ 20.6
Loan bearing interest rate		3.00%
Maturity date		Dec. 31, 2019

XML

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Income Statement [Abstract]
Net product sales	$ 508,276	$ 475,787
Services revenue	226,909	192,434
Net product sales and services revenue	735,185	668,221
License and royalty revenue	4,064	2,908
Net revenue	739,249	671,129
Cost of net product sales	253,078	225,554
Cost of services revenue	120,158	90,860
Cost of net product sales and services revenue	373,236	316,414
Cost of license and royalty revenue	1,756	1,644
Cost of net revenue	374,992	318,058
Gross profit	364,257	353,071
Operating expenses:
Research and development	41,454	39,000
Sales and marketing	156,456	158,578
General and administrative	135,858	120,435
Total operating expenses	333,768	318,013
Operating income	30,489	35,058
Interest expense, including amortization of original issue discounts and deferred financing costs	(57,399)	(50,727)
Other income (expense), net	(470)	11,831
Loss before benefit for income taxes	(27,380)	(3,838)
Benefit for income taxes	(36,871)	(1,455)
Income (loss) before equity earnings of unconsolidated entities, net of tax	9,491	(2,383)
Equity earnings of unconsolidated entities, net of tax	2,934	3,412
Net income	12,425	1,029
Less: Net loss attributable to non-controlling interests	(25)	(185)
Net income attributable to Alere Inc. and Subsidiaries	12,450	1,214
Preferred stock dividends	(5,250)	(5,309)
Net income (loss) available to common stockholders	$ 7,200	$ (4,095)
Basic net income (loss) per common share attributable to Alere Inc. and Subsidiaries:	$ 0.09	$ (0.05)
Diluted net income (loss) per common share attributable to Alere Inc. and Subsidiaries:	$ 0.09	$ (0.05)
Weighted-average shares-basic	81,199	80,240
Weighted-average shares-diluted	81,300	80,240

XML

Note Receivable from FGST Investments, Inc - Additional Information (Detail) (FGST Investments Inc. [Member], USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2012
FGST Investments Inc. [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Short term note issued to unrelated party	$ 40.0
Short term note interest rate	3.25%
Notes obtained call option at a strike price	$ 40.0

XML

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Cash Flows from Operating Activities:
Net income	$ 12,425	$ 1,029
Adjustments to reconcile net income to net cash provided by operating activities:
Non-cash interest expense, including amortization of original issue discounts and write-off of deferred financing costs	5,217	5,278
Depreciation and amortization	104,970	102,721
Non-cash charges for sale of inventories revalued at the date of acquisition	461	4,681
Non-cash stock-based compensation expense	4,123	3,874
Impairment of inventory		5
Impairment of long-lived assets		134
Loss on sale of fixed assets	172	566
Equity earnings of unconsolidated entities, net of tax	(2,934)	(3,412)
Deferred income taxes	(50,907)	(13,752)
Other non-cash items	1,941
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net	(20,167)	(12,942)
Inventories, net	(17,171)	9,351
Prepaid expenses and other current assets	(5,833)	3,521
Accounts payable	(1,988)	(17,806)
Accrued expenses and other current liabilities	39,957	3,985
Other non-current liabilities	795	14,697
Net cash provided by (used in) operating activities	71,061	101,930
Cash Flows from Investing Activities:
(Increase) decrease in restricted cash	(8,573)	6,302
Purchases of property, plant and equipment	(36,105)	(30,385)
Proceeds from sale of property, plant and equipment	1,143	527
Cash paid for acquisitions, net of cash acquired	(158,421)	(38,008)
Cash received from equity method investment	10,771	6,066
Cash paid for marketable securities		(2)
Increase in other assets	(5,569)	(8,554)
Net cash used in investing activities	(196,754)	(64,054)
Cash Flows from Financing Activities:
Cash paid for financing costs	(1,427)	(1,876)
Cash paid for contingent purchase price consideration	(19,098)	(48)
Proceeds from issuance of common stock, net of issuance costs	6,135	7,674
Proceeds from issuance of long-term debt	10,053	199,141
Payments on long-term debt	(19,638)	(16,911)
Net proceeds under revolving credit facilities	162,483	1,339
Payments on short-term debt		(6,240)
Cash paid for dividends	(5,323)	(5,323)
Excess tax benefits on exercised stock options	104	148
Principal payments on capital lease obligations	(1,721)	(1,720)
Net cash provided by financing activities	131,568	176,184
Foreign exchange effect on cash and cash equivalents	(6,988)	864
Net increase (decrease) in cash and cash equivalents	(1,113)	214,924
Cash and cash equivalents, beginning of period	328,346	299,173
Cash and cash equivalents, end of period	$ 327,233	$ 514,097

XML

Long-term Debt - Long-Term Debt Balances Outstanding (Detail) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2013	Dec. 31, 2012
Debt Instrument [Line Items]
Long-term debt, Total	$ 3,841,052	$ 3,688,907
Less: Current portion	(52,210)	(60,232)
Long-term debt, after discount, Total	3,788,842	3,628,675
A term loans [Member]
Debt Instrument [Line Items]
Long-term debt, Total	866,875	878,438
B term loans [Member]
Debt Instrument [Line Items]
Long-term debt, Total	911,125	913,438
Incremental B-1 term loans [Member]
Debt Instrument [Line Items]
Long-term debt, Total	246,875	247,500
Incremental B-2 term loans [Member]
Debt Instrument [Line Items]
Long-term debt, Total	196,314	196,739
Revolving line of credit [Member]
Debt Instrument [Line Items]
Long-term debt, Total	192,500	22,500
7.25% Senior notes [Member]
Debt Instrument [Line Items]
Long-term debt, Total	450,000	450,000
7.875% Senior notes [Member]
Debt Instrument [Line Items]
Long-term debt, Total		1,809
9% Senior subordinated notes [Member]
Debt Instrument [Line Items]
Long-term debt, Total	393,383	392,933
8.625% Senior subordinated notes [Member]
Debt Instrument [Line Items]
Long-term debt, Total	400,000	400,000
3% Convertible senior subordinated notes [Member]
Debt Instrument [Line Items]
Long-term debt, Total	150,000	150,000
Other lines of credit [Member]
Debt Instrument [Line Items]
Long-term debt, Total	1,328	31,957
Other [Member]
Debt Instrument [Line Items]
Long-term debt, Total	$ 32,652	$ 3,593

XML

Long-term Debt (Tables)

3 Months Ended

Mar. 31, 2013

Debt Disclosure [Abstract]

Long-Term Debt Balances Outstanding

We had the following long-term debt balances outstanding (in thousands):

	March 31, 2013			December 31, 2012
A term loans(1)(2)	$	866,875		$	878,438
B term loans(1)		911,125			913,438
Incremental B-1 term loans(1)		246,875			247,500
Incremental B-2 term loans(1)		196,314			196,739
Revolving line of credit(1)		192,500			22,500
7.25% Senior notes		450,000			450,000
7.875% Senior notes		—			1,809
9% Senior subordinated notes		393,383			392,933
8.625% Senior subordinated notes		400,000			400,000
3% Convertible senior subordinated notes		150,000			150,000
Other lines of credit		1,328			31,957
Other		32,652			3,593
		3,841,052			3,688,907
Less: Current portion		(52,210	)		(60,232	)
	$	3,788,842		$	3,628,675

⁽¹⁾  Incurred under our secured credit facility.

⁽²⁾  Includes “A” term loans and “Delayed Draw” term loans under our secured credit facility.

Long-Term Debt Interest Expense

In connection with our significant long-term debt issuances, we recorded interest expense, including amortization and write-offs of deferred financing costs and original issue discounts, in our accompanying Consolidated Statements of Operations for the three months ended March 31, 2013 and 2012, respectively, as follows (in thousands):

	Three Months Ended March 31,
	2013			2012
Secured credit facility (1)	$	27,275		$	22,851
7.25% Senior notes		8,356			—
7.875% Senior notes		(27	)		5,758
9% Senior subordinated notes		10,394			10,354
8.625% Senior subordinated notes		9,273			9,274
3% Convertible senior subordinated notes		1,246			1,246
	$	56,517		$	49,483

⁽¹⁾  Includes “A” term loans, including the “Delayed-Draw” term loans; “B” term loans; “Incremental B-1” term loans; “Incremental B-2” term loans; and revolving line of credit loans. For the three months ended March 31, 2013 and 2012, the amounts include $1.0 million and $1.3 million, respectively, related to the amortization of fees paid for certain debt modifications.

XML

Fair Value Measurements - Changes in Fair Value of Contingent Consideration Obligations (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Dec. 31, 2012
Fair Value Assets And Liabilities Measured On Recurring Basis [Abstract]
Fair value of contingent consideration obligations, January 1, 2013	$ 176,172
Acquisition date fair value of contingent consideration obligations recorded	75,295	75,620
Foreign currency	(557)
Payments	(21,323)
Present value accretion	3,474
Adjustments, net (income) expense	7,543
Fair value of contingent consideration obligations, March 31, 2013	$ 240,604

XML

Other Arrangements

3 Months Ended

Mar. 31, 2013

Text Block [Abstract]

Other Arrangements

(16) Other Arrangements

On February 19, 2013, we entered into an agreement with the Bill and Melinda Gates Foundation, or the Gates Foundation, whereby we were awarded a grant by the Gates Foundation in the amount of $21.6 million to support the development and commercialization of a validated, low-cost, nucleic-acid assay for clinical Tuberculosis, or TB, detection and drug-resistance test cartridges and adaptation of an analyzer platform capable of operation in rudimentary laboratories in low-resource settings. In connection with this agreement, we also entered into a loan agreement with the Gates Foundation, or the Gates Loan Agreement, which provides for the making of subordinated term loans by the Gates Foundation to us from time to time, subject to the achievement of certain milestones, in an aggregate principal amount of up to $20.6 million. Funding under the Gates Loan Agreement will be used in connection with the purchase of equipment for an automated high-throughput manufacturing line and other uses as necessary for the manufacture of the TB and HIV-related products. All loans under the Gates Loan Agreement are evidenced by promissory notes that we have executed and delivered to the Gates Foundation, bear interest at the rate of 3% per annum and, except to the extent earlier repaid by us, mature and are required to be repaid in full on December 31, 2019. As of March 31, 2013, we had borrowed no amounts under the Gates Loan Agreement. As of March 31, 2013, we had received approximately $7.9 million in grant-related funding from the Gates Foundation, which was recorded as restricted cash and deferred grant funding. The deferred grant funding is classified within accrued expenses and other current liabilities on our accompanying consolidated balance sheet. As qualified expenditures are incurred under the terms of the grant, we use the deferred funding to recognize a reduction of our related qualified research and development expenditures. For the three months ended March 31, 2013, we recognized $0.5 million of qualified expenditures, which was recorded as an offset to our research and development expenses.

XML

Derivative Financial Instruments (Tables)

3 Months Ended

Mar. 31, 2013

Derivative Instruments And Hedging Activities Disclosure [Abstract]

Summary of Effect of Derivative Instruments in Consolidated Statement of Operations and in Accumulated Other Comprehensive Loss

The following table summarize the effect of derivative instruments in our accompanying Consolidated Statement of Operations (in thousands):

Derivative Instruments	Location of Gain Recognized in Income	Amount of Gain Recognized During the Three Months Ended March 31, 2012
Foreign currency forward contracts	Other comprehensive income (loss)	$	1,107
Total gain	Other comprehensive income (loss)	$	1,107

XML

Recent Accounting Pronouncements

3 Months Ended

Mar. 31, 2013

Accounting Changes And Error Corrections [Abstract]

Recent Accounting Pronouncements

(18) Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position, results of operations, comprehensive income or cash flows upon adoption.

Recently Adopted Standards

Effective January 1, 2013, we adopted ASU No. 2012-02, Intangibles —   Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment, or ASU 2012-02. ASU 2012-02 allows an entity the option to first assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that the indefinite-lived intangible asset is impaired. If an entity concludes that it is not more likely than not that the indefinite-lived intangible asset is impaired, then the entity is not required to take further action. However, if an entity concludes otherwise, then it is required to determine the fair value of the indefinite-lived intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying amount. An entity also has the option to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to performing the quantitative impairment test. An entity will be able to resume performing the qualitative assessment in any subsequent period. The adoption of this standard is not expected to have an impact on our financial position, results of operations, comprehensive income or cash flows.

XML

Financial Information by Segment - Performance of Our Operating Segments Based on Revenue and Operating Income (Loss) (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Dec. 31, 2012
Segment Reporting Information [Line Items]
Net revenue	$ 739,249	$ 671,129
Operating income (loss)	30,489	35,058
Depreciation and amortization	104,970	102,721
Non-cash charge associated with acquired inventory	461	4,681
Restructuring charge	3,992	5,528
Stock-based compensation	4,123	3,874
Assets	7,248,475		7,067,928
Professional Diagnostics [Member]
Segment Reporting Information [Line Items]
Net revenue	582,492	518,357
Operating income (loss)	59,840	70,179
Depreciation and amortization	82,794	77,467
Non-cash charge associated with acquired inventory	461	4,681
Restructuring charge	1,389	4,794
Stock-based compensation
Assets	6,414,701		6,214,847
Health Information Solutions [Member]
Segment Reporting Information [Line Items]
Net revenue	134,207	130,784
Operating income (loss)	(13,893)	(19,356)
Depreciation and amortization	20,737	23,774
Non-cash charge associated with acquired inventory
Restructuring charge	2,503	717
Stock-based compensation
Assets	608,161		593,172
Consumer Diagnostics [Member]
Segment Reporting Information [Line Items]
Net revenue	22,550	21,988
Operating income (loss)	2,280	365
Depreciation and amortization	1,153	1,259
Non-cash charge associated with acquired inventory
Restructuring charge
Stock-based compensation
Assets	175,285		192,748
Corporate and Other [Member]
Segment Reporting Information [Line Items]
Net revenue
Operating income (loss)	(17,738)	(16,130)
Depreciation and amortization	286	221
Non-cash charge associated with acquired inventory
Restructuring charge		17
Stock-based compensation	4,123	3,874
Assets	$ 50,328		$ 67,161

XML

Basis of Presentation of Financial Information

3 Months Ended

Mar. 31, 2013

Accounting Policies [Abstract]

Basis of Presentation of Financial Information

(1) Basis of Presentation of Financial Information

The accompanying Consolidated Financial Statements of Alere Inc. are unaudited. In the opinion of management, the unaudited Consolidated Financial Statements contain all adjustments considered normal and recurring and necessary for their fair statement. Interim results are not necessarily indicative of results to be expected for the year. These interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these Consolidated Financial Statements do not include all of the information and footnotes necessary for a complete presentation of financial position, results of operations, comprehensive income and cash flows. Our audited Consolidated Financial Statements for the year ended December 31, 2012 included information and footnotes necessary for such presentation and were included in our Annual Report on Form 10-K, as amended, filed with the Securities and Exchange Commission, or SEC, on March 1, 2013. These unaudited Consolidated Financial Statements should be read in conjunction with our audited Consolidated Financial Statements and notes thereto for the year ended December 31, 2012.

Certain reclassifications of prior period amounts have been made to conform to current period presentation. These reclassifications had no effect on net income or equity.

Certain amounts presented may not recalculate directly, due to rounding.

XML

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 12,425	$ 1,029
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment	(75,355)	35,939
Unrealized gains on available for sale securities		431
Unrealized gains on hedging instruments	11	1,107
Minimum pension liability adjustment	605	(165)
Other comprehensive income (loss), before tax	(74,739)	37,312
Income tax benefit related to items of other comprehensive income		(41)
Other comprehensive income (loss), net of tax	(74,739)	37,353
Comprehensive income (loss)	(62,314)	38,382
Less: Comprehensive loss attributable to non-controlling interests	(25)	(185)
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	$ (62,289)	$ 38,567

XML

Derivative Financial Instruments

3 Months Ended

Mar. 31, 2013

Derivative Instruments And Hedging Activities Disclosure [Abstract]

Derivative Financial Instruments

(11) Derivative Financial Instruments

We may manage our economic and transaction exposure to certain market-based risks through the use of derivative instruments. Our objective for holding derivative instruments has been to reduce volatility of net earnings and cash flows associated with changes in interest rates and foreign currency exchange rates. We do not hold or issue derivative financial instruments for speculative purposes.

(a) Foreign Currency Risk

In connection with our acquisition of Axis-Shield, we acquired a number of foreign currency forward contracts. The specific risk hedged in these contracts was the undiscounted foreign currency spot rate risk on forecasted foreign currency revenue. As of December 31, 2012, all of the acquired foreign currency forward contracts were settled. We report the effective portion of the gain or loss on a cash flow hedge as a component of other comprehensive income, and it was subsequently reclassified into net earnings in the period in which the hedged transaction affected net earnings or the forecasted transaction was no longer probable of occurring.

The following table summarize the effect of derivative instruments in our accompanying Consolidated Statement of Operations (in thousands):

Derivative Instruments	Location of Gain Recognized in Income	Amount of Gain Recognized During the Three Months Ended March 31, 2012
Foreign currency forward contracts	Other comprehensive income (loss)	$	1,107
Total gain	Other comprehensive income (loss)	$	1,107

XML

Document and Entity Information	3 Months Ended
	Mar. 31, 2013	May 06, 2013
Document Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q1
Trading Symbol	ALR
Entity Registrant Name	ALERE INC.
Entity Central Index Key	0001145460
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		81,288,432

XML

Fair Value Measurements

3 Months Ended

Mar. 31, 2013

Fair Value Disclosures [Abstract]

Fair Value Measurements

(12) Fair Value Measurements

We apply fair value measurement accounting to value our financial assets and liabilities. Fair value measurement accounting provides a framework for measuring fair value under U.S. GAAP and requires expanded disclosures regarding fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value.

Described below are the three levels of inputs that may be used to measure fair value:

Level 1—Quoted prices in active markets for identical assets or liabilities.

Level 2—Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2013 and December 31, 2012, and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value (in thousands):

Description	March 31,  2013		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Unobservable Inputs (Level 3)
Assets:
Marketable securities	$	884	$	884	$	—	$	—
Total assets	$	884	$	884	$	—	$	—
Liabilities:
Contingent consideration obligations (1)	$	240,604	$	—	$	—	$	240,604
Total liabilities	$	240,604	$	—	$	—	$	240,604
Description	December 31, 2012		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Unobservable Inputs (Level 3)
Assets:
Marketable securities	$	904	$	904	$	—	$	—
Total assets	$	904	$	904	$	—	$	—
Liabilities:
Contingent consideration obligations (1)	$	176,172	$	—	$	—	$	176,172
Total liabilities	$	176,172	$	—	$	—	$	176,172

⁽¹⁾  We determine the fair value of the contingent consideration obligations based on a probability-weighted approach derived from earn-out criteria estimates and a probability assessment with respect to the likelihood of achieving the various earn-out criteria. The measurement is based upon significant inputs not observable in the market. Significant increases or decreases in any of these inputs could result in a significantly higher or lower fair value measurement. Changes in the fair value of these contingent consideration obligations are recorded as income or expense within operating income in our Consolidated Statements of Operations.

Changes in the fair value of our Level 3 contingent consideration obligations during the three months ended March 31, 2013 were as follows (in thousands):

Fair value of contingent consideration obligations, January 1, 2013	$	176,172
Acquisition date fair value of contingent consideration obligations recorded		75,295
Foreign currency		(557	)
Payments		(21,323	)
Present value accretion		3,474
Adjustments, net (income) expense		7,543
Fair value of contingent consideration obligations, March 31, 2013	$	240,604

At March 31, 2013 and December 31, 2012, the carrying amounts of cash and cash equivalents, restricted cash, receivables, accounts payable and other current liabilities approximated their estimated fair values.

The carrying amount and estimated fair value of our long-term debt were $3.8 billion and $3.9 billion, respectively, at March 31, 2013. The carrying amount and estimated fair value of our long-term debt were $3.7 billion at December 31, 2012. The estimated fair value of our long-term debt was determined using market sources that were derived from available market information (Level 2 in the fair value hierarchy) and may not be representative of actual values that could have been or will be realized in the future.

XML

Guarantor Financial Information - Consolidating Balance Sheet (Detail) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2013	Dec. 31, 2012	Mar. 31, 2012	Dec. 31, 2011
Current assets:
Cash and cash equivalents	$ 327,233	$ 328,346	$ 514,097	$ 299,173
Restricted cash	11,649	3,076
Marketable securities	884	904
Accounts receivable, net of allowances	540,093	524,332
Inventories, net	336,442	337,121
Deferred tax assets	83,530	67,722
Prepaid expenses and other current assets	167,346	145,236
Intercompany receivables
Total current assets	1,467,177	1,406,737
Property, plant and equipment, net	529,164	534,469
Goodwill	3,116,857	3,048,405
Other intangible assets with indefinite lives	58,393	36,451
Finite-lived intangible assets, net	1,874,636	1,834,225
Deferred financing costs, net and other non-current assets	99,300	108,857
Investments in subsidiaries
Investments in unconsolidated entities	94,295	90,491
Deferred tax assets	8,653	8,293
Intercompany notes receivable
Total assets	7,248,475	7,067,928
Current liabilities:
Current portion of long-term debt	52,210	60,232
Current portion of capital lease obligations	6,146	6,684
Accounts payable	166,012	169,974
Accrued expenses and other current liabilities	470,919	411,919
Intercompany payables
Total current liabilities	695,287	648,809
Long-term liabilities:
Long-term debt, net of current portion	3,788,842	3,628,675
Capital lease obligations, net of current portion	11,615	12,917
Deferred tax liabilities	415,452	428,188
Other long-term liabilities	212,376	166,635
Intercompany notes payables
Total long-term liabilities	4,428,285	4,236,415
Stockholders' equity	2,122,646	2,180,422
Non-controlling interests	2,257	2,282
Total equity	2,124,903	2,182,704	2,276,333	2,231,574
Total liabilities and equity	7,248,475	7,067,928
Issuer [Member]
Current assets:
Cash and cash equivalents	8,626	3,623	243,062	12,451
Restricted cash	7,933
Marketable securities
Accounts receivable, net of allowances
Inventories, net
Deferred tax assets	32,145	12,193
Prepaid expenses and other current assets	453,291	(20,636)
Intercompany receivables	312,349	298,812
Total current assets	814,344	293,992
Property, plant and equipment, net	2,387	2,679
Goodwill
Other intangible assets with indefinite lives
Finite-lived intangible assets, net	10,927	24,701
Deferred financing costs, net and other non-current assets	69,133	78,522
Investments in subsidiaries	4,345,418	4,114,478
Investments in unconsolidated entities	34,384	33,979
Deferred tax assets
Intercompany notes receivable	1,672,676	1,724,650
Total assets	6,949,269	6,273,001
Current liabilities:
Current portion of long-term debt	45,000	45,000
Current portion of capital lease obligations
Accounts payable	7,390	7,993
Accrued expenses and other current liabilities	84,912	(388,830)
Intercompany payables	584,562	557,578
Total current liabilities	721,864	221,741
Long-term liabilities:
Long-term debt, net of current portion	3,770,784	3,617,068
Capital lease obligations, net of current portion
Deferred tax liabilities	(15,907)	(5,329)
Other long-term liabilities	18,099	17,678
Intercompany notes payables	331,783	241,421
Total long-term liabilities	4,104,759	3,870,838
Stockholders' equity	2,122,646	2,180,422
Non-controlling interests
Total equity	2,122,646	2,180,422
Total liabilities and equity	6,949,269	6,273,001
Guarantor Subsidiaries [Member]
Current assets:
Cash and cash equivalents	52,407	67,449	67,724	95,212
Restricted cash	2,309	1,680
Marketable securities	771	787
Accounts receivable, net of allowances	242,772	241,050
Inventories, net	147,580	142,413
Deferred tax assets	37,079	39,601
Prepaid expenses and other current assets	(315,140)	99,271
Intercompany receivables	603,711	1,254,727
Total current assets	771,489	1,846,978
Property, plant and equipment, net	290,253	293,260
Goodwill	1,820,992	1,820,438
Other intangible assets with indefinite lives	13,900	14,600
Finite-lived intangible assets, net	1,092,551	1,132,656
Deferred financing costs, net and other non-current assets	10,357	10,341
Investments in subsidiaries	353,666	358,088
Investments in unconsolidated entities
Deferred tax assets		782
Intercompany notes receivable	752,565	722,552
Total assets	5,105,773	6,199,695
Current liabilities:
Current portion of long-term debt	985	349
Current portion of capital lease obligations	3,207	3,209
Accounts payable	67,623	76,256
Accrued expenses and other current liabilities	199,618	586,116
Intercompany payables	133,102	806,507
Total current liabilities	404,535	1,472,437
Long-term liabilities:
Long-term debt, net of current portion	299	374
Capital lease obligations, net of current portion	4,845	5,412
Deferred tax liabilities	319,914	333,388
Other long-term liabilities	69,963	72,890
Intercompany notes payables	1,602,374	1,630,376
Total long-term liabilities	1,997,395	2,042,440
Stockholders' equity	2,703,843	2,684,818
Non-controlling interests
Total equity	2,703,843	2,684,818
Total liabilities and equity	5,105,773	6,199,695
Non-Guarantor Subsidiaries [Member]
Current assets:
Cash and cash equivalents	266,200	257,274	203,311	191,510
Restricted cash	1,407	1,396
Marketable securities	113	117
Accounts receivable, net of allowances	297,321	283,282
Inventories, net	209,509	203,230
Deferred tax assets	11,367	13,138
Prepaid expenses and other current assets	29,231	66,634
Intercompany receivables	64,077	55,847
Total current assets	879,225	880,918
Property, plant and equipment, net	236,980	239,082
Goodwill	1,295,865	1,227,967
Other intangible assets with indefinite lives	44,493	21,851
Finite-lived intangible assets, net	771,158	676,868
Deferred financing costs, net and other non-current assets	19,881	20,065
Investments in subsidiaries	(67,215)	(67,799)
Investments in unconsolidated entities	48,363	56,512
Deferred tax assets	8,653	7,511
Intercompany notes receivable	64,766	1,278
Total assets	3,302,169	3,064,253
Current liabilities:
Current portion of long-term debt	6,225	14,883
Current portion of capital lease obligations	2,939	3,475
Accounts payable	90,999	85,725
Accrued expenses and other current liabilities	186,418	214,659
Intercompany payables	262,472	245,300
Total current liabilities	549,053	564,042
Long-term liabilities:
Long-term debt, net of current portion	17,759	11,233
Capital lease obligations, net of current portion	6,770	7,505
Deferred tax liabilities	111,497	100,216
Other long-term liabilities	124,385	76,138
Intercompany notes payables	555,850	576,684
Total long-term liabilities	816,261	771,776
Stockholders' equity	1,934,598	1,726,153
Non-controlling interests	2,257	2,282
Total equity	1,936,855	1,728,435
Total liabilities and equity	3,302,169	3,064,253
Eliminations [Member]
Current assets:
Cash and cash equivalents
Restricted cash
Marketable securities
Accounts receivable, net of allowances
Inventories, net	(20,647)	(8,522)
Deferred tax assets	2,939	2,790
Prepaid expenses and other current assets	(36)	(33)
Intercompany receivables	(980,137)	(1,609,386)
Total current assets	(997,881)	(1,615,151)
Property, plant and equipment, net	(456)	(552)
Goodwill
Other intangible assets with indefinite lives
Finite-lived intangible assets, net
Deferred financing costs, net and other non-current assets	(71)	(71)
Investments in subsidiaries	(4,631,869)	(4,404,767)
Investments in unconsolidated entities	11,548
Deferred tax assets
Intercompany notes receivable	(2,490,007)	(2,448,480)
Total assets	(8,108,736)	(8,469,021)
Current liabilities:
Current portion of long-term debt
Current portion of capital lease obligations
Accounts payable
Accrued expenses and other current liabilities	(29)	(26)
Intercompany payables	(980,136)	(1,609,385)
Total current liabilities	(980,165)	(1,609,411)
Long-term liabilities:
Long-term debt, net of current portion
Capital lease obligations, net of current portion
Deferred tax liabilities	(52)	(87)
Other long-term liabilities	(71)	(71)
Intercompany notes payables	(2,490,007)	(2,448,481)
Total long-term liabilities	(2,490,130)	(2,448,639)
Stockholders' equity	(4,638,441)	(4,410,971)
Non-controlling interests
Total equity	(4,638,441)	(4,410,971)
Total liabilities and equity	$ (8,108,736)	$ (8,469,021)

XML

CONSOLIDATED BALANCE SHEETS (USD $) In Thousands, unless otherwise specified	Mar. 31, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 327,233	$ 328,346
Restricted cash	11,649	3,076
Marketable securities	884	904
Accounts receivable, net of allowances of $41,337 and $36,395 at March 31, 2013 and December 31, 2012, respectively	540,093	524,332
Inventories, net	336,442	337,121
Deferred tax assets	83,530	67,722
Prepaid expenses and other current assets	167,346	145,236
Total current assets	1,467,177	1,406,737
Property, plant and equipment, net	529,164	534,469
Goodwill	3,116,857	3,048,405
Other intangible assets with indefinite lives	58,393	36,451
Finite-lived intangible assets, net	1,874,636	1,834,225
Deferred financing costs, net, and other non-current assets	99,300	108,857
Investments in unconsolidated entities	94,295	90,491
Deferred tax assets	8,653	8,293
Total assets	7,248,475	7,067,928
Current liabilities:
Current portion of long-term debt	52,210	60,232
Current portion of capital lease obligations	6,146	6,684
Accounts payable	166,012	169,974
Accrued expenses and other current liabilities	470,919	411,919
Total current liabilities	695,287	648,809
Long-term liabilities:
Long-term debt, net of current portion	3,788,842	3,628,675
Capital lease obligations, net of current portion	11,615	12,917
Deferred tax liabilities	415,452	428,188
Other long-term liabilities	212,376	166,635
Total long-term liabilities	4,428,285	4,236,415
Commitments and contingencies (Note 17)
Stockholders' equity:
Series B preferred stock, $0.001 par value (liquidation preference: $709,763 at March 31, 2013 and December 31, 2012); Authorized: 2,300 shares; Issued: 2,065 shares at March 31, 2013 and December 31, 2012; Outstanding: 1,774 shares at March 31, 2013 and December 31, 2012	606,468	606,468
Common stock, $0.001 par value; Authorized: 200,000 shares; Issued: 88,959 shares at March 31, 2013 and 88,576 shares at December 31, 2012; Outstanding: 81,280 shares at March 31, 2013 and 80,897 shares at December 31, 2012	89	89
Additional paid-in capital	3,304,448	3,299,935
Accumulated deficit	(1,552,523)	(1,564,973)
Treasury stock, at cost, 7,679 shares at March 31, 2013 and December 31, 2012	(184,971)	(184,971)
Accumulated other comprehensive income (loss)	(50,865)	23,874
Total stockholders' equity	2,122,646	2,180,422
Non-controlling interests	2,257	2,282
Total equity	2,124,903	2,182,704
Total liabilities and equity	$ 7,248,475	$ 7,067,928

XML

Net Income (Loss) per Common Share

3 Months Ended

Mar. 31, 2013

Earnings Per Share [Abstract]

Net Income (Loss) per Common Share

(6) Net Income (Loss) per Common Share

The following table sets forth the computation of basic and diluted net income (loss) per common share for the three months ended March 31, 2013 and 2012 (in thousands, except per share data):

	Three Months Ended March 31,
	2013			2012
Numerator:
Net income	$	12,425		$	1,029
Preferred stock dividends		(5,250	)		(5,309	)
Less: Net loss attributable to non-controlling interest		(25	)		(185	)
Net income (loss) available to common stockholders	$	7,200		$	(4,095	)
Denominator:
Weighted-average common shares outstanding—basic		81,199			80,240
Effect of dilutive securities:
Stock options		101			—
Weighted-average common shares outstanding—diluted		81,300			80,240
Basic net income (loss) per common share attributable to Alere Inc. and Subsidiaries	$	0.09		$	(0.05	)
Diluted net income (loss) per common share attributable to Alere Inc. and Subsidiaries	$	0.09		$	(0.05	)

The following potential dilutive securities were not included in the calculation of diluted net income (loss) per common share because the inclusion thereof would be antidilutive (in thousands):

	Three Months Ended March 31,
	2013		2012
Denominator:
Options to purchase shares of common stock		9,987		9,776
Warrants		4		152
Conversion shares related to 3% convertible senior subordinated notes		3,411		3,411
Conversion shares related to subordinated convertible promissory notes		27		27
Conversion shares related to Series B convertible preferred stock		10,239		10,239
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding		23,668		23,605

XML

Stock-based Compensation

3 Months Ended

Mar. 31, 2013

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-based Compensation

(5) Stock-based Compensation

We recorded stock-based compensation expense in our Consolidated Statements of Operations for the three months ended March 31, 2013 and 2012, respectively, as follows (in thousands):

	Three Months Ended March 31,
	2013			2012
Cost of net revenue	$	232		$	269
Research and development		747			771
Sales and marketing		716			917
General and administrative		2,428			1,917
		4,123			3,874
Benefit for income taxes		(862	)		(541	)
	$	3,261		$	3,333

XML

Material Contingencies

3 Months Ended

Mar. 31, 2013

Commitments And Contingencies Disclosure [Abstract]

Material Contingencies

(17) Material Contingencies

(a) Acquisition-related Contingent Consideration Obligations

The following summarizes our principal contractual acquisition-related contingent consideration obligations as of March 31, 2013 that have changed significantly since December 31, 2012. Other acquisition-related contingent consideration obligations that were presented in our Annual Report on Form 10-K, as amended, for the year ended December 31, 2012, but which are omitted below, represent those that have not changed significantly since that date.

• Accordant

With respect to Accordant, the terms of the acquisition agreement require us to pay an earn-out upon successfully meeting certain revenue and cash collection targets starting after the second anniversary of the acquisition date and completed prior to the third anniversary of the acquisition date. An earn-out totaling $4.5 million was earned and accrued as of December 31, 2012. A payment of $1.5 million was made during the first quarter of 2013 and the remaining payments will be made in quarterly installments of $1.5 million during the second and third quarter of 2013.

• Branan

With respect to Branan, the terms of the acquisition agreement require us to pay earn-outs upon successfully achieving various regulatory product approval milestones by the second anniversary of the acquisition date. Four milestones were achieved during 2012, resulting in an accrual totaling approximately $2.0 million as of December 31, 2012. During the first quarter of 2013, two additional milestones were achieved, resulting in an incremental accrual of $1.0 million. Payment of these earn-outs was made during the first quarter of 2013. The maximum remaining amount of the earn-out payments is $2.0 million.

• Epocal

With respect to Epocal, the terms of the acquisition agreement require us to pay earn-outs and management incentive payments upon successfully meeting certain product development and United States Food and Drug Administration regulatory approval milestones from the date of acquisition through December 31, 2018. The maximum amount of the earn-out payments is $90.5 million, of which $15.0 million was paid at the acquisition closing date. The maximum amount of the management incentive payments is $9.4 million.

• ROAR

With respect to Forensics Limited, or ROAR, the terms of the acquisition agreement require us to pay an earn-out upon successfully meeting certain EBITDA targets during 2012 through 2014. Payment of the 2012 earn-out totaling approximately £1.0 million (approximately $1.5 million), which was previously accrued, was made during the first quarter of 2013. The maximum remaining amount of the earn-out payments is £9.5 million (approximately $14.4 million at March 31, 2013).

XML

Defined Benefit Pension Plan

3 Months Ended

Mar. 31, 2013

Compensation And Retirement Disclosure [Abstract]

Defined Benefit Pension Plan

(13) Defined Benefit Pension Plan

Our subsidiary in England, Unipath Ltd., has a defined benefit pension plan established for certain of its employees. The net periodic benefit costs are as follows (in thousands):

	Three Months Ended March 31,
	2013			2012
Service cost	$	—		$	—
Interest cost		182			198
Expected return on plan assets		(156	)		(152	)
Amortization of prior service cost		103			104
Realized losses		—			—
Net periodic benefit cost	$	129		$	150

XML

Restructuring Plans

3 Months Ended

Mar. 31, 2013

Restructuring And Related Activities [Abstract]

Restructuring Plans

(9) Restructuring Plans

The following table sets forth aggregate restructuring charges recorded in our Consolidated Statements of Operations for the three months ended March 31, 2013 and 2012 (in thousands):

	Three Months Ended March 31,
Statement of Operations Caption	2013		2012
Cost of net revenue	$	623	$	964
Research and development		—		624
Sales and marketing		1,099		827
General and administrative		2,170		3,113
Total operating expenses		3,892		5,528
Interest expense, including amortization of original issue discounts and deferred financing costs		55		60
Total charges	$	3,947	$	5,588

(a) 2013 Restructuring Plans

In 2013, management developed cost reduction efforts within our professional diagnostics and health information solutions business segments, including businesses in our Europe and Asia Pacific regions. The following table summarizes the restructuring activities related to our 2013 restructuring plans for the three months ended March 31, 2013 (in thousands):

	Professional Diagnostics		Health Information Solutions		Total
Severance-related costs	$	833	$	69	$	902
Facility and transition costs		13		—		13
Total charges	$	846	$	69	$	915

We anticipate incurring approximately $1.4 million in additional costs under our 2013 restructuring plans related primarily to our professional diagnostics business segment in Europe and may develop additional plans over the remainder of 2013. As of March 31, 2013, $0.1 million in severance costs arising under our 2013 restructuring plans remain unpaid.

(b) 2012 Restructuring Plans

In 2012, management developed cost reduction plans within our professional diagnostics business segment, including the integration of our business in Brazil, Europe and the United States. Additionally, management developed new plans to continue our efforts to reduce costs within our health information solutions business segment, including the termination of certain projects, which resulted in charges for the impairment of related fixed assets and intangibles. The following table summarizes the restructuring activities related to our 2012 restructuring plans for the three months ended March 31, 2013 and 2012 and since inception (in thousands):

	Three Months Ended March 31,					Since
Professional Diagnostics	2013			2012		Inception
Severance-related costs	$	62		$	1,973	$	4,794
Facility and transition costs		63			—		182
Cash charges		125			1,973		4,976
Fixed asset and inventory impairments		—			—		304
Total charges	$	125		$	1,973	$	5,280
	Three Months Ended March 31,					Since
Health Information Solutions	2013			2012		Inception
Severance-related costs	$	1,819		$	797	$	4,864
Facility and transition costs		659			—		1,893
Other exit costs		20			—		35
Cash charges		2,498			797		6,792
Fixed asset and inventory impairments		—			—		2,689
Intangible asset impairments		—			5		2,988
Other non-cash (recoveries)		(45	)		—		(76	)
Total charges	$	2,453		$	802	$	12,393

We anticipate incurring approximately $3.7 million in additional severance and facility costs under these plans related primarily to our health information solutions business segment through 2014. As of March 31, 2013, $3.8 million in severance and exit costs under these plans remain unpaid.

(b) 2011, 2010 and 2008 Restructuring Plans

In 2011, management executed a company-wide cost reduction plan, which impacted our corporate and other business segment, as well as the health information solutions and professional diagnostics business segments. Management also developed plans within our professional diagnostics business segment to consolidate operating activities among certain of our U.S., European and Asia Pacific subsidiaries, including transferring the manufacturing of our Panbio products from Australia to our Standard Diagnostics facility in South Korea and eliminating redundant costs among our newly acquired Axis-Shield subsidiaries. Additionally, within our health information solutions business segment, management executed plans to further reduce costs and improve efficiencies, as well as cease operations at our GeneCare Medical Genetics Center, Inc., or GeneCare, facility in Chapel Hill, North Carolina and transfer the majority of our Quality Assured Services, Inc. operation in Orlando, Florida to our facility in Livermore, California.

In 2010, management developed several plans to reduce costs and improve efficiencies within our health information solutions and professional diagnostics business segments. Additionally in 2008, management developed and initiated plans to transition the businesses of Cholestech to our San Diego, California facility.

The following table summarizes the restructuring activities related to our 2011, 2010 and 2008 restructuring plans for the three months ended March 31, 2013 and 2012 and since inception (in thousands):

	Three Months Ended March 31,					Since
Professional Diagnostics	2013		2012			Inception
Severance-related costs	$	250	$	1,965		$	19,963
Facility and transition costs		169		723			7,396
Other exit costs		16		19			714
Cash charges		435		2,707			28,073
Fixed asset and inventory impairments		—		134			6,374
Total charges	$	435	$	2,841		$	34,447
	Three Months Ended March 31,					Since
Health Information Solutions	2013		2012			Inception
Severance-related costs	$	—	$	—		$	6,901
Facility and transition costs (recoveries)		—		(86	)		8,010
Other exit costs		19		41			531
Cash charges (recoveries)		19		(45	)		15,442
Fixed asset and inventory impairments		—		—			1,114
Intangible asset impairments		—		—			2,935
Other non-cash charges		—		—			761
Total charges (recoveries)	$	19	$	(45	)	$	20,252
	Three Months Ended March 31,					Since
Corporate and Other	2013		2012			Inception
Severance-related costs	$	—	$	17		$	1,190
Cash charges		—		17			1,190
Fixed asset and inventory impairments		—		—			3
Total charges	$	—	$	17		$	1,193

We anticipate incurring approximately $1.6 million in additional costs under these plans related primarily to our professional diagnostics business segment. A majority of these additional costs relate to the transfer of the Panbio product manufacturing to Korea and are for severance and facility exit costs. We may also incur impairment charges on assets as plans are finalized. We do not anticipate incurring significant additional costs under these plans related to our health information solutions business segment. As of March 31, 2013, $2.6 million in cash charges remain unpaid, primarily related to facility lease obligations.

(e) Restructuring Reserves

The following table summarizes our restructuring reserves related to the plans described above, of which $5.4 million is included in accrued expenses and other current liabilities and $1.0 million is included in other long-term liabilities on our accompanying Consolidated Balance Sheets (in thousands):

	Severance- related Costs			Facility and Transition Costs			Other Exit Costs			Total
Balance, December 31, 2012	$	3,167		$	2,429		$	622		$	6,218
Cash charges		3,033			904			55			3,992
Payments		(2,923	)		(763	)		(72	)		(3,758	)
Currency adjustments		(4	)		—			—			(4	)
Balance, March 31, 2013	$	3,273		$	2,570		$	605		$	6,448

XML

Long-term Debt - Long-Term Debt Interest Expense (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Debt Instrument [Line Items]
Long-term debt issuance cost	$ 56,517	$ 49,483
Secured credit facility [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	27,275	22,851
7.25% Senior notes [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	8,356
7.875% Senior notes [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	(27)	5,758
9% Senior subordinated notes [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	10,394	10,354
8.625% Senior subordinated notes [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	9,273	9,274
3% Convertible senior subordinated notes [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	$ 1,246	$ 1,246

XML

Stockholders' Equity and Non-controlling Interests

3 Months Ended

Mar. 31, 2013

Equity [Abstract]

Stockholders' Equity and Non-controlling Interests

(7) Stockholders’ Equity and Non-controlling Interests

(a) Preferred Stock

For both the three months ended March 31, 2013 and 2012, Series B preferred stock dividends amounted to $5.3 million which reduced earnings available to common stockholders for purposes of calculating net income (loss) per common share for each of the respective periods. As of April 15, 2013, payments have been made covering all dividend periods through March 31, 2013.

The Series B preferred stock dividends for the three months ended March 31, 2013 and 2012 were paid in cash.

(b) Changes in Stockholders’ Equity and Non-controlling Interests

A summary of the changes in stockholders’ equity and non-controlling interests comprising total equity for the three months ended March 31, 2013 and 2012 is provided below (in thousands):

	Three Months Ended March 31,
	2013									2012
	Total Stockholders’ Equity			Non- controlling Interests			Total Equity			Total Stockholders’ Equity			Non- controlling Interests			Total Equity
Equity, beginning of period	$	2,180,422		$	2,282		$	2,182,704		$	2,229,234		$	2,340		$	2,231,574
Exercise of common stock options, warrants and shares issued under employee stock purchase plan		6,135			—			6,135			7,674			—			7,674
Preferred stock dividends		(5,323	)		—			(5,323	)		(5,323	)		—			(5,323	)
Stock-based compensation related to grants of common stock options		4,123			—			4,123			3,874			—			3,874
Excess tax benefits on exercised stock options		(422	)		—			(422	)		104			—			104
Net income (loss)		12,450			(25	)		12,425			1,214			(137	)		1,077
Total other comprehensive income (loss)		(74,739	)		—			(74,739	)		37,353			—			37,353
Equity, end of period	$	2,122,646		$	2,257		$	2,124,903		$	2,274,130		$	2,203		$	2,276,333

XML

Business Combinations

3 Months Ended

Mar. 31, 2013

Business Combinations [Abstract]

Business Combinations

(8) Business Combinations

Acquisitions are accounted for using the acquisition method and the acquired companies’ results have been included in the accompanying Consolidated Financial Statements from their respective dates of acquisition. During the three months ended March 31, 2013 and 2012, we expensed acquisition-related costs of $0.9 million and $1.5 million, respectively, in general and administrative expense.

Our business acquisitions have historically been made at prices above the fair value of the assets acquired and liabilities assumed, resulting in goodwill, based on our expectations of synergies and other benefits of combining the businesses. These synergies and benefits include elimination of redundant facilities, functions and staffing; use of our existing commercial infrastructure to expand sales of the products of the acquired businesses; and use of the commercial infrastructure of the acquired businesses to expand product sales in a cost-efficient manner.

Net assets acquired are recorded at their fair value and are subject to adjustment upon finalization of the fair value analysis. We are not aware of any information that indicates the final fair value analysis will differ materially from the preliminary estimates. The estimated useful lives of the individual categories of intangible assets were based on the nature of the applicable intangible asset and the expected future cash flows to be derived from the intangible asset. Amortization of intangible assets with finite lives is recognized over the shorter of the respective lives of the agreement or the period of time the intangible assets are expected to contribute to future cash flows. We amortize our finite-lived intangible assets based on patterns on which the respective economic benefits are expected to be realized.

(a) Acquisitions in 2013

(i) Epocal

On February 1, 2013, we acquired Epocal, Inc., or Epocal, located in Ottawa, Canada, a provider of technologies that support blood gas and electrolyte testing at the point of care. The preliminary aggregate purchase price was approximately $248.5 million, which consisted of $173.5 million in cash and a contingent consideration obligation with an aggregate acquisition date fair value of $75.0 million. The operating results of Epocal are included in our professional diagnostics reporting unit and business segment. The amount allocated to goodwill from this acquisition is not deductible for tax purposes.

(ii) Mega Medika

On January 7, 2013, we acquired certain assets of PT Mega Medika Mandiri, or Mega Medika, located in South Jakarta, Indonesia, a distributor of infectious disease products to the Indonesian marketplace as well as materials for vaccines to a pharmaceutical customer. The preliminary aggregate purchase price was approximately $10.7 million, which consisted of $10.4 million in cash and a contingent consideration obligation with an aggregate acquisition date fair value of $0.3 million. Included in our Consolidated Statement of Operations for the three months ended March 31, 2013 is revenue totaling approximately $0.4 million related to Mega Medika. The operating results of Mega Medika are included in our professional diagnostics reporting unit and business segment. The amount allocated to goodwill from this acquisition is deductible for tax purposes.

A summary of the preliminary fair values of the net assets acquired for the acquisitions consummated in 2013 is as follows (in thousands):

	Epocal		Mega Medika		Total
Current assets(1)	$	11,935	$	1,142	$	13,077
Property, plant and equipment		1,267		229		1,496
Goodwill		99,519		655		100,174
Intangible assets		164,400		9,460		173,860
Other non-current assets		17,610		—		17,610
Total assets acquired		294,731		11,486		306,217
Current liabilities		2,543		549		3,092
Non-current liabilities		43,727		211		43,938
Total liabilities assumed		46,270		760		47,030
Net assets acquired		248,461		10,726		259,187
Less:
Contingent consideration		75,000		295		75,295
Cash paid	$	173,461	$	10,431	$	183,892

⁽¹⁾  Includes approximately $2.6 million of acquired cash.

The following are the intangible assets acquired and their respective fair values and weighted-average useful lives (dollars in thousands):

	Epocal		Mega Medika		Total		Weighted- average Useful Life
Core technology and patents	$	119,700	$	—	$	119,700		20.0 years
Trademarks and trade names		20,500		—		20,500		19.2 years
Customer relationships		—		9,460		9,460		21.0 years
In-process research and development		24,200		—		24,200		N/A
Total intangible assets	$	164,400	$	9,460	$	173,860

(b) Acquisitions in 2012

During 2012, we acquired the following businesses for a preliminary aggregate purchase price of $494.8 million, which included cash payments totaling $419.2 million and contingent consideration obligations with aggregate acquisition date fair values of $75.6 million.

• Reatrol Comercializacao De Produtos De Saude, LDA, subsequently renamed Alere Lda, located in Vila Nova de Gaia, Portugal, a distributor of products for drugs of abuse testing (Acquired January 2012)

• Kullgren Holding AB, or Kullgren, located in Gensta, Sweden, a company that manufactures and distributes high-quality intimacy and pharmaceutical products (Acquired February 2012)

• Wellogic ME FZ-LLC, or Wellogic UAE, located in Dubai, United Arab Emirates, a company that provides development services to Alere Wellogic, LLC, which acquired the assets of Method Factory, Inc. (d/b/a Wellogic), or Wellogic, in December 2011 (Acquired February 2012)

• certain assets, primarily including customer and patient lists, of AmMed Direct LLC, or AmMed, located near Nashville, Tennessee, a privately-owned mail-order provider of home-diabetes testing products and supplies (Acquired March 2012)

• eScreen, Inc., or eScreen, headquartered in Overland Park, Kansas, a technology-enabled provider of employment drug screening solutions for hiring and maintaining healthier and more efficient workforces (Acquired April 2012)

• MedApps Holding Company, Inc., or MedApps, headquartered in Scottsdale, Arizona, a developer of innovative remote health monitoring solutions that deliver efficient cost-effective connectivity between patient, care provider and electronic medical records (Acquired July 2012)

• Amedica Biotech, Inc., or Amedica, located in Hayward, California, a company focused on the development and manufacture of in vitro diagnostic tests (Acquired July 2012)

• DiagnosisOne, Inc., or DiagnosisOne, located in Lowell, Massachusetts, a software company that provides clinical analytics technology and data-driven content to hospitals, physician groups, insurers and governments (Acquired July 2012)

• Seelen Care Laege-og & Hospitalsartikler ApS, or Seelen, located in Holstebro, Denmark, a distributor of consumables, instruments and equipment to doctors, specialists and physiotherapists (Acquired August 2012)

• certain assets of Diagnostik Nord, or Diagnostik, located in Schwerin, Germany, a company focused on the sale of drug screening and in vitro diagnostic medical devices and a provider of diagnostic solutions (Acquired September 2012)

• Healthcare Connections Limited, or HCC, located in Buckinghamshire, United Kingdom, an occupational health provider specializing in employment medical programs, preventative health schemes and drug and alcohol sample collection services (Acquired November 2012)

• the diagnostic division of Medial spol. s.r.o., subsequently renamed Alere s.r.o., located in Prague, Czech Republic, a distributor of laboratory diagnostic devices, devices operating in the point-of-care testing regime, diagnostic kits and tests for biochemistry, hematology, and microbiology (Acquired November 2012)

• certain assets of Quantum Diagnostics, or Quantum Australia, located in Australia, an on-line medical supply company that provides a range of affordable drug and alcohol tests for personal, business and professional medical use (Acquired November 2012)

• certain assets of NationsHealth, Inc., or NationsHealth, headquartered in Sunrise, Florida, a privately-owned mail-order provider of diabetes home-testing products and supplies, and a share acquisition of NationsHealth’s subsidiary in the Philippines, or NationsHealth Philippines (Acquired December 2012)

• Branan Medical Corporation, or Branan, headquartered in Irvine, California, a manufacturer of drugs of abuse testing products (Acquired December 2012)

The operating results of Alere Lda, AmMed, eScreen, MedApps, Amedica, Seelen, Diagnostik, HCC, Alere s.r.o., Quantum Australia, NationsHealth and Branan are included in our professional diagnostics reporting unit and business segment. The operating results of Wellogic UAE and DiagnosisOne are included in our health information solutions reporting unit and business segment. The operating results of Kullgren are included in our consumer diagnostics reporting unit and business segment.

Our Consolidated Statement of Operations for the three months ended March 31, 2012 included revenue totaling approximately $1.4 million related to the businesses that were acquired during that period. Goodwill has been recognized in all of these acquisitions and amounted to approximately $259.2 million. Goodwill related to the acquisitions of AmMed, Diagnostik and the U.S.-based assets of NationsHealth, which totaled $8.8 million, is deductible for tax purposes. The goodwill related to the remaining 2012 acquisitions is not deductible for tax purposes.

A summary of the preliminary fair values of the net assets acquired for the acquisitions consummated in 2012 is as follows (in thousands):

Current assets(1)	$	46,041
Property, plant and equipment		9,029
Goodwill		259,231
Intangible assets		325,223
Other non-current assets		629
Total assets acquired		640,153
Current liabilities		28,802
Non-current liabilities		116,580
Total liabilities assumed		145,382
Net assets acquired		494,771
Less:
Contingent consideration		75,620
Cash paid	$	419,151

⁽¹⁾  Includes approximately $3.8 million of acquired cash.

The following are the intangible assets acquired and their respective fair values and weighted-average useful lives (dollars in thousands):

	Amount		Weighted- average Useful Life
Core technology and patents	$	148,103		18.7 years
Trademarks and trade names		19,390		18.3 years
Customer relationships		136,485		18.1 years
Non-competition agreements		1,118		5.1 years
Other		15,227		9.2 years
In-process research and development		4,900		N/A
Total intangible assets	$	325,223

XML

Long-term Debt

3 Months Ended

Mar. 31, 2013

Debt Disclosure [Abstract]

Long-term Debt

(10) Long-term Debt

We had the following long-term debt balances outstanding (in thousands):

	March 31, 2013			December 31, 2012
A term loans(1)(2)	$	866,875		$	878,438
B term loans(1)		911,125			913,438
Incremental B-1 term loans(1)		246,875			247,500
Incremental B-2 term loans(1)		196,314			196,739
Revolving line of credit(1)		192,500			22,500
7.25% Senior notes		450,000			450,000
7.875% Senior notes		—			1,809
9% Senior subordinated notes		393,383			392,933
8.625% Senior subordinated notes		400,000			400,000
3% Convertible senior subordinated notes		150,000			150,000
Other lines of credit		1,328			31,957
Other		32,652			3,593
		3,841,052			3,688,907
Less: Current portion		(52,210	)		(60,232	)
	$	3,788,842		$	3,628,675

⁽¹⁾  Incurred under our secured credit facility.

⁽²⁾  Includes “A” term loans and “Delayed Draw” term loans under our secured credit facility.

In connection with our significant long-term debt issuances, we recorded interest expense, including amortization and write-offs of deferred financing costs and original issue discounts, in our accompanying Consolidated Statements of Operations for the three months ended March 31, 2013 and 2012, respectively, as follows (in thousands):

	Three Months Ended March 31,
	2013			2012
Secured credit facility (1)	$	27,275		$	22,851
7.25% Senior notes		8,356			—
7.875% Senior notes		(27	)		5,758
9% Senior subordinated notes		10,394			10,354
8.625% Senior subordinated notes		9,273			9,274
3% Convertible senior subordinated notes		1,246			1,246
	$	56,517		$	49,483

⁽¹⁾  Includes “A” term loans, including the “Delayed-Draw” term loans; “B” term loans; “Incremental B-1” term loans; “Incremental B-2” term loans; and revolving line of credit loans. For the three months ended March 31, 2013 and 2012, the amounts include $1.0 million and $1.3 million, respectively, related to the amortization of fees paid for certain debt modifications.

The following summarizes the material terms of our secured credit facility that have changed significantly since December 31, 2012. All other terms of our secured credit facility as described in our Annual Report on Form 10-K, as amended, for the year ended December 31, 2012, but omitted below, have not changed since that date.

On March 22, 2013, we and certain of our subsidiaries entered into a fourth amendment to the credit agreement that governs our secured credit facility, or the credit agreement. The fourth amendment provides for 50 basis point reductions in the interest rate margins applicable to the “B” term loans, the “Incremental B-1” term loans and the “Incremental B-2” term loans and certain other changes. Under the terms of the credit agreement as amended by the fourth amendment, the “B” term loans, the “Incremental B-1” term loans and the “Incremental B-2” term loans bear interest at a rate per annum of, at our option, either (i) the Base Rate, as defined in the credit agreement, plus an applicable margin, which varies between 2.00% and 2.75% depending on our consolidated secured leverage ratio, or (ii) the Eurodollar Rate, as defined in the credit agreement, plus an applicable margin, which varies between 3.00% and 3.75% depending on our consolidated secured leverage ratio. Interest on “B” term loans, “Incremental B-1” term loans and “Incremental B-2” term loans based on the Eurodollar Rate is subject to a 1.00% floor with respect to the base Eurodollar Rate. Furthermore, under the terms of the credit agreement as amended by the fourth amendment, we may make optional prepayments of the term loans under our secured credit facility from time to time without any premium or penalty, except that if, on or before September 22, 2013, we repay or prepay any “B” term loans, “Incremental B-1” term loans or “Incremental B-2” term loans with the proceeds of, or convert any “B” term loans, “Incremental B-1” term loans or “Incremental B-2” term loans into, any new term loans bearing interest with an effective yield (as defined in the credit agreement) less than the effective yield applicable to the “B” term loans, the “Incremental B-1” term loans or the “Incremental B-2” term loans, as applicable, we must pay a premium equal to 1.0% of the principal amount of the “B” term loans, “Incremental B-1” term loans or “Incremental B-2” term loans so repaid, prepaid or converted.

XML

Fair Value Measurements - Fair Value Assets and Liabilities Measured on Recurring Basis, Valuation Techniques (Detail) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2013	Dec. 31, 2012
Liabilities:
Contingent consideration obligations	$ 240,604	$ 176,172
Fair Value, Measurements, Recurring [Member]
Assets:
Marketable securities	884	904
Total assets	884	904
Liabilities:
Contingent consideration obligations	240,604	176,172
Total liabilities	240,604	176,172
Quoted Prices in Active Markets (Level 1) [Member] | Fair Value, Measurements, Recurring [Member]
Assets:
Marketable securities	884	904
Total assets	884	904
Liabilities:
Contingent consideration obligations
Total liabilities
Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member]
Assets:
Marketable securities
Total assets
Liabilities:
Contingent consideration obligations
Total liabilities
Unobservable Inputs (Level 3) [Member] | Fair Value, Measurements, Recurring [Member]
Assets:
Marketable securities
Total assets
Liabilities:
Contingent consideration obligations	240,604	176,172
Total liabilities	$ 240,604	$ 176,172

XML

Fair Value Measurements - Additional Information (Detail) (USD $)	Mar. 31, 2013	Dec. 31, 2012
Debt Disclosure [Abstract]
Estimated fair value of our long-term debt	$ 3,900,000,000	$ 3,700,000,000
Carrying amount of our long-term debt	$ 3,841,052,000	$ 3,688,907,000

XML

Derivative Financial Instruments - Summary of Effect of Derivative Instruments in Consolidated Statement of Operations and in Accumulated Other Comprehensive Loss (Detail) (Other comprehensive income (loss) [Member], USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2012
Derivative Instruments [Line Items]
Amount of Gain Recognized	$ 1,107
Foreign currency forward contracts [Member]
Derivative Instruments [Line Items]
Amount of Gain Recognized	$ 1,107

XML

Restructuring Plans (Tables)

3 Months Ended

Mar. 31, 2013

Restructuring And Related Activities [Abstract]

Aggregate Charges Associated with Restructuring Plans Recorded in Operating Income

The following table sets forth aggregate restructuring charges recorded in our Consolidated Statements of Operations for the three months ended March 31, 2013 and 2012 (in thousands):

	Three Months Ended March 31,
Statement of Operations Caption	2013		2012
Cost of net revenue	$	623	$	964
Research and development		—		624
Sales and marketing		1,099		827
General and administrative		2,170		3,113
Total operating expenses		3,892		5,528
Interest expense, including amortization of original issue discounts and deferred financing costs		55		60
Total charges	$	3,947	$	5,588

Restructuring Activities Related to Restructuring Plans

The following table summarizes the restructuring activities related to our 2013 restructuring plans for the three months ended March 31, 2013 (in thousands):

	Professional Diagnostics		Health Information Solutions		Total
Severance-related costs	$	833	$	69	$	902
Facility and transition costs		13		—		13
Total charges	$	846	$	69	$	915

The following table summarizes the restructuring activities related to our 2012 restructuring plans for the three months ended March 31, 2013 and 2012 and since inception (in thousands):

	Three Months Ended March 31,					Since
Professional Diagnostics	2013			2012		Inception
Severance-related costs	$	62		$	1,973	$	4,794
Facility and transition costs		63			—		182
Cash charges		125			1,973		4,976
Fixed asset and inventory impairments		—			—		304
Total charges	$	125		$	1,973	$	5,280
	Three Months Ended March 31,					Since
Health Information Solutions	2013			2012		Inception
Severance-related costs	$	1,819		$	797	$	4,864
Facility and transition costs		659			—		1,893
Other exit costs		20			—		35
Cash charges		2,498			797		6,792
Fixed asset and inventory impairments		—			—		2,689
Intangible asset impairments		—			5		2,988
Other non-cash (recoveries)		(45	)		—		(76	)
Total charges	$	2,453		$	802	$	12,393

The following table summarizes the restructuring activities related to our 2011, 2010 and 2008 restructuring plans for the three months ended March 31, 2013 and 2012 and since inception (in thousands):

	Three Months Ended March 31,					Since
Professional Diagnostics	2013		2012			Inception
Severance-related costs	$	250	$	1,965		$	19,963
Facility and transition costs		169		723			7,396
Other exit costs		16		19			714
Cash charges		435		2,707			28,073
Fixed asset and inventory impairments		—		134			6,374
Total charges	$	435	$	2,841		$	34,447
	Three Months Ended March 31,					Since
Health Information Solutions	2013		2012			Inception
Severance-related costs	$	—	$	—		$	6,901
Facility and transition costs (recoveries)		—		(86	)		8,010
Other exit costs		19		41			531
Cash charges (recoveries)		19		(45	)		15,442
Fixed asset and inventory impairments		—		—			1,114
Intangible asset impairments		—		—			2,935
Other non-cash charges		—		—			761
Total charges (recoveries)	$	19	$	(45	)	$	20,252
	Three Months Ended March 31,					Since
Corporate and Other	2013		2012			Inception
Severance-related costs	$	—	$	17		$	1,190
Cash charges		—		17			1,190
Fixed asset and inventory impairments		—		—			3
Total charges	$	—	$	17		$	1,193

Cash Activity for Restructuring Reserves

The following table summarizes our restructuring reserves related to the plans described above, of which $5.4 million is included in accrued expenses and other current liabilities and $1.0 million is included in other long-term liabilities on our accompanying Consolidated Balance Sheets (in thousands):

	Severance- related Costs			Facility and Transition Costs			Other Exit Costs			Total
Balance, December 31, 2012	$	3,167		$	2,429		$	622		$	6,218
Cash charges		3,033			904			55			3,992
Payments		(2,923	)		(763	)		(72	)		(3,758	)
Currency adjustments		(4	)		—			—			(4	)
Balance, March 31, 2013	$	3,273		$	2,570		$	605		$	6,448

XML

Business Combinations - Additional Information (Detail) (USD $)	3 Months Ended					3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Dec. 31, 2012	Mar. 31, 2013 Epocal [Member]	Feb. 01, 2013 Epocal [Member]	Mar. 31, 2013 Mega Medika [Member]	Jan. 07, 2013 Mega Medika [Member]
Business Acquisition [Line Items]
General and administrative expense related to acquisition	$ 900,000	$ 1,500,000
Preliminary aggregate purchase price		494,800,000			248,500,000		10,700,000
Total cash payments	183,892,000		419,151,000	173,461,000	173,500,000	10,431,000	10,400,000
Acquisition date fair value investment	75,295,000		75,620,000	75,000,000	75,000,000	295,000	300,000
Total revenue related to acquisition		1,400,000				400,000
Goodwill	100,174,000		259,231,000	99,519,000		655,000
Goodwill deductible for tax purposes			$ 8,800,000

XML

Related Party Transactions

3 Months Ended

Mar. 31, 2013

Related Party Transactions [Abstract]

Related Party Transactions

(15) Related Party Transactions

In May 2007, we completed the formation of SPD, our 50/50 joint venture with P&G, for the development, manufacturing, marketing and sale of existing and to-be-developed consumer diagnostic products, outside the cardiology, diabetes and oral care fields. Upon completion of the arrangement to form the joint venture, we ceased to consolidate the operating results of our consumer diagnostic products business related to the joint venture and instead account for our 50% interest in the results of the joint venture under the equity method of accounting.

We had a net receivable from the joint venture of $0.6 million and $2.3 million as of March 31, 2013 and December 31, 2012, respectively. Included in the $0.6 million receivable balance as of March 31, 2013 is approximately $1.5 million of costs incurred in connection with our 2008 SPD-related restructuring plans. Included in the $2.3 million receivable balance as of December 31, 2012 is approximately $1.6 million of costs incurred in connection with our 2008 SPD-related restructuring plans. We have also recorded a long-term receivable totaling approximately $13.7 million and $14.6 million as of March 31, 2013 and December 31, 2012, respectively, related to the 2008 SPD-related restructuring plans. Additionally, customer receivables associated with revenue earned after the joint venture was completed have been classified as other receivables within prepaid and other current assets on our accompanying Consolidated Balance Sheets in the amount of $8.9 million and $6.9 million as of March 31, 2013 and December 31, 2012, respectively. In connection with the joint venture arrangement, the joint venture bears the collection risk associated with these receivables. Sales to the joint venture under our manufacturing agreement totaled $17.1 million during each of the three-month periods ended March 31, 2013 and 2012. Additionally, services revenue generated pursuant to the long-term services agreement with the joint venture totaled $0.3 million during each of the three-month periods ended March 31, 2013 and 2012. Sales under our manufacturing agreement and long-term services agreement are included in net product sales and services revenue, respectively, in our accompanying Consolidated Statements of Operations.

Under the terms of our product supply agreement, the joint venture purchases products from our manufacturing facilities in the U.K. and China. The joint venture in turn sells a portion of those tests back to us for final assembly and packaging. Once packaged, the tests are sold to P&G for distribution to third-party customers in North America. As a result of these related transactions, we have recorded $8.7 million and $7.3 million of trade receivables which are included in accounts receivable on our accompanying Consolidated Balance Sheets as of March 31, 2013 and December 31, 2012, respectively, and $15.7 million and $21.3 million of trade accounts payable which are included in accounts payable on our accompanying Consolidated Balance Sheets as of March 31, 2013 and December 31, 2012, respectively. During the three months ended March 31, 2013 and 2012, we received $10.8 million and $6.1 million, respectively, in cash from SPD as a return of capital.

The following table summarizes our related party balances with SPD within our Consolidated Balance Sheets (in thousands):

Balance Sheet Caption	March 31, 2013		December 31, 2012
Accounts receivable, net of allowances	$	8,667	$	7,317
Prepaid expenses and other current assets	$	9,425	$	9,161
Deferred financing costs, net, and other non-current assets	$	13,665	$	14,629
Accounts payable	$	15,676	$	21,258

XML

Guarantor Financial Information

3 Months Ended

Mar. 31, 2013

Text Block [Abstract]

Guarantor Financial Information

(20) Guarantor Financial Information

Our 7.25% senior notes due 2018, our 9% senior subordinated notes due 2016, and our 8.625% senior subordinated notes due 2018 are guaranteed by certain of our consolidated wholly owned subsidiaries, or the Guarantor Subsidiaries. The guarantees are full and unconditional and joint and several. The following supplemental financial information sets forth, on a consolidating basis, balance sheets as of March 31, 2013 and December 31, 2012, the related statements of operations, statements of comprehensive income (loss) and cash flows for each of the three months ended March 31, 2013 and 2012, for Alere Inc., the Guarantor Subsidiaries and our other subsidiaries, or the Non-Guarantor Subsidiaries. The supplemental financial information reflects the investments of Alere Inc. and the Guarantor Subsidiaries in the Guarantor and Non-Guarantor Subsidiaries using the equity method of accounting.

We have extensive transactions and relationships between various members of the consolidated group. These transactions and relationships include intercompany pricing agreements, intellectual property royalty agreements and general and administrative and research and development cost-sharing agreements. Because of these relationships, it is possible that the terms of these transactions are not the same as those that would result from transactions among wholly unrelated parties.

For comparative purposes, certain amounts for prior periods have been reclassified to conform to the current period classification.

CONSOLIDATING STATEMENT OF OPERATIONS

For the Three Months Ended March 31, 2013

(in thousands)

	Issuer			Guarantor Subsidiaries			Non- Guarantor Subsidiaries			Eliminations			Consolidated
Net product sales	$	—		$	233,493		$	320,897		$	(46,114	)	$	508,276
Services revenue		—			206,171			20,738			—			226,909
Net product sales and services revenue		—			439,664			341,635			(46,114	)		735,185
License and royalty revenue		—			3,035			3,533			(2,504	)		4,064
Net revenue		—			442,699			345,168			(48,618	)		739,249
Cost of net product sales		948			120,594			173,216			(41,680	)		253,078
Cost of services revenue		—			115,611			8,502			(3,955	)		120,158
Cost of net product sales and services revenue		948			236,205			181,718			(45,635	)		373,236
Cost of license and royalty revenue		—			17			4,243			(2,504	)		1,756
Cost of net revenue		948			236,222			185,961			(48,139	)		374,992
Gross profit (loss)		(948	)		206,477			159,207			(479	)		364,257
Operating expenses:
Research and development		4,423			17,380			19,651			—			41,454
Sales and marketing		1,392			82,838			72,226			—			156,456
General and administrative		14,027			64,983			56,848			—			135,858
Total operating expenses		19,842			165,201			148,725			—			333,768
Operating income (loss)		(20,790	)		41,276			10,482			(479	)		30,489
Interest expense, including amortization of original issue discounts and deferred financing costs		(56,858	)		(7,021	)		(3,417	)		9,897			(57,399	)
Other income (expense), net		4,770			6,259			(1,603	)		(9,896	)		(470	)
Income (loss) before provision (benefit) for income taxes		(72,878	)		40,514			5,462			(478	)		(27,380	)
Provision (benefit) for income taxes		(62,811	)		17,926			8,127			(113	)		(36,871	)
Income (loss) before equity earnings of unconsolidated entities, net of tax		(10,067	)		22,588			(2,665	)		(365	)		9,491
Equity in earnings (losses) of subsidiaries, net of tax		22,244			(614	)		—			(21,630	)		—
Equity earnings of unconsolidated entities, net of tax		248			—			2,688			(2	)		2,934
Net income		12,425			21,974			23			(21,997	)		12,425
Less: Net loss attributable to non-controlling interests		—			—			(25	)		—			(25	)
Net income attributable to Alere Inc. and Subsidiaries		12,425			21,974			48			(21,997	)		12,450
Preferred stock dividends		(5,250	)		—			—			—			(5,250	)
Net income available to common stockholders	$	7,175		$	21,974		$	48		$	(21,997	)	$	7,200

CONSOLIDATING STATEMENT OF OPERATIONS

For the Three Months Ended March 31, 2012

(in thousands)

	Issuer			Guarantor Subsidiaries			Non- Guarantor Subsidiaries			Eliminations			Consolidated
Net product sales	$	—		$	223,417		$	285,599		$	(33,229	)	$	475,787
Services revenue		—			176,715			15,719			—			192,434
Net product sales and services revenue		—			400,132			301,318			(33,229	)		668,221
License and royalty revenue		—			4,304			2,546			(3,942	)		2,908
Net revenue		—			404,436			303,864			(37,171	)		671,129
Cost of net product sales		850			106,202			151,598			(33,096	)		225,554
Cost of services revenue		—			83,643			7,217			—			90,860
Cost of net product sales and services revenue		850			189,845			158,815			(33,096	)		316,414
Cost of license and royalty revenue		—			5			5,581			(3,942	)		1,644
Cost of net revenue		850			189,850			164,396			(37,038	)		318,058
Gross profit (loss)		(850	)		214,586			139,468			(133	)		353,071
Operating expenses:
Research and development		5,196			17,482			16,322			—			39,000
Sales and marketing		1,057			86,337			71,184			—			158,578
General and administrative		11,631			64,644			44,160			—			120,435
Total operating expenses		17,884			168,463			131,666			—			318,013
Operating income (loss)		(18,734	)		46,123			7,802			(133	)		35,058
Interest expense, including amortization of original issue discounts and deferred financing costs		(49,716	)		(11,067	)		(3,254	)		13,310			(50,727	)
Other income (expense), net		(8,074	)		9,428			23,787			(13,310	)		11,831
Income (loss) before provision (benefit) for income taxes		(76,524	)		44,484			28,335			(133	)		(3,838	)
Provision (benefit) for income taxes		(26,998	)		16,782			8,690			71			(1,455	)
Income (loss) before equity earnings of unconsolidated entities, net of tax		(49,526	)		27,702			19,645			(204	)		(2,383	)
Equity in earnings (losses) of subsidiaries, net of tax		49,895			(348	)		—			(49,547	)		—
Equity earnings of unconsolidated entities, net of tax		660			—			2,736			16			3,412
Net income		1,029			27,354			22,381			(49,735	)		1,029
Less: Net loss attributable to non-controlling interests		—			—			(185	)		—			(185	)
Net income attributable to Alere Inc. and Subsidiaries		1,029			27,354			22,566			(49,735	)		1,214
Preferred stock dividends		(5,309	)		—			—			—			(5,309	)
Net income (loss) available to common stockholders	$	(4,280	)	$	27,354		$	22,566		$	(49,735	)	$	(4,095	)

CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS)

For the Three Months Ended March 31, 2013

(in thousands)

	Issuer			Guarantor Subsidiaries		Non-Guarantor Subsidiaries			Eliminations			Consolidated
Net income	$	12,425		$	21,974	$	23		$	(21,997	)	$	12,425
Other comprehensive loss, before tax:
Changes in cumulative translation adjustment		(201	)		—		(75,154	)		—			(75,355	)
Unrealized gains on hedging instruments		—			—		11			—			11
Minimum pension liability adjustment		—			—		605			—			605
Other comprehensive loss, before tax		(201	)		—		(74,538	)		—			(74,739	)
Income tax provision (benefit) related to items of other comprehensive loss		—			—		—			—			—
Other comprehensive loss, net of tax		(201	)		—		(74,538	)		—			(74,739	)
Comprehensive income (loss)		12,224			21,974		(74,515	)		(21,997	)		(62,314	)
Less: Comprehensive loss attributable to non-controlling interests		—			—		(25	)		—			(25	)
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	$	12,224		$	21,974	$	(74,490	)	$	(21,997	)	$	(62,289	)

CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

For the Three Months Ended March 31, 2012

(in thousands)

	Issuer		Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations			Consolidated
Net income	$	1,029	$	27,354		$	22,381		$	(49,735	)	$	1,029
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment		329		(306	)		35,251			665			35,939
Unrealized gains on available for sale securities		429		2			—			—			431
Unrealized gains on hedging instruments		17		—			1,090			—			1,107
Minimum pension liability adjustment		—		—			(165	)		—			(165	)
Other comprehensive income (loss), before tax		775		(304	)		36,176			665			37,312
Income tax benefit related to items of other comprehensive income		—		—			(41	)		—			(41	)
Other comprehensive income (loss), net of tax		775		(304	)		36,217			665			37,353
Comprehensive income		1,804		27,050			58,598			(49,070	)		38,382
Less: Comprehensive loss attributable to non-controlling interests		—		—			(185	)		—			(185	)
Comprehensive income attributable to Alere Inc. and Subsidiaries	$	1,804	$	27,050		$	58,783		$	(49,070	)	$	38,567

CONSOLIDATING BALANCE SHEET

March 31, 2013

(in thousands)

	Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations			Consolidated
ASSETS
Current assets:
Cash and cash equivalents	$	8,626		$	52,407		$	266,200		$	—		$	327,233
Restricted cash		7,933			2,309			1,407			—			11,649
Marketable securities		—			771			113			—			884
Accounts receivable, net of allowances		—			242,772			297,321			—			540,093
Inventories, net		—			147,580			209,509			(20,647	)		336,442
Deferred tax assets		32,145			37,079			11,367			2,939			83,530
Prepaid expenses and other current assets		453,291			(315,140	)		29,231			(36	)		167,346
Intercompany receivables		312,349			603,711			64,077			(980,137	)		—
Total current assets		814,344			771,489			879,225			(997,881	)		1,467,177
Property, plant and equipment, net		2,387			290,253			236,980			(456	)		529,164
Goodwill		—			1,820,992			1,295,865			—			3,116,857
Other intangible assets with indefinite lives		—			13,900			44,493			—			58,393
Finite-lived intangible assets, net		10,927			1,092,551			771,158			—			1,874,636
Deferred financing costs, net and other non-current assets		69,133			10,357			19,881			(71	)		99,300
Investments in subsidiaries		4,345,418			353,666			(67,215	)		(4,631,869	)		—
Investments in unconsolidated entities		34,384			—			48,363			11,548			94,295
Deferred tax assets		—			—			8,653			—			8,653
Intercompany notes receivable		1,672,676			752,565			64,766			(2,490,007	)		—
Total assets	$	6,949,269		$	5,105,773		$	3,302,169		$	(8,108,736	)	$	7,248,475
LIABILITIES AND EQUITY
Current liabilities:
Current portion of long-term debt	$	45,000		$	985		$	6,225		$	—		$	52,210
Current portion of capital lease obligations		—			3,207			2,939			—			6,146
Accounts payable		7,390			67,623			90,999			—			166,012
Accrued expenses and other current liabilities		84,912			199,618			186,418			(29	)		470,919
Intercompany payables		584,562			133,102			262,472			(980,136	)		—
Total current liabilities		721,864			404,535			549,053			(980,165	)		695,287
Long-term liabilities:
Long-term debt, net of current portion		3,770,784			299			17,759			—			3,788,842
Capital lease obligations, net of current portion		—			4,845			6,770			—			11,615
Deferred tax liabilities		(15,907	)		319,914			111,497			(52	)		415,452
Other long-term liabilities		18,099			69,963			124,385			(71	)		212,376
Intercompany notes payables		331,783			1,602,374			555,850			(2,490,007	)		—
Total long-term liabilities		4,104,759			1,997,395			816,261			(2,490,130	)		4,428,285
Stockholders’ equity		2,122,646			2,703,843			1,934,598			(4,638,441	)		2,122,646
Non-controlling interests		—			—			2,257			—			2,257
Total equity		2,122,646			2,703,843			1,936,855			(4,638,441	)		2,124,903
Total liabilities and equity	$	6,949,269		$	5,105,773		$	3,302,169		$	(8,108,736	)	$	7,248,475

CONSOLIDATING BALANCE SHEET

December 31, 2012

(in thousands)

	Issuer			Guarantor Subsidiaries		Non-Guarantor Subsidiaries			Eliminations			Consolidated
ASSETS
Current assets:
Cash and cash equivalents	$	3,623		$	67,449	$	257,274		$	—		$	328,346
Restricted cash		—			1,680		1,396			—			3,076
Marketable securities		—			787		117			—			904
Accounts receivable, net of allowances		—			241,050		283,282			—			524,332
Inventories, net		—			142,413		203,230			(8,522	)		337,121
Deferred tax assets		12,193			39,601		13,138			2,790			67,722
Prepaid expenses and other current assets		(20,636	)		99,271		66,634			(33	)		145,236
Intercompany receivables		298,812			1,254,727		55,847			(1,609,386	)		—
Total current assets		293,992			1,846,978		880,918			(1,615,151	)		1,406,737
Property, plant and equipment, net		2,679			293,260		239,082			(552	)		534,469
Goodwill		—			1,820,438		1,227,967			—			3,048,405
Other intangible assets with indefinite lives		—			14,600		21,851			—			36,451
Finite-lived intangible assets, net		24,701			1,132,656		676,868			—			1,834,225
Deferred financing costs, net and other non-current assets		78,522			10,341		20,065			(71	)		108,857
Investments in subsidiaries		4,114,478			358,088		(67,799	)		(4,404,767	)		—
Investments in unconsolidated entities		33,979			—		56,512			—			90,491
Deferred tax assets		—			782		7,511			—			8,293
Intercompany notes receivable		1,724,650			722,552		1,278			(2,448,480	)		—
Total assets	$	6,273,001		$	6,199,695	$	3,064,253		$	(8,469,021	)	$	7,067,928
LIABILITIES AND EQUITY
Current liabilities:
Current portion of long-term debt	$	45,000		$	349	$	14,883		$	—		$	60,232
Current portion of capital lease obligations		—			3,209		3,475			—			6,684
Accounts payable		7,993			76,256		85,725			—			169,974
Accrued expenses and other current liabilities		(388,830	)		586,116		214,659			(26	)		411,919
Intercompany payables		557,578			806,507		245,300			(1,609,385	)		—
Total current liabilities		221,741			1,472,437		564,042			(1,609,411	)		648,809
Long-term liabilities:
Long-term debt, net of current portion		3,617,068			374		11,233			—			3,628,675
Capital lease obligations, net of current portion		—			5,412		7,505			—			12,917
Deferred tax liabilities		(5,329	)		333,388		100,216			(87	)		428,188
Other long-term liabilities		17,678			72,890		76,138			(71	)		166,635
Intercompany notes payables		241,421			1,630,376		576,684			(2,448,481	)		—
Total long-term liabilities		3,870,838			2,042,440		771,776			(2,448,639	)		4,236,415
Stockholders’ equity		2,180,422			2,684,818		1,726,153			(4,410,971	)		2,180,422
Non-controlling interests		—			—		2,282			—			2,282
Total equity		2,180,422			2,684,818		1,728,435			(4,410,971	)		2,182,704
Total liabilities and equity	$	6,273,001		$	6,199,695	$	3,064,253		$	(8,469,021	)	$	7,067,928

CONSOLIDATING STATEMENT OF CASH FLOWS

For the Three Months Ended March 31, 2013

(in thousands)

	Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations			Consolidated
Cash Flows from Operating Activities:
Net income	$	12,425		$	21,974		$	23		$	(21,997	)	$	12,425
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Equity in earnings (losses) of subsidiaries, net of tax		(22,244	)		614			—			21,630			—
Non-cash interest expense, including amortization of original issue discounts and write-off of deferred financing costs		5,153			55			9			—			5,217
Depreciation and amortization		1,287			61,956			41,756			(29	)		104,970
Non-cash charges for sale of inventories revalued at the date of acquisition		—			—			461			—			461
Non-cash stock-based compensation expense		1,660			1,096			1,367			—			4,123
(Gain) loss on sale of fixed assets		—			227			(55	)		—			172
Equity earnings of unconsolidated entities, net of tax		(248	)		—			(2,688	)		2			(2,934	)
Deferred income taxes		(30,889	)		(10,300	)		(9,605	)		(113	)		(50,907	)
Other non-cash items		(762	)		275			2,428			—			1,941
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net		—			(1,722	)		(18,445	)		—			(20,167	)
Inventories, net		—			(10,475	)		(7,271	)		575			(17,171	)
Prepaid expenses and other current assets		(473,927	)		413,773			35,134			19,187			(5,833	)
Accounts payable		(604	)		(7,960	)		6,576			—			(1,988	)
Accrued expenses and other current liabilities		478,082			(387,332	)		(31,606	)		(19,187	)		39,957
Other non-current liabilities		(126	)		(2,946	)		3,867			—			795
Intercompany payable (receivable)		63,473			(80,252	)		16,779			—			—
Net cash provided by (used in) operating activities		33,280			(1,017	)		38,730			68			71,061
Cash Flows from Investing Activities:
Increase in restricted cash		(7,933	)		(630	)		(10	)		—			(8,573	)
Purchases of property, plant and equipment		(37	)		(14,354	)		(26,736	)		5,022			(36,105	)
Proceeds from sale of property, plant and equipment		—			2,106			4,085			(5,048	)		1,143
Cash paid for acquisitions, net of cash acquired		(151,372	)		—			(7,049	)		—			(158,421	)
Cash received from equity method investments		—			—			10,771			—			10,771
Increase in other assets		(3,210	)		(928	)		(1,431	)		—			(5,569	)
Net cash used in investing activities		(162,552	)		(13,806	)		(20,370	)		(26	)		(196,754	)
Cash Flows from Financing Activities:
Cash paid for financing costs		(1,427	)		—			—			—			(1,427	)
Cash paid for contingent purchase price consideration		(19,098	)		—			—			—			(19,098	)
Proceeds from issuance of common stock, net of issuance costs		6,135			—			—			—			6,135
Proceeds from issuance of long-term debt		—			1,007			9,046			—			10,053
Payments on long-term debt		(16,845	)		(445	)		(2,348	)		—			(19,638	)
Net proceeds (payments) under revolving credit facilities		170,000			—			(7,517	)		—			162,483
Cash paid for dividends		(5,323	)		—			—			—			(5,323	)
Excess tax benefits on exercised stock options		71			17			16			—			104
Principal payments on capital lease obligations		—			(814	)		(907	)		—			(1,721	)
Net cash provided by (used in) financing activities		133,513			(235	)		(1,710	)		—			131,568
Foreign exchange effect on cash and cash equivalents		762			16			(7,724	)		(42	)		(6,988	)
Net increase (decrease) in cash and cash equivalents		5,003			(15,042	)		8,926			—			(1,113	)
Cash and cash equivalents, beginning of period		3,623			67,449			257,274			—			328,346
Cash and cash equivalents, end of period	$	8,626		$	52,407		$	266,200		$	—		$	327,233

CONSOLIDATING STATEMENT OF CASH FLOWS

For the Three Months Ended March 31, 2012

(in thousands)

	Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations			Consolidated
Cash Flows from Operating Activities:
Net income	$	1,029		$	27,354		$	22,381			$(49,735)		$	1,029
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Equity in earnings (losses) of subsidiaries, net of tax		(49,895	)		348			—			49,547			—
Non-cash interest expense, including amortization of original issue discounts and write-off of deferred financing costs		5,219			59			—			—			5,278
Depreciation and amortization		2,074			63,363			37,345			(61	)		102,721
Non-cash charges for sale of inventories revalued at the date of acquisition		—			1,400			3,281			—			4,681
Non-cash stock-based compensation expense		1,007			1,377			1,490			—			3,874
Impairment of inventory		—			5			—			—			5
Impairment of long-lived assets		—			134			—			—			134
Loss on sale of fixed assets		—			508			58			—			566
Equity earnings of unconsolidated entities, net of tax		(660	)		—			(2,736	)		(16	)		(3,412	)
Deferred income taxes		(11,105	)		(614	)		(2,033	)		—			(13,752	)
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net		—			(4,605	)		(8,337	)		—			(12,942	)
Inventories, net		—			13,349			(3,733	)		(265	)		9,351
Prepaid expenses and other current assets		10,526			(4,386	)		(2,619	)		—			3,521
Accounts payable		(863	)		(4,101	)		(12,842	)		—			(17,806	)
Accrued expenses and other current liabilities		(14,901	)		34,232			(15,346	)		—			3,985
Other non-current liabilities		4,309			(10,015	)		20,332			71			14,697
Intercompany payable (receivable)		131,413			(128,235	)		(3,178	)		—			—
Net cash provided by (used in) operating activities		78,153			(9,827	)		34,063			(459	)		101,930
Cash Flows from Investing Activities:
Decrease in restricted cash		—			—			6,302			—			6,302
Purchases of property, plant and equipment		(4	)		(17,375	)		(13,465	)		459			(30,385	)
Proceeds from sale of property, plant and equipment		—			201			326			—			527
Cash paid for acquisitions, net of cash acquired		(22,500	)		—			(15,508	)		—			(38,008	)
Cash received from equity method investments		—			—			6,066			—			6,066
Cash paid for marketable securities		—			(2	)		—			—			(2	)
Increase in other assets		(6,144	)		(397	)		(2,013	)		—			(8,554	)
Net cash used in investing activities		(28,648	)		(17,573	)		(18,292	)		459			(64,054	)
Cash Flows from Financing Activities:
Cash paid for financing costs		(1,876	)		—			—			—			(1,876	)
Cash paid for contingent purchase price consideration		(48	)		—			—			—			(48	)
Proceeds from issuance of common stock, net of issuance costs		7,674			—			—			—			7,674
Proceeds from issuance of long-term debt		198,000			951			190			—			199,141
Payments on long-term debt		(10,750	)		(656	)		(5,505	)		—			(16,911	)
Net proceeds under revolving credit facilities		—			(2	)		1,341			—			1,339
Payments on short-term debt		(6,240	)		—			—			—			(6,240	)
Cash paid for dividends		(5,323	)		—			—			—			(5,323	)
Excess tax benefits on exercised stock options		98			48			2			—			148
Principal payments on capital lease obligations		—			(502	)		(1,218	)		—			(1,720	)
Net cash provided by (used in) financing activities		181,535			(161	)		(5,190	)		—			176,184
Foreign exchange effect on cash and cash equivalents		(429	)		73			1,220			—			864
Net increase (decrease) in cash and cash equivalents		230,611			(27,488	)		11,801			—			214,924
Cash and cash equivalents, beginning of period		12,451			95,212			191,510			—			299,173
Cash and cash equivalents, end of period	$	243,062		$	67,724		$	203,311		$	—		$	514,097

XML

Stockholders' Equity and Non-controlling Interests - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Class of Stock [Line Items]
Preferred stock dividends	$ 5,250	$ 5,309
Series B preferred stock [Member]
Class of Stock [Line Items]
Preferred stock dividends	$ 5,250	$ 5,309

XML

Equity Investments (Tables)

3 Months Ended

Mar. 31, 2013

Equity Method Investments And Joint Ventures [Abstract]

Financial Information for SPD and Techlab on Combined Condensed Results of Operations

Summarized financial information for SPD and TechLab on a combined basis is as follows (in thousands):

	Three Months Ended March 31,
Combined Condensed Results of Operations:	2013		2012
Net revenue	$	49,155	$	52,525
Gross profit	$	37,113	$	35,179
Net income after taxes	$	5,577	$	6,993

Financial Information for SPD and Techlab on Combined Condensed Balance Sheets

Combined Condensed Balance Sheet:	March 31, 2013		December 31, 2012
Current assets	$	65,835	$	79,842
Non-current assets		37,603		38,991
Total assets	$	103,438	$	118,833
Current liabilities	$	32,950	$	45,084
Non-current liabilities		6,986		6,791
Total liabilities	$	39,936	$	51,875

XML

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $) In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2013	Dec. 31, 2012
Statement Of Financial Position [Abstract]
Accounts receivable, allowances	$ 41,337	$ 36,395
Series B preferred stock, par value	$ 0.001	$ 0.001
Series B preferred stock, liquidation preference	$ 709,763	$ 709,763
Series B preferred stock, shares authorized	2,300	2,300
Series B preferred stock, shares issued	2,065	2,065
Series B preferred stock, shares outstanding	1,774	1,774
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000	200,000
Common stock, shares issued	88,959	88,576
Common stock, shares outstanding	81,280	80,897
Treasury stock, shares	7,679	7,679

XML

Note Receivable from FGST Investments, Inc.

3 Months Ended

Mar. 31, 2013

Receivables [Abstract]

Note Receivable from FGST Investments, Inc.

(4) Note Receivable from FGST Investments, Inc.

                In December 2012, we entered into an arrangement whereby we issued a $40.0 million short-term note to an unrelated party, FGST Investments, Inc., or FGST, for the primary purpose of providing funding in connection with FGST’s acquisition of the Polymedica Corporation (“Liberty”) line of business, a medical supply business, from a subsidiary of Express Scripts Holding Company. The note bears interest at a rate of 3.25% per annum and is collateralized by substantially all of the assets of FGST and its parent entity, ATLS Acquisition, LLC, or ATLS, and was guaranteed by various subsidiaries of FGST. The $40.0 million short-term note is classified within prepaid expenses and other current assets on our Consolidated Balance Sheet as of March 31, 2013. In connection with the note, we obtained a call option to purchase certain of the assets acquired by FGST for a purchase price of $40.0 million. Under the terms of the option, we could exercise the option and satisfy the purchase price by cancellation of the principal amount of the note. On February 4, 2013, we exercised the option. On February 15, 2013, the issuer of the note filed for protection under Chapter 11 of the U.S. Bankruptcy Code. Subsequently, in April 2013, we entered into an amendment of the option agreement and settlement stipulation related to these matters. (See Note 21)

XML

Restructuring Plans - Cash Activity for Restructuring Reserves (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Beginning Balance	$ 6,218
Cash charges	3,992	5,528
Payments	(3,758)
Currency adjustments	(4)
Restructuring Reserve, Ending Balance	6,448
Severance-related costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Beginning Balance	3,167
Cash charges	3,033
Payments	(2,923)
Currency adjustments	(4)
Restructuring Reserve, Ending Balance	3,273
Facility and transition costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Beginning Balance	2,429
Cash charges	904
Payments	(763)
Restructuring Reserve, Ending Balance	2,570
Other exit costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Beginning Balance	622
Cash charges	55
Payments	(72)
Restructuring Reserve, Ending Balance	$ 605

XML

Subsequent Event - Additional Information (Detail) (USD $) In Millions, unless otherwise specified		12 Months Ended		1 Months Ended
	Mar. 31, 2012	Dec. 31, 2012 FGST Investments Inc. [Member]	Apr. 26, 2013 Subsequent Event [Member]	Apr. 26, 2013 Subsequent Event [Member] FGST Investments Inc. [Member]
Subsequent Event [Line Items]
Short term note issued to unrelated party		$ 40.0		$ 40.0
Acquisition of Liberty Assets	494.8		17.5
Cash received on settlement of note receivable			$ 22.5

XML

Financial Information by Segment - Summary of Company's Net Revenue from Professional Diagnostics and Health Information Solutions Reporting Segments by Groups of Similar Products and Services (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Segment Reporting Information [Line Items]
Net product sales and services revenue	$ 735,185	$ 668,221
License and royalty revenue	4,064	2,908
Net revenue	739,249	671,129
Professional Diagnostics [Member]
Segment Reporting Information [Line Items]
Net product sales and services revenue	578,628	515,449
License and royalty revenue	3,864	2,908
Net revenue	582,492	518,357
Professional Diagnostics [Member] | Cardiology [Member]
Segment Reporting Information [Line Items]
Net product sales and services revenue	114,933	138,826
Professional Diagnostics [Member] | Infectious disease [Member]
Segment Reporting Information [Line Items]
Net product sales and services revenue	189,844	151,016
Professional Diagnostics [Member] | Toxicology [Member]
Segment Reporting Information [Line Items]
Net product sales and services revenue	149,049	121,740
Professional Diagnostics [Member] | Diabetes [Member]
Segment Reporting Information [Line Items]
Net product sales and services revenue	50,083	28,161
Professional Diagnostics [Member] | Other [Member]
Segment Reporting Information [Line Items]
Net product sales and services revenue	74,719	75,706
Health Information Solutions [Member]
Segment Reporting Information [Line Items]
Net revenue	134,207	130,784
Health Information Solutions [Member] | Disease and case management [Member]
Segment Reporting Information [Line Items]
Net product sales and services revenue	54,126	53,380
Health Information Solutions [Member] | Wellness [Member]
Segment Reporting Information [Line Items]
Net product sales and services revenue	26,300	27,026
Health Information Solutions [Member] | Women's & children's health [Member]
Segment Reporting Information [Line Items]
Net product sales and services revenue	29,080	29,771
Health Information Solutions [Member] | Patient self-testing services [Member]
Segment Reporting Information [Line Items]
Net product sales and services revenue	$ 24,701	$ 20,607

XML

Subsequent Event

3 Months Ended

Mar. 31, 2013

Subsequent Events [Abstract]

Subsequent Event

(21) Subsequent Event

On April 26, 2013, we settled our $40.0 million note receivable with FGST (see Note 4). In exchange for our surrender of the note, we acquired certain of the assets of the Medicare fee-for-service diabetes business (the “Liberty Assets”) of FGST, and its affiliates, including Liberty Medical, for $17.5 million and received $22.5 million in cash, along with all accrued and unpaid interest.

XML

Equity Investments - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended					3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013 TechLab [Member]	Mar. 31, 2012 TechLab [Member]	May 31, 2006 TechLab [Member]	Mar. 31, 2013 Swiss Precision Diagnostics [Member]	Mar. 31, 2012 Swiss Precision Diagnostics [Member]	May 31, 2007 Swiss Precision Diagnostics [Member]
Schedule of Equity Method Investments [Line Items]
Equity earnings (losses) of unconsolidated entities, net of tax	$ 2,934	$ 3,412	$ 200	$ 700		$ 2,500	$ 2,800
Ownership percentage					49.00%			50.00%

XML

Defined Benefit Pension Plan (Tables)

3 Months Ended

Mar. 31, 2013

Compensation And Retirement Disclosure [Abstract]

Net Periodic Benefit Costs

The net periodic benefit costs are as follows (in thousands):

	Three Months Ended March 31,
	2013			2012
Service cost	$	—		$	—
Interest cost		182			198
Expected return on plan assets		(156	)		(152	)
Amortization of prior service cost		103			104
Realized losses		—			—
Net periodic benefit cost	$	129		$	150

XML

Financial Information by Segment

3 Months Ended

Mar. 31, 2013

Segment Reporting [Abstract]

Financial Information by Segment

(14) Financial Information by Segment

Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision-making group is composed of the chief executive officer and members of senior management. Our reportable operating segments are professional diagnostics, health information solutions, consumer diagnostics and corporate and other. Our operating results include license and royalty revenue which are allocated to professional diagnostics and consumer diagnostics on the basis of the original license or royalty agreement.

We evaluate performance of our operating segments based on revenue and operating income (loss). Segment information for the three months ended March 31, 2013 and 2012 is as follows (in thousands):

	Professional Diagnostics		Health Information Solutions			Consumer Diagnostics		Corporate and Other			Total
Three Months Ended March 31, 2013:
Net revenue	$	582,492	$	134,207		$	22,550	$	—		$	739,249
Operating income (loss)	$	59,840	$	(13,893	)	$	2,280	$	(17,738	)	$	30,489
Depreciation and amortization	$	82,794	$	20,737		$	1,153	$	286		$	104,970
Non-cash charge associated with acquired inventory	$	461	$	—		$	—	$	—		$	461
Restructuring charge	$	1,389	$	2,503		$	—	$	—		$	3,892
Stock-based compensation	$	—	$	—		$	—	$	4,123		$	4,123
Three Months Ended March 31, 2012:
Net revenue	$	518,357	$	130,784		$	21,988	$	—		$	671,129
Operating income (loss)	$	70,179	$	(19,356	)	$	365	$	(16,130	)	$	35,058
Depreciation and amortization	$	77,467	$	23,774		$	1,259	$	221		$	102,721
Non-cash charge associated with acquired inventory	$	4,681	$	—		$	—	$	—		$	4,681
Restructuring charge	$	4,794	$	717		$	—	$	17		$	5,528
Stock-based compensation	$	—	$	—		$	—	$	3,874		$	3,874
Assets:
As of March 31, 2013	$	6,414,701	$	608,161		$	175,285	$	50,328		$	7,248,475
As of December 31, 2012	$	6,214,847	$	593,172		$	192,748	$	67,161		$	7,067,928

The following tables summarize our net revenue from the professional diagnostics and health information solutions reporting segments by groups of similar products and services for the three months ended March 31, 2013 and 2012 (in thousands):

	Three Months Ended March 31,
Professional Diagnostics Segment	2013		2012
Cardiology	$	114,933	$	138,826
Infectious disease		189,844		151,016
Toxicology		149,049		121,740
Diabetes		50,083		28,161
Other		74,719		75,706
Net product sales and services revenue		578,628		515,449
License and royalty revenue		3,864		2,908
Professional diagnostics net revenue	$	582,492	$	518,357
	Three Months Ended March 31,
Health Information Solutions Segment	2013		2012
Disease and case management	$	54,126	$	53,380
Wellness		26,300		27,026
Women’s & children’s health		29,080		29,771
Patient self-testing services		24,701		20,607
Health information solutions net revenue	$	134,207	$	130,784